<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003545.pub2" GROUP_ID="SCHIZ" ID="801797091810311629" MERGED_FROM="" MODIFIED="2010-04-14 15:40:53 +0200" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;REMEMBER i2 issue&lt;/p&gt;" NOTES_MODIFIED="2009-01-19 15:13:59 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="001" REVMAN_SUB_VERSION="5.0.17" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2010-04-14 15:40:53 +0200" MODIFIED_BY="Claire Irving">
<TITLE>Trifluoperazine for schizophrenia</TITLE>
<CONTACT MODIFIED="2010-04-14 15:40:53 +0200" MODIFIED_BY="Claire Irving"><PERSON ID="1185178F82E26AA201DC7B3ECF255AC6" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Luciana de Oliveira</FIRST_NAME><LAST_NAME>Marques</LAST_NAME><POSITION>Reviewer</POSITION><EMAIL_1>lucianaomarques@uol.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Psychiatry</DEPARTMENT><ORGANISATION>Mestrado de Saúde e Comportamento-Universidade Católica de Pelotas</ORGANISATION><ADDRESS_1>Gonçalves Chaves 962 sala 302</ADDRESS_1><CITY>Pelotas</CITY><ZIP>96015-560</ZIP><REGION>Rio Grande do Sul</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>053-2253200</PHONE_1><PHONE_2>053-2257825</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-04-14 15:40:53 +0200" MODIFIED_BY="Claire Irving"><PERSON ID="1185178F82E26AA201DC7B3ECF255AC6" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Luciana de Oliveira</FIRST_NAME><LAST_NAME>Marques</LAST_NAME><POSITION>Reviewer</POSITION><EMAIL_1>lucianaomarques@uol.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Psychiatry</DEPARTMENT><ORGANISATION>Mestrado de Saúde e Comportamento-Universidade Católica de Pelotas</ORGANISATION><ADDRESS_1>Gonçalves Chaves 962 sala 302</ADDRESS_1><CITY>Pelotas</CITY><ZIP>96015-560</ZIP><REGION>Rio Grande do Sul</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>053-2253200</PHONE_1><PHONE_2>053-2257825</PHONE_2></ADDRESS></PERSON><PERSON ID="9639" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bernardo</FIRST_NAME><LAST_NAME>Soares</LAST_NAME><POSITION>Honorary Fellow</POSITION><EMAIL_1>bgos@terra.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT><ORGANISATION>Universidade Federal de São Paulo</ORGANISATION><ADDRESS_1>Rua Pedro de Toledo 598</ADDRESS_1><CITY>São Paulo</CITY><ZIP>04039-001</ZIP><REGION>SP</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5575 2970</PHONE_1><FAX_1>+55 11 5579 0469</FAX_1></ADDRESS></PERSON><PERSON ID="13374" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Mauricio</FIRST_NAME><LAST_NAME>Silva de Lima</LAST_NAME><SUFFIX>M.D. Ph.D.</SUFFIX><POSITION>Medical Director - Eli Lilly UK &amp; RoI</POSITION><EMAIL_1>msilvadelima@yahoo.com.br</EMAIL_1><EMAIL_2>limama@lilly.com</EMAIL_2><ADDRESS><DEPARTMENT>Medical</DEPARTMENT><ORGANISATION>Eli Lilly &amp; Co</ORGANISATION><ADDRESS_1>Lilly House</ADDRESS_1><ADDRESS_2>Priestley Road</ADDRESS_2><CITY>Basingstoke</CITY><ZIP>RG24 9NL</ZIP><REGION>Hampshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+441256775252</PHONE_1><FAX_1>+441256775441</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-10-31 14:53:20 +0000" MODIFIED_BY="John  Rathbone" NOTES="&lt;p&gt;Minor update: 11/26/03&lt;/p&gt;" NOTES_MODIFIED="2008-10-31 14:53:20 +0000" NOTES_MODIFIED_BY="John  Rathbone">
<UP_TO_DATE>
<DATE DAY="20" MONTH="11" YEAR="2003"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="11" YEAR="2003"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="11" YEAR="2005"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2010-04-14 15:40:53 +0200" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-14 15:40:53 +0200" MODIFIED_BY="Claire Irving"><DATE DAY="14" MONTH="4" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2010-04-14 15:40:53 +0200" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-14 15:40:53 +0200" MODIFIED_BY="Claire Irving"><DATE DAY="15" MONTH="2" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-02-15 16:23:46 +0100" MODIFIED_BY="Claire Irving">
<DATE DAY="31" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY></HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Universidade Católica de Pelotas</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Universidade Federal de Pelotas</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-31 14:57:18 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-10-31 14:53:41 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-31 14:53:41 +0000" MODIFIED_BY="[Empty name]">Trifluoperazine for schizophrenia</TITLE>
<SUMMARY_BODY>
<P>Trifluoperazine is inexpensive and widely accessible. Thousands of people with schizophrenia have participated in studies and therefore we are reasonably sure that it is a potent antipsychotic drug and as good as similar older drugs. Most people taking it do experience adverse effects, but this also applies to other older drugs. Not enough comparisons with newer generations of drugs have been undertaken to be sure of how trifluoperazine compares to them.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Trifluoperazine is an inexpensive accessible 'high potency' antipsychotic drug, widely used to treat schizophrenia or related psychoses.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To estimate the effects of trifluoperazine compared with placebo and other drugs.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Searches of the Cochrane Schizophrenia Group's register of trials (March 2002), supplemented with hand searching, reference searching, personal communication and contact with industry.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All clinical randomised trials involving people with schizophrenia and comparing trifluoperazine with any other treatment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Studies were reliably selected and quality rated and data was extracted. For dichotomous data, relative risks (RR) were estimated, with 95% confidence intervals (CI). Where possible, we undertook intention-to-treat analyses. For statistically significant results, the number needed to treat (NNT) was calculated. We estimated heterogeneity (I-square technique) and publication bias.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>1162 people from 13 studies were randomised to trifluoperazine or placebo. For global improvement, small short-term studies favoured trifluoperazine (n=95, 3 RCTs, RR 0.62 CI 0.49 to 0.78 NNT 3 CI 2 to 4). Loss to follow up was about 12% in both groups (n=280, 7 RCTs, RR 0.99 CI 0.62 to 1.57) and more people allocated trifluoperazine used antiparkinson drugs to alleviate movements disorders compared with placebo (n=195, 4 RCTs, RR 5.06 CI 2.49 to 10.27, NNH 4 CI 2 to 9). 2230 people from 49 studies were randomised to trifluoperazine or another older generation antipsychotic. Trifluoperazine was not clearly different in terms of 'no substantial improvement' (n=1016, 27 RCTs, RR 1.06 CI 0.98 to 1.14) or leaving the study early (n=930, 22 RCTs, RR 1.15 CI 0.83 to 1.58). Almost identical numbers of people reported at least one adverse event (~60%) in each group (n=585, 14 RCTs, RR 0.99 CI 0.87 to 1.13), although trifluoperazine was more likely to cause extrapyramidal adverse effects overall when compared to low potency antipsychotics such as chlorpromazine (n=130, 3 RCTs, RR 1.66 CI 1.03 to 2.67, NNH 6 CI 3 to 121). One small study (n=38) found no clear differences between trifluoperazine and the atypical drug, sulpiride.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Although there are shortcomings and gaps in the data, there appears to be enough consistency over different outcomes and periods to confirm that trifluoperazine is an antipsychotic of similar efficacy to other commonly used neuroleptics for people with schizophrenia. Its adverse events profile is similar to that of other drugs. It has been claimed that trifluoperazine is effective at low doses for patients with schizophrenia but this does not appear to be based on good quality trial based evidence.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-31 14:57:18 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>The most commonly prescribed antipsychotic drugs (chlorpromazine, haloperidol and trifluoperazine), are the benchmarks against which all others are compared. They have too rarely been the subjects of quantitative, systematic reviews. Now that synthesis of trials comparing placebo with chlorpromazine, and placebo with haloperidol, for people with schizophrenia are maintained in the Cochrane Library (<LINK REF="REF-Thornley-2001" TYPE="REFERENCE">Thornley 2001</LINK>, <LINK REF="REF-Joy-2001" TYPE="REFERENCE">Joy 2001</LINK>), only trifluoperazine remains to be reviewed.</P>
<P>Trifluoperazine is a long-established, widely used 'conventional' antipsychotic drug. It has been claimed that it is effective at low doses (<LINK REF="REF-Ban-1966" TYPE="REFERENCE">Ban 1966</LINK>, <LINK REF="REF-Bazire-2000" TYPE="REFERENCE">Bazire 2000</LINK>, <LINK REF="REF-Reardon-1989" TYPE="REFERENCE">Reardon 1989</LINK>). Trifluoperazine has been considered effective and safe since the 1960s (<LINK REF="REF-Reardon-1989" TYPE="REFERENCE">Reardon 1989</LINK>, <LINK REF="REF-APA-1997" TYPE="REFERENCE">APA 1997</LINK>), and is considered a first-line drug for people in the acute phase of schizophrenia (<LINK REF="REF-APA-1997" TYPE="REFERENCE">APA 1997</LINK>). Conventional antipsychotic medications vary, both in potency and propensity to induce adverse effects such as, the so-called 'extrapyramidal adverse effects', or EPS. With EPS, the normally fluid movements of everyday living become stiff and tremulous, facial expression becomes limited and some repetitive movements of the mouth and face may become gross and disfiguring. These EPS are said to occur more frequently with 'high-potency' compounds such as haloperidol and trifluoperazine. Sedation and low blood pressure, so often associated with antipsychotic drugs, is said to be less frequent with the 'high potency' trifluoperazine (<LINK REF="REF-APA-1997" TYPE="REFERENCE">APA 1997</LINK>).</P>
<P>The search to identify antipsychotic drugs with minimal adverse effects, and a broader spectrum of efficacy, has produced a class of drug known as atypical antipsychotics. As a group, it is claimed that these cause reduced EPS and have some efficacy in the treatment of the negative symptoms of schizophrenia (apathy, inability to express emotions, poverty of speech and lack of motivation). From the whole class of 'atypicals' , only clozapine has proved to be more potent for treating refractory symptoms (<LINK REF="REF-Wahlbeck-2001" TYPE="REFERENCE">Wahlbeck 2001</LINK>, <LINK REF="REF-Duggan-2002" TYPE="REFERENCE">Duggan 2002</LINK>, <LINK REF="REF-Hunter-2003" TYPE="REFERENCE">Hunter 2003</LINK>), although even this is in question (<LINK REF="REF-Geddes-2000" TYPE="REFERENCE">Geddes 2000</LINK>). Atypical antipsychotics are more expensive than the conventional drugs, and cost has become part of the controversy concerning their prescribing (<LINK REF="REF-Wood-Mackenzie-1998" TYPE="REFERENCE">Wood Mackenzie 1998</LINK>, <LINK REF="REF-Meltzer-1996" TYPE="REFERENCE">Meltzer 1996</LINK>). Cost is a major influence on accessibility of treatments, especially for middle or low-income countries. </P>
<P>Technical background<BR/>Trifluoperazine is a phenothiazine derivative, 10-[3-(4-methyl-1-piperazinyl)propyl]-2-trifluoromethylpheno thiazine(hydrochloride), sold as Stelazine by GlaxoSmithkline (tablets of 1mg, 2 mg, 5mg and 10 mg). The daily dose ranges from 12 to 50 mg (<LINK REF="REF-APA-1997" TYPE="REFERENCE">APA 1997</LINK>). It may be administered orally once or twice a day.</P>
<P>Trifluoperazine is related chemically to chlorpromazine, but it has high milligram potency, and an adverse effect profile (mainly the incidence of extrapyramidal symptoms) similar to haloperidol (<LINK REF="STD-Luckey-1967" TYPE="STUDY">Luckey 1967</LINK>). It has a specific action on the brain: D2 receptors blockade. The blockade of postsynaptic D2 receptors in mesolimbic and mesocortical projection is responsible for initiating the therapeutic actions of typical antipsychotic drugs. The blockade in striatum is responsible for the extrapyramidal effects and in the tuberoinfundubular system of the hypothalamus can produce hyperprolactinemia (<LINK REF="REF-Arana-2000" TYPE="REFERENCE">Arana 2000</LINK>). Although D2 blockade takes hours, clinical effects usually take weeks, probably because the decrease of homovallinic acid levels (principal metabolite of dopamine) is expected to take several weeks (<LINK REF="REF-Bazire-2000" TYPE="REFERENCE">Bazire 2000</LINK>). The risk of extrapyramidal reactions (pseudo parkinsonism, acute dystonic reaction, akathisia and tardive dyskinesia) is suggested to be higher than in other phenothiazines. Trifluoperazine has a low potency of cholinergic blockade (confusion, agitation, dry mouth, blurred vision, urinary retention) and causes less sedation and orthostatic hypotension (histaminic and alpha-adrenergic antagonism). It is usually well tolerated (<LINK REF="REF-Kaplan-1998" TYPE="REFERENCE">Kaplan 1998</LINK>).<BR/>
</P>
</BACKGROUND>
<OBJECTIVES>
<P>To examine the effects of trifluoperazine compared to placebo, and other antipsychotic drugs, for people with schizophrenia.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-31 14:57:18 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-10-31 14:56:18 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All relevant randomised controlled trials were included. Where a trial was described as 'double-blind' but it was implied that the study was randomised and the demographic details of each group were similar, it was included. Quasi-randomised studies, such as those allocated by using alternate days of the week, were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with schizophrenia and non-affective serious/chronic mental illness irrespective of mode of diagnosis, age, sex and chronicity of illness.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. Trifluoperazine: any dose and mode or pattern of administration. If a high/low dichotomy was not provided within the trial, high dose was defined as over 30 mg/day, and low dose as any lesser dose. If different doses of trifluoperazine were randomised these studies were also of interest. </P>
<P>2. Placebo.</P>
<P>3. Other typical antipsychotics: any dose and mode or pattern of administration. Examples of such drugs are chlorpromazine and haloperidol.</P>
<P>4. Atypical antipsychotics: any dose and mode or pattern of administration. Examples of such drugs are clozapine, olanzapine, quetiapine, and risperidone.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-31 14:56:18 +0000" MODIFIED_BY="[Empty name]">
<P>As schizophrenia is often a life-long illness, and trifluoperazine is used as an ongoing treatment, outcomes were grouped according to time periods: immediate (seven days or less), short term (eight days to three months), medium term (&gt; three months to one year) and long term (more than one year).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-31 14:55:53 +0000" MODIFIED_BY="[Empty name]">
<P>1. Service utilisation outcomes<BR/>1.1 Hospital admission.</P>
<P>2. Global outcomes<BR/>2.1 No clinically significant response in global state - as defined by each of the studies.</P>
<P>3. Mental state<BR/>3.1 No clinically significant response in mental state - as defined by each of the studies.</P>
<P>4. Extrapyramidal adverse effects<BR/>4.1 Incidence of use of antiparkinsonian drugs.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-10-31 14:56:10 +0000" MODIFIED_BY="[Empty name]">
<P>1. Death<BR/>1.1 Suicide.<BR/>1.2 Other causes.</P>
<P>2. Service utilisation outcomes<BR/>2.1 Days in hospital.<BR/>
<BR/>3. Global outcomes<BR/>3.1 Average score/change in global state.</P>
<P>4. Mental state<BR/>4.1 Average score/change in mental state.<BR/>4.2 No clinically significant response on negative symptoms - as defined by each of the studies.<BR/>4.3 Average score/change in negative symptoms.<BR/>4.4 Relapse as defined in the study.</P>
<P>5. Behaviour<BR/>5.1 Leaving the study early.<BR/>5.2 No clinically significant response in behaviour - as defined by each of the studies.<BR/>5.3 Average score/change in behaviour.</P>
<P>6. Extrapyramidal adverse effects<BR/>6.1 No clinically significant extrapyramidal adverse effects - as defined by each of the studies.<BR/>6.2 Average score/change in extrapyramidal adverse effects.</P>
<P>7. Other adverse effects, general and specific<BR/>7.1 Number of people dropping out due to adverse effects.<BR/>7.2 Cardiac effects.<BR/>7.3 Anticholinergic effects.<BR/>7.4 Antihistaminic effects.<BR/>7.5 Prolactin related symptoms.</P>
<P>8. Social functioning<BR/>8.1 No clinically significant response in social functioning - as defined by each of the studies.<BR/>8.2 Average score/change in social functioning.</P>
<P>9. Economic outcomes</P>
<P>10. Quality of life/ satisfaction with care for either recipients of care or careers.<BR/>10.1 Significant change in quality of life / satisfaction - as defined by each of the studies.<BR/>10.2 Average score/change in quality of life / satisfaction.<BR/>10.3 Employment status.</P>
<P>11. Cognitive functioning</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-31 14:57:18 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2008-10-31 14:57:13 +0000" MODIFIED_BY="[Empty name]">
<P>Trifluoperazine is known by many names. We constructed the following search phrase to assist identification:</P>
<P>Trifluoperazine-phrase = *10-[3-(4-methyl-1-piperazinyl)propyl]-2-trifluoromethylpheno thiazine (hydrochloride)* or *terfluzine* or *terfluzinor discimer* or *eskazine foille* or *iremo* or *piero* or *jatroneural* or *modalina* or *oxyperazine* or *sedofren* or *sporalon* or *stelazine* or *stelazina* or *stelium* or *terflurazine* or *terfluoperazine* or *SKF 5019* or *7623 RP* or *trifluoperazine* or *Solazine*.</P>
<P>1. The Cochrane Schizophrenia Group's Register (March 2002) was searched using the phrase:</P>
<P>{[(trifluoperazine-phrase) in title, abstract or index terms of REFERENCE] or [*trifluoperazine* in interventions of STUDY]}</P>
<P>This register is compiled by methodical searches of BIOSIS, CINAHL, Dissertation abstracts, EMBASE, LILACS, MEDLINE, PSYNDEX, PsycINFO, RUSSMED, Sociofile, supplemented with hand searching of relevant journals and numerous conference proceedings (see Group Module).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-10-31 14:56:40 +0000" MODIFIED_BY="[Empty name]">
<P>1. Reference searching<BR/>References of all identified studies were also inspected for more trials.<BR/>
<BR/>SCISEARCH - Science Citation Index (1974 to 2001) was used to trace papers that had cited included trials. These reports were inspected in order to identify further studies.</P>
<P>2. Personal contact<BR/>The first author of each included study was contacted for information regarding unpublished trials.</P>
<P>3. Industry<BR/>Pharmaceutical companies were contacted for additional data or reports of trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>1. Selection of trials <BR/>All reports of identified studies were inspected by the principal reviewer (LOM). A random sample of ten percent of reports was re inspected by MSL in order to ensure reliability of selection. Where disagreement occurred this was resolved by discussion, or, when there was still doubt, reviewers acquired the full article for further inspection. Once the full articles were obtained LOM decided whether they met review criteria and this was checked by MSL on a 10% sample. Again, if disagreement occurred this was resolved by discussion and when this was not possible further information was sought. These trials were added to the list of those awaiting assessment pending acquisition of this further information.<BR/>
<BR/>2. Quality assessment <BR/>Trials were classified into three quality categories, as described in the Cochrane Collaboration Handbook (<LINK REF="REF-Clarke-2001" TYPE="REFERENCE">Clarke 2001</LINK>) by the lead reviewer (LOM). A random sample (10%) of trial reports was re inspected by MSL. When disputes arose regarding which category a trial should be allocated to, again, resolution was attempted by discussion. When this was not possible, and further information was necessary, data were not entered into the analyses and the study was allocated to the list of those awaiting assessment. Only trials in Category A or B were included in the review. <BR/>
<BR/>3. Data extraction <BR/>Data from selected trials were extracted twice by LOM blind to the first extraction. A random selection were independently re inspected by MSL (10%). When disputes arose reviewers attempted resolution by discussion. If doubt remained and further information was necessary to resolve the dilemma, reviewers did not enter the data and added them to the list of those awaiting assessment, pending further information. </P>
<P>4. Data synthesis<BR/>4.1 Data types<BR/>Outcomes are assessed using continuous (for example, average changes on a behaviour scale), categorical (for example, one of three categories on a behaviour scale, such as 'little change', 'moderate change' or 'much change') or dichotomous measures (for example, either 'no important changes' or 'important changes' in a person's behaviour). RevMan software does not currently support categorical data so they were only presented in the text of the review.<BR/>
<BR/>4.2 Incomplete data <BR/>With the exception of the outcome of leaving the study early, trial outcomes were not included if more than 40% of people were not reported in the final analysis. Reviewers felt that such a degree of attrition would threaten the validity of any findings.<BR/>
<BR/>4.3 Dichotomous data<BR/>Where the original authors of the studies gave outcomes such as 'clinically improved' or 'not clinically improved' based on their clinical judgment, predetermined criteria or any scale, this was recorded in RevMan. If data was from a rater not clearly stated to be independent then it was only included if it did not change the results, otherwise it was presented separately with a label 'prone to bias'. </P>
<P>Where possible, efforts were made to convert relevant categorical or continuous outcome measures to dichotomous data by identifying cut off points on rating scales and dividing people accordingly into groups. We used the cut off points 'moderate or severe impairment' for end of study data or 'no better or worse' for change data. For example, the Brief Psychiatric Rating Scale (BPRS - <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) is frequently used as a measure of change of symptoms in studies. The reviewers defined a 50% change on this particular scale as clinically important, although it was recognised that for many people, especially those with chronic or severe illnesses, a less rigorous definition of important improvement, for example, 25% on the BPRS, would be equally valid. If individual patient data were available, the 50% cut off was used for non-chronically ill people and 25% for those with chronic illness. </P>
<P>This review presents an intention to treat analysis. As long as over 60% of people completed the study, everyone allocated to the intervention was counted whether or not they completed follow up. It was assumed that those who left the study early had a negative outcome, with the exception of the outcome of death. Also with regard to 'reasons for leaving the study early' because of adverse events or relapse, only patients not accounted for were assumed to have a negative outcome. This was felt to be a more reasonable interpretation of limited data. These data were included as long as this did not change the results. This was tested by a sensitivity analysis. </P>
<P>Where trialists presented data as 'last result carried forward' for those who left the study early, these data were only included if they did not change the overall results, otherwise, they were presented separately with the label 'prone to bias'. Where there was genuine uncertainty as to how the trialists had handled data, this uncertainty was tested using a range of possible missing values. If this affected the results then it was presented separately with a label 'prone to bias'.</P>
<P>We used relative risk (RR) and 95% confidence interval (CI) based on the random effects model as the preferred statistic for summation, as this takes into account differences between studies even if heterogeneity is not statistically significant. Data were inspected to see if analysis using a Mantel-Haenszel odds ratio and fixed effects models made a substantive difference. Where possible, reviewers estimated the number needed to treat / harm (NNT/H).<BR/>
<BR/>4.4 Continuous data<BR/>In the case of continuous data, completer analysis is presented.<BR/>
<BR/>4.4.1 Rating scales<BR/>A wide range of instruments is available to measure mental health outcomes. These instruments vary in quality and many are not valid, or even ad hoc. For outcome instruments some minimum standards have to be set. They are that: i. the psychometric properties of the instrument should have been described in a peer-reviewed journal; ii. the instrument should either be a self-report, or completed by an independent rater or relative (not the therapist); and iii. the instrument should be a global assessment of an area of functioning.<BR/>
<BR/>4.4.2 Normal distribution <BR/>Mental health continuous data are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data the following standards were applied to all data before inclusion: i. standard deviations and means were reported in the paper or were obtainable from the authors; ii. if the data were finite measures from, for example 0-100, when the standard deviation was multiplied by two, the result should be less than the mean, otherwise the mean was unlikely to be an appropriate measure of the centre of the distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). Continuous data, if normally distributed, were summated using a calculation of the weighted mean difference (WMD). Non-normally distributed data were reported in the 'Other data types' tables. Endpoint scale-derived data is finite, ranging from one score to another. Change data is more problematic and for it the rule described above does not hold. Although most change scores are likely to be skewed, it cannot be proven, so they were presented in MetaView. Where both endpoint and change were available for the same outcome the reviewers presented the former in preference.<BR/>
<BR/>4.5 Sensitivity analyses<BR/>4.5.1 Primary outcomes for an intention-to-treat analysis were compared with those from a completer-only analysis. </P>
<P>4.6 Subgroup analysis<BR/>4.6.1 Trials that used low doses of trifluoperazine were compared with those where high doses (over 30 mg/day) were employed.</P>
<P>4.6.2 Studies with less than 40% of people leaving early were compared with those with higher rates.</P>
<P>5. Heterogeneity<BR/>As well as inspecting the graphical presentations, the reviewers checked whether the differences between results of trials were greater than would be expected by chance alone using tests of heterogeneity (Chi squared). A significance level of less than 0.10 was interpreted as evidence of heterogeneity. When heterogeneity was present, a sensitivity analysis was undertaken. Outlying studies were removed from the pooled measure if they caused a substantive change in the overall findings and these data were presented and discussed separately.</P>
<P>6. Assessing the presence of publication bias <BR/>Data from all included trials were entered into a funnel graph (trial effect versus trial size or 'precision') in an attempt to investigate the likelihood of overt publication bias. A formal test of funnel plot asymmetry (which suggests potential publication bias) was undertaken where appropriate, according to the methods of <LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>. Significance levels of p &lt; 0.1 were set a priori to detect the presence of asymmetry. Where only 3-4 studies reported an outcome, or there was little variety in sample size (or precision estimate) between studies, tests of asymmetry were not appropriate.</P>
<P>7. Tables and figures <BR/>Where possible, data were entered into RevMan so the area to the left of the line of no effect indicated a favourable outcome for trifluoperazine.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Please also see Included and Excluded studies tables. </P>
<P>1. Awaiting assessment<BR/>Four studies have been ordered but not yet obtained (<LINK REF="STD-Toru-1969" TYPE="STUDY">Toru 1969</LINK>, <LINK REF="STD-Gallant-2000" TYPE="STUDY">Gallant 2000</LINK>, <LINK REF="STD-Kogeorgos-1995" TYPE="STUDY">Kogeorgos 1995</LINK>, <LINK REF="STD-Ortega_x002d_Soto-1996" TYPE="STUDY">Ortega-Soto 1996</LINK>). A further eighteen did not fulfil inclusion criteria but we have contacted the authors and await their response before these are excluded. One Polish paper has not yet been translated (<LINK REF="STD-Terminska-1989" TYPE="STUDY">Terminska 1989</LINK>). </P>
<P>2. Excluded studies<BR/>The majority of excluded studies either did not have a control group (n=7) or were not stated to be randomised (n=32). Some randomised studies used interventions that were not the focus of this review or involved people who did not suffer from schizophrenia (n=7). Ten randomised trials had to be excluded as no data were usable, for example, one was a crossover study with no information for the first stage. Two trials did not report the number of people randomised to each group. </P>
<P>3. Included studies<BR/>Fifty studies were included. </P>
<P>3.1 Methods<BR/>All included studies were described as randomised. Follow-up periods ranged from three days to 13 months. Twenty-eight were in the short duration category (less than three months) and six were of intermediate duration (three months to one year). Only one was over one year (long duration, <LINK REF="STD-Donlon-1978" TYPE="STUDY">Donlon 1978</LINK>). </P>
<P>3.2 Participants <BR/>The number of people in the included studies ranged from 18 to 360 (mean 52 SD 50). 47% of studies had 40 or fewer participants but a total of 2583 people have participated in the 50 trials. </P>
<P>From the studies reporting information on the sex of participants, there were 1271 men and 971 women. Ages ranged from 14 to 74 years (mean from 18 studies was about 43 years). Only two studies specifically focused on adolescents (<LINK REF="STD-Bagadia-1980" TYPE="STUDY">Bagadia 1980</LINK>, <LINK REF="STD-Malik-1980" TYPE="STUDY">Malik 1980</LINK>). </P>
<P>Most participants had a diagnosis of schizophrenia although some studies were included if most people had schizophrenia or a schizophrenia-like illness. For example, <LINK REF="STD-Coons-1962" TYPE="STUDY">Coons 1962</LINK> reported that 79% of participants had schizophrenia, and <LINK REF="STD-Marjerrison-1964" TYPE="STUDY">Marjerrison 1964</LINK> and <LINK REF="STD-Denber-1972" TYPE="STUDY">Denber 1972</LINK> that over 80% of included people suffered from schizophrenia. <LINK REF="STD-Rubin-1971" TYPE="STUDY">Rubin 1971</LINK> included one person with manic-depressive disorder and <LINK REF="STD-Brauzer-1968" TYPE="STUDY">Brauzer 1968</LINK> included a single person with chronic brain syndrome with psychoses. <LINK REF="STD-Andersen-1974" TYPE="STUDY">Andersen 1974</LINK> randomised 40 people with schizophrenia or "paranoid syndrome" and the participants in <LINK REF="STD-O_x0027_Brien-1974" TYPE="STUDY">O'Brien 1974</LINK> were 30 people with hostility, suspiciousness, paranoia and aggressiveness. </P>
<P>Only nine studies described the diagnostic criteria used; the remainder appeared to have made a clinical diagnosis without the use of operational criteria. Many trials (n=30) involved only people with chronic illness, two during an acute exacerbation of this illness. Two studies involved people whose illness was designated as highly treatment resistant. The remainder included acutely ill people and first episode patients.</P>
<P>3.3 Setting <BR/>Most studies were conducted in inpatient settings. Only six trials included only people who were not in hospital. Most trial centres were in USA (30) or Canada (10). Five were in India, two in Australia, two in Europe (Sweden, UK) and one in Peru. </P>
<P>3.4 Interventions <BR/>The mean dose of trifluoperazine, based on the 25 studies which reported it, was about 28 mg/day (SD ~20 mg/day, median 26 mg/day) and the range, taken from 35 studies, was 4 to 100 mg/day. Three studies used intramuscular trifluoperazine (<LINK REF="STD-Brauzer-1968" TYPE="STUDY">Brauzer 1968</LINK>, <LINK REF="STD-Gallant-1968-II" TYPE="STUDY">Gallant 1968 II</LINK>, <LINK REF="STD-Perales-1974" TYPE="STUDY">Perales 1974</LINK>).</P>
<P>Eleven studies employed a separate placebo arm. Forty-nine studies compared trifluoperazine with oral typical antipsychotics (for comparison compounds and their frequency of use please see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). For the purposes of this review, loxapine and molindone are considered as typical drugs. Only <LINK REF="STD-Edwards-1980" TYPE="STUDY">Edwards 1980</LINK> compared trifluoperazine to an atypical antipsychotic (sulpiride). Twenty-four studies stated they used other medications to alleviate adverse effects or problematic behaviour as required. These drugs included benztropine mesylate, biperiden, trihexphenidyl, chloral hydrate, metyprylon, phenobarbital, chlorpromazine, thioridazine, and short action sedatives. <LINK REF="STD-Rubin-1971" TYPE="STUDY">Rubin 1971</LINK> reported that some patients received psychotherapy in addition to medication.</P>
<P>3.5 Outcomes <BR/>Most outcomes were reported as dichotomous (yes-no/binary outcomes), and are presented as such. Scale derived data was usually categorical and therefore easily dichotomised. Four studies used the Clinical Global Impression (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) and reported categorical data. Another 27 studies, undertaken before 1976, used comparable data to report global ratings of improvement. Thirty five studies used the Brief Psychiatric Rating Scale (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) and 17 employed the Nurses Observational Scale of Inpatients Evaluation (NOSIE, <LINK REF="REF-Honingfeld-1965" TYPE="REFERENCE">Honingfeld 1965</LINK>) but these data were either impossible to extract from graphs or so incomplete as to render them unusable. <LINK REF="STD-Menon-1972" TYPE="STUDY">Menon 1972</LINK> reported dichotomous global state data on the Wings rating Scale. <LINK REF="STD-_x002a_Doongaji-1989" TYPE="STUDY">*Doongaji 1989</LINK> provided continuous data on mean daily dose of an antiparkinson agent but information collected on adverse events and side effects was not standardised.</P>
<P>3.5.1 Scales </P>
<P>3.5.1.1 Global State <BR/>Clinical Global Impression - CGI (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) <BR/>CGI is a rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. A seven-point scoring system is usually used, with low scores indicating decreased severity and/or greater recovery. In this review, absence of clinical improvement was considered to be when patients had moderate, slight or no improvement. <BR/>
<B>
<BR/>
</B>3.5.1.2 Mental state<BR/>Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) <BR/>A brief rating scale used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The original scale has 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven-point scale varying from 'not present' to 'extremely severe', scoring from 0-6 or 1-7. Scores can range from 0-126, with high scores indicating more severe symptoms. </P>
<P>3.5.1.3 Behaviour <BR/>Nurses Observational Scale of Inpatients Evaluation - NOSIE (<LINK REF="REF-Honingfeld-1965" TYPE="REFERENCE">Honingfeld 1965</LINK>). <BR/>An 80-item scale which ranks items from 0-4 (0=never present). Ratings are taken from behaviour over the previous three days. The seven headings are: social competence, social interest, personal neatness, co-operation, irritability, manifest psychosis and finally, psychotic depression. Scoring ranges from 0-320. </P>
<P>Wing Behaviour Rating Scale (<LINK REF="REF-Wing-1961" TYPE="REFERENCE">Wing 1961</LINK>)<BR/>This scale consists of two parts. The first rates four typical symptoms of schizophrenic mental state, based on a brief psychiatric interview, on a 5-point scale. The second is a 12-item behavioural schedule that rates on a three-point scale. The more acute the patient's condition, the higher <BR/>the score on the scale.</P>
<P>3.5.1.4 Adverse events <BR/>Treatment Emergent Symptoms Scale - TESS (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) <BR/>This side effect tool is a checklist where the degree and severity of an adverse event is recorded. The TESS records the presence or absence of a list of side effects. </P>
<P>3.5.2 Missing outcomes<BR/>No study reported on negative symptoms, neither were there usable cognitive outcomes. Death, suicide or self-harm were not mentioned in any of the trials. Only one included study attempted to quantify levels of satisfaction or quality of life (<LINK REF="STD-Malik-1980" TYPE="STUDY">Malik 1980</LINK>) and no trial attempted to any direct economic evaluation of trifluoperazine.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>1. Randomisation <BR/>Only four studies described the method used to generate random allocation (<LINK REF="STD-Clark-1975" TYPE="STUDY">Clark 1975</LINK>, <LINK REF="STD-Edwards-1980" TYPE="STUDY">Edwards 1980</LINK>, <LINK REF="STD-Perales-1974" TYPE="STUDY">Perales 1974</LINK>, <LINK REF="STD-_x002a_Pinard-1972" TYPE="STUDY">*Pinard 1972</LINK>). All used tables of random numbers. Eleven trials reported that allocation was undertaken independently (<LINK REF="STD-Angus-1969" TYPE="STUDY">Angus 1969</LINK>, <LINK REF="STD-Clark-1975" TYPE="STUDY">Clark 1975</LINK>, <LINK REF="STD-Coons-1962" TYPE="STUDY">Coons 1962</LINK>, <LINK REF="STD-Edwards-1980" TYPE="STUDY">Edwards 1980</LINK>, <LINK REF="STD-Needham-1969" TYPE="STUDY">Needham 1969</LINK>, <LINK REF="STD-O_x0027_Brien-1974" TYPE="STUDY">O'Brien 1974</LINK>, <LINK REF="STD-Perales-1974" TYPE="STUDY">Perales 1974</LINK>, <LINK REF="STD-Schiele-1969" TYPE="STUDY">Schiele 1969</LINK>, <LINK REF="STD-_x002a_Simpson-1971" TYPE="STUDY">*Simpson 1971</LINK>, <LINK REF="STD-Simpson-1976" TYPE="STUDY">Simpson 1976</LINK>). <LINK REF="STD-Coons-1962" TYPE="STUDY">Coons 1962</LINK> described a form of allocation concealment (sealed envelopes). <LINK REF="STD-Denber-1972" TYPE="STUDY">Denber 1972</LINK> and <LINK REF="STD-Sugerman-1965" TYPE="STUDY">Sugerman 1965</LINK> reported that the random code was unknown until the end of study. For the other studies little assurance was given that bias was minimised during the allocation procedure. Twenty-six studies reported that the numbers allocated to each treatment group were identical, without reporting the use of block randomisation. When allocating by chance this is improbable.</P>
<P>2. Blinding <BR/>Thirty-six of the fifty included trials described precautions taken to make the investigation blind (identical capsules). Two studies (<LINK REF="STD-Gallant-1968-II" TYPE="STUDY">Gallant 1968 II</LINK>, <LINK REF="STD-Gallant-1972" TYPE="STUDY">Gallant 1972</LINK>) gave no indication that blinding had been attempted. <LINK REF="STD-Menon-1972" TYPE="STUDY">Menon 1972</LINK> reported that only research workers were blind. The remaining eleven trials indicated that an attempt at blinding had been made, but they gave no description of how this had been undertaken. </P>
<P>3. Loss to follow-up <BR/>Thirty-two studies gave data on loss to follow-up and 15 reported a full breakdown of the reasons for leaving the study.</P>
<P>4. Data reporting<BR/>This was generally poor. Overall very little of the data from the fifty included trials was usable. Continuous data were particularly problematic. The most common reason for exclusion was lack of standard deviations and/or failure to give any information about outcomes at all. Many studies also presented findings in graphs, in percentiles or by inexact p-values. 'P'-values are commonly used as a measure of association between intervention and outcomes instead of showing the strength of the association. We were unable to carry out an intention to treat analysis in some studies because the data on leaving the study early were not provided or were not fully or not clearly reported. These studies were preceded by a '*'.</P>
<P>5. Overall quality <BR/>Only studies allocated to Category A or B according to the Cochrane Handbook criteria were included in this review. As only twelve studies could be allocated to Category A, the data from the remaining 38 studies must be considered to be prone to a moderate degree of bias.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>1. The search <BR/>The Cochrane Schizophrenia Group's Register (March 2002- BIOSIS, CINAHL, Dissertation abstracts, EMBASE, LILACS, MEDLINE, PSYNDEX, PsycINFO, RUSSMED, Sociofile, supplemented with hand searching of relevant journals and numerous conference proceedings) provided 124 records. Of these, after removal of duplicates, 99 were obtained as full publications. A further 25 were acquired after hand searching the references, but only two of the latter could be included. Contacting authors of included studies has not yielded further studies. To date, contacting the relevant drug company (GlaxoSmithkline) has not led to further usable data. Fifty eight publications were sufficiently close to the review's inclusion criteria but had to be excluded (see Excluded Studies table). Twenty three papers or studies still await assessment. </P>
<P>2. COMPARISON 1. TRIFLUOPERAZINE versus PLACEBO<BR/>A total of 1162 patients from 13 studies were randomised to this comparison. </P>
<P>2.1 Global state <BR/>Studies presented data on global impression in several ways. Three small short-term studies (three months or less) favoured trifluoperazine (n=95, RR not substantially improved 0.62 CI 0.49 to 0.78, NNT 3 CI 2 to 4). At six months, three other studies tended to favour trifluoperazine (n=320, RR not substantially improved 0.93 CI 0.86 to 1.0). When all information was pooled, heterogeneous data (p=0.0002, I<SUP>2</SUP> 79%) favoured trifluoperazine (n=415, RR not substantially improved 0.79 CI 0.67 to 0.94, NNT 6.5 CI 5 to 10). </P>
<P>
<LINK REF="STD-Clark-1975" TYPE="STUDY">Clark 1975</LINK> compared ratings by nurses and doctors for this outcome. This small study (n=27) found no significant differences, although doctors did tend to rate the experimental group more favourably. <LINK REF="STD-Prien-1969" TYPE="STUDY">Prien 1969</LINK> evaluated different doses of trifluoperazine compared with placebo and found no clear differences in response.</P>
<P>One study provided data on whether or not patients were discharged from hospital (<LINK REF="STD-Prien-1969" TYPE="STUDY">Prien 1969</LINK>). Most people were in hospital throughout this study and treatment with either high or low dose trifluoperazine made little difference (n=240, RR not discharged on low dose trifluoperazine 0.98 CI 0.96 to 1.01). <BR/>
<B>
<BR/>
</B>Two trials reported on 'use of additional antipsychotics/sedatives'. There was no clear difference between trifluoperazine and placebo (n=77, 2 RCTs, RR 1.07 CI 0.18 to 6.31).</P>
<P>2.2 Mental state<BR/>Only <LINK REF="STD-Reardon-1966" TYPE="STUDY">Reardon 1966</LINK> (n=23) directly reported mental state outcomes. Delusions and hallucinations were a little less prevalent for people given trifluoperazine (RR 0.44 CI 0.19 to 0.99, NNT 3 CI 5 to 100).</P>
<P>2.3 Behaviour<BR/>Only one small study reported overall impression of effects on behaviour (<LINK REF="STD-Menon-1972" TYPE="STUDY">Menon 1972</LINK>). Dichotomised data from the Wings Behaviour Rating Scale favoured trifluoperazine (n=40, RR 0.4 CI 0.23 to 0.68). Another small study reported data on whether a person was agitated (<LINK REF="STD-Gwynne-1962" TYPE="STUDY">Gwynne 1962</LINK>, n=52). Trifluoperazine did not seem to have much advantage over placebo (RR agitation 1.0 CI 0.22 to 4.51).</P>
<P>2.4 Leaving the study early <BR/>There was no significant difference between trifluoperazine and placebo for the outcome 'leaving for any reason' (n=280, 7 RCTs, RR 0.99 CI 0.62 to 1.57). Nearly thirteen percent of the trifluoperazine group left early compared to 11.6% of people allocated to placebo. When different reasons for leaving early the study were analysed separately, this result did not change.<BR/>
<BR/>2.5 Adverse events <BR/>When studies reported on the non-specific outcome of 'any adverse event', trifluoperazine was no more likely to cause this than placebo (n=77, 2 RCTs, RR 1.4 CI 0.90 to 2.18). Most adverse event data comes from one or two small studies and selective reporting could be an issue. Cardiovascular problems such as minor ECG abnormalities (~40% of participants in the one study that recorded them, <LINK REF="STD-Clark-1975" TYPE="STUDY">Clark 1975</LINK>) and hypertension were equally common in the trifluoperazine and placebo groups. </P>
<P>Trifluoperazine may well cause more extrapyramidal events than placebo (n=70, 2 RCTs, RR any moment disorder 2.27 CI 1.19 to 4.33, NNH 4 CI 2 to 23) and more people in the trifluoperazine group used antiparkinson drugs to alleviate movements disorders (n=195, 4 RCTs, RR 5.06 CI 2.49 to 10.27, NNH 4 CI 2 to 9). Other studies reported on more specific movement disorders such as oculogyric crisis (n=27, 1 RCT, RR oculogyric crisis 3.71 CI 0.47 to 29.06) and akathisia but were too underpowered to highlight a real difference. Most results, however, did suggest that trifluoperazine does tend to cause a full spectrum of movement disorders.</P>
<P>Only one study reported haematological outcomes (<LINK REF="STD-Clark-1975" TYPE="STUDY">Clark 1975</LINK>, n=27). Such disorders were rare and trifluoperazine did not seem implicated. </P>
<P>
<LINK REF="STD-Gwynne-1962" TYPE="STUDY">Gwynne 1962</LINK> (n=52) reported neurological outcomes and trifluoperazine did not clearly cause convulsions (RR 0.50 CI 0.10 to 2.50), or faintness (RR 0.67 CI 0.12 to 3.67). Trifluoperazine may, however, be sedating (n=119, 3 RCTs, RR 2.94 CI 1.42 to 6.10, NNH 4 CI 2 to 18).</P>
<P>More people given trifluoperazine lost weight (7/14) than gained it (4/14) but neither effect was statistically significant (<LINK REF="STD-Clark-1975" TYPE="STUDY">Clark 1975</LINK>). Trifluoperazine may cause more blurred vision than placebo (n=119, 3 RCTs, RR 1.72 CI 0.47 to 6.26). </P>
<P>3. COMPARISON 2. TRIFLUOPERAZINE versus TYPICAL ANTIPSYCHOTIC <BR/>This comparison includes 2230 people from 49 studies. </P>
<P>3.1 Global state <BR/>In terms of the outcome of 'no substantial improvement', trifluoperazine was not clearly different than other older generation drugs (n=1016, 27 RCTs, RR 1.06 CI 0.98 to 1.14). This applies to the short term (n=816, 21 RCTs, RR 1.04 CI 0.94 to 1.15), medium term (n=175, 5 RCTs, RR 1.07 CI 0.93 to 1.24), and to the one long term trial (n=25, RR 1.09 CI 0.92 to 1.29). </P>
<P>Acutely ill people responded similarly (n=351, 10 RCTs, RR 1.03 CI 0.84 to 1.27) to those with a more chronic illness (n=482, 13 RCTs, RR 1.06 CI 0.97 to 1.15). Involving people with mixed diagnoses, such as those with affective disorders, did not effect the outcome of 'no substantial improvement' (n=115, 4 RCTs RR 1.11 CI 0.8 to 1.53). </P>
<P>Three studies, dating from the 1970's, do not suggest that trifluoperazine has any clear advantage over other drugs for the outcome of discharge from hospital (n=121, RR 1.10 CI 0.82 to 1.47). In these trials about 40% of participants were still in hospital by one year follow up. </P>
<P>Trifluoperazine was no better than other drugs in avoiding the need for additional sedation (n=78, 3 RCTs, RR 0.79 CI 0.33 to 1.91).</P>
<P>3.2 Mental state<BR/>One small study (<LINK REF="STD-Reardon-1966" TYPE="STUDY">Reardon 1966</LINK>) specifically reported whether hallucinations and delusions were present in participants. Most people in both the trifluoperazine and chlorpromazine group did not complain of these key psychotic symptoms (n=22, RR delusions or hallucinations 1.33 CI 0.39 to 4.62). Several other less specific aspects of mental state were reported. Compared with other older generation drugs, trifluoperazine was not clearly better in reducing anxiety, depression or excitement. </P>
<P>3.3 Behaviour<BR/>One study reported general effects on behaviour (<LINK REF="STD-Menon-1972" TYPE="STUDY">Menon 1972</LINK>, n=40). Compared with trifluperidol, trifluoperazine was not clearly advantageous (RR no behavioural improvement 1.00 CI 0.47 to 2.14). Similar findings were reported for specific aspects of behaviour such as lethargy and aggression. </P>
<P>3.4 Leaving the study early <BR/>Twenty-two short-term studies (n=930) found no clear differences between trifluoperazine and other typical antipsychotics for the outcome 'leaving for any reason' (RR 1.15 CI 0.83 to 1.58). This held true for the nine medium term studies (n=345, RR 1.8 CI 0.99 to 3.27) and the one long term trial (<LINK REF="STD-Donlon-1978" TYPE="STUDY">Donlon 1978</LINK>, n=25, RR 0.18 CI 0.03 to 1.36). For the more specific outcome of leaving due to adverse effects, trifluoperazine was no more toxic than other older generation drugs, with very few people leaving for this reason (n=320, 8 RCTs, RR leaving due to adverse effects 1.24 CI 0.49 to 3.11). Leaving due to relapse was similar (n=431, 13 RCTs, RR leaving due to relapse 1.31 CI 0.72 to 2.38) as was leaving due to treatment refusal (n=110, 3 RCTs, RR leaving due to treatment refusal 0.83 CI 0.27 to 2.50).</P>
<P>3.5 Adverse events <BR/>A huge number of adverse events were listed in many different ways. There were no statistically differences between trifluoperazine and other drugs for all comparisons. Almost identical numbers of people reported at least one adverse event (~60%) in each group (n=585, 14 RCTs, RR 0.99 CI 0.87 to 1.13).</P>
<P>We will not reiterate all adverse effects here but just highlight some of the most noteworthy. Trifluoperazine did not cause more blurred vision than other first generation drugs (n=606, 14 RCTs, RR 1.18 CI 0.91 to 1.55). It did tend to encourage considerable weight gain, but not quite to the conventional level of statistical significance (n=207, 5 RCTs, RR &gt;10lb weight gain 1.25 CI 0.92 to 1.71). Data with a moderate degree of inconsistency (I<SUP>2</SUP> 46%) did not suggest that trifluoperazine causes more unspecified movement disorders than other older generation drugs (n=485, 12 RCTs, RR 1.11 CI 0.87 to 1.43). Similarly heterogeneous data (I<SUP>2</SUP> 56%) did not suggest that using trifluoperazine results in more need for anticholinergic drugs than typical antipsychotics (n=707, 19 RCTs, RR 1.04 CI 0.87 to 1.24). Trifluoperazine does not seem to cause any more akathisia (n=719, 18 RCTs, RR 0.91 CI 0.70 to 1.17), dystonia (n=520, 13 RCTs, RR 1.09 CI 0.72 to 1.65) or tremor (n=612, 13 RCTs, RR 0.92 CI 0.75 to 1.12) than other old antipsychotics. </P>
<P>We carried out subgroup analyses in some comparisons where heterogeneity was detected. Drugs used in the control group were pooled according their potency for blocking dopamine receptors. Trifluoperazine was more likely to cause extrapyramidal adverse effects overall when compared to the low potency group (n=130, 3 RCTs, RR 1.66 CI 1.03 to 2.67, NNH 6 CI 3 to 121) and there was no difference in the high potency group (n=355, 9 RCTs, RR 1.02 CI 0.78 to 1.34), but heterogeneity remained for this subgroup (p=0.047, I<SUP>2</SUP> 46%). The same pattern was apparent for the high versus low potency comparison sub-groups for the outcome of rigidity and use of antiparkinsonian drugs. Finally for this sub-group analysis, data from the high potency control group was pooled excluding loxapine because of its different extrapyramidal profile (<LINK REF="REF-Fenton-2002" TYPE="REFERENCE">Fenton 2002</LINK>) but this made little difference (n=225, 5 RCTs, RR extrapyramidal effects 1.15 CI 0.91 to 1.46).</P>
<P>Trifluoperazine did not cause more nausea (n=457, 11 RCTs, RR 0.82 CI 0.51 to 1.32), or drowsiness (n=816, 20 RCTs, RR 0.89 CI 0.72 to 1.10) than the comparison drugs</P>
<P>3.6 Patient's preference<BR/>One small study (<LINK REF="STD-Malik-1980" TYPE="STUDY">Malik 1980</LINK>, n=54) asked patients if they preferred one medication over the other. 50-60% in each group did express a preference for the other medication.</P>
<P>4. COMPARISON 3. TRIFLUOPERAZINE versus ATYPICAL ANTIPSYCHOTIC <BR/>Only one study compared trifluoperazine with atypical antipsychotics (sulpiride) in a six-week trial <LINK REF="STD-Edwards-1980" TYPE="STUDY">Edwards 1980</LINK> (n=38).</P>
<P>4.1 Global state <BR/>Raters using the Clinical Global Impression scale, found no difference between the drugs in terms of global state (RR no substantial improvement 0.89 CI 0.44 to 1.81). This also applied to the outcomes of 'severely ill or worse' (RR 1.00 CI 0.43 to 2.3) and use of additional sedatives (RR 2.00 CI 0.58 to 6.85).</P>
<P>4.2 Mental state<BR/>The small study did not find any effects of trifluoperazine on emotional state (RR lability 0.14 CI 0.01 to 2.59, RR euphoria 0.33 CI 0.04 to 2.93).</P>
<P>4.3 Leaving the study early <BR/>Very few people left the study. One patient left each group because of worsening symptoms and another person allocated to sulpiride left the hospital (differences not significant).</P>
<P>4.4 Behaviour<BR/>Less people given trifluoperazine were agitated compared with those in the sulpiride group (0 vs 4) but this was not statistically significant as confidence intervals were wide (RR 0.11 CI 0.01 to 1.93).</P>
<P>4.5 Adverse events<BR/>We have roughly grouped adverse events into movement disorders and others. <LINK REF="STD-Edwards-1980" TYPE="STUDY">Edwards 1980</LINK> involved only 38 people so any statistically significant differences would be surprising. None were found, although in keeping with the findings from the trifluoperazine versus placebo comparison it seems that the older drug is more prone to cause problems with movement. </P>
<P>5. Publication bias <BR/>We used funnel plots to investigate the possibility of publication bias (see Methods). No asymmetry was detected but many of the outcomes had a small number of trials which limits the value of the plot. Such plots are not powerful investigative tools and are further weakened when there is little variation in study size (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).<BR/>
<BR/>6. Statistical model for measuring effect <BR/>The findings noted above were not changed by using odds ratios or by using a fixed effects model for relative risk.</P>
<P>7. Sensitivity analyses<BR/>We had hoped to undertake a sensitivity analysis for intention-to-treat analyses versus completer-only analyses when heterogeneity was present. This is not complete and will be presented in the updates of this review.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>1. Applicability<BR/>The 50 included studies involved many people who would be recognisable in everyday medical practice. Only two studies (<LINK REF="STD-Bagadia-1980" TYPE="STUDY">Bagadia 1980</LINK>, <LINK REF="STD-Malik-1980" TYPE="STUDY">Malik 1980</LINK>) focused on adolescents and none on childhood or old age. These trials presented similar results to those including other scopes of participants. In most of the studies the diagnosis was clinical and only a few operational criteria were used. People with schizophrenia who also had any kind of comorbidity such as alcoholism or kidney insufficiency were, however, frequently excluded in original studies and most studies were undertaken in hospital. Applying findings to people with additional health problems and in community settings could be problematic. Overall the daily doses of trifluoperazine were probably a little higher than would be seen in everyday practice (mean 28mg/day, SD 20) but do fit with American Psychiatric Association recommendations (<LINK REF="REF-APA-1997" TYPE="REFERENCE">APA 1997</LINK>). </P>
<P>2. Limitations and strengths<BR/>The main limitation of this review is that it includes a large number of small studies from many years ago. Valuable additional information could not be obtained as it proved impossible to contact many authors. We were unable to carry out an intention to treat analysis in some studies because the data on leaving the study early were not provided or were not fully or not clearly reported. Despite the fact that most of the included trials predate the CONSORT statement (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>, <LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>) which encourages high standards of trial reporting, twelve trials did receive a quality rating of 'A' (good) and all remaining studies were rated 'B' (medium). This review is the most current and comprehensive synthesis of these data for a widely used antipsychotic.</P>
<P>3. COMPARISON 1. TRIFLUOPERAZINE versus PLACEBO<BR/>With 1162 people involved in this comparison, these data must represent one of the most powerful placebo comparisons in the whole of antipsychotic research. </P>
<P>3.1 Global state<BR/>These old placebo-controlled studies could probably not be repeated now. Although they are dogged with inconsistency in terms of the choice of measures used for similar outcomes, their results do indicate that the number of people needed to be given trifluoperazine in order for one person to improve to an important extent in the medium term is about six. In this respect trifluoperazine is similar to other older generation antipsychotic drugs (<LINK REF="REF-Joy-2001" TYPE="REFERENCE">Joy 2001</LINK>, <LINK REF="REF-Thornley-2001" TYPE="REFERENCE">Thornley 2001</LINK>). </P>
<P>Most of the included studies were undertaken in hospital and were carried out at a time when community care was less prevalent. However, in health systems where hospital care still dominates, it may be relevant that the use of trifluoperazine, at any dose, did not make clear differences in the rate of discharge (though it should be noted that 56% of patients in the study from which these findings are derived had been in hospital for more than ten years). Oddly, being allocated to trifluoperazine did not decrease the risk of needing additional antipsychotics/sedatives. Perhaps this was because the populations in the two studies (total n=77) were not very disturbed or that placebo is also calming.</P>
<P>3.2 Mental state<BR/>In such a large review, with thousands of patients included, only a single small study (n=23, <LINK REF="STD-Reardon-1966" TYPE="STUDY">Reardon 1966</LINK>) directly reported mental state outcomes. Even within a study of such low power, trifluoperazine did seem to be effective and delusions and hallucinations were decreased (NNT 3 CI 5 to 100). Ideally, of course, this finding should be replicated in order to increase the confidence in the result. </P>
<P>3.3 Behaviour<BR/>Again, as for mental state outcomes, too few studies with too few participants reported on this for any firm conclusions to be taken from the data. <LINK REF="STD-Menon-1972" TYPE="STUDY">Menon 1972</LINK> (n=40) favoured trifluoperazine but <LINK REF="STD-Gwynne-1962" TYPE="STUDY">Gwynne 1962</LINK> (n=52) found no clear differences between trifluoperazine and placebo. </P>
<P>3.4 Leaving the study early <BR/>Considerably fewer people left these studies early than is common in modern studies where attrition of 40-50% is common (<LINK REF="REF-Duggan-2002" TYPE="REFERENCE">Duggan 2002</LINK>, <LINK REF="REF-Srisurapanont-2002" TYPE="REFERENCE">Srisurapanont 2002</LINK>). This could well be due to the different research climate of three decades ago rather than some advantageous aspect of study design. Nevertheless, the latter is also possible and it could be that modern researchers have lost skills or been so constrained by regulations that design has suffered and so have those likely to benefit from the research. In seven studies (total n=280) trifluoperazine was as acceptable as placebo. It can be concluded that in the climate in which these studies were undertaken, adverse effects were not an obstacle to compliance with study protocol.<BR/>
<BR/>3.5 Adverse events <BR/>It is difficult to interpret some of the adverse effect data. Often a single study reported on an effect that was attributed to trifluoperazine and reporting biases could well be in operation. However, the more consistently reported findings do fit with clinical impression. Trifluoperazine may well cause more extrapyramidal events than placebo (n=70, 2 RCTs, NN to cause any moment disorder 4 CI 2 to 23) and more people in the trifluoperazine group used antiparkinson drugs to alleviate movement disorders (n=195, 4 RCTs, NNH 4 CI 2 to 9). It is likely that trifluoperazine may be sedating (n=119, 3 RCTs, NNH 4 CI 2 to 18) and cause anticholinergic effects (n=119, 3 RCTs, RR blurred vision 1.72 CI 0.47 to 6.26). </P>
<P>4. TRIFLUOPERAZINE versus TYPICAL ANTIPSYCHOTIC <BR/>This comparison includes over 2000 people (49 RCTs) and so is one of the largest in the evaluation of the care of people with schizophrenia.</P>
<P>4.1 Global state <BR/>Analyses of various measures of global state consistently failed to find clear differences between trifluoperazine and other typical antipsychotics (n=1016, 27 RCTs, RR 1.06 CI 0.98 to 1.14) and splitting the data by chronic illness versus non-chronic, mixed diagnoses versus only people with 'pure' schizophrenia did not materially change the results. Trifluoperazine is as effective as other older generation drugs but there are no data to support its reputed 'activating effects' at low doses.</P>
<P>4.2 Mental state<BR/>Considering the amount of data for other outcomes, it is surprising that so few have been collected on direct mental state symptoms such as delusions and hallucinations. <LINK REF="STD-Reardon-1966" TYPE="STUDY">Reardon 1966</LINK> (n=22) did record mental state outcomes but the results are too imprecise for conclusions to be drawn. Even after over 40 years of research based on randomised studies, clinicians and recipients of care have to continue to be unsure of the direct effects on delusions and hallucinations of trifluoperazine compared with other similar drugs. </P>
<P>4.3 Behaviour<BR/>Behavioural improvement was also a rare outcome (<LINK REF="STD-Menon-1972" TYPE="STUDY">Menon 1972</LINK>, n=40) so results are imprecise and not clearly different from those of trifluperidol. </P>
<P>4.4 Leaving the study early <BR/>Taking trifluoperazine is as acceptable as other typical antipsychotics for people with schizophrenia (14% attrition vs 11%) and, because of the relatively large numbers of people involved, we can be fairly certain of these results (short term n=930, medium term n=345). When data were reported with reasons for attrition specified, once more trifluoperazine is no different in terms of leaving the study because of adverse effects, relapse or due to due to treatment refusal. Again, because the numbers of people in these outcomes is relatively large we can be confident of the findings. </P>
<P>4.5 Adverse events <BR/>Trifluoperazine does cause some kind of adverse effect in about 60% of people, but, according to the data from 14 trials (n=585) so do all other drugs of comparison. There was no difference between the typical antipsychotics and trifluoperazine for a whole series of adverse outcomes for which reasonable amounts of data were available (blurred vision n=606, weight gain n=207, unspecified movement disorders n=485, need for anticholinergic drugs n=707, akathisia n=719, dystonia n=520, or tremor n=612). Use of trifluoperazine carries with it a burden of adverse effects, but no more so than other similar drugs. </P>
<P>The sub-group analyses must be viewed with a degree of caution as all results are heterogeneous, but the findings do coincide with clinical impression. Trifluoperazine is more likely to cause extrapyramidal adverse effects, the need for additional anticholinergic drugs, and rigidity when compared to the low potency drugs such a chlorpromazine (n~130, 3 RCTs). This difference disappeared in comparisons with only high potency drugs such as haloperidol (n~355, 9 RCTs). It is a pity that more studies did not ask patients if they preferred a different medication. With the above results it would be expected that people with schizophrenia would prefer the low potency drugs. Only <LINK REF="STD-Malik-1980" TYPE="STUDY">Malik 1980</LINK> (n=54) asked patients if they preferred trifluoperazine to loxapine, an unusual low potency drug. There was no clear preference but with such small numbers the confidence in the final result is limited. </P>
<P>5. TRIFLUOPERAZINE versus SULPIRIDE (ATYPICAL DRUGS)<BR/>Only one study compared trifluoperazine with an atypical antipsychotic (<LINK REF="STD-Edwards-1980" TYPE="STUDY">Edwards 1980</LINK>, n=38, duration six weeks).</P>
<P>5.1 Global state, mental state, leaving the study early, and adverse effects<BR/>The precision of all findings is poor as numbers are small but, in terms of measures of global state, mental state, study attrition, and adverse effects trifluoperazine seems little different to sulpiride. </P>
<P>This seems a little implausible and the equivocal findings are probably due to imprecision in the reporting of results. It would be interesting to compare these findings with those of other atypical studies where benchmark drugs such as clozapine have been used, particularly because there is some controversy as to whether sulpiride is really an atypical drug (<LINK REF="REF-Soares-2002" TYPE="REFERENCE">Soares 2002</LINK>),</P>
<P>6. Publication bias <BR/>Even for the outcomes which many studies reported on, funnel plot analyses are limited in power, but it is heartening that no suggestion of small study-biases were found. Perhaps, as trifluoperazine is an old drug in which there is little current commercial interest, we have managed to identify all relevant trials.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>1. For people with schizophrenia<BR/>Trifluoperazine is an antipsychotic which is as effective as other commonly used typical drugs for treating schizophrenia and, in common with the other drugs, about 60% of people do experience an adverse effect. Whether to use trifluoperazine or another typical drug may, therefore, be a matter of personal preference, and there is some indication that trifluoperazine may cause more adverse effects than drugs such as chlorpromazine. </P>
<P>2. For clinicians <BR/>Although there are shortcomings and gaps in the data, there appears to be enough overall consistency over different outcomes and time scales to confirm that trifluoperazine is an antipsychotic of similar efficacy to other commonly used antipsychotics, such as chlorpromazine. The adverse effect profile of trifluoperazine seems similar to that of typical drugs overall, but, in common with haloperidol, it may have a higher level of extrapyramidal adverse events. The common claim that trifluoperazine is a particularly useful in the treatment of withdrawal patients is not based on trial derived evidence. </P>
<P>3. For managers, funders, decision makers <BR/>Trifluoperazine is inexpensive and is as effective as other typical antipsychotics. It might be an alternative when newer and more expensive antipsychotics are not readily available.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>1. General<BR/>All studies considerably preceded the CONSORT statement (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>, <LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>), so the quality of data reporting might be expected to be lower than at present, although some studies were very clearly presented. If data from past studies is still available, we would be most interested in hearing from the authors of trials. Future studies should rigorously apply the standards of reporting as outlined in CONSORT and also make all data freely available. Continuous data were particularly poorly reported and authors should present raw data rather than graphical format. </P>
<P>2. Specific <BR/>Trifluoperazine does seem comparable to other typical antipsychotics in terms of efficacy but most existing randomised studies are of short-term duration and were undertaken in hospital settings. Given the clinical dilemma as to whether to use trifluoperazine or, perhaps a drug such as chlorpromazine, there is still a need for more well designed, conducted and reported randomised studies of considerable duration undertaken in real world circumstances.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>LOM would like to thank Clive Adams, Nancy Owens, Mark Fenton, Gillian Rizzello, Shazia Akhtar (from the Cochrane Schizophrenia Group, UK) for their administrative help and support.</P>
<P>The reviewers sent many letters to authors, asking for extra information. Dr George Simpson (University of Southern California), Dr Charles O'Brien (University of Pennsylvania, School of Medicine), Dr Maryanne O'Donnell (in memoriam of Dr Leslie Kiloh; Prince of Wales Hospital, UK) and Dr Guy Edwards (Royal South Hants Hospital, UK) were kind enough to respond, for which we are very grateful.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Luciana de Oliveira Marques - wrote the protocol, carried out data extraction and analysis and wrote the review.</P>
<P>Bernardo Garcia de Oliveira Soares - wrote the protocol and participated in the analysis and writing of the review.</P>
<P>Maurício Silva de Lima - wrote the protocol, carried out the data extraction and helped to write the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-01-19 15:13:59 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-01-19 15:13:59 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-01-19 15:00:23 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-_x002a_Bankier-1973" NAME="*Bankier 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bankier RG</AU>
<TI>A comparison of fluspirilene and trifluoperazine in the treatment of acute schizophrenic psychosis</TI>
<SO>The Journal of Clinical Pharmacology and New Drugs</SO>
<YR>1973</YR>
<VL>13</VL>
<NO>1</NO>
<PG>44-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="73067018"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x002a_Doongaji-1989" MODIFIED="2009-01-19 14:45:41 +0000" MODIFIED_BY="[Empty name]" NAME="*Doongaji 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-01-19 14:45:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doongaji DR, Satoskar RS, Sheth AS, Apte JS, Desai AB, Shah BR</AU>
<TI>Centbutindole vs trifluoperazine: a double-blind controlled clinical study in acute schizophrenia</TI>
<SO>Journal of Postgraduate Medicine</SO>
<YR>1989</YR>
<VL>35</VL>
<NO>1</NO>
<PG>3-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x002a_Goldstein-1966" NAME="*Goldstein 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein BJ, Clyde DJ</AU>
<TI>Haloperidol in controlling the symptoms of acute psychoses. Part II: A double-blind evaluation of haloperidol and trifluoperazine</TI>
<SO>Current Therapeutic Research</SO>
<YR>1966</YR>
<VL>8</VL>
<NO>5</NO>
<PG>236-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="66127671"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x002a_Itil-1971" NAME="*Itil 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Itil TM, Polvan N, Ucok A, Eper E, Guven F, Hsu W</AU>
<TI>Comparison of the clinical and electroencephalographical effects of molindone and trifluoperazine in acute schizophrenic patients</TI>
<SO>Behavioral Neuropsychiatry</SO>
<YR>1971</YR>
<VL>3</VL>
<NO>5</NO>
<PG>25-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Itil TM, Polvan N, Ucok A, Eper E, Guven F, Hsu W</AU>
<TI>Comparison of the clinical and electroencephalographical effects of molindone and trifluoperazine in acute schizophrenic patients.</TI>
<SO>Behavioral Neuropsychiatry</SO>
<YR>1971</YR>
<VL>3</VL>
<NO>9</NO>
<PG>6-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="72234881"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x002a_Pinard-1972" NAME="*Pinard 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinard G, Prenoveau Y, Fliesen W, Elie R, Bielmann P, Lamontagne Y, Tetreault L</AU>
<TI>Pimozide: a comparative study in the treatment of chronic schizophrenic patients</TI>
<SO>International Journal of Clinical Pharmacology Therapy and Toxicology</SO>
<YR>1972</YR>
<VL>6</VL>
<NO>1</NO>
<PG>22-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x002a_Simpson-1971" MODIFIED="2009-01-19 14:55:27 +0000" MODIFIED_BY="[Empty name]" NAME="*Simpson 1971" YEAR="1971">
<REFERENCE MODIFIED="2009-01-19 14:55:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Amin M, Edwards G</AU>
<TI>A Double-blind comparison of molindone and trifluoperazine in the treatment of acute schizophrenia</TI>
<SO>The Journal of Clinical Pharmacology and New Drugs</SO>
<YR>1971</YR>
<VL>11</VL>
<PG>227-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x002a_Vestre-1970" NAME="*Vestre 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vestre ND, Schiele BC</AU>
<TI>Differential drug effects of the two phenothiazines. (A controlled comparison of thioridazine and trifluoperazine in chronic schizophrenics)</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1970</YR>
<VL>31</VL>
<NO>12</NO>
<PG>821-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="71101664"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amin-1977" MODIFIED="2009-01-19 14:56:02 +0000" MODIFIED_BY="[Empty name]" NAME="Amin 1977" YEAR="1977">
<REFERENCE MODIFIED="2009-01-19 14:56:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amin MM, Ban TA, Lehmann HE</AU>
<TI>A standard (trifluoperazine) controlled clinical study with pimozide in the maintenance treatment of schizophrenic patients</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1977</YR>
<VL>13</VL>
<NO>3</NO>
<PG>15-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andersen-1974" NAME="Andersen 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andersen K, D'Elia G, Hallberg B, Perris C, Rapp W, Roman G</AU>
<TI>The treatment of chronic schizophrenia. Preliminary results of a controlled comparison of pimozide (Orap) with trifluoperazine</TI>
<SO>Clinical Trials Journal</SO>
<YR>1971</YR>
<VL>8</VL>
<NO>2</NO>
<PG>72-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andersen K, d'Elia G, Hallberg B, Perris C, Rapp W, Roman G</AU>
<TI>A controlled trial of pimozide and trifluoperazine in chronic schizophrenic syndromes</TI>
<SO>Acta Psychiatr Scand Acta Psychiatr Scand</SO>
<YR>1974</YR>
<VL>249 supplement</VL>
<PG>43-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="75029588"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Angus-1969" NAME="Angus 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angus JW, Deutsch LJ, Edwards JG, Simpson GM</AU>
<TI>A double-blind comparison of the acridane derivative, clomacran phosphate and trifluoperazine in schizophrenia</TI>
<SO>Behavioral Neuropsychiatry</SO>
<YR>1969</YR>
<VL>1</VL>
<PG>13-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bagadia-1980" NAME="Bagadia 1980" YEAR="1980">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bagadia VN, Shah LP, Abhyankar RR</AU>
<TI>A double-blind controlled trial of loxapine and trifluoperazine in adolescent schizophrenia</TI>
<SO>Current Therapeutic Research Clinical &amp; Experimental</SO>
<YR>1980</YR>
<VL>27</VL>
<NO>6</NO>
<PG>886-896</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bankier-1968" NAME="Bankier 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bankier RG, Pettit DE, Bergen B</AU>
<TI>A comparative study of fluphenazine enanthate and trifluoperazine in chronic schizophrenic patients</TI>
<SO>Diseases of The Nervous System</SO>
<YR>1968</YR>
<VL>29</VL>
<NO>1</NO>
<PG>56-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bishop-1963" NAME="Bishop 1963" YEAR="1963">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bishop MP, Buddington RW, Robinson WG, Silva F</AU>
<TI>A comparison of SKF-7261 and trifluoperazine (Stelazine) in the treatment of chronic schizophrenic patients</TI>
<SO>Journal of Neuropsychiatry</SO>
<YR>1963</YR>
<VL>5</VL>
<PG>23-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bishop-1964" NAME="Bishop 1964" YEAR="1964">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bishop MP, Gallant DM, Nesselhof W, Sprehe DJ</AU>
<TI>A controlled evaluation of butaperazine in chronic schizophrenic patients</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1964</YR>
<VL>25</VL>
<PG>674-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bishop-1966" NAME="Bishop 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bishop MP, Fulmer TE, Gallant DM</AU>
<TI>Thiothixene versus trifluoperazine in newly-admitted schizophrenic patients</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1966</YR>
<VL>8</VL>
<NO>11</NO>
<PG>509-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bishop-1967" NAME="Bishop 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bishop M, Gallant D</AU>
<TI>A controlled study of SKF 14336 in acute schizophrenia</TI>
<SO>Journal of Clinical Pharmacology and the Journal of New Drugs</SO>
<YR>1967</YR>
<VL>7</VL>
<NO>6</NO>
<PG>342-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bishop-1970" NAME="Bishop 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bishop MP, Gallant DM</AU>
<TI>Loxapine: a controlled evaluation in chronic schizophrenic patients</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1970</YR>
<VL>12</VL>
<NO>9</NO>
<PG>594-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brauzer-1968" NAME="Brauzer 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brauzer B, Goldstein BJ</AU>
<TI>Comparative effects of intramuscular thiothixene and trifluoperazine in psychotic patients</TI>
<SO>The Journal of Clinical Pharmacology and New Drugs</SO>
<YR>1968</YR>
<VL>8</VL>
<NO>6</NO>
<PG>400-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="69087651"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brauzer-1971" NAME="Brauzer 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brauzer B, Goldstein BJ</AU>
<TI>A clinical comparison of molindone hydrochloride with trifluoperazine in psychotic outpatients</TI>
<SO>Current Therapeutic Research</SO>
<YR>1971</YR>
<VL>13</VL>
<NO>3</NO>
<PG>152-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Claghorn-1974" NAME="Claghorn 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Claghorn JL</AU>
<TI>A double-blind comparison of pimozide vs. trifluoperazine in schizophrenic outpatients</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1974</YR>
<VL>16</VL>
<NO>9</NO>
<PG>1005-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="75038229"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clark-1975" NAME="Clark 1975" YEAR="1975">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Clark ML, Paredes A, Costiloe JP, Wood F, Barrett A</AU>
<TI>Loxapine in newly admitted chronic schizophrenic patients</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1975</YR>
<VL>15</VL>
<NO>4 Pt 1</NO>
<PG>286-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coons-1962" NAME="Coons 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coons WH, Boyd BA, White JG</AU>
<TI>Chlorpromazine, trifluoperazine and placebo with long-term mental hospital patients</TI>
<SO>Canadian Psychiatric Association Journal</SO>
<YR>1962</YR>
<VL>7</VL>
<PG>159-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Denber-1972" NAME="Denber 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Denber HC, Turns D</AU>
<TI>Double blind comparison of thiothixene and trifluoperazine in acute schizophrenia</TI>
<SO>Psychosomatics</SO>
<YR>1972</YR>
<VL>13</VL>
<NO>2</NO>
<PG>100-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="74300368"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donlon-1978" MODIFIED="2009-01-19 14:59:42 +0000" MODIFIED_BY="[Empty name]" NAME="Donlon 1978" YEAR="1978">
<REFERENCE MODIFIED="2009-01-19 14:59:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donlon PT, Meyer JE</AU>
<TI>A twelve month comparison of penfluridol and trifluoperazine in chronic schizophrenic outpatients</TI>
<SO>Journal of Clinical Psychiatry Journal of Clinical Psychiatry</SO>
<YR>1978</YR>
<VL>39</VL>
<NO>6</NO>
<PG>582-3, 586-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edwards-1980" NAME="Edwards 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edwards JG, Alexander JR, Alexander MS, Gordon A, Zutchi T</AU>
<TI>Controlled trial of sulpiride in chronic schizophrenic patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>137</VL>
<PG>522-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="81161746"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freeman-1968" NAME="Freeman 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freeman H, Oktem N, Oktem MR</AU>
<TI>A double-blind study of SKF 14336 vs. trifluoperazine in schizophrenic patients</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1968</YR>
<VL>10</VL>
<NO>10</NO>
<PG>537-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="69007477"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallant-1968" NAME="Gallant 1968" YEAR="1968">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gallant DM, Bishop MP</AU>
<TI>Molindone: a controlled evaluation in chronic schizophrenic patients</TI>
<SO>Current Therapeutic Research Clinical &amp; Experimental</SO>
<YR>1968</YR>
<VL>10</VL>
<NO>9</NO>
<PG>441-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallant-1968-II" NAME="Gallant 1968 II" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallant DM, Bishop MP, Bishop G, Steele CA</AU>
<TI>Thiothixene: a controlled evaluation of the intramuscular antipsychotic preparation</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1968</YR>
<VL>10</VL>
<NO>11</NO>
<PG>561-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="69089379"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallant-1972" NAME="Gallant 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallant DM, Bishop MP, Guerrero-Figueroa R</AU>
<TI>GP-45795: a controlled evaluation in chronic schizophrenic patients</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1972</YR>
<VL>14</VL>
<NO>4</NO>
<PG>215-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="72182265"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gross-1974" NAME="Gross 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gross HS</AU>
<TI>A double-blind comparison of once-a-day pimozide, trifluoperazine and placebo in the maintenance care of chronic schizophrenic outpatients</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1974</YR>
<VL>16</VL>
<NO>7</NO>
<PG>696-705</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="74276721"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gwynne-1962" NAME="Gwynne 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gwynne PH, Hundziak M, Kavtschitsch J, Lefton M, Pasamanick B</AU>
<TI>Efficacy of trifluoperazine on withdrawal in chronic schizophrenia</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1962</YR>
<VL>134</VL>
<PG>451-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kiloh-1976" NAME="Kiloh 1976" YEAR="1976">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kiloh LG, Williams P, Grant DA, Whetton PS</AU>
<TI>A double-blind comparative trial of loxapine and trifluoperazine in acute and chronic schizophrenic patients</TI>
<SO>Journal of International Medical Research</SO>
<YR>1976</YR>
<VL>4</VL>
<NO>6</NO>
<PG>441-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malik-1980" NAME="Malik 1980" YEAR="1980">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Malik SC, Kumar K</AU>
<TI>Loxapine in adolescent schizophrenia- a comparative study with trifluoperazine</TI>
<SO>Current Therapeutic Research Clinical &amp; Experimental</SO>
<YR>1980</YR>
<VL>28</VL>
<NO>3</NO>
<PG>432-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marjerrison-1964" NAME="Marjerrison 1964" YEAR="1964">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marjerrison G, Irvine D, Stewart CN, Williams R, Matheu H, Demay M</AU>
<TI>Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients</TI>
<SO>Canadian Psychiatric Association Journal</SO>
<YR>1964</YR>
<VL>60</VL>
<PG>290-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marjerrison-1966" NAME="Marjerrison 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marjerrison G, Hrychuk W, Varsanyi EL</AU>
<TI>A comparison of two butirophenones with trifluoperazine</TI>
<SO>Canadian Psychiatric Association Journal</SO>
<YR>1966</YR>
<VL>11</VL>
<NO>1</NO>
<PG>26-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="66073400"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menon-1972" NAME="Menon 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menon MS, Ramachandran V</AU>
<TI>A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1972</YR>
<VL>14</VL>
<NO>1</NO>
<PG>17-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Needham-1969" NAME="Needham 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Needham RFH, Blignault WJ</AU>
<TI>A comparison of an acridan derivative (Smith Kline and French 14336) and trifluoperazine in the treatment of chronic schizophrenia</TI>
<SO>The Medical Journal of Australia</SO>
<YR>1969</YR>
<VL>2</VL>
<NO>11</NO>
<PG>550-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Brien-1974" MODIFIED="2009-01-19 15:00:23 +0000" MODIFIED_BY="[Empty name]" NAME="O'Brien 1974" YEAR="1974">
<REFERENCE MODIFIED="2009-01-19 15:00:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien CP, Di Giacomo JN, Webb W</AU>
<TI>Management of hostile, suspicious patients: trifluoperazine versus haloperidol</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1974</YR>
<VL>35</VL>
<NO>2</NO>
<PG>75-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perales-1974" MODIFIED="2008-11-05 09:12:59 +0000" MODIFIED_BY="[Empty name]" NAME="Perales 1974" YEAR="1974">
<REFERENCE MODIFIED="2008-11-05 09:12:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perales JA, Garcia A, Infantes V, Valle G</AU>
<TI>Comparative study of clotiapine and trifluoperazine in acute paranoid schizophrenia</TI>
<TO>Estudio Comparativo de la Clotiapina y de la Trifluoperazina en Episodios Agudos de Esquizofrenia Paranoide</TO>
<SO>Acta Psiquiatrica y Psicologica de America Latina</SO>
<YR>1974</YR>
<VL>20</VL>
<NO>3</NO>
<PG>207-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="75001144"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prien-1969" NAME="Prien 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prien RF, Levine J, Cole JO</AU>
<TI>High dose trifluoperazine therapy in chronic schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1969</YR>
<VL>126</VL>
<PG>305-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramsay-1970" NAME="Ramsay 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ramsay RA, Ban TA, Lehmann HE, Saxena BM, Bennet J</AU>
<TI>A comparative study of molindone and trifluoperazine</TI>
<SO>Current Therapeutic Research</SO>
<YR>1970</YR>
<VL>12</VL>
<NO>7</NO>
<PG>438-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramsay RA, Lehmann HE, Ban TA, Saxena BM, Bennett J</AU>
<TI>Clinical evaluation of a new psychotropic drug-Molindone</TI>
<SO>International Journal of Clinical Pharmacology, Therapy and Toxicology</SO>
<YR>1970</YR>
<VL>3</VL>
<NO>1</NO>
<PG>46-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reardon-1966" NAME="Reardon 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reardon JD, Abrams S</AU>
<TI>Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo)</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1966</YR>
<VL>27</VL>
<NO>4</NO>
<PG>265-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="66138639"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rubin-1971" NAME="Rubin 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubin R</AU>
<TI>A double-blind comparison of the onset of activity of haloperidol and trifluoperazine</TI>
<SO>Alabama Journal of Mental Science</SO>
<YR>1971</YR>
<VL>8</VL>
<NO>4</NO>
<PG>414-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiele-1961" NAME="Schiele 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiele BC, Vestre ND, Stein KE</AU>
<TI>A comparison of thioridazine, trifluoperazine, chlorpromazine and placebo: A double-blind controlled study on the treatment of chronic hospitalized schizophrenic patients</TI>
<SO>Journal of Clinical and Experimental Psychopathology</SO>
<YR>1961</YR>
<VL>22</VL>
<PG>151-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiele-1969" NAME="Schiele 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiele BC, Janecek J, Zimmermann R</AU>
<TI>A double-blind comparison of trifluperidol and trifluoperazine in acute schizophrenic patients</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>1969</YR>
<VL>10</VL>
<NO>5</NO>
<PG>355-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seth-1979" NAME="Seth 1979" YEAR="1979">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Seth S, Mahal AS, Kumar KA</AU>
<TI>A double-blind comparative trial of loxapine and trifluoperazine in chronic schizophrenic patients</TI>
<SO>Current Therapeutic Research</SO>
<YR>1979</YR>
<VL>25</VL>
<NO>2</NO>
<PG>320-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-1976" NAME="Simpson 1976" YEAR="1976">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Cuculic Z</AU>
<TI>A double-blind comparison of loxapine succinate and trifluoperazine in newly admitted schizophrenic patients</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1976</YR>
<VL>16</VL>
<NO>1</NO>
<PG>60-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stewart-1969" NAME="Stewart 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stewart A, Lafave HG, Segovia G</AU>
<TI>Haloperidol-new addition to the drug treatment of schizophrenia</TI>
<SO>Behavioral Neuropsychiatry</SO>
<YR>1969</YR>
<VL>1</VL>
<NO>7</NO>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sugerman-1965" NAME="Sugerman 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sugerman AA, Williams BH</AU>
<TI>Trifluperidol and trifluoperazine in acute schizophrenic patients</TI>
<SO>Journal of New Drugs</SO>
<YR>1965</YR>
<VL>5</VL>
<NO>5</NO>
<PG>318-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vergara-1977" NAME="Vergara 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vergara L, Amin MM, Ban TA</AU>
<TI>A standard (trifluoperazine) controlled clinical study with pimozide in the maintenance treatment of schizophrenic patients, II</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1977</YR>
<VL>13</VL>
<NO>3</NO>
<PG>17-19</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="77234972"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-01-19 15:07:04 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abraham-1987" NAME="Abraham 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abraham KR, Kulhara P</AU>
<TI>The efficacy of electroconvulsive therapy in the treatment of schizophrenia. A comparative study</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>151</VL>
<PG>152-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barsa-1959" NAME="Barsa 1959" YEAR="1959">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barsa JA, Saunders JC, Kline NS</AU>
<TI>Trifluoperazine in the treatment of chronic schizophrenics</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1959</YR>
<VL>115</VL>
<PG>812</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brannen-1969" NAME="Brannen 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brannen JO, Jewett RE</AU>
<TI>Effects of selected phenothiazines on REM sleep in schizophrenics</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1969</YR>
<VL>21</VL>
<NO>3</NO>
<PG>284-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buffaloe-1961" NAME="Buffaloe 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buffaloe Wj, Sandifer Mg</AU>
<TI>A study combined therapy with stelazine and parnate(SKF 385) in chronic anergic schizophrenics</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1961</YR>
<VL>117</VL>
<PG>1030-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cabrera-1990" NAME="Cabrera 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cabrera GJ, Reyes GB, Fernandez LO, Rojas PM, Molina LM, Perez I, Lopez SP, Apezteguia R</AU>
<TI>Treatment of schizophrenia with interferon. A double-blind study</TI>
<TO>Tratamiento de la Esquizofrenia con Interferon. Estudio a Doble-Ciegas</TO>
<SO>Revista del Hospital Psiquiatrico de la Habana</SO>
<YR>1990</YR>
<VL>31</VL>
<NO>2</NO>
<PG>251-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Calwell-1964" NAME="Calwell 1964" YEAR="1964">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calwell WPK, Jacobsen M, Skarbek A</AU>
<TI>A comparative study of oxypertine and trifluoperazine in chronic schizophrenia - a new application of the Wing Rating Scale</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1964</YR>
<VL>110</VL>
<PG>520-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carscallen-1968" NAME="Carscallen 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carscallen HB, Rochman H, Lovegrove TD</AU>
<TI>High dosage trifluoperazine in schizophrenia. Comparison of the efficacy of high and usual doses of trifluoperazine in the treatment of chronic schizophrenics</TI>
<SO>Canadian Psychiatric Association Journal</SO>
<YR>1968</YR>
<VL>13</VL>
<NO>5</NO>
<PG>459-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="69016256"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casey-1961" NAME="Casey 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casey JF, Hollister LE, Klett CJ, Lasky JJ, Caffey EM</AU>
<TI>Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextroamphetamine, imipramine, isocarboxazid and trifluoperazine added to maintanence doses of chlorpromazine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1961</YR>
<VL>117</VL>
<PG>997-1003</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Childers-1961" NAME="Childers 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Childers RT, Therrien R</AU>
<TI>A comparison of the effectiveness of trifluoperazine and chlorpromazine in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1961</YR>
<VL>118</VL>
<PG>552-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Childers-1962" NAME="Childers 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Childers RT</AU>
<TI>Procyclidine and benzotropine methanesulfonate compared in drug induced extrapyramidal reactions</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1962</YR>
<VL>1456</VL>
<PG>462-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Childres-1962-b" NAME="Childres 1962 b" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Childers RT</AU>
<TI>Selective effectiveness of chlorpromazine and trifluoperazine in schizophrenia</TI>
<SO>Disease of the Nervous System</SO>
<YR>1962</YR>
<VL>23</VL>
<PG>156-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crane-1970" NAME="Crane 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crane GE, Chase C</AU>
<TI>High doses of trifluoperazine and tardive dyskinesia</TI>
<SO>Archives of Neurology</SO>
<YR>1970</YR>
<VL>22</VL>
<PG>176-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Elia-1974" NAME="D'Elia 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Elia G, Perris C, Rapp W</AU>
<TI>Objective evaluation of EEG amplitude in chronic schizophrenic patients during a controlled trial of pimozide and trifluoperazine</TI>
<SO>Acta Psychiatrica Scandinava Supplementum</SO>
<YR>1974</YR>
<VL>249</VL>
<PG>78-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Den-Boer-2000" NAME="Den Boer 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Den Boer JA, Vahine JO, Post P, Heck AH, Daubenton F, Olbrich R</AU>
<TI>Ritanserin as add on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia</TI>
<SO>Human Psychopharmacology</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>3</NO>
<PG>179-89</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Embase 2000170004"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dewolfe-1971" NAME="Dewolfe 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeWolfe AS, Barrell RP, London L, Spaner FE</AU>
<TI>Prolixin enanthate and thorazine-stelazine regimens in the treatment of schizophrenic patients. An experimental evaluation</TI>
<SO>Psychosomatics</SO>
<YR>1971</YR>
<VL>12</VL>
<PG>186-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DiMascio-1965" NAME="DiMascio 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DiMascio A, Havens LL, Klerman GL</AU>
<TI>The psychopharmacology of phenothiazine compounds: a comparative study of the effects of chlorpromazine, promethazine, trifluoperazine and perphenazine in normal males-I. Introduction, aims and methods</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1965</YR>
<VL>136</VL>
<PG>15-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eitan-1992" NAME="Eitan 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eitan N, Levin Y, Ben-Artzi E, Levy A, Neumann M</AU>
<TI>Effects of antipsychotic drugs on memory functions of schizophrenic patients</TI>
<SO>Acta Psychiatica Scandinavica</SO>
<YR>1992</YR>
<VL>85</VL>
<NO>1</NO>
<PG>74-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fish-1966" NAME="Fish 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fish B, Shapiro T, Campbell M</AU>
<TI>Long-term prognosis and the response of schizophrenic children to drug therapy: a controlled study of trifluoperazine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1966</YR>
<VL>123</VL>
<NO>1</NO>
<PG>32-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="66135917"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Forrester-1958" MODIFIED="2008-11-05 09:11:33 +0000" MODIFIED_BY="[Empty name]" NAME="Forrester 1958" YEAR="1958">
<REFERENCE MODIFIED="2008-11-05 09:11:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Forrester ME</AU>
<TI>Disturbed chronic psychotic patients: pilot trial of stelazine</TI>
<SO>British Medical Journal</SO>
<YR>1958</YR>
<VL>2</VL>
<PG>90-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gardos-1968" NAME="Gardos 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gardos G, rapkin RM, DiMascio A</AU>
<TI>Trifluoperazine and chlorpromazine in combination and individually</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1968</YR>
<VL>10</VL>
<NO>12</NO>
<PG>609-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gottfries-1971" NAME="Gottfries 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gottfries CG</AU>
<TI>Flupenthixol and trifluoperazine: A double-blind investigation in the treatment of schizophrenics</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1971</YR>
<VL>119</VL>
<PG>547-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guido-1960" NAME="Guido 1960" YEAR="1960">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guido JA, Abe GY</AU>
<TI>Trifluoperazine: a report of a clinical trial in back ward psychotic patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1960</YR>
<VL>117</VL>
<PG>453-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Held-1970" NAME="Held 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Held JM, Cromwell RL, Frank ET Jr, Fann WE</AU>
<TI>Effect of phenothiazines on reaction time in schizophrenics</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>1970</YR>
<VL>7</VL>
<NO>3</NO>
<PG>209-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janecek-1963" NAME="Janecek 1963" YEAR="1963">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janecek J, Schiele BC, Bellville T, Anderson R</AU>
<TI>The effects of withdrawal of trifluoperazine on patients maintained on the combination of tranylcypromine and trifluoperazine: a double-blind study</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1963</YR>
<VL>85</VL>
<PG>608-15</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Acc. No. 1965-00966-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1970" NAME="Jones 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones IH, Davies J, Buckle R, Hanna WH, Pikler N</AU>
<TI>Comparison of methylperidol and trifluoperazine in the treatment of chronic, underactive schizophrenic patients</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>1970</YR>
<VL>4</VL>
<PG>143-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1971" NAME="Jones 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones IH, Pikler N</AU>
<TI>Effects of chlorpromazine and trifluoperazine on the activity of chronic schizophrenics</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1971</YR>
<VL>119</VL>
<PG>545-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="72090720"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joshi-1980" NAME="Joshi 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joshi VG, Eswaran S</AU>
<TI>Vitamins B1, B6 and B12 in the adjunctive treatment of schizophrenia</TI>
<SO>Journal of Orthomolecular Psychiatry</SO>
<YR>1980</YR>
<VL>9</VL>
<NO>1</NO>
<PG>35-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joshi-1982" NAME="Joshi 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joshi VG, Nagesh R, Eswaran S</AU>
<TI>Vitamins B1, B6 and B12 in the adjunctive treatment of schizophrenia-further studies to examine the effect of reduction of chlorpromazine dosage</TI>
<SO>Journal of Orthomolecular Psychiatry</SO>
<YR>1982</YR>
<VL>11</VL>
<NO>1</NO>
<PG>45-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalinin-1986" NAME="Kalinin 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalinin VV, Rudik VA</AU>
<TI>The place of insulin coma therapy among modern methods of treatment of paroxysmal schizophrenia patients</TI>
<SO>Zhurnal Nevropatologii i Psikhiatrii imeni S.S. Korsakova</SO>
<YR>1986</YR>
<VL>86</VL>
<NO>5</NO>
<PG>745-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kline-1977" NAME="Kline 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kline F, Burgoyne RW, Yamamoto J</AU>
<TI>Comparison of pimozide and trifluoperazine as once-daily therapy in chronic schizophrenic outpatients</TI>
<SO>Current Therapeutic Research</SO>
<YR>1977</YR>
<VL>21</VL>
<NO>6</NO>
<PG>768-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knight-1979" NAME="Knight 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knight RG, Harrison A</AU>
<TI>A double-blind comparison of thiothixene and trifluoperazine-chlorpromazine composite in the treatment of chronic schizophrenia</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1979</YR>
<VL>89</VL>
<NO>634</NO>
<PG>302-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lal-1974" NAME="Lal 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lal S, Ettigi P</AU>
<TI>Comparison of thiopropazate and trifluoperazine on oral dyskinesia- a double-blind study</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1974</YR>
<VL>16</VL>
<NO>9</NO>
<PG>990-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapolla-1965" NAME="Lapolla 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lapolla A</AU>
<TI>A study of stelazine</TI>
<SO>Western Medicine the Medical Journal of the West</SO>
<YR>1965</YR>
<VL>6</VL>
<NO>9</NO>
<PG>240-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lovett-1987" NAME="Lovett 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lovett WC, Stokes DK, Taylor LB, Young ML, Free SM, Phelan DG</AU>
<TI>Management of behaviour symptoms in disturbed elderly patients: comparison of trifluoperazine and haloperidol</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1987</YR>
<VL>48</VL>
<NO>6</NO>
<PG>234-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luckey-1967" NAME="Luckey 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luckey WT, Schiele BC</AU>
<TI>A comparison of haloperidol and trifluoperazine. (A double-blind controlled study on chronic schizophrenic outpatients)</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1967</YR>
<VL>28</VL>
<NO>3</NO>
<PG>181-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="67125692"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macdonald-1959" NAME="Macdonald 1959" YEAR="1959">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macdonald R, Watts TPS</AU>
<TI>Trifluoperazine dihydrochloride("Stelazine") in paranoid schizophrenia</TI>
<SO>British Medical Journal</SO>
<YR>1959</YR>
<VL>1</VL>
<PG>549-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mandel-1962" NAME="Mandel 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mandel W, Evans P</AU>
<TI>Comparison of butyrylperazine and trifluoperazine in chronic schizophrenic subjects</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1962</YR>
<VL>119</VL>
<PG>70-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mena-1964" NAME="Mena 1964" YEAR="1964">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mena A, Heistad G, Schiele BC, Janecek J</AU>
<TI>A comparison of tranylcypromine alone with tranylcypromine plus trifluoperazine in the treatment of chronic outpatients: a double-blind controlled study</TI>
<SO>Journal of Cardiovascular Nursing</SO>
<YR>1964</YR>
<VL>53</VL>
<PG>542-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Acc. No. 1965-00966-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monroe-1965" NAME="Monroe 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monroe RR, Kramer MD, Goulding R, Wise S</AU>
<TI>EEG activation of patients receiving phenothiazines and chlordiazepoxide</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1965</YR>
<VL>141</VL>
<PG>100-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montero-1971" NAME="Montero 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Montero E</AU>
<TI>Thioridazine compared with a combination of chlorpromazine and trifluoperazine hydrochloride in schizophrenic patients</TI>
<SO>5th World Congress of Psychiatry; 1971 Nov 28- Dec 4, Ciudad de Mexico, Mexico</SO>
<YR>1971</YR>
<PG>433</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="72095778"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morton-1968" NAME="Morton 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morton MR</AU>
<TI>A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1968</YR>
<VL>124</VL>
<NO>11</NO>
<PG>1585-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="68203217"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moyano-1975" NAME="Moyano 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moyano CZ</AU>
<TI>A double-blind comparison of loxitane-loxapine succinate and trifluoperazine hydrocloride in chronic schizophrenic patients</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1975</YR>
<VL>36</VL>
<PG>301-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oybir-1962" NAME="Oybir 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oybir F</AU>
<TI>Trifluoperazine in chronic withdrawn schizophrenics (a double-blind study)</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1962</YR>
<VL>23</VL>
<PG>348-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pecknold-1977" NAME="Pecknold 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pecknold JC, Ban TA, Lehmann HE</AU>
<TI>A standard (trifluoperazine) controlled clinical study with clomacran in newly admitted schizophrenic patients</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1977</YR>
<VL>13</VL>
<NO>3</NO>
<PG>14-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polvan-1971" NAME="Polvan 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polvan N, Akpinar S, Ahmed MB, Itil TM</AU>
<TI>Different effects of trifluoperazine when administered daytime or night</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1971</YR>
<VL>119</VL>
<NO>553</NO>
<PG>601-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rudy-1958" NAME="Rudy 1958" YEAR="1958">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rudy L, Rinaldi E, Himwich H, Tuteur W, Glotzer J</AU>
<TI>Trifluoperazine in the treatment of psychotic patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1958</YR>
<VL>115</VL>
<PG>364-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiele-1963" NAME="Schiele 1963" YEAR="1963">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiele BC, Vestre ND</AU>
<TI>Treatment of hospitalized schizophrenics with trifluoperazine plus tranylcypromine: a double-blind controlled study</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>1963</YR>
<VL>4</VL>
<NO>2</NO>
<PG>66-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharpley-1964" NAME="Sharpley 1964" YEAR="1964">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharpley P, Mena A, Schiele BC, Heistad G</AU>
<TI>A comparison of pargyline and tranylcypromine with and without the addition of trifluoperazine: a double-blind study</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1964</YR>
<VL>15</VL>
<PG>344-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stanley-1961" NAME="Stanley 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stanley WJ, Walton D</AU>
<TI>Trifluoperazine (Stelazine) a controlled clinical trial in chronic schizophrenia</TI>
<SO>Journal of Mental Science</SO>
<YR>1961</YR>
<VL>107</VL>
<PG>250-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Talbot-1964" NAME="Talbot 1964" YEAR="1964">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Talbot DR</AU>
<TI>Are tranquilizers combinations more effective than a single tranquilizer?</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1964</YR>
<VL>121</VL>
<PG>597-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teja-1975" NAME="Teja 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teja JS, Grey WH, Clum Jm, Warren C</AU>
<TI>Tranquilizers or anti-depressants for chronic schizophrenics: A long term study</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>1975</YR>
<VL>9</VL>
<NO>4</NO>
<PG>241-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tetreault-1968" MODIFIED="2009-01-19 15:01:26 +0000" MODIFIED_BY="[Empty name]" NAME="Tetreault 1968" YEAR="1968">
<REFERENCE MODIFIED="2009-01-19 15:01:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tetreault L, Filotto J, Bordeleau JM</AU>
<TI>Neuroleptics and extrapyramidal effects: correlation between antipsychotic and extrapyramidal properties</TI>
<TO>Neuroleptiques et Effets Extra-Pyramidaux: Correlation Entre Les Proprietes Antipsychotiques Et Extra-Pyramidales</TO>
<SO>Canadian Psychiatric Association Journal</SO>
<YR>1968</YR>
<VL>13</VL>
<NO>6</NO>
<PG>507-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tolan-1959" NAME="Tolan 1959" YEAR="1959">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tolan EJ, Peppel HH</AU>
<TI>Preliminary observations of trifluoperazine in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1959</YR>
<VL>115</VL>
<PG>935</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uddyback-1962" NAME="Uddyback 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uddyback OT, Chen Ch</AU>
<TI>Thioridazine (Mellaril) on regressed schizophrenic patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1962</YR>
<VL>119</VL>
<PG>740-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vogt-1961" MODIFIED="2009-01-19 15:02:03 +0000" MODIFIED_BY="[Empty name]" NAME="Vogt 1961" YEAR="1961">
<REFERENCE MODIFIED="2009-01-19 15:02:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vogt AH</AU>
<TI>The use of stelazine and parnate in chronic, withdrawn patients</TI>
<SO>American journal of Psychiatry</SO>
<YR>1961</YR>
<VL>118</VL>
<PG>256-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weckowicz-1960" NAME="Weckowicz 1960" YEAR="1960">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weckowicz TE, Ward TF</AU>
<TI>Clinical trial of "stelazine"on apathetic chronic schizophrenics</TI>
<SO>Journal of Mental Science(British Journal of Psychiatry from 1963)</SO>
<YR>1960</YR>
<VL>106</VL>
<PG>1008-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weston-1961" NAME="Weston 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weston FK, Loftus AP</AU>
<TI>A terminal double-blind trial of trifluoperazine ("stelazine") in chronic schizophrenia</TI>
<SO>The Medical Journal of Australia</SO>
<YR>1961</YR>
<VL>48</VL>
<NO>1</NO>
<PG>776-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1961" MODIFIED="2009-01-19 15:07:04 +0000" MODIFIED_BY="[Empty name]" NAME="Wilson 1961" YEAR="1961">
<REFERENCE MODIFIED="2009-01-19 15:07:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson IC, Mckay J, Sandifer MG</AU>
<TI>A double-blind trial to investigate the effects of thorazine (largactil, chlorpromazine), compazine (stemetil, prochlorperazine) and stelazine (trifluoperazine) in paranoid schizophrenia</TI>
<SO>Journal of Mental Science</SO>
<YR>1961</YR>
<VL>107</VL>
<PG>90-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winnik-1962" NAME="Winnik 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winnik HZ, Assael M, Gabbai F</AU>
<TI>Clinical trial of stelazine therapy in schizophrenia refractory to alternative treatments</TI>
<SO>Dapim Rafuiim</SO>
<YR>1962</YR>
<VL>21</VL>
<PG>161-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-01-19 15:13:59 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abuzzahab-1977" NAME="Abuzzahab 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abuzzahab FS</AU>
<TI>The treatment of schizophrenia with long-acting oral neuroleptics: A six-month double-blind investigation of penfluridol versus trifluoperazine</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1977</YR>
<VL>13</VL>
<NO>3</NO>
<PG>26-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barron-1961" NAME="Barron 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barron A, Beckering B, Rudy LH, Smith JA</AU>
<TI>A double-blind study comparing RO 4-0403, trifluoperazine and placebo in chronically ill mental patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1961</YR>
<VL>118</VL>
<PG>347-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bora-1968" NAME="Bora 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bora G</AU>
<TI>Comparison of dosage ranges of carphenazine and trifluoperazine in elderly chronic schizophrenics</TI>
<SO>Disease of the Nervous System</SO>
<YR>1968</YR>
<VL>29</VL>
<NO>10</NO>
<PG>695-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cahan-1960" NAME="Cahan 1960" YEAR="1960">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cahan RB</AU>
<TI>Efficacy of trifluoperazine in chronic mental ilness</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1960</YR>
<VL>116</VL>
<PG>838-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Claghorn-1969" NAME="Claghorn 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Claghorn JL</AU>
<TI>Psychopharmacologic characteristics of an indole compound-molindone</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1969</YR>
<VL>11</VL>
<NO>8</NO>
<PG>524-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="69268231"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freeman-1969" NAME="Freeman 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freeman H, Frederick AN</AU>
<TI>Comparison of trifluoperazine and molindone in chronic schizophrenic patients</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1969</YR>
<VL>11</VL>
<NO>11</NO>
<PG>670-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallant-2000" NAME="Gallant 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Gallant</AU>
<TI>GP-45795 vs. trifluoperazine</TI>
<SO>Early Clinical Drug Evaluation Unit Reports</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gardos-1970" NAME="Gardos 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gardos G, Finnerty RJ, Cole JO</AU>
<TI>Thiothixene and trifluoperazine in a step system</TI>
<SO>Psychosomatics</SO>
<YR>1970</YR>
<VL>11</VL>
<NO>1</NO>
<PG>36-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamilton-1963" NAME="Hamilton 1963" YEAR="1963">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M, Hordern A, Waldrop FN, Lofft J</AU>
<TI>A controlled trial on the value of prochlorperazine, trifluoperazine and intensive group treatment</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1963</YR>
<VL>109</VL>
<PG>510-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holden-1971" NAME="Holden 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holden JMC, Itil TM, Gannon PJ, Keskiner A</AU>
<TI>The clinical effects of intramuscular thiothixene and trifluoperazine in chronic schizophrenia: a comparative study</TI>
<SO>Current Therapeutic Research</SO>
<YR>1971</YR>
<VL>13</VL>
<NO>5</NO>
<PG>298-310</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hunt-1967" NAME="Hunt 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hunt PV</AU>
<TI>A comparison of the effects of the oxypertine and trifluoperazine in withdrawal schizophrenics</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1967</YR>
<VL>113</VL>
<NO>505</NO>
<PG>1419-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="68103521"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khorana-1988" NAME="Khorana 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khorana AB, Patel Y</AU>
<TI>Comparative short term evaluation on penfluridol and trifluoperazine in chronic schizophrenia</TI>
<SO>Indian Journal of Physiology and Pharmacology</SO>
<YR>1988</YR>
<VL>32</VL>
<PG>293-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kogeorgos-1995" NAME="Kogeorgos 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kogeorgos J, Kanellos P, Michalakeas A, Ioannidis J</AU>
<TI>Sulpiride and risperidone vs. "classical neuroleptics" in schizophrenia: a follow up study</TI>
<SO>8th Congress of the European College of Neuropsychopharmacology; 1995 Sep 30- Oct 4, Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madgwick-1958" MODIFIED="2009-01-19 15:08:44 +0000" MODIFIED_BY="[Empty name]" NAME="Madgwick 1958" YEAR="1958">
<REFERENCE MODIFIED="2009-01-19 15:08:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madgwick JRA, McNeill DLM, Driver M, Preston GC</AU>
<TI>Stelazine (trifluoperazine) A preliminary report on a clinical trial</TI>
<SO>Journal of Mental Science</SO>
<YR>1958</YR>
<VL>104</VL>
<PG>1195-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ortega_x002d_Soto-1996" MODIFIED="2009-01-19 15:09:39 +0000" MODIFIED_BY="[Empty name]" NAME="Ortega-Soto 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-01-19 15:09:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ortega-Soto HA, Brunner E, Apiquian R, de la Torre MP, Ulloa RE</AU>
<TI>Typical antipsychotics: the threshold doses strategy</TI>
<SO>20th Congress of Collegium Internationale Neuro-psychopharmacologicum; 1996 june 23-27, Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ortega-Soto HA, Brunner E, Apiquian R, de la Torre P, Ulloa RE, Mendizabal A</AU>
<TI>Optimal minimum doses of trifluoperazine in acute schizophrenia</TI>
<SO>149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9, New York, USA</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Platz-1967" NAME="Platz 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Platz AR, Klett CJ, Caffey EM</AU>
<TI>Selective drug action related to chronic schizophrenic subtype</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1967</YR>
<VL>28</VL>
<NO>9</NO>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spiegel-1967" NAME="Spiegel 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spiegel DE, Spiegel KP</AU>
<TI>The effects of carphenazine, trifluoperazine and chlorpromazine on ward behaviour, physiological functioning and psychological test scores in chronic schizophrenic patients</TI>
<SO>The Journal of Nervous and Mental Disease</SO>
<YR>1967</YR>
<VL>144</VL>
<NO>2</NO>
<PG>111-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1975" MODIFIED="2009-01-19 15:13:59 +0000" MODIFIED_BY="[Empty name]" NAME="Svestka 1975" YEAR="1975">
<REFERENCE MODIFIED="2009-01-19 15:13:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svetska J, Nahunek K, Rodova A, Ceskova E</AU>
<TI>The position of trifluoperazine in the group of neuroleptics (a controlled clinical comparative study)</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1975</YR>
<VL>17</VL>
<NO>3</NO>
<PG>208</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terminska-1989" NAME="Terminska 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terminska K, Mrowiec W</AU>
<TI>Comparison of influence of perazine, fluphenazine, trifluoperazine, chlorpromazine and haloperidol on primary and deficit schizophrenic symptoms in patients first hospitalized because of paranoid schizophrenia</TI>
<TO>Badanie porównawcze wplywu perazyny, flufenazyny, trifluoroperazyny, chloropromazyny i haloperydolu na objawy pierwotne i deficytowe pierwszego zachorowania na schizofrenie paranoidalna</TO>
<SO>Psychiatria Polska</SO>
<YR>1989</YR>
<VL>23</VL>
<PG>24-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toru-1969" NAME="Toru 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toru M, Kobayashi K, Shimazono Y</AU>
<TI>A double-blind cross-over comparison of oxypertine with trifluoperazine in chronic schizophrenia</TI>
<SO>Rinsyo Igaku</SO>
<YR>1969</YR>
<VL>11</VL>
<NO>10</NO>
<PG>787-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vinar-1966" NAME="Vinar 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vinar O, Taussigova D</AU>
<TI>Clinical experience with trifluoperazine</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1966</YR>
<VL>8</VL>
<PG>448-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vinar-1971" NAME="Vinar 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vinar O, Taussigova D</AU>
<TI>Thiothixene in schizophrenic psychoses</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1971</YR>
<VL>13</VL>
<NO>3</NO>
<PG>174-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wijsenbeek-1974" NAME="Wijsenbeek 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wijsenbeek H, Steiner M, Goldberg SC</AU>
<TI>Trifluoperazine: a comparison between regular and high doses</TI>
<SO>Psychopharmacologia</SO>
<YR>1974</YR>
<VL>36</VL>
<PG>147-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-05 09:03:26 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-05 09:03:26 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1997" NAME="APA 1997" TYPE="JOURNAL_ARTICLE">
<AU>American Psychiatric Association</AU>
<TI>Practice guideline for the treatment of patients with schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<NO>4</NO>
<PG>1-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arana-2000" NAME="Arana 2000" TYPE="BOOK">
<AU>Arana G, Rosenbaum J</AU>
<SO>Handbook of Psychiatric Drug Therapy</SO>
<YR>2000</YR>
<EN>Fourth</EN>
<PB>Lippincott Williams &amp; Wilkins</PB>
<CY>Philadelphia, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ban-1966" NAME="Ban 1966" TYPE="JOURNAL_ARTICLE">
<AU>Ban TA</AU>
<TI>Clinical pharmacology of the phenothiazines</TI>
<SO>Applied Therapeutics</SO>
<YR>1966</YR>
<VL>8</VL>
<NO>5</NO>
<PG>423-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bazire-2000" NAME="Bazire 2000" TYPE="BOOK">
<AU>Bazire S</AU>
<SO>Psychotropic Drug Directory</SO>
<YR>2000</YR>
<PB>Butler and Tanner Limited</PB>
<CY>New York, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF</AU>
<TI>Improving the quality of randomized controlled trials. The CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2001" MODIFIED="2008-11-05 08:57:43 +0000" MODIFIED_BY="[Empty name]" NAME="Clarke 2001" TYPE="OTHER">
<AU>Clarke M, Oxman D</AU>
<TI>Cochrane Collaboration Handbook</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>1</NO>
<PB>Update software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2002" MODIFIED="2008-11-05 09:02:11 +0000" MODIFIED_BY="[Empty name]" NAME="Duggan 2002" TYPE="COCHRANE_REVIEW">
<AU>Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S</AU>
<TI>Olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford, UK</CY>
<IDENTIFIERS MODIFIED="2008-11-05 09:02:11 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 09:02:11 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001359.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, Antes G</AU>
<TI>Language bias in randomised controlled trials published in English and German</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>326-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fenton-2002" MODIFIED="2008-11-05 08:58:26 +0000" MODIFIED_BY="[Empty name]" NAME="Fenton 2002" TYPE="COCHRANE_REVIEW">
<AU>Fenton M, Murphy B, Wood J, Bagnall AM, Chue P, Leitner M</AU>
<TI>Loxapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<PB>Update Software</PB>
<CY>Oxford, UK</CY>
<IDENTIFIERS MODIFIED="2008-11-05 08:58:26 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 08:58:26 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001943.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Geddes-2000" NAME="Geddes 2000" TYPE="JOURNAL_ARTICLE">
<AU>Geddes J, Freemantle N, Harrison P, Bebbington P</AU>
<TI>Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis</TI>
<SO>BMJ</SO>
<YR>2000</YR>
<VL>321</VL>
<PG>1371-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology</SO>
<YR>1976</YR>
<PG>217-22</PG>
<PB>National Institute of Mental Health</PB>
<CY>Washington DC, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Honingfeld-1965" NAME="Honingfeld 1965" TYPE="JOURNAL_ARTICLE">
<AU>Honingfeld G, Klett CJ</AU>
<TI>The Nurses Observation Scale for Impatient Evaluation (NOSIE): a new scale for measuring improvment in chronic schizophrenia</TI>
<SO>Journal of Clinical Psychology</SO>
<YR>1965</YR>
<VL>21</VL>
<PG>65-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunter-2003" MODIFIED="2008-11-05 09:00:37 +0000" MODIFIED_BY="[Empty name]" NAME="Hunter 2003" TYPE="COCHRANE_REVIEW">
<AU>Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F</AU>
<TI>Risperidone versus typical antipsychotic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>Issue 4</NO>
<PB>Update Software</PB>
<CY>Oxford, UK</CY>
<IDENTIFIERS MODIFIED="2008-11-05 09:00:37 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 09:00:37 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000440"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Joy-2001" MODIFIED="2008-11-05 08:59:06 +0000" MODIFIED_BY="[Empty name]" NAME="Joy 2001" TYPE="COCHRANE_REVIEW">
<AU>Joy CB, Adams CE, Lawrie SM</AU>
<TI>Haloperidol versus placebo for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<PB>Update Software</PB>
<CY>Oxford, UK</CY>
<IDENTIFIERS MODIFIED="2008-11-05 08:59:06 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 08:59:06 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003082.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kaplan-1998" NAME="Kaplan 1998" TYPE="BOOK">
<AU>Kaplan H, Sadock B</AU>
<SO>Pocket handbook of clinical psychiatry</SO>
<YR>1998</YR>
<EN>2nd</EN>
<PB>Williams &amp; Wilkins</PB>
<CY>New York, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Luckey-1967" NAME="Luckey 1967" TYPE="JOURNAL_ARTICLE">
<AU>Luckey WT, Schiele BC</AU>
<TI>A comparison of haloperidol and trifluoperazine.A double-blind, controlled study on chronic schizophrenic outpatients</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1967</YR>
<VL>28</VL>
<NO>3</NO>
<PG>181-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meltzer-1996" NAME="Meltzer 1996" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY</AU>
<TI>Cost-efectiveness of clozapine treatment</TI>
<SO>Journal of Clinical Psychiatry. Monograph Series</SO>
<YR>1996</YR>
<VL>14</VL>
<PG>16-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D, CONSORT Group</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reardon-1989" NAME="Reardon 1989" TYPE="JOURNAL_ARTICLE">
<AU>Reardon GT, Rifkin A, Schwartz A, Myerson A, Siris SG</AU>
<TI>Changing patterns of neuroleptic dosage over a decade</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>146</VL>
<PG>726-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soares-2002" MODIFIED="2008-11-05 09:01:44 +0000" MODIFIED_BY="[Empty name]" NAME="Soares 2002" TYPE="COCHRANE_REVIEW">
<AU>Soares BGO, Fenton M, Chue P</AU>
<TI>Sulpiride for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<PB>Update Software</PB>
<CY>Oxford, UK</CY>
<IDENTIFIERS MODIFIED="2008-11-05 09:01:44 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 09:01:44 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001162"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Srisurapanont-2002" MODIFIED="2008-11-05 09:03:26 +0000" MODIFIED_BY="[Empty name]" NAME="Srisurapanont 2002" TYPE="COCHRANE_REVIEW">
<AU>Srisurapanont M, Disayavanish C, Taimkaew K</AU>
<TI>Quetiapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford, UK</CY>
<IDENTIFIERS MODIFIED="2008-11-05 09:03:26 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 09:03:26 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000967.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thornley-2001" MODIFIED="2008-11-05 08:59:54 +0000" MODIFIED_BY="[Empty name]" NAME="Thornley 2001" TYPE="COCHRANE_REVIEW">
<AU>Thornley B, Adams CE, Awad G</AU>
<TI>Chlorpromazine versus placebo for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<PB>Update Software</PB>
<CY>Oxford, UK</CY>
<IDENTIFIERS MODIFIED="2008-11-05 08:59:54 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 08:59:54 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000284.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wahlbeck-2001" MODIFIED="2008-11-05 09:01:08 +0000" MODIFIED_BY="[Empty name]" NAME="Wahlbeck 2001" TYPE="COCHRANE_REVIEW">
<AU>Wahlbeck K, Cheine M, Essali MA</AU>
<TI>Clozapine versus typical neuroleptic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<PB>Update Software</PB>
<CY>Oxford, UK</CY>
<IDENTIFIERS MODIFIED="2008-11-05 09:01:08 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 09:01:08 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000059"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wing-1961" NAME="Wing 1961" TYPE="JOURNAL_ARTICLE">
<AU>Wing JK</AU>
<TI>A simple and reliable subclassification of chronic schizophrenia</TI>
<SO>Journal of Mental Science</SO>
<YR>1961</YR>
<VL>107</VL>
<PG>862-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-Mackenzie-1998" NAME="Wood Mackenzie 1998" TYPE="JOURNAL_ARTICLE">
<AU>Wood Mackenzie</AU>
<TI>Review of the global schizophrenia market</TI>
<SO>PharmaForum</SO>
<YR>1998</YR>
<VL>39</VL>
<PG>9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-_x002a_Bankier-1973">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further details.<BR/>Blindness: double (identical oral preparations, but not in IM preparation - saline by a senior nurse).<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 16 weeks.<BR/>Analysis: not clearly described in the report, (ITT)?*<BR/>Country: Canada.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=24.<BR/>Age: mean 33.1 years.<BR/>Sex: M 15, F 9.<BR/>Setting: hospital.<BR/>History: acutely disturbed (mean length of illness 98.5 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose (mean 40 mg/day). N=13.<BR/>2. Fluspirilene: dose (mean 3.25 ml, 1 amp IM/week). N=11.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Side effects.</P>
<P>Unable to use -<BR/>Mental state: (BPRS - only graph; NOSIE - no data).<BR/>Laboratory tests - no data.<BR/>EKG - no data.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*ITT unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-_x002a_Doongaji-1989">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further information.<BR/>Blindness: double.<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 6 weeks (preceded by one placebo week).<BR/>Analysis: not clearly described in the report, (ITT)?*.<BR/>Country: India.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (RDC, instrument 58 New York State Psychiatric Institute, 1975).<BR/>N=40.<BR/>Age: range 18-45 years, mean ~30 years.<BR/>Sex: M 22, F 7.<BR/>Setting: hospital.<BR/>History: acute (mean duration of illness 9.7 months).<BR/>Exclusion: those who totalled 35 points on BPRS initially, or whose total score reduced by 20% at one placebo week; concurrent systemic illness; pregnant women.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 15-22.5 mg/day. N=20.<BR/>2. Centbutindole: range 3-45 mg/day. N=20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Side effects.<BR/>Mean dose of antiparkinson drug.</P>
<P>Unable to use - <BR/>Global state: (CGI - no SD).<BR/>Mental state: (BPRS - no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*ITT unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-_x002a_Goldstein-1966">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further information.<BR/>Blindness: double (identical capsules).<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: no data.<BR/>Analysis: no (ITT)*<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (clinical diagnosis).<BR/>N=21.<BR/>Age: range 21-55 years.<BR/>Sex: no data.<BR/>Setting: hospital.<BR/>History: newly addmitted. <BR/>Exclusion: childhood psychoses, brain syndromes, mental deficiency, alcoholism, epilepsy, drug addiction, abnormal laboratory tests.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1.Trifluoperazine: range 7-20 mg/day. N=10.<BR/>2. Haloperidol: range 10-22 mg/day. N=8.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Side effects. </P>
<P>Unable to use - <BR/>Mental state: (IMPS - no SD).<BR/>Behaviour: (WBRS - no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* ITT not performed, dropouts each group not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-_x002a_Itil-1971">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further details.<BR/>Blindness: double.<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 12 weeks.<BR/>Analysis: not clearly described in the report, (ITT)?*<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=60.<BR/>Age: range 16-46 years, mean 28.2 years.<BR/>Sex: M 44, F 14*.<BR/>Setting: hospital.<BR/>History: acute schizophrenics (length of illness 3 weeks to 35 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 10-160 mg/day. N=30.<BR/>2. Molindone: range 10-160 mg/day. N=30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Global state: (discharged from hospital).<BR/>Side effects: (cataracts, cardiovascular, laboratory abnormalities).</P>
<P>Unable to use - <BR/>EEG: (no usable data).<BR/>Mental state: (BPRS - no data).<BR/>Behaviour: (NOSIE - no data).<BR/>Global state: (ECDU - no data).<BR/>Side effects - not known how many incidents took place in the same patient.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* ITT unclear<BR/># Demographic characteristics only reported for 58 patients.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-_x002a_Pinard-1972">
<CHAR_METHODS>
<P>Allocation: randomly assigned (random number table, blocks of 5, matched for treatment symptom severity (BPRS), sex, ward, evaluator).<BR/>Blindness: double.<BR/>Design: 5 parallel groups.<BR/>Duration: 70 days-preceeded by 21 days where all had chlorpromazine 100 mg/day.<BR/>Analysis: not clearly described in the report, (ITT?)*.<BR/>Country: Canada.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: "schizophrenics", no further details.<BR/>N=80.<BR/>Age: range 20-60 years.<BR/>Sex: "equally represented".<BR/>Setting: hospital.<BR/>History: chronic, hospitalised for the last 2 years, no exacerbation in last year, in hospital for only social or personal reasons.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose 5 mg/tds. N=16.<BR/>2. Trifluoperazine: dose 15 mg/day. N=16.<BR/>3. Pimozide: dose 3 mg/day. N=16.<BR/>4. Pimozide: dose 6 mg/day. N=16.<BR/>5. Placebo: N=16.<BR/>Chlorpromazine, methyprylon, benztropine as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.</P>
<P>Unable to use - <BR/>Mental state: (BPRS - 'p' values only).<BR/>Behavior: (NOSIE - graph only).<BR/>Side effects: (Extrapyramidal symptom rating BEP - graph only).<BR/>Insight scale: (Echelle D"Autocritique - no usable data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* ITT unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-_x002a_Simpson-1971">
<CHAR_METHODS>
<P>Allocation: randomly assigned acording to a code prepared in advanced and held by the pharmacist" - no information how the code was prepared.<BR/>Blindness: double.<BR/>Duration: 4 weeks (preceeded by 3 days washout).<BR/>Design: 2 parallel groups, single centre.<BR/>Analysis: intention to treat performed only for global change in condition, others outcomes were not clearly described*.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: described elsewhere - Angus 1969.<BR/>N=52.<BR/>Age: range 20-48 years, mean 37.3 years.<BR/>Sex: M 16, F 36.<BR/>Setting: hospital.<BR/>History: acute schizophrenia or acute exacerbation of chronic schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 20-45 mg/day (mean 35mg). N=25.<BR/>2. Molindone: range 40-120 mg/day (mean 75mg). N=27.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (global rating of change in condition).<BR/>Side effects.<BR/>Use of antiparkinson agents.<BR/>Leaving the study early.</P>
<P>Unable to use - <BR/>Mental state: (BPRS - no SD).<BR/>Behaviour: (NOSIE - no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* ITT unclear in some outcomes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-_x002a_Vestre-1970">
<CHAR_METHODS>
<P>Allocation: randomised after ranking for withdrawal on Psychotic Reaction Profile, no further details.<BR/>Blindness: double (raters reported as blind, identical capsules).<BR/>Design: double cross-over, single centre.<BR/>Duration: 2 week placebo washout, 7 weeks on one drug, 2 weeks placebo washout, 7 weeks on second drug.<BR/>Analysis: intention-to-treat not clearly described in the report.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=60.<BR/>Age: range 23-65 years, mean 43 years.<BR/>Sex: all male.<BR/>Setting: hospital.<BR/>History: chronic illness (mean hospitalisation 15 years).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 5-40 mg/day. N=30.<BR/>2. Thioridazine: range 200-800 mg/day. N=30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.</P>
<P>Unable to use - <BR/>Mental state: (BPRS; Psychotic Reaction Profile - only significance tests).<BR/>Adverse events: (only significance tests).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Amin-1977">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further details.<BR/>Blindness: double.<BR/>Design: 2 parallel groups.<BR/>Duration: 16 weeks.<BR/>Analysis: intention-to-treat not performed in the trial.<BR/>Country: Canada.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=20.<BR/>Age: range 20-63 years, mean 38.6 years.<BR/>Sex: M 6, F 14.<BR/>Setting: outpatients.<BR/>History: maintenance treatment of chronic schizophrenics (minimum of 2 years of illness).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 5-30 mg/day. N=10.<BR/>2. Pimozide: range 2-12 mg/day. N=10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (CGI).<BR/>Leaving the study early.<BR/>Side effects.</P>
<P>Unable to use - <BR/>Mental state: (BPRS - no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Andersen-1974">
<CHAR_METHODS>
<P>Allocation: randomly assigned (described on Andersen 1972 preliminary results), no further details.<BR/>Blindness: double (commercial preparations but administered by people not involved in the trial).<BR/>Design: 2 parallel groups.<BR/>Duration: 3 months.<BR/>Analysis: intention-to-treat not performed in the trial.<BR/>Country: Sweden.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia or paranoid syndrome.**<BR/>N=40.<BR/>Age: range 21-65 years.<BR/>Sex: M 19, F19.<BR/>Setting: hospital.<BR/>History: chronic patients. <BR/>Inclusion: hospitalisation &lt; 10 years, no organic disorders, no substance abuse, no depression episodes, no violent patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 3-12 mg/bid (mean 4.34 mg). N=20.<BR/>2. Pimozide: range 3-14 mg/day (mean 3.92 mg). N=20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Side effects. <BR/>Use of antiparkinson agents.<BR/>Leaving the study early.</P>
<P>Unable to use - <BR/>Mental state: (scale - 'p' values only).<BR/>Behaviour: (Wing behaviour scale - 'p' values only).<BR/>Side effects: (point rating scale - validity unknown).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>** Mixed diagnosis.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Angus-1969">
<CHAR_METHODS>
<P>Allocation: randomly assigned (according to a code prepared in advance and held by the pharmacist).<BR/>Blindness: double.<BR/>Design: 2 parallel group, single centre. <BR/>Duration: 6 months (results in 6 weeks).<BR/>Analysis: intention-to-treat.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: Scheneider criteria.<BR/>N=42.<BR/>Age: range 17-57 years, mean 38.5 years.<BR/>Sex: M 14, F 28.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1.Trifluoperazine: range 7.5-45 mg/day. N=22.<BR/>2.SK&amp;F 14,336: range 100-600 mg/day. N=20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (global ratings of improvement).<BR/>Side-effects.<BR/>Use of antiparkinson agents.</P>
<P>Unable to use - <BR/>Mental state: (BPRS - no data).<BR/>Behaviour: (NOSIE - no data).<BR/>Leaving the study early - no usable data.<BR/>Global state: (degree of severity of the illness scale - no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bagadia-1980">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further information.<BR/>Blindness: double (identical capsules).<BR/>Design: 2 parallel groups.<BR/>Duration: 28 days.<BR/>Analysis: intention-to-treat not performed by the authors.<BR/>Country: India.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (ICD, 8th revision).<BR/>N=55.<BR/>Age: 14-24 years, mean 17.4 years.<BR/>Sex: M 33, F 17.<BR/>Setting: outpatients.<BR/>History: adolescents (onset of illness between the ages of 13 to 19).<BR/>Exclusion: hypersensitivity to compounds; 3 weeks previous treatment with phenothiazines or MAOI; 8 weeks with ECT; insulin coma or subcoma therapy; acute or chronic brain syndrome; convulsive disorders; mental retardation; childhood psychoses; serious renal, hepatic, cardiovascular or metabolic diseases or history of dependences.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose (mean 24.4 mg/day; maximum 30 mg/day). N=28.<BR/>2. Loxapine: dose (mean 96.3 mg/day; maximum 120 mg/day). N=27.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Side effects.<BR/>Global state: (patients' self-evaluations).</P>
<P>Unable to use - <BR/>Mental state: (BPRS - no SD).<BR/>Global state: (CGI - no SD).<BR/>Behaviour: (NOSIE - no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bankier-1968">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further information.<BR/>Blindness: double (identical capsules and IM preparations).<BR/>Design: 2 parallel groups arranged into 8 subgroups with 8 to 10 patients in each, single centre.<BR/>Duration: 6 months (phase III and VI) preceded by phase II (2 weeks washout) plus phase I (2 weeks assessment period).<BR/>Analysis: intention-to-treat.<BR/>Country: Canada.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=70.<BR/>Age: mean 47.8 years.<BR/>Sex: M 48, F24 (report 2 more patients)#.<BR/>Setting: hospital.<BR/>History: chronic (mean 17.5 years of hospitalisation).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose no data, only the equivalence between both drugs. N=35.<BR/>2. Fluphenazine enanthate (Prolixin): dose no data, only the equivalence between both drugs. N=35.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Side effects.<BR/>Leaving the study early.</P>
<P>Mental state: (psychological tests; Bender-Gestalt Score; Hooper VOT scores, MSRPP ratings - no SD).<BR/>Behaviour: (daily ward reports - nursing staff).<BR/>Laboratory tests.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P># report 48 male plus 24 female=72 patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bishop-1963">
<CHAR_METHODS>
<P>Allocation: randomly divided, no further details.<BR/>Blindness: double (identical capsules, coded bottles).<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 8 weeks (preceded by one placebo week and off of study medication for at least 60 days).<BR/>Analysis: intention-to-treat not performed.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further information.<BR/>N=40.<BR/>Age: range 22-49 years.<BR/>Sex: M 20, F 18.<BR/>Setting: hospital.<BR/>History: chronic (length of hospitalisation 3-17 years).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose (weeks 2 to 5, 15 mg/day, weeks 6 to 9, 24 mg/day). N=20.<BR/>2. SK&amp;F 7261: dose (weeks 2 to 5, 3 mg/day), (weeks 6 to 9, 6 mg/day). N=20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Side effects: (total number, weight gain).<BR/>Global state: (change in condition).</P>
<P>Unable to use - <BR/>Psychological findings.<BR/>Mental state: (Lorr psychiatric rating scale).<BR/>Laboratory tests.<BR/>Vital signs.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bishop-1964">
<CHAR_METHODS>
<P>Allocation: "randomly divided", no further details.<BR/>Blindness: double (identical capsules dispensed from individual bottles).<BR/>Design: 3 parallel groups, single centre.<BR/>Duration: 10 weeks (preceeded by 60 days washout).<BR/>Analysis: intention to treat.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=42.<BR/>Age: range 21-53 years, mean 41 years.<BR/>Sex: M 21, F21.<BR/>Setting: hospital.<BR/>History: chronic schizophrenia (time in hospital 3-27 years). <BR/>Excluded: physical or neurologic disorders.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose 5 mg/day (week 1) increasing to 40 mg/day by (week 5). N=14.<BR/>2. Butaperazine: dose 25 mg/day (week 1) increasing to 200 mg/day by (week 5). N=14.<BR/>3. Placebo. N=14.<BR/>* Half of the patients in each group received Artane 2 mg t.i.d., and the others "placebo Artane".<BR/>Use of prophylactic antiparkinson medication.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state.<BR/>Side effects: (Extrapyramidal, lethargy).</P>
<P>Unable to use - <BR/>Mental state: (Psychotic Reaction Profile; Beckomberga rating scale).<BR/>Behaviour: (Tulane test battery; Minimal Social Behavior).<BR/>Laboratory tests: (no data).<BR/>Physiological measures.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bishop-1966">
<CHAR_METHODS>
<P>Allocation: "prearranged randomised procedure", no further details.<BR/>Blindeness: double, (identical capsules supplied in individual bottles only with the subjects study number).<BR/>Design: 2 parallel groups, two centres.<BR/>Duration: 30 days.<BR/>Analysis: intention-to-treat.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further information.<BR/>N=40.<BR/>Age: range 18-54 years, mean 34.3 years.<BR/>Sex: M 21, F 19.<BR/>Setting: hospital.<BR/>History: newly admitted patients, trifluoperazine group &gt; paranoid diagnosis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 5-30 mg/day. N=21.<BR/>2. Thiothixene: range 5-30 mg/day. N=19.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (global ratings of improvement).<BR/>Side effects: (EPS).</P>
<P>Unable to use - <BR/>Mental state: (BPRS, only graphs).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>#The groups differ on sex, age and diagnostic type.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bishop-1967">
<CHAR_METHODS>
<P>Allocation: "prearranged randomised procedure".<BR/>Blindness: double (identical capsules in individual bottles labeled with the subjects' study number).<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 6 weeks (preceded for 2 weeks washout).<BR/>Analysis: intention-to-treat described only for side effects and use of antiparkinson agents.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further information.<BR/>N=52.<BR/>Age: range 19-51 years, mean 30.8 years.<BR/>Sex: M 15, F 37.<BR/>Setting: hospital.<BR/>History: first admission, or no more than 2 hospitalisations with good remissions.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 7.5-30 mg/day. N=27.<BR/>2. SK&amp;F 14336 (acridanes) range 100-400 mg/day. N=25.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (CGI).<BR/>Leaving the study early.<BR/>Side effects.<BR/>Use of antiparkinson agents.</P>
<P>Unable to use - <BR/>Mental state: (BPRS - only "p" value).<BR/>Behaviour: (NOSIE - only "p" value).<BR/>Laboratory tests - no data.<BR/>Vital signs - no data.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bishop-1970">
<CHAR_METHODS>
<P>Allocation: divided on a random basis, no further details.<BR/>Blindness: double, no further information.<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 8 weeks (preceded by 4 weeks washout + 2 weeks assessment period).<BR/>Analysis: intention-to-treat.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=24.<BR/>Age: range 30-55 years, mean 43.9 years.<BR/>Setting: hospital.<BR/>Sex: 12 M, 12 F.<BR/>History: chronic, mean length of hospitalisation ~ 17 years, range 5-29 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 10-60 mg/day. N=12.<BR/>2. Loxapine: range 20-120 mg/day. N=12.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (CGI).<BR/>Side effects: (EPS, hypotension).</P>
<P>Unable to use - <BR/>Mental state: (BPRS - no usable data).<BR/>Behaviour: (NOSIE - no usable data).<BR/>Laboratory tests: (ECG - no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brauzer-1968">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further details.<BR/>Blindness: double (identical 10cc multiple dose vials).<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 72 h.<BR/>Analysis: intention-to-treat.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM).<BR/>N=36.<BR/>Age: at least 21 years.<BR/>Sex: M 17, F 19.<BR/>Setting: hospital.<BR/>History: acute patients, recently hospitalised **include one chronic brain syndrome with psychosis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose maximum 20 mg/day IM. N=18.<BR/>2. Thiothixene: dose maximum 20 mg/day IM. N=18.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state.<BR/>Side effects.<BR/>Use of antiparkinson agents.</P>
<P>Unable to use - <BR/>Mental state: (IMPS; BPRS - no data).<BR/>Physiological measures - no data available.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>** Mixed diagnosis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brauzer-1971">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further description.<BR/>Blindness: double.<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 1 to 3 months.<BR/>Analysis: intention-to-treat not performed in the trial.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia**.<BR/>N=25.<BR/>Age: mean 41.8 years.<BR/>Sex: M 11, F 14.<BR/>Setting: outpatients.<BR/>History: only 20% are paranoid schizophrenics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose initially 5 mg/day followed by minimum 8 mg/day and maximum of 19 mg/day, then maintenance dose 13 mg/day. N=13.<BR/>2. Molindone: dose initially 10 mg/day, followed by minimum of 18 mg/day and maximum of 38 mg/day, then maintenance dose 25 mg/day. N=12.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Use of antiparkinson agents.<BR/>Leaving the study early.</P>
<P>Unable to use - <BR/>Mental state: (BPRS - no SD). <BR/>Side effects - no data.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>**Mixed diagnosis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Claghorn-1974">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further details.<BR/>Blindness: double (identical capsules).<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 24 weeks.<BR/>Analysis: intention-to-treat.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia no further details.<BR/>N=87.<BR/>Age: range 22-65 years, mean 42.5 years.<BR/>Sex: M 23, F 64.<BR/>Setting: outpatients.<BR/>History: maintenance treatment of chronic (at least 2 years duration) adults.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range: 5-19 mg/day (mean 12.53 mg/day). N=44.<BR/>2. Pimozide: range 2-8 mg/day (mean 5.16 mg/day). N=43.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Side effects.<BR/>Laboratory tests.</P>
<P>Unable to use - <BR/>Mental state: (BPRS).<BR/>Global state: (CGI).<BR/>Behaviour: (Evaluation of Social Functioning).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Clark-1975">
<CHAR_METHODS>
<P>Allocation: pre-randomised list, blocks of 3, provided by drug company.<BR/>Blindness: double (identical capsules).<BR/>Design: 3 parallel groups, single centre.<BR/>Duration: 4 weeks.<BR/>Analysis: intention-to-treat performed only for some outcomes.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, confirmed by research psychiatry.<BR/>N=42.<BR/>Age: range: 21-57 years.<BR/>Sex: M 21, F 16.<BR/>Setting: hospital.<BR/>History: newly admitted chronic patients. <BR/>Excluded: &lt; 2 years of illness; &lt; 18 years of age; mental deficiency, epilepsy, organic brain disease, metabolic disorders, liver, renal or cardiac disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose 10 mg/day initially, then increasing to maximum 50 mg/day (mean 36 mg). N=14.<BR/>2. Loxapine: dose 20 mg/day initially, then increased to maximum 100 mg/day, (mean 71mg). N=15.<BR/>3. Placebo: 2-10 capsules. N=13.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Side effects: (total; EPS; insomnia; weight; EKG).<BR/>Global state: (CGI; use of additional sedation).<BR/>Laboratory tests.</P>
<P>Unable to use - <BR/>Mental state: (BPRS - no SD).<BR/>Efficacy: (analysis of covariance - no usable data).<BR/>Behaviour: (NOSIE - no usable data).<BR/>Physiological measures: (BP, pulse - no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Coons-1962">
<CHAR_METHODS>
<P>Allocation: randomly assigned (by Dr. Coons independently, code in a sealed envelope).<BR/>Blindness: double (identical capsules, coded bottles).<BR/>Design: 3 parallel groups, single centre.<BR/>Duration: 6 weeks (preceded by 8 days washout).<BR/>Analysis: intention-to-treat.<BR/>Country: Canada.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: ** mixed (~79,4% schizophrenia; ~12% affective psychoses; ~5% psychoneuroses; ~3.6% outros, ~12% leucotomy).<BR/>N=117.<BR/>Age: ~47 years.<BR/>Sex: female.<BR/>Setting: hospital.<BR/>History: long term hospital patients (mean~141 months).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose 15 mg/day. N=39.<BR/>2. Chlorpromazine: dose 150 mg/day. N=39.<BR/>3. Placebo. N=39.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Use of antiparkinson agents.</P>
<P>Unable to use - <BR/>Behaviour: (Hospital Adjustment Scale - no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>** Mixed diagnosis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Denber-1972">
<CHAR_METHODS>
<P>Allocation: randomly assigned, (random code was unknown until the end of study).<BR/>Blindness: double (identical capsules dispensed by the research nurse).<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: average of 36 days.<BR/>Analysis: intention-to-treat.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: ** 26 schizophrenics; 1 psychose + mental deficiency and 3 involutional psychoses.<BR/>N=31 (30 patients, one patient participated twice).<BR/>Age: no data.<BR/>Sex: only female.<BR/>Setting: hospital.<BR/>History: acute illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose (mean 58.7 mg/day). N=15.<BR/>1. Thiothixene: dose (mean 49 mg/day). N=16.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Side effects: (total number; specific).<BR/>Global state: (global clinical evaluation). <BR/>Weight changes.<BR/>Use of antiparkinson agents.<BR/>Leaving the study early.</P>
<P>Unable to use - <BR/>Mental state: (IMPS).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>** Mixed diagnosis, one patient participated twice.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Donlon-1978">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further details.<BR/>Blindness: double (identical drug and placebo capsules).<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 52 weeks.<BR/>Analysis: intention-to-treat not performed in the trial.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details. <BR/>N=25.<BR/>Age: mean 41 years.<BR/>Sex: M 12, F 13.<BR/>History: chronic.<BR/>Inclusion: no depression, good health, no previous hospitalisation during last 6 months, symptoms stabilised with neuroleptics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 20-40 mg/day. N=13.<BR/>2. Penfluridol: dose range once a week 80-160 mg plus 6 days of placebo. N=12.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early<BR/>Global state: (CGI, use of additional medication).<BR/>Adverse effects: (TESS; ophtalmologic; abnormal laboratory values).</P>
<P>Unable to use - <BR/>Mental state: (BPRS - only graphs, Hamilton's Psychiatric Scale for depression factors - no data).<BR/>Social state: (Evaluation of Social Functioning factors -no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Edwards-1980">
<CHAR_METHODS>
<P>Allocation: randomly assigned in advance and held by the hospital pharmacist (open list of random numbers). Blindness: double.<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 6 weeks (preceded by 1 month washout if possible).<BR/>Analysis: intention-to-treat not performed in the trial. <BR/>Country: UK.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, Schneider 1959.<BR/>N=38.<BR/>Age: range 25-74 years, majority 55-64 years.<BR/>Sex: M 33, F 5.<BR/>Setting: hospital.<BR/>History: long-stay inpatients, 36 ill &gt;10 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 15-45 mg/day (mean 27.7 mg). N=19.<BR/>2. Sulpiride: range 600-1800 mg/day (mean 1212 mg). N=19.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (change in condition; severity of illness).<BR/>Leaving the study early.<BR/>Use of hypnotic.<BR/>Use of antiparkinson agents.<BR/>Side effects: (specific list).</P>
<P>Unable to use - <BR/>Mental state: (BPRS - no SD).<BR/>Side effects: (Simpson and Angus Scale - no SD).<BR/>Physiological measures: (handwriting, weight, pulse, blood pressure - no SD).<BR/>Live events - denominator unclear.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Freeman-1968">
<CHAR_METHODS>
<P>Allocation: randomly assigned, random code not broken to the end of study.<BR/>Blindness: double (identical capsules).<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 12 weeks (preceded by 4 weeks washout).<BR/>Analysis: intention-to-treatnot performed in the trial.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=41.<BR/>Age: mean 30 years.<BR/>Sex: M 14, F 27.<BR/>Setting: hospital.<BR/>History: majority of cases undifferentiated and paranoid.<BR/>Inclusion: duration of present illness of not more than 2 years and hospital admissions not longer than 5 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose 15 mg/day (first week), 30 mg/day (second week), maximum 45 mg/day (mean 26 mg). N=20.<BR/>2. SKF 14336: dose 200 mg/day (first week), 400 mg/day (second week), maximum 600 mg/day (mean 385 mg). N=21.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (global judgement of the psychiatrists).<BR/>Use of antiparkinson agents.<BR/>Side effects. <BR/>Leaving the study early.<BR/>Side effects: (abnormal laboratory tests).</P>
<P>Unable to use - <BR/>Mental state: (BPRS; IMPS - only graphs).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gallant-1968">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further details.<BR/>Blindness: double.<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 9 weeks (preceded by minimum of 17 days washout).<BR/>Analysis: intention-to-treat.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=24.<BR/>Age: average 43 years.<BR/>Sex: M 12, F 12.<BR/>Setting: hospital.<BR/>History: chronic.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose up to 80 mg/day. N=12.<BR/>2. Molindone: dose up to 80 mg/day. N=12.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (global ratings of improvement).<BR/>Side effects: (EPS).<BR/>Use of antiparkinson agents.</P>
<P>Unable to use - <BR/>Mental state: (BPRS - no data).<BR/>Behaviour: (NOSIE - no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gallant-1968-II">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further details.<BR/>Blindness: no data#.<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 1 week (preceded by minimum of 26 days washout).<BR/>Analysis: intention-to-treat.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=52.<BR/>Age: range 31-58 years, mean 45 years.<BR/>Setting: hospital.<BR/>Sex: M 26, F 26.<BR/>History: chronic Illness (average length of hospitalisation 16.5 years, range 4-28 years).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose 20 mg/day IM (maximum). N=26.<BR/>2. Thiothixene: dose 20 mg/day IM (maximum). N=26.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (global ratings of improvment).<BR/>Side effects: (EPS, sedation, local tissue reactions).</P>
<P>Mental state: (BPRS - no data).<BR/>Behaviour: (NOSIE - no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P># Blindness: no data.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gallant-1972">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further details.<BR/>Blindness: no data#.<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 8 weeks (preceded by 2 weeks of baseline examinations, 25 days washout).<BR/>Analysis: intention-to-treat.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=24.<BR/>Age: median ~ 39.5 years.<BR/>Sex: males and females, no further details.<BR/>Setting: hospital.<BR/>History: chronic Illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose 10-100 mg/day. N=12.<BR/>2. GP-45795 (tricyclic dibenzothiepin): dose 50-500 mg/day. N=12.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (global ratings of clinical change).<BR/>Side effects: (EPS, hypotension).</P>
<P>Unable to use - <BR/>Mental state: (BPRS - only "p" value).<BR/>Behaviour: (NOSIE - only "p" value).<BR/>EKG.<BR/>Photosensitivity skin tests.<BR/>Laboratory tests.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P># Blindness: no data.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gross-1974">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further information.<BR/>Blindness: double (identical capsules).<BR/>Design: 3 parallel groups, single centre.<BR/>Duration: 16 weeks (preceded by 4 weeks neuroleptic treatment not exceeding chlorpromazine 500 mg/d, thioridazine 500 mg/d, trifluoperazine 30 mg/d, fluphenazine 30 mg/d) + 36 weeks (extended open evaluation)).<BR/>Analysis: intention-to-treat.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=61.<BR/>Age: mean ~ 46 years.<BR/>Sex: M 37, F 24.<BR/>Setting: formerly hospitalised (residents of Harbor View House).<BR/>History: chronic schizophrenia (ill&gt; 2 years or past 3 months hospitalisation with continuous antipsychotic treatment ).<BR/>Excluded: epilepsy, drug addiction, severe depression, mental retardation, organic brain disease, physical disease, and those receiving heavy sedation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 5-30 mg/day, mean 17.5 mg. N=20.<BR/>2. Pimozide: range 2-12 mg/day (mean 6.3 mg). N=21.<BR/>3. Placebo: N=20.<BR/>Antiparkinson medication and chloral hydrate if necessary.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (CGI).<BR/>Leaving the study early.</P>
<P>Unable to use - <BR/>Mental state: (BPRS - only graphs).<BR/>Global state: (CGI - no usable data).<BR/>Social functioning: (Family Rating Form - no usable data; Harbor view house Resident Rating Report - unpublished scale).<BR/>Adverse events: (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>##High dropout rate(40,1%).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gwynne-1962">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further details.<BR/>Blindness: double (identical capsules).<BR/>Design: 3 parallel groups, single centre.<BR/>Duration: 16 weeks (preceded by at least 1 month washout).<BR/>Analysis: intention-to-treat not performed in the trial.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=78.<BR/>Age: mean 49 years.<BR/>Sex: M 39, F 39.<BR/>Setting: hospital.<BR/>History: chronic illness (average time in hospital 20 years); withdrawal for at least 1 year; poor response to previous therapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 10-40 mg/day, mean at week-16, 11.2 mg. N=26.<BR/>2. Chlorpromazine: range 100-400 mg/day, mean at week-16, 146mg. N=26.<BR/>3. Placebo: N=26.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Side effects.</P>
<P>Unable to use - <BR/>Mental state: (Lorr Multidimensional Scale for Rating Psychiatric Patients - only "p" value).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kiloh-1976">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further details.<BR/>Blindness: double (identical capsules).<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 12 weeks (preceded by 2 weeks washout).<BR/>Analysis: intention-to-treat not performed in the trial.<BR/>Country: Australia.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, Clinical Psychiatry by Slater and Roth 1969.<BR/>N=57. <BR/>Age: range 20-69 years.<BR/>Sex: male and female, no further details. <BR/>Setting: hospital at the beginning, then continued on an out-patients basis.<BR/>History: acute (ill for less than 2 years) and chronic (over than 2 years) schizophrenic patients.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: mean doses, acute 23.5 mg/day (N=10), chronic 31mg/day (N=11).<BR/>2. Loxapine: mean doses, acute 37mg/day (N=17), chronic 56 mg/day (N=8).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Use of antiparkinson agents.<BR/>Global state: (global rating changes).<BR/>Side effects.<BR/>Leaving the study early.</P>
<P>Unable to use - <BR/>Mental state: (BPRS - no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Malik-1980">
<CHAR_METHODS>
<P>Allocation: randomly allocated.<BR/>Blindness: double (identical capsules).<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 28 days.<BR/>Analysis: intention-to-treat not performed in the trial.<BR/>Country: India.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=54.<BR/>Age: range 14-19 years mean ~17 years.<BR/>Sex: M 25, F 27 (2 not reported).<BR/>Setting: hospital.<BR/>History: adolescent schizophrenics. <BR/>Exclusion: sensivity to study drugs, ECT in the last 8 weeks, brain syndrome, convulsive disorders, mental retardation or autism.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose mean 23.57 mg/day, maximum 35 mg. N=27.<BR/>2. Loxapine succinate: dose mean 91.5 mg/day, maximum 120 mg. N=27.<BR/>Antiparkinson medication as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (CGI, patient's self evaluation).<BR/>Patient's drug preference.<BR/>Leaving the study early.</P>
<P>Unable to use - <BR/>Mental state: (BPRS - no SD).<BR/>Use of antiparkinson drugs - no data.<BR/>Physiological measures: (BP, pulse - no data).<BR/>Laboratory tests - no data.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Marjerrison-1964">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further details.<BR/>Blindness: double (multiplicity of forms, individual coded bottles).<BR/>Design: 4 parallel groups, single centre.<BR/>Duration: phase I, five-months; phase II, two-months.<BR/>Analysis: intention-to-treat not performed in the trial.<BR/>Country: Canada.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: **schizophrenia but 12 with other diagnoses distributed among the groups.<BR/>N=88.<BR/>Age: mean 48 years.<BR/>Sex: M 38, F 40.<BR/>Setting: hospital.<BR/>History: chronic psychotics; highly treatment resistant.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose phase I, 29 mg/day, phase II, 27 mg/day. N=16.<BR/>2. Chlorprothixene: dose phase I, 200 mg/day, phase II, 270 mg/day. N=8.<BR/>3. Placebo. N=34.<BR/>4. Usual Phenothiazines: dose variated. N=30 (drugs were chosen clinically).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Global state: (numbers of subjects receiving barbiturate medication).<BR/>Use of antiparkinson agents.</P>
<P>Unable to use - <BR/>Mental state: (PRP; Ward Inventory scores).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>** Mixed diagnosis.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Marjerrison-1966">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further details.<BR/>Blindness: double (coded bottles).<BR/>Design: 3 parallel groups, single centre.<BR/>Duration: 12 weeks (preceded by a 7-month drug-withdrawal project).<BR/>Analysis: intention-to-treat.<BR/>Country: Canada.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=27.<BR/>Age: range 32-63 years, median 47 years.<BR/>Sex: male and female. <BR/>Setting: hospital.<BR/>History: highly treatment resistant, long-term chronic patients (length of hospitalisation range 3-33 years).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose initial mean 27.5 mg/day, final 26 mg. N=8.<BR/>2. Triperidol: dose initial mean 10 mg/day, final 6.4 mg. N=8.<BR/>3. Haloanisone: dose initial mean 35 mg/day, final 45 mg. N=11.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Use of antiparkinson agents.</P>
<P>Unable to use - <BR/>Mental state: (PRP; IMPS - no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Menon-1972">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further details.<BR/>Blindness: research workers blind, no further information.<BR/>Design: 3 parallel groups, single centre.<BR/>Duration: 10 weeks (preceded by 6 weeks washout).<BR/>Analysis: intention-to-treat.<BR/>Country: India.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (clinical criteria).<BR/>N=60.<BR/>Age: range 20-60 years.<BR/>Sex: M 30, F 30.<BR/>Setting: hospital.<BR/>History: chronic, length of hospitalisation 1.5-10 years; continuously hospitalised &gt; 1 year.<BR/>Excluded: mental deficiency and physical complications.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose 15 mg/day. N=20.<BR/>2. Trifluperidol: dose 1.5 mg/day. N=20.<BR/>3. Placebo: N=20.<BR/>* Antiparkinson drugs if necessary.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (QPSS scale).<BR/>Behaviour: (Wings scale).<BR/>Side effects: (EPS, nausea and vomiting).</P>
<P>Unable to use - <BR/>Laboratory tests - no data.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Needham-1969">
<CHAR_METHODS>
<P>Allocation: randomly assigned by the pharmacist, no further details.<BR/>Blindness: double (identical capsules).<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 24 weeks (preceded by 4 weeks washout).<BR/>Analysis: intention-to-treat not performed in global state.<BR/>Country: Australia.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=54.<BR/>Age: mean 45 years. <BR/>Sex: only male.<BR/>History: average duration of illness 22 years; majority chronic undifferentiated schizophrenics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 11.25-37.5 mg/day. N=27.<BR/>2. SKF 14336: range 150-500 mg/day. N=27.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Global state: (Global evaluation of improvement).<BR/>Side effects: (EPS, skin and eyes changes).</P>
<P>Unable to use - <BR/>Mental state: (BPRS - no SD).<BR/>Behaviour: (NOSIE - no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-O_x0027_Brien-1974">
<CHAR_METHODS>
<P>Allocation: randomly assigned (code held by a technician who was not responsible for allocation).<BR/>Blindness: double (identical capsules, coded bottles).<BR/>Design: 2 parallel groups, 2 centres.<BR/>Duration: 3 weeks.<BR/>Analysis: intention-to-treat not performed in the trial.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: patients with symptoms of hostility, suspiciousness, paranoia and aggressiveness; 20 schizophrenics*.<BR/>N=30.<BR/>Age: mean ~30 years.<BR/>Sex: M 22, F 2.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose 9-48 mg/day. N=15.<BR/>2. Haloperidol: dose 3-20 mg/day. N=15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state.<BR/>Leaving the study early.<BR/>Use of antiparkinson agents.</P>
<P>Unable to use - <BR/>Mental state: (BPRS; Global Hostility; Global Paranoia - no SD).<BR/>Psychological Tests: (Buss-Durkee hostility inventory; Rozenzweig picture frustration test; MMPI and Rorshach test - no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>**Mixed diagnosis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Perales-1974">
<CHAR_METHODS>
<P>Allocation: randomly assigned by random table (independently and secretly by the head of the project).<BR/>Blindness: double (treatment and evaluation made by 2 independent psychiatrists blind to drug taken).<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 45 days.<BR/>Analysis: intention-to-treat.<BR/>Country: Peru.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia no further details.<BR/>N=30.<BR/>Age: range 19-43 years, mean 31.3 years. <BR/>Sex: M 26, F 4.<BR/>Setting: hospital.<BR/>History: acute state of paranoid schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose first 5 days 2-8 amp (2-8 mg IM), then 10-40 mg. N=15.<BR/>2. Clotiapine: dose first 5 days 1-4 amp (40-160 mg IM), then 40-60 mg. N=15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (clinical evaluation).<BR/>Side effects.</P>
<P>Unable to use - <BR/>Mental state: (BPRS).<BR/>Side effects: (Extrapiramidal signs - Bordeau scale). <BR/>Use of antiparkinson agents.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Prien-1969">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further details.<BR/>Blindness: double (identical capsules).<BR/>Design: 3 parallel groups, at 6 hospitals centres.<BR/>Duration: 24 weeks (no washout period).<BR/>Analysis: intention-to-treat.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=360.<BR/>Age: mean 41.8 years.<BR/>Sex: M 180, F 180.<BR/>History: chronic (55% more than ten years of hospitalisation).<BR/>Exclusion: organic brain disease, mental deficiency or medical conditions contraindicated with high dose drugs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1.Trifluoperazine: dose 80 mg/day. N=120.<BR/>2.Trifluoperazine: dose 15 mg/day. N=120.<BR/>3. Placebo: N=120.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (Global psychiatric change).<BR/>Side effects.<BR/>Leaving the study early.<BR/>Opthalmologic changes.<BR/>DRI (Discharge readiness Inventory).</P>
<P>Unable to use - <BR/>Mental state: (BPRS; IMPS - no data).<BR/>Behaviour: (NOSIE - no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ramsay-1970">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further information.<BR/>Blindness: double (identical capsules).<BR/>Design: 2 parallel groups.<BR/>Duration: 12 weeks, single centre.<BR/>Analysis: intention-to-treat.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenics, no further details.<BR/>N=20.<BR/>Age: range 29-55 years, mean 44.4 years.<BR/>Sex: M 14, F 6.<BR/>Setting: hospital.<BR/>History: "chronic" (hospitalised for at least 2 years).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 10-60 mg/day. N=10.<BR/>2. Molindone: range 20-120 mg/day. N=10.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early<BR/>Side effects: (total number, EPS). </P>
<P>Unable to use - <BR/>Global state: (CGI).<BR/>Mental state: (BPRS).<BR/>Behaviour: (NOSIE).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Reardon-1966">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further description.<BR/>Blindness: double.<BR/>Design: 3 parallel groups, single centre.<BR/>Duration: minimum 4 weeks, maximum 12 weeks.<BR/>Analysis: intention-to-treat not performed in the trial.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: paranoid schizophrenia (Bleuler criteria).<BR/>N=34.<BR/>Age: not stated.<BR/>Sex: M 22, F 12.<BR/>Setting: hospital.<BR/>History: "acute" illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose 20 mg/day (week 1), 40 mg/day thereafter. N=11.<BR/>2. Chlorpromazine: dose 300 mg/day (week 1) 600 mg/day thereafter. N=11.<BR/>3. Placebo: 2-4 cc/day (week 1), 5-10 cc/day thereafter. N=12.<BR/>Artane 10 mg/day prophylactically.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving study early.<BR/>Global state: (lack of previously observed delusions and hallucinations). </P>
<P>Unable to use - <BR/>Mental state: (MMPI - no SD).<BR/>Shipley Hartford.<BR/>WAIS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rubin-1971">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further description. <BR/>Blindness: double (identical capsules).<BR/>Design: 2 parallel groups.<BR/>Duration: minimum 5 days, maximum 79 days.<BR/>Analysis: intention-to-treat.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: *psychotic patients: paranoid schizophrenics (13); undifferentiated schizophrenia (4); Manic-depressive (1).<BR/>N=18.<BR/>Age: range 26-49 years, mean 37.5 years.<BR/>Sex: only male.<BR/>Setting: hospital.<BR/>History: acute illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 6-60 mg/day. N=8.<BR/>2. Haloperidol: range 2-20 mg/day. N=10.<BR/>3 patients receiving TFP began group psychotherapy.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (Mental Status Schedule; discharged from hospital.</P>
<P>Unable to use - <BR/>Average time of onset of Therapeutic Effect: (only patients who improved).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>**Mixed diagnosis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schiele-1961">
<CHAR_METHODS>
<P>Allocation: randomly assigned (held by the pharmacist).<BR/>Blindness: double (identical capsules, coded bottles).<BR/>Design: 4 parallel groups, single centre.<BR/>Duration: 16 weeks (in strict double-blind conditions) + 22 weeks, no washout period.<BR/>Analysis: intention to treat.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=80.<BR/>Age: mean 40.6 years.<BR/>Sex: males.<BR/>Setting: hospital.<BR/>History: chronic (average hospitalisation 10 years).<BR/>Excluded: people &gt; 55 years and organic factors.<BR/>Included: inadvertently 3 with lobotomies (2 in the thioridazine group and other in the chlorpromazine).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: 10-50 mg/day, maximum 35 mg, 12 received less than the maximum. N=20.<BR/>2. Thioridazine: 200-1000 mg/day, maximum 958 mg, 3 received less than the maximum. N=20.<BR/>3. Chlorpromazine: 200-1000 mg/day, maximum 894 mg/day, 3 received less than the maximum. N=20.<BR/>4. Placebo: 2-10 capsules.<BR/>Occasional additional medication, phenobarbital and benzotropine methansulfonate.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (Clinical Evaluation).<BR/>Side effects.<BR/>Leaving the study early.<BR/>Use of antiparkinson agents.</P>
<P>Unable to use - <BR/>Behaviour: (Behaviour rating scale - no SD).<BR/>Mental state: (MMPI - only 43 patients took the tests).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schiele-1969">
<CHAR_METHODS>
<P>Allocation: randomly assigned (by administrative personnel not involved with patient treatment or evaluation).<BR/>Blindness: double (identical capsules).<BR/>Design: 2 parallel groups.<BR/>Duration: 4 weeks, but it was permitted to remove patients at the end of 2 weeks or to continue beyond the 4 weeks.<BR/>Analysis: only 2 weeks ratings were analysed because of the small sample size.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further information.<BR/>N=21.<BR/>Age: range 16-48 years, mean 24 years.<BR/>Sex: no information.<BR/>Setting: hospital.<BR/>History: acute illness; patients must not have been hospitalised during the preceding 12 months, or have childhood schizophrenia, or brain syndrome, or mental deficiency, alcoholism, epilepsy or drug addiction.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 15-30 mg/day. N=10.<BR/>2. Trifluperidol: range 3-6 mg/day. N=11.<BR/>Without washout period; using antiparkinson drug only if dose reduction of the antipsychotic did not provide relief.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early (at the end of 2 weeks).</P>
<P>Unable to use - <BR/>Global state: (Global rating of Pathology; Global rating of improvement - no SD).<BR/>Mental state: (BPRS; MMPI; IMPS - no SD).<BR/>Side effects: (no data available).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P># Analysis performed in 2 weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Seth-1979">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further information.<BR/>Blindness: double (identical capsules).<BR/>Design: 2 parallel groups.<BR/>Duration: 12 weeks.<BR/>Analysis: intention-to-treat not performed in the trial.<BR/>Country: India.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenics, no further details.<BR/>N=72.<BR/>Age: range 20-49 years, mean 30 years.<BR/>Sex: M 28, F 36.<BR/>Setting: hospital.<BR/>History: chronic illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 5-45 mg/day. N=36.<BR/>Medication free for at least 4 weeks.<BR/>2. Loxapine: range 20-90 mg/day. N=36.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Side effects.</P>
<P>Unable to use - <BR/>Mental state: (BPRS).<BR/>Behaviour: (NOSIE).<BR/>Global state: (CGI).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Simpson-1976">
<CHAR_METHODS>
<P>Allocation: randomly assigned (by a person who was not responsible for recruiting patients). <BR/>Blindness: double (identical capsules, coded bottles).<BR/>Design: 2 parallel groups, single center.<BR/>Duration: 4 weeks preceded by 3 days washout (evaluation carried out by the same physician, study lasted over 3 years).<BR/>Analysis: intention-to-treat.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: acute schizophrenia, no further details.<BR/>N=43.<BR/>Age: range 16-61 years, mean 31.7 years.<BR/>Sex : M 27, F 16.<BR/>Setting: hospital.<BR/>History: newly hospitalised, mean admitted ~2 times, 6 first admissions.<BR/>Exclusion: ill health.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 20-50 mg/day, mean 35 mg. N=19.<BR/>2. Loxapine succinate: range 40-80 mg/day, mean 74 mg. N=24.<BR/>Antiparkinson drugs and chlorayl hydrate as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (discharge).<BR/>Leaving the study early.<BR/>Side effects: (unwanted effects checklist, use of neurological rating scale).<BR/>Use of antiparkinson agents.<BR/>Laboratory tests.</P>
<P>Unable to use - <BR/>Global state: (CGI - no usable data).<BR/>Mental state: (BPRS - no usable data).<BR/>Physiological measures: (BP, EEG, opthalmic tests, pulse - no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stewart-1969">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further information.<BR/>Blindness: double (identical capsules).<BR/>Design: crossover.<BR/>Duration: 14 days (washout) + 28 days (1st placebo period) + 56 days (first drug period) + 28 days (2nd placebo period) + 56 days (2nd drug period).<BR/>Analysis: intention-to-treat.<BR/>Country: Canada.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=50.<BR/>Age: range 33-59 years, mean 48.6 years.<BR/>Sex: M 17, F 8 each group.<BR/>Setting: hospital.<BR/>History: "chronic" (hospitalised from 3-37 years); free of epilepsy, chronic brain syndrome and arterioesclerosis and none lobotomized.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 4-16 mg/day. N=25.<BR/>2. Haloperidol: range 4-16 mg/day. N=25.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (overall Improvement).</P>
<P>Unable to use - <BR/>Mental state: (BPRS; IMPS; Rockland-Pollin Scale). <BR/>Side effects.<BR/>Behaviour: (MACC - modified).<BR/>Laboratory tests.<BR/>Vital signs.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sugerman-1965">
<CHAR_METHODS>
<P>Allocation: randomly assigned (according to a number code that had broken only when the study was concluded).<BR/>Blindness: double (identical capsules, individual bottles).<BR/>Design: 2 parallel groups, single centre.<BR/>Duration: 1 month.<BR/>Analysis: intention-to-treat.<BR/>Country: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (clinical criteria).<BR/>N=22.<BR/>Age: mean 32.5 years. <BR/>Sex: M 6, F 16.<BR/>Setting: hospital.<BR/>History: majority was schizophrenic reaction, acute indifferentiated type.<BR/>Exclusion: organic disease and pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: range 4-30 mg/day, mean 10.4 mg. N=11.<BR/>2. Trifluperidol: range 1-7.5 mg/day, mean 2.1 mg. N=11.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Use of antiparkinson agents.<BR/>Leaving the study early.<BR/>Global state: (global clinical rating of change).<BR/>Side effects.<BR/>Tomkins-Horn Picture Arrangement Test.</P>
<P>Unable to use - <BR/>Mental state: (BPRS - no SD).<BR/>Behaviour: (NOSIE - no SD).<BR/>Hoffer-Osmond Diagnostic Test.<BR/>Tulane Behavioral rating Scale.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Vergara-1977">
<CHAR_METHODS>
<P>Allocation: randomly assigned, no further details.<BR/>Blindness: double.<BR/>Design: 2 parallel groups.<BR/>Duration: 16 weeks (pre study neuroleptic medication was discontinued between the 28th and 84th day).<BR/>Analysis: intention-to-treat.<BR/>Country: Canada.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenics, no further details.<BR/>N=20.<BR/>Age: range 20-55 years, mean 38.4 years.<BR/>Sex: M 13, F 7.<BR/>Setting: outpatients.<BR/>History: chronic illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trifluoperazine: dose 5-30 mg/day. N=10.<BR/>2. Pimozide: dose 2-12 mg/day. N=10.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: (CGI).<BR/>Side effects.<BR/>Leaving the study early.</P>
<P>Unable to use - <BR/>Mental state: (BPRS - no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AIMS = Abnormal Involuntary Movement Scale<BR/>BPRS = Brief Psychiatric Rating Scale<BR/>CGI = Clinical Global Improvement<BR/>DSM-III-R = Diagnostic and Statistical Manual, 3-rd revised edition<BR/>EKG = Electrocardiogram <BR/>EPS = Extrapyraminal Rating Scale<BR/>IMPS = Inpatient Multidimensional Psychiatric Scale<BR/>ITT= Intention to treat<BR/>MMPI = The Minnesota multiphasic personality inventory <BR/>NOSIE = Nurses Observational Scale of Inpatients Evaluation <BR/>TESS = Treatment Emergent Symptom Scale<BR/>WAIS = Wechsler Adult Intelligence Scale<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Abraham-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: trifluoperazine and ECT versus trifluoperazine with simulated ECT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barsa-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brannen-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with chronic schizophrenia.<BR/>Interventions: promethazine versus trifluoperazine versus placebo.<BR/>Outcomes: no usable data, 57% lost to follow up.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Buffaloe-1961">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, double-blind crossover study.<BR/>Participants: people with schizophrenia.<BR/>Interventions: first phase only trifluoperazine, second phase trifluoperazine plus parnate versus trifluoperazine.<BR/>Outcomes: no data available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cabrera-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, double-blind study.<BR/>Participants: people with schizophrenia.<BR/>Interventions: interferon "intratecal" + oral placebo versus trifluoperazine + chlorpromazine + trihexifenidil + lumbar injection of distilled water.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Calwell-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: "randomly divided" - no further description, multiple crossover (medication was changed every 4 weeks). <BR/>Participants: women with chronic schizophrenia.<BR/>Interventions: oxypertine versus trifluoperazine.<BR/>Outcomes: no data reported for first arm of crossover.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carscallen-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: "double-blind technique" - no further details.<BR/>Participants: people with schizophrenia.<BR/>Interventions: trifluoperazine 10 mg/day versus trifluoperazine 100 mg/day.<BR/>Outcomes: no data available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Casey-1961">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: d-amphetamine versus isocarboxazid versus imipramine versus trifluoperazine versus placebo but chlorpromazine given to everyone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Childers-1961">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Childers-1962">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with extrapyramidal symptoms.<BR/>Interventions: benzotropine methanesulfonate plus chlorpromazine or trifluoperazine or fluphenazine versus procyclidine plus chlorpromazine or trifluoperazine or fluphenazine, no data for trifluroperazine group alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Childres-1962-b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, "placed in temporal sequence".</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Crane-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: trifluoperazine 80 mg/day versus trifluoperazine 16 mg/day versus placebo.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-D_x0027_Elia-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: trifluoperazine versus pimozide.<BR/>Outcomes: EEG study, no data available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Den-Boer-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: double-blind procedure.<BR/>Participants: people with schizophrenia.<BR/>Interventions: neuroleptic treatment (trifluoperazine, chlorpromazine, haloperidol, thioridazine) plus ritanserin versus neuroleptic treatment plus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dewolfe-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossover trial.<BR/>Interventions: prolixin enanthate versus thorazine-stelazine, not stelazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-DiMascio-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised<BR/>Participants: healthy volunteers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eitan-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: "were assigned", no further details, double-blind crossover study .<BR/>Participants: people with schizophrenia.<BR/>Interventions: chlorpromazine versus thioridazine versus trifluoperazine versus haloperidol versus placebo.<BR/>Outcomes: no data reported for individual arms of cross-over.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fish-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Forrester-1958">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gardos-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: "were assigned" - no further details.<BR/>Participants: psychotic patients - no further details.<BR/>Interventions: two different samples, withdrawn group (trifluoperazine 10 mg versus trifluoperazine 5 mg + chlorpromazine 50 mg) and agitated group (chlorpromazine 200 mg versus trifluoperazine 5 mg+ chlorpromazine 200 mg).<BR/>Outcomes: no data available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gottfries-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guido-1960">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Held-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: thorazine versus melleril versus stelazine versus prolixin versus proketazine versus trifalon versus haloperidol versus placebo.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Janecek-1963">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jones-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jones-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Joshi-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear - double-blind study.<BR/>Participants: people with schizophrenia.<BR/>Interventions: combined modality therapy (trifluoperazine + vitamins versus trifluoperazine + placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Joshi-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear - double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: combined modality therapy (trifluoperazine, vitamins B1, B6, B12, chlorpromazine and placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kalinin-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: insulin coma therapy versus individual pharmacotherapy (haloperidol, trifluoperazine plus sedatives - amitriptyline and lithium).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kline-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Knight-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: double-blind crossover trial.<BR/>Participants: people with chronic schizophrenia.<BR/>Interventions: thiothixene versus combination of trifluoperazine and chlorpromazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lal-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - crossover study.<BR/>Participants: people with oral dyskinesia.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lapolla-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: "preponderance of schizophrenia".<BR/>Interventions: only trifluoperazine, no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lovett-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Luckey-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol versus trifluoperazine.<BR/>Outcomes: 66% of people were not reported in the final analysis. <BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Macdonald-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mandel-1962">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossover trial.<BR/>Participants: people with schizophrenia.<BR/>Interventions: trifluoperazine versus butyrylperazine.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mena-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: double-blind controlled study.<BR/>Participants: "chronic outpatients".</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Monroe-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomisation not mentioned, described as controlled.<BR/>Participants: mixed diagnosis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Montero-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: "double-blind".<BR/>Participants: people with paranoid schizophrenia.<BR/>Interventions: thioridazine versus trifluoperazine plus chlorpromazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morton-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - withdrawal study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moyano-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: trifluoperazine versus loxapine succinate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oybir-1962">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pecknold-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised<BR/>Participants: people with schizophrenia.<BR/>Interventions: clomacran versus trifluoperazine.<BR/>Outcomes: 50% left the study.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Polvan-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rudy-1958">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schiele-1963">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: trifluoperazine plus tranilcipromine versus trifluoperazine plus placebo.<BR/>Outcomes: no data reported for the individual drugs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sharpley-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: "double-blind study".<BR/>Interventions: pargyline plus tranylcypromine versus pargyline plus tranylcypromine plus trifluoperazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stanley-1961">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case control study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Talbot-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with schizophrenia.<BR/>Interventions: trifluoperazine plus chlorpromazine versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Teja-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: trifluoperazine versus chlorpromazine versus thiothixene versus haloperidol versus placebo.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tetreault-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with chronic mental disease.<BR/>Interventions: trial 1 - trifluperidol versus trifluoperazine, trial 2 - TPS-23 versus chlorpromazine versus placebo.<BR/>Outcomes: no data available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tolan-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Uddyback-1962">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vogt-1961">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weckowicz-1960">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weston-1961">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: trifluoperazine versus placebo.<BR/>Outcomes: no data available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wilson-1961">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, "Latin square", crossover design.<BR/>Participants: people with schizophrenia.<BR/>Interventions: chlorpromazine versus prochlorperazine versus trifluoperazine versus placebo.<BR/>Outcomes: no data available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Winnik-1962">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Abuzzahab-1977">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Barron-1961">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Bora-1968">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Cahan-1960">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Claghorn-1969">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Freeman-1969">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Gallant-2000">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Gardos-1970">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Hamilton-1963">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Holden-1971">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Hunt-1967">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Khorana-1988">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Kogeorgos-1995">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Madgwick-1958">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Ortega_x002d_Soto-1996">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Platz-1967">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Spiegel-1967">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Svestka-1975">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Terminska-1989">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Toru-1969">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Vinar-1966">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Vinar-1971">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Wijsenbeek-1974">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-_x002a_Bankier-1973">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-_x002a_Doongaji-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-_x002a_Goldstein-1966">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-_x002a_Itil-1971">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-_x002a_Pinard-1972">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-_x002a_Simpson-1971">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-_x002a_Vestre-1970">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Amin-1977">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Andersen-1974">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Angus-1969">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bagadia-1980">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bankier-1968">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bishop-1963">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bishop-1964">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bishop-1966">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bishop-1967">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bishop-1970">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Brauzer-1968">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Brauzer-1971">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Claghorn-1974">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Clark-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Coons-1962">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Denber-1972">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Donlon-1978">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Edwards-1980">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Freeman-1968">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gallant-1968">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gallant-1968-II">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gallant-1972">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gross-1974">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gwynne-1962">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kiloh-1976">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Malik-1980">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Marjerrison-1964">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Marjerrison-1966">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Menon-1972">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Needham-1969">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-O_x0027_Brien-1974">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Perales-1974">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Prien-1969">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ramsay-1970">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Reardon-1966">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rubin-1971">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Schiele-1961">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Schiele-1969">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Seth-1979">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Simpson-1976">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stewart-1969">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sugerman-1965">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vergara-1977">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Comparison compounds used in trifluoperazine studies</TITLE>
<TABLE COLS="2" ROWS="19">
<TR>
<TH>
<P>Drug</P>
</TH>
<TH>
<P>Number of studies</P>
</TH>
</TR>
<TR>
<TD>
<P>loxapine</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>pimozide</P>
</TD>
<TD>
<P>6</P>
</TD>
</TR>
<TR>
<TD>
<P>thiothixene</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>molindone</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>SKF 14336 - acridan derivative</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>chlorpromazine</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>haloperidol</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>trifluperidol</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>fluphenazine</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>fluspirilene</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>penfluridol</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>cetbutindole</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>triperidol</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>clorprothixene</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>clothiapine</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>butaperazine</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>SKF 7261</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>GP-45795</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>TRIFLUOPERAZINE versus PLACEBO</NAME>
<DICH_OUTCOME CHI2="20.757041211800043" CI_END="0.9438675424148669" CI_START="0.6620727650036872" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.790511855448004" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="203" I2="75.9117884433472" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.025088948111407845" LOG_CI_START="-0.17909427687006177" LOG_EFFECT_SIZE="-0.10209161249073483" METHOD="MH" NO="1" P_CHI2="9.002922791859769E-4" P_Q="0.0" P_Z="0.009361624945822836" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.029412270665561752" TOTALS="YES" TOTAL_1="208" TOTAL_2="207" WEIGHT="100.0" Z="2.598557922875976">
<NAME>Global state: 1a. No substantial improvement (defined as slight improvement or worse) - by time period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0733846081493323" CI_END="0.7916222673623567" CI_START="0.49703944260023997" DF="2.0" EFFECT_SIZE="0.6272698705658705" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="46" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.10148199812331458" LOG_CI_START="-0.30360914642973885" LOG_EFFECT_SIZE="-0.20254557227652675" NO="1" P_CHI2="0.9639727007303506" P_Z="8.564003559500661E-5" STUDIES="3" TAU2="0.0" TOTAL_1="48" TOTAL_2="47" WEIGHT="33.79361618903865" Z="3.928042622836821">
<NAME>short term (0-3 months)</NAME>
<DICH_DATA CI_END="0.973846837818861" CI_START="0.44077864724280563" EFFECT_SIZE="0.6551724137931034" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="-0.01150934160250785" LOG_CI_START="-0.35577945228974645" LOG_EFFECT_SIZE="-0.18364439694612714" ORDER="11170" O_E="0.0" SE="0.20222596718221628" STUDY_ID="STD-Bishop-1964" TOTAL_1="14" TOTAL_2="14" VAR="0.040895341802782814" WEIGHT="11.639768695328993"/>
<DICH_DATA CI_END="1.0004449067349859" CI_START="0.38304953333131375" EFFECT_SIZE="0.6190476190476191" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="1.931775701507404E-4" LOG_CI_START="-0.41674506242431575" LOG_EFFECT_SIZE="-0.20827594242708247" ORDER="11171" O_E="0.0" SE="0.2449115860503234" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="0.05998168498168496" WEIGHT="9.1545825523335"/>
<DICH_DATA CI_END="0.8730721990003566" CI_START="0.42585538623093666" EFFECT_SIZE="0.6097560975609756" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" LOG_CI_END="-0.058949840680528824" LOG_CI_START="-0.3707378554148669" LOG_EFFECT_SIZE="-0.21484384804769788" ORDER="11172" O_E="0.0" SE="0.18314582323051437" STUDY_ID="STD-Menon-1972" TOTAL_1="20" TOTAL_2="20" VAR="0.03354239256678282" WEIGHT="12.99926494137616"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.8405435088529227" CI_END="1.0035358899810118" CI_START="0.8463184248553658" DF="2.0" EFFECT_SIZE="0.9215806604386605" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="157" I2="29.590939418222597" ID="CMP-001.01.02" LOG_CI_END="0.001532909002862505" LOG_CI_START="-0.07246620417293007" LOG_EFFECT_SIZE="-0.03546664758503377" NO="2" P_CHI2="0.2416486642361949" P_Z="0.06027703113460794" STUDIES="3" TAU2="0.002004300854198543" TOTAL_1="160" TOTAL_2="160" WEIGHT="66.20638381096136" Z="1.8787617563444172">
<NAME>medium term (+3 months-1 year)</NAME>
<DICH_DATA CI_END="1.089942761339205" CI_START="0.8301523643947886" EFFECT_SIZE="0.9512195121951219" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.037403691438561856" LOG_CI_START="-0.08084219082503442" LOG_EFFECT_SIZE="-0.021719249693236308" ORDER="11173" O_E="0.0" SE="0.0694582165681937" STUDY_ID="STD-Gross-1974" TOTAL_1="20" TOTAL_2="20" VAR="0.004824443848834098" WEIGHT="23.90312149573388"/>
<DICH_DATA CI_END="0.9886212924270802" CI_START="0.8790051020225096" EFFECT_SIZE="0.9322033898305084" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="118" LOG_CI_END="-0.004970040158869425" LOG_CI_START="-0.05600860413693128" LOG_EFFECT_SIZE="-0.03048932214790036" ORDER="11174" O_E="0.0" SE="0.029980305125679865" STUDY_ID="STD-Prien-1969" TOTAL_1="120" TOTAL_2="120" VAR="8.988186954288664E-4" WEIGHT="26.998843126554455"/>
<DICH_DATA CI_END="0.9986358551201121" CI_START="0.5436779435716739" EFFECT_SIZE="0.7368421052631579" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="-5.928450491188232E-4" LOG_CI_START="-0.2646582855000631" LOG_EFFECT_SIZE="-0.13262556527459096" ORDER="11175" O_E="0.0" SE="0.15511334686589623" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="0.024060150375939837" WEIGHT="15.304419188673013"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8911715458533287" CI_END="1.0962644571959523" CI_START="0.5405087901776257" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7697665720682574" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" I2="47.12272389077306" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.039915333752911134" LOG_CI_START="-0.26719723881595153" LOG_EFFECT_SIZE="-0.11364095253152019" METHOD="MH" NO="2" P_CHI2="0.16907006327431717" P_Q="0.0" P_Z="0.14692135155119418" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03384692744410582" TOTALS="SUB" TOTAL_1="28" TOTAL_2="26" WEIGHT="200.0" Z="1.450492060729055">
<NAME>Global state: 1b. No substantial improvement (short term) - by rater's role</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0004449067349859" CI_START="0.38304953333131375" DF="0.0" EFFECT_SIZE="0.6190476190476191" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="1.931775701507404E-4" LOG_CI_START="-0.41674506242431575" LOG_EFFECT_SIZE="-0.20827594242708247" NO="1" P_CHI2="1.0" P_Z="0.050212673757183975" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="99.99999999999999" Z="1.9581477871093675">
<NAME>doctor rated</NAME>
<DICH_DATA CI_END="1.0004449067349859" CI_START="0.38304953333131375" EFFECT_SIZE="0.6190476190476191" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="1.931775701507404E-4" LOG_CI_START="-0.41674506242431575" LOG_EFFECT_SIZE="-0.20827594242708247" ORDER="11176" O_E="0.0" SE="0.2449115860503234" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="0.05998168498168496" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2053005281098914E-30" CI_END="1.1071621047576499" CI_START="0.6745510608993008" DF="0.0" EFFECT_SIZE="0.8641975308641975" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" I2="100.0" ID="CMP-001.02.02" LOG_CI_END="0.04421121261097413" LOG_CI_START="-0.17098517033976" LOG_EFFECT_SIZE="-0.06338697886439294" NO="2" P_CHI2="0.0" P_Z="0.24824163085341422" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0" Z="1.1546308907195124">
<NAME>nurse rated</NAME>
<DICH_DATA CI_END="1.1071621047576499" CI_START="0.6745510608993008" EFFECT_SIZE="0.8641975308641975" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.04421121261097413" LOG_CI_START="-0.17098517033976" LOG_EFFECT_SIZE="-0.06338697886439294" ORDER="11177" O_E="0.0" SE="0.12640742058453686" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="0.015978835978835995" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.047833228575773754" CI_END="0.975390540057922" CI_START="0.8994162321835137" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9366333778199125" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="236" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.01082146078112095" LOG_CI_START="-0.04603927878262477" LOG_EFFECT_SIZE="-0.02843036978187283" METHOD="MH" NO="3" P_CHI2="0.8268774476884209" P_Q="0.0" P_Z="0.0015537669751173374" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="240" TOTAL_2="240" WEIGHT="200.0" Z="3.1644493612436357">
<NAME>Global state: 1c. No substantial improvement - by dose of trifluoperazine</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9886212924270802" CI_START="0.8790051020225095" DF="0.0" EFFECT_SIZE="0.9322033898305084" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="118" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.004970040158869425" LOG_CI_START="-0.05600860413693134" LOG_EFFECT_SIZE="-0.03048932214790036" NO="1" P_CHI2="1.0" P_Z="0.019197204658622805" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="120" WEIGHT="100.0" Z="2.341679258398026">
<NAME>low dose (15mg/day)</NAME>
<DICH_DATA CI_END="0.9886212924270802" CI_START="0.8790051020225096" EFFECT_SIZE="0.9322033898305084" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="118" LOG_CI_END="-0.004970040158869425" LOG_CI_START="-0.05600860413693128" LOG_EFFECT_SIZE="-0.03048932214790036" ORDER="11178" O_E="0.0" SE="0.029980305125679865" STUDY_ID="STD-Prien-1969" TOTAL_1="120" TOTAL_2="120" VAR="8.988186954288664E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9948780145548922" CI_START="0.8894306869421715" DF="0.0" EFFECT_SIZE="0.940677966101695" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="118" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-0.002230166343153041" LOG_CI_START="-0.050887890695782846" LOG_EFFECT_SIZE="-0.02655902851946793" NO="2" P_CHI2="1.0" P_Z="0.032384760013717255" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="120" WEIGHT="100.00000000000001" Z="2.139629012868781">
<NAME>high dose (80mg/day)</NAME>
<DICH_DATA CI_END="0.9948780145548923" CI_START="0.8894306869421715" EFFECT_SIZE="0.940677966101695" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="118" LOG_CI_END="-0.002230166343152993" LOG_CI_START="-0.050887890695782846" LOG_EFFECT_SIZE="-0.02655902851946793" ORDER="11179" O_E="0.0" SE="0.028581788144354844" STUDY_ID="STD-Prien-1969" TOTAL_1="120" TOTAL_2="120" VAR="8.169186135287831E-4" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0032875058439013" CI_START="0.9639115916132758" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.983402489626556" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="240" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.0014254039170490942" LOG_CI_START="-0.01596279704657815" LOG_EFFECT_SIZE="-0.007268696564764542" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.10129106894842049" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="240" TOTAL_2="240" WEIGHT="199.99999999999997" Z="1.6386265044082717">
<NAME>Global state: 2. Not discharged from hospital - by dose of trifluoperazine</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0116414566577223" CI_START="0.9559517853279411" DF="0.0" EFFECT_SIZE="0.983402489626556" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="120" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.005026618249250755" LOG_CI_START="-0.019564011378779795" LOG_EFFECT_SIZE="-0.007268696564764542" NO="1" P_CHI2="1.0" P_Z="0.24658507035417487" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="120" WEIGHT="99.99999999999999" Z="1.1586839130990971">
<NAME>low dose (15mg/day)</NAME>
<DICH_DATA CI_END="1.0116414566577223" CI_START="0.9559517853279411" EFFECT_SIZE="0.983402489626556" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="120" LOG_CI_END="0.005026618249250755" LOG_CI_START="-0.019564011378779795" LOG_EFFECT_SIZE="-0.007268696564764542" ORDER="11180" O_E="0.0" SE="0.014444657569084968" STUDY_ID="STD-Prien-1969" TOTAL_1="120" TOTAL_2="120" VAR="2.0864813228812368E-4" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0116414566577223" CI_START="0.9559517853279411" DF="0.0" EFFECT_SIZE="0.983402489626556" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="120" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.005026618249250755" LOG_CI_START="-0.019564011378779795" LOG_EFFECT_SIZE="-0.007268696564764542" NO="2" P_CHI2="1.0" P_Z="0.24658507035417487" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="120" WEIGHT="99.99999999999999" Z="1.1586839130990971">
<NAME>high dose (80mg/day)</NAME>
<DICH_DATA CI_END="1.0116414566577223" CI_START="0.9559517853279411" EFFECT_SIZE="0.983402489626556" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="120" LOG_CI_END="0.005026618249250755" LOG_CI_START="-0.019564011378779795" LOG_EFFECT_SIZE="-0.007268696564764542" ORDER="11181" O_E="0.0" SE="0.014444657569084968" STUDY_ID="STD-Prien-1969" TOTAL_1="120" TOTAL_2="120" VAR="2.0864813228812368E-4" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7098422576785595" CI_END="6.311676106964553" CI_START="0.18175863459679711" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0710749886068227" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="63.09748299309975" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.8001447043066909" LOG_CI_START="-0.7405049484542419" LOG_EFFECT_SIZE="0.02981987792622463" METHOD="MH" NO="5" P_CHI2="0.09973092210341894" P_Q="0.0" P_Z="0.9395211383736922" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.100723234083422" TOTALS="YES" TOTAL_1="30" TOTAL_2="47" WEIGHT="100.0" Z="0.07587174235757342">
<NAME>Global state: 3. Use of additional antipsychotics or sedatives</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.159668931342585" CI_START="0.8460067601241484" EFFECT_SIZE="2.0892857142857144" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.7126218361419807" LOG_CI_START="-0.07262616666205822" LOG_EFFECT_SIZE="0.31999783473996124" ORDER="11182" O_E="0.0" SE="0.4612585638873957" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="0.21275946275946273" WEIGHT="62.353183089304366"/>
<DICH_DATA CI_END="2.7017901437939917" CI_START="0.04642626595773903" EFFECT_SIZE="0.3541666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.43165161303104993" LOG_CI_START="-1.3332362450256763" LOG_EFFECT_SIZE="-0.4507923159973133" ORDER="11183" O_E="0.0" SE="1.0367038641583162" STUDY_ID="STD-Marjerrison-1964" TOTAL_1="16" TOTAL_2="34" VAR="1.0747549019607845" WEIGHT="37.646816910695634"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9924339567261451" CI_START="0.1918648811338879" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.43636363636363634" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.0032983844980822843" LOG_CI_START="-0.7170045110671933" LOG_EFFECT_SIZE="-0.36015144778263786" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.04791969531403317" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0" Z="1.9780798857008957">
<NAME>Mental state: Delusions and hallucinations by the end of the study</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9924339567261451" CI_START="0.1918648811338879" EFFECT_SIZE="0.43636363636363634" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.0032983844980822843" LOG_CI_START="-0.7170045110671933" LOG_EFFECT_SIZE="-0.36015144778263786" ORDER="11184" O_E="0.0" SE="0.4192345116490003" STUDY_ID="STD-Reardon-1966" TOTAL_1="11" TOTAL_2="12" VAR="0.17575757575757572" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6994829609200701" CI_START="0.24578365009231373" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4146341463414634" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.15522286025509788" LOG_CI_START="-0.6094470104278253" LOG_EFFECT_SIZE="-0.38233493534146157" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="9.684748605399781E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.299528230789823">
<NAME>Behaviour: 1. No improvement (Wings Behaviour Rating Scale) - by &gt;8 weeks - 6 months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6994829609200701" CI_START="0.24578365009231373" EFFECT_SIZE="0.4146341463414634" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.15522286025509788" LOG_CI_START="-0.6094470104278253" LOG_EFFECT_SIZE="-0.38233493534146157" ORDER="11185" O_E="0.0" SE="0.2668135142572659" STUDY_ID="STD-Menon-1972" TOTAL_1="20" TOTAL_2="20" VAR="0.07118945139031224" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.578150689352258" CI_START="0.2794739760334205" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.5536586263867793" LOG_CI_START="-0.5536586263867793" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="0.0">
<NAME>Behaviour: 2. Agitation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.578150689352258" CI_START="0.2794739760334205" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5536586263867793" LOG_CI_START="-0.5536586263867793" LOG_EFFECT_SIZE="0.0" ORDER="11186" O_E="0.0" SE="0.6504436355879909" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.42307692307692313" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.333928351592295" CI_END="1.3244331090491057" CI_START="0.6530487058813639" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9300103912811672" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.12203002899455614" LOG_CI_START="-0.18505442683107537" LOG_EFFECT_SIZE="-0.03151219891825961" METHOD="MH" NO="9" P_CHI2="0.9573601640771563" P_Q="0.0" P_Z="0.6874980659710981" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="294" TOTAL_2="333" WEIGHT="300.0" Z="0.40225269486464005">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.665621942201902" CI_END="1.4838834821497087" CI_START="0.589495890614291" DF="6.0" EFFECT_SIZE="0.935277079200425" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.17139980050762724" LOG_CI_START="-0.22951921803243394" LOG_EFFECT_SIZE="-0.029059708762403314" NO="1" P_CHI2="0.849490953367743" P_Z="0.7763129664330898" STUDIES="7" TAU2="0.0" TOTAL_1="139" TOTAL_2="141" WEIGHT="100.0" Z="0.28412711765551896">
<NAME>any reason</NAME>
<DICH_DATA CI_END="4.0465633374992125" CI_START="0.13900684434798108" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6070863424330394" LOG_CI_START="-0.8569638156496393" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="11187" O_E="0.0" SE="0.8599903100229288" STUDY_ID="STD-_x002a_Pinard-1972" TOTAL_1="32" TOTAL_2="16" VAR="0.7395833333333333" WEIGHT="7.49896636029466"/>
<DICH_DATA CI_END="23.52490498352026" CI_START="0.32987185653114676" EFFECT_SIZE="2.7857142857142856" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3715278779987132" LOG_CI_START="-0.4816547353021907" LOG_EFFECT_SIZE="0.44493657134826115" ORDER="11188" O_E="0.0" SE="1.0885686404548336" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="1.184981684981685" WEIGHT="4.680334394693179"/>
<DICH_DATA CI_END="1.5301313618884815" CI_START="0.4374928220392194" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.18472871663091092" LOG_CI_START="-0.3590290680687112" LOG_EFFECT_SIZE="-0.08715017571890014" ORDER="11189" O_E="0.0" SE="0.3194060143770026" STUDY_ID="STD-Gross-1974" TOTAL_1="20" TOTAL_2="20" VAR="0.102020202020202" WEIGHT="54.362865662655906"/>
<DICH_DATA CI_END="3.6661857415089174" CI_START="0.12122802164996731" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5642144640274329" LOG_CI_START="-0.9163969821387954" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="11190" O_E="0.0" SE="0.869718492622904" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.7564102564102564" WEIGHT="7.332146134059291"/>
<DICH_DATA CI_END="9.39024411468714" CI_START="0.48088472939028054" EFFECT_SIZE="2.125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.9726768826051433" LOG_CI_START="-0.3179590138324826" LOG_EFFECT_SIZE="0.32735893438633035" ORDER="11191" O_E="0.0" SE="0.7581259143181852" STUDY_ID="STD-Marjerrison-1964" TOTAL_1="16" TOTAL_2="34" VAR="0.5747549019607843" WEIGHT="9.649522811168074"/>
<DICH_DATA CI_END="2.866026228999057" CI_START="0.2335713053948908" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.457280160610325" LOG_CI_START="-0.6315805120481253" LOG_EFFECT_SIZE="-0.08715017571890014" ORDER="11192" O_E="0.0" SE="0.6396021490668312" STUDY_ID="STD-Reardon-1966" TOTAL_1="11" TOTAL_2="12" VAR="0.409090909090909" WEIGHT="13.557159091180857"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528004" LOG_EFFECT_SIZE="0.0" ORDER="11193" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="2.9190055459480306"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7931596424114087" CI_END="5.112055683188304" CI_START="0.2440854007464697" DF="2.0" EFFECT_SIZE="1.1170399097925217" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.7085955757390974" LOG_CI_START="-0.6124581958587632" LOG_EFFECT_SIZE="0.048068689940167046" NO="2" P_CHI2="0.407962622389514" P_Z="0.8865800698949701" STUDIES="3" TAU2="0.0" TOTAL_1="62" TOTAL_2="80" WEIGHT="100.0" Z="0.14263295422531727">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="3.919915520931636" CI_START="0.0102043015433387" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5932767075335775" LOG_CI_START="-1.991216716205615" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="11194" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Gross-1974" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="26.12703504090976"/>
<DICH_DATA CI_END="20.722972310630787" CI_START="0.19302250372394794" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3164520467067224" LOG_CI_START="-0.7143920553787599" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11195" O_E="0.0" SE="1.1929278784054478" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="1.423076923076923" WEIGHT="42.31436408684794"/>
<DICH_DATA CI_END="31.853267518772448" CI_START="0.14176332137162245" EFFECT_SIZE="2.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.5031539890288512" LOG_CI_START="-0.8484361202561904" LOG_EFFECT_SIZE="0.32735893438633035" ORDER="11196" O_E="0.0" SE="1.3813356707528108" STUDY_ID="STD-Marjerrison-1964" TOTAL_1="16" TOTAL_2="34" VAR="1.9080882352941178" WEIGHT="31.5586008722423"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0040981646284726" CI_END="1.6168626092779288" CI_START="0.49699920596561886" DF="4.0" EFFECT_SIZE="0.8964259216280113" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="0.20867311788568763" LOG_CI_START="-0.3036443051198382" LOG_EFFECT_SIZE="-0.047485593617075245" NO="3" P_CHI2="0.7350051811330788" P_Z="0.716358652757494" STUDIES="5" TAU2="0.0" TOTAL_1="93" TOTAL_2="112" WEIGHT="100.0" Z="0.36332964328237877">
<NAME>due to relapse or worsening</NAME>
<DICH_DATA CI_END="1.9841868635676467" CI_START="0.5039847901230231" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.29758257003327615" LOG_CI_START="-0.2975825700332762" LOG_EFFECT_SIZE="0.0" ORDER="11197" O_E="0.0" SE="0.3496029493900505" STUDY_ID="STD-Gross-1974" TOTAL_1="20" TOTAL_2="20" VAR="0.12222222222222222" WEIGHT="74.09745296343308"/>
<DICH_DATA CI_END="3.973711466115117" CI_START="0.010066156121573125" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5991963295017" LOG_CI_START="-1.9971363381737377" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="11198" O_E="0.0" SE="1.5250986610465322" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="2.3259259259259255" WEIGHT="3.893655967823714"/>
<DICH_DATA CI_END="31.853267518772448" CI_START="0.14176332137162245" EFFECT_SIZE="2.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.5031539890288512" LOG_CI_START="-0.8484361202561904" LOG_EFFECT_SIZE="0.32735893438633035" ORDER="11199" O_E="0.0" SE="1.3813356707528108" STUDY_ID="STD-Marjerrison-1964" TOTAL_1="16" TOTAL_2="34" VAR="1.9080882352941178" WEIGHT="4.746297993290341"/>
<DICH_DATA CI_END="3.5705924916828753" CI_START="0.14813385203345344" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.552740287405811" LOG_CI_START="-0.8293456837383739" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="11200" O_E="0.0" SE="0.8118441408859887" STUDY_ID="STD-Reardon-1966" TOTAL_1="11" TOTAL_2="12" VAR="0.659090909090909" WEIGHT="13.74067710126499"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11201" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="3.5219159741878685"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0760857307481395" CI_END="2.1818232207666286" CI_START="0.904378831890204" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4047045012342796" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.33881955956316256" LOG_CI_START="-0.04364961140945648" LOG_EFFECT_SIZE="0.14758497407685303" METHOD="MH" NO="10" P_CHI2="0.7826737166951621" P_Q="0.0" P_Z="0.13038156021263958" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="33" WEIGHT="100.0" Z="1.5125989533447532">
<NAME>Adverse events: 1. At least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4232124557934696" CI_START="0.7261779548119002" EFFECT_SIZE="1.3265306122448979" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.38439149269045986" LOG_CI_START="-0.13895693946177606" LOG_EFFECT_SIZE="0.12271727661434188" ORDER="11202" O_E="0.0" SE="0.3074174596627435" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="0.0945054945054945" WEIGHT="53.408577878103834"/>
<DICH_DATA CI_END="2.8592753848835426" CI_START="0.7869126604227532" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.45625598549989865" LOG_CI_START="-0.10407346738853616" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="11203" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="46.591422121896166"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0031830088691844277" CI_END="5.328033001361555" CI_START="0.6668774779897866" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8849788355826034" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.7265669061518902" LOG_CI_START="-0.17595394947281784" LOG_EFFECT_SIZE="0.27530647833953625" METHOD="MH" NO="11" P_CHI2="0.9550087201328745" P_Q="0.0" P_Z="0.23179750610110172" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="34" TOTAL_2="33" WEIGHT="200.0" Z="1.1957414144907554">
<NAME>Adverse events: 2. Cardiovascular</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4020769995139077E-31" CI_END="5.937551124600795" CI_START="0.5808757717549125" DF="0.0" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="100.0" ID="CMP-001.11.01" LOG_CI_END="0.7736073620916895" LOG_CI_START="-0.2359167375065295" LOG_EFFECT_SIZE="0.26884531229257996" NO="1" P_CHI2="0.0" P_Z="0.29652614958521384" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.00000000000001" Z="1.0439119377449084">
<NAME>ECG abnormalities - minor</NAME>
<DICH_DATA CI_END="5.937551124600795" CI_START="0.5808757717549125" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.7736073620916895" LOG_CI_START="-0.2359167375065295" LOG_EFFECT_SIZE="0.26884531229257996" ORDER="11204" O_E="0.0" SE="0.5929994533288809" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="0.3516483516483517" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.332240770599807" CI_START="0.19673188238966538" DF="0.0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="1.3081852438953019" LOG_CI_START="-0.7061252525673394" LOG_EFFECT_SIZE="0.3010299956639812" NO="2" P_CHI2="1.0" P_Z="0.5579989793003175" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.585816288803313">
<NAME>hypertension</NAME>
<DICH_DATA CI_END="20.332240770599807" CI_START="0.19673188238966538" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3081852438953019" LOG_CI_START="-0.7061252525673394" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11205" O_E="0.0" SE="1.1832159566199232" STUDY_ID="STD-Gross-1974" TOTAL_1="20" TOTAL_2="20" VAR="1.4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.435923826897547" CI_END="5.114760228343179" CI_START="2.1507106302414702" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.316680448013339" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.7088252795050325" LOG_CI_START="0.3325819816830001" LOG_EFFECT_SIZE="0.5207036305940163" METHOD="MH" NO="12" P_CHI2="0.6837491430257561" P_Q="0.0" P_Z="5.795382040935915E-8" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="217" TOTAL_2="231" WEIGHT="700.0" Z="5.425002217933237">
<NAME>Adverse events: 3. Extrapyramidal</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03741645873122892" CI_END="4.328196413748576" CI_START="1.1907829573492852" DF="1.0" EFFECT_SIZE="2.2702296195654084" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="0.6363069608488957" LOG_CI_START="0.07583261033635322" LOG_EFFECT_SIZE="0.3560697855926244" NO="1" P_CHI2="0.8466196793468863" P_Z="0.012762336696959165" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="39" WEIGHT="100.0" Z="2.4903332511335883">
<NAME>non-specific - any movement disorder</NAME>
<DICH_DATA CI_END="7.373929997980033" CI_START="0.8315130840753907" EFFECT_SIZE="2.4761904761904763" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.8676990104554385" LOG_CI_START="-0.0801309126536788" LOG_EFFECT_SIZE="0.3937840489008799" ORDER="11206" O_E="0.0" SE="0.556759988668084" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="0.30998168498168494" WEIGHT="34.966378482228635"/>
<DICH_DATA CI_END="4.822738085443822" CI_START="0.9733981736668224" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.6832936767808601" LOG_CI_START="-0.011709472934473818" LOG_EFFECT_SIZE="0.3357921019231931" ORDER="11207" O_E="0.0" SE="0.408248290463863" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.16666666666666666" WEIGHT="65.03362151777137"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5109187087230498" CI_END="10.269909994918118" CI_START="2.492671450821854" DF="3.0" EFFECT_SIZE="5.059595976641059" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="8" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="1.011566637474426" LOG_CI_START="0.39666503963566246" LOG_EFFECT_SIZE="0.7041158385550442" NO="2" P_CHI2="0.6797526317360667" P_Z="7.167304056998467E-6" STUDIES="4" TAU2="0.0" TOTAL_1="89" TOTAL_2="106" WEIGHT="100.0" Z="4.4886586385939875">
<NAME>non-specific - antiparkinson drugs needed</NAME>
<DICH_DATA CI_END="11.422244353569283" CI_START="0.6793939826027013" EFFECT_SIZE="2.7857142857142856" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0577514466947702" LOG_CI_START="-0.1678783039982477" LOG_EFFECT_SIZE="0.44493657134826115" ORDER="11208" O_E="0.0" SE="0.7199409825221914" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="0.5183150183150182" WEIGHT="25.17054704209592"/>
<DICH_DATA CI_END="23.208628654495772" CI_START="1.3033945456376737" EFFECT_SIZE="5.5" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.3656494797329406" LOG_CI_START="0.11507589925554733" LOG_EFFECT_SIZE="0.7403626894942439" ORDER="11209" O_E="0.0" SE="0.7345931116114822" STUDY_ID="STD-Coons-1962" TOTAL_1="39" TOTAL_2="39" VAR="0.5396270396270396" WEIGHT="24.17646187659506"/>
<DICH_DATA CI_END="39.25625632038841" CI_START="2.3293460666168593" EFFECT_SIZE="9.5625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.5939088806710164" LOG_CI_START="0.3672340156523315" LOG_EFFECT_SIZE="0.980571448161674" ORDER="11210" O_E="0.0" SE="0.7205548878504876" STUDY_ID="STD-Marjerrison-1964" TOTAL_1="16" TOTAL_2="34" VAR="0.5191993464052288" WEIGHT="25.127675220416236"/>
<DICH_DATA CI_END="18.270642568115434" CI_START="1.1083354033392778" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.2617538215112387" LOG_CI_START="0.04467120603944865" LOG_EFFECT_SIZE="0.6532125137753437" ORDER="11211" O_E="0.0" SE="0.7149203529842405" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="0.5111111111111111" WEIGHT="25.525315860892782"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.5152908317231" CI_START="0.12946791838627933" DF="0.0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.12.03" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.4771212547196624" NO="3" P_CHI2="1.0" P_Z="0.49327758741034355" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6851051308492763">
<NAME>specific - akathisia (motor restlessness)</NAME>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="11212" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="29.059735666850496" CI_START="0.4747434224972819" DF="0.0" EFFECT_SIZE="3.714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-001.12.04" LOG_CI_END="1.4632916595507734" LOG_CI_START="-0.32354104363765107" LOG_EFFECT_SIZE="0.569875307956561" NO="4" P_CHI2="1.0" P_Z="0.2112322618059259" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0" Z="1.2501842811366424">
<NAME>specific - dyskinesia</NAME>
<DICH_DATA CI_END="29.059735666850496" CI_START="0.4747434224972819" EFFECT_SIZE="3.7142857142857144" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4632916595507734" LOG_CI_START="-0.32354104363765107" LOG_EFFECT_SIZE="0.5698753079565612" ORDER="11213" O_E="0.0" SE="1.049594374817411" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="1.1016483516483517" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="29.059735666850496" CI_START="0.4747434224972819" DF="0.0" EFFECT_SIZE="3.714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-001.12.05" LOG_CI_END="1.4632916595507734" LOG_CI_START="-0.32354104363765107" LOG_EFFECT_SIZE="0.569875307956561" NO="5" P_CHI2="1.0" P_Z="0.2112322618059259" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0" Z="1.2501842811366424">
<NAME>specific - oculogyric crisis</NAME>
<DICH_DATA CI_END="29.059735666850496" CI_START="0.4747434224972819" EFFECT_SIZE="3.7142857142857144" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4632916595507734" LOG_CI_START="-0.32354104363765107" LOG_EFFECT_SIZE="0.5698753079565612" ORDER="11214" O_E="0.0" SE="1.049594374817411" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="1.1016483516483517" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="64.58919722585904" CI_START="1.2540796832751275" DF="0.0" EFFECT_SIZE="9.000000000000002" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" ID="CMP-001.12.06" LOG_CI_END="1.81015988676414" LOG_CI_START="0.0983251321145101" LOG_EFFECT_SIZE="0.954242509439325" NO="6" P_CHI2="1.0" P_Z="0.028880154398691224" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.1851185646724414">
<NAME>specific - rigidity</NAME>
<DICH_DATA CI_END="64.58919722585904" CI_START="1.2540796832751275" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.81015988676414" LOG_CI_START="0.0983251321145101" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="11215" O_E="0.0" SE="1.0055402085998904" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="1.011111111111111" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.723921203524791" CI_START="0.014385324265142151" DF="0.0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.12.07" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" NO="7" P_CHI2="1.0" P_Z="0.49327758741034344" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6851051308492764">
<NAME>specific - tremors</NAME>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11216" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06758775849414123" CI_END="3.6050803770430333" CI_START="0.699962178248091" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5885275929219773" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.5569149519728183" LOG_CI_START="-0.15492542601705342" LOG_EFFECT_SIZE="0.20099476297788244" METHOD="MH" NO="13" P_CHI2="0.966770755975073" P_Q="0.0" P_Z="0.2683682378585256" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="42" TOTAL_2="39" WEIGHT="300.0" Z="1.1068281842349195">
<NAME>Adverse events: 4. Haematological</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.49353058949211" CI_START="0.40607136873135985" DF="0.0" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="0.929088255238763" LOG_CI_START="-0.3913976306536031" LOG_EFFECT_SIZE="0.26884531229257996" NO="1" P_CHI2="1.0" P_Z="0.4248236858717267" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0" Z="0.7980806688437873">
<NAME>eosinophilia &gt;5%</NAME>
<DICH_DATA CI_END="8.49353058949211" CI_START="0.40607136873135985" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.929088255238763" LOG_CI_START="-0.3913976306536031" LOG_EFFECT_SIZE="0.26884531229257996" ORDER="11217" O_E="0.0" SE="0.7756599458837306" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="0.6016483516483517" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.221654966947847" CI_START="0.4586907276934237" DF="0.0" EFFECT_SIZE="1.5476190476190474" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-001.13.02" LOG_CI_END="0.7178081714123898" LOG_CI_START="-0.3384800389224796" LOG_EFFECT_SIZE="0.18966406624495508" NO="2" P_CHI2="1.0" P_Z="0.4815255949490993" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="99.99999999999999" Z="0.7038509667426505">
<NAME>leukocytosis</NAME>
<DICH_DATA CI_END="5.221654966947847" CI_START="0.4586907276934237" EFFECT_SIZE="1.5476190476190477" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7178081714123898" LOG_CI_START="-0.3384800389224796" LOG_EFFECT_SIZE="0.1896640662449551" ORDER="11218" O_E="0.0" SE="0.620468923461671" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="0.384981684981685" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.053290790329684" CI_START="0.27505615152972895" DF="0.0" EFFECT_SIZE="1.3928571428571428" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.13.03" LOG_CI_END="0.8483917891377037" LOG_CI_START="-0.5605786377691437" LOG_EFFECT_SIZE="0.14390657568427995" NO="3" P_CHI2="1.0" P_Z="0.6888871952820483" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0" Z="0.400365685600474">
<NAME>urea nitrogen increase</NAME>
<DICH_DATA CI_END="7.053290790329684" CI_START="0.27505615152972895" EFFECT_SIZE="1.3928571428571428" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8483917891377037" LOG_CI_START="-0.5605786377691437" LOG_EFFECT_SIZE="0.14390657568427995" ORDER="11219" O_E="0.0" SE="0.8276362032811789" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="0.684981684981685" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3870658968984062" CI_END="1.778697676679225" CI_START="0.28046886774019353" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7063068196119411" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.2501021377929945" LOG_CI_START="-0.552115338753674" LOG_EFFECT_SIZE="-0.15100660048033976" METHOD="MH" NO="14" P_CHI2="0.8240427466607212" P_Q="0.0" P_Z="0.46059134495952014" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="78" TOTAL_2="78" WEIGHT="300.0" Z="0.7378734745180462">
<NAME>Adverse events: 5. Neurological</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.496356013675377" CI_START="0.10014597222129622" DF="0.0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="0.3973065216149974" LOG_CI_START="-0.9993665129429598" LOG_EFFECT_SIZE="-0.3010299956639812" NO="1" P_CHI2="1.0" P_Z="0.398179935046339" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.00000000000001" Z="0.8448762669129465">
<NAME>convulsions</NAME>
<DICH_DATA CI_END="2.496356013675377" CI_START="0.10014597222129622" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3973065216149974" LOG_CI_START="-0.9993665129429598" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11220" O_E="0.0" SE="0.820412654142367" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.6730769230769231" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6661857415089174" CI_START="0.12122802164996731" DF="0.0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.14.02" LOG_CI_END="0.5642144640274329" LOG_CI_START="-0.9163969821387954" LOG_EFFECT_SIZE="-0.17609125905568127" NO="2" P_CHI2="1.0" P_Z="0.6410704195718875" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="0.46620269839883416">
<NAME>faintness</NAME>
<DICH_DATA CI_END="3.6661857415089174" CI_START="0.12122802164996731" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5642144640274329" LOG_CI_START="-0.9163969821387954" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="11221" O_E="0.0" SE="0.869718492622904" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.7564102564102564" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.504828095259613" CI_START="0.22198405329879073" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-001.14.03" LOG_CI_END="0.6536782229056234" LOG_CI_START="-0.6536782229056235" LOG_EFFECT_SIZE="0.0" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="0.0">
<NAME>urinary incontinence</NAME>
<DICH_DATA CI_END="4.504828095259613" CI_START="0.22198405329879073" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6536782229056234" LOG_CI_START="-0.6536782229056235" LOG_EFFECT_SIZE="0.0" ORDER="11222" O_E="0.0" SE="0.7679476477883045" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.5897435897435898" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.9271588106361595" CI_END="5.344656203599135" CI_START="1.0838629173773058" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4068391440251413" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="11" I2="18.817311279569886" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.7279197743377142" LOG_CI_START="0.03497435785618086" LOG_EFFECT_SIZE="0.3814470660969475" METHOD="MH" NO="15" P_CHI2="0.2948535029623187" P_Q="0.0" P_Z="0.030942553879532837" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.16180775570543884" TOTALS="SUB" TOTAL_1="94" TOTAL_2="92" WEIGHT="200.0" Z="2.1578106840061926">
<NAME>Adverse events: 6. Somnolesence</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9575395145257306" CI_END="6.10230018989792" CI_START="1.4191130378232302" DF="2.0" EFFECT_SIZE="2.9427629466532483" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="8" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="0.7854935680408158" LOG_CI_START="0.15201699006469854" LOG_EFFECT_SIZE="0.46875527905275716" NO="1" P_CHI2="0.3757731983817755" P_Z="0.003724025158211361" STUDIES="3" TAU2="0.0" TOTAL_1="60" TOTAL_2="59" WEIGHT="100.0" Z="2.900639096844602">
<NAME>drowsiness</NAME>
<DICH_DATA CI_END="40.26499304661003" CI_START="0.7709132419468774" EFFECT_SIZE="5.571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6049276284298328" LOG_CI_START="-0.11299449440534803" LOG_EFFECT_SIZE="0.7459665670122424" ORDER="11223" O_E="0.0" SE="1.0091159588050416" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="1.0183150183150185" WEIGHT="17.33656195166227"/>
<DICH_DATA CI_END="9.790623287720528" CI_START="1.4363232642846442" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="0.9908103406081608" LOG_CI_START="0.15725219484727707" LOG_EFFECT_SIZE="0.5740312677277188" ORDER="11224" O_E="0.0" SE="0.4896361809993107" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.23974358974358975" WEIGHT="50.95057410278362"/>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.4668351214936106" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="11225" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="31.712863945554115"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.026213362917174" CI_END="12.050511006385454" CI_START="0.07016390275808085" DF="1.0" EFFECT_SIZE="0.9195166569656105" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="50.646855938197795" ID="CMP-001.15.02" LOG_CI_END="1.0810054637198416" LOG_CI_START="-1.1538862620143298" LOG_EFFECT_SIZE="-0.036440399147244035" NO="2" P_CHI2="0.15460579556543563" P_Z="0.9490376821249709" STUDIES="2" TAU2="1.7906107524747106" TOTAL_1="34" TOTAL_2="33" WEIGHT="100.00000000000001" Z="0.0639152842067998">
<NAME>insomnia</NAME>
<DICH_DATA CI_END="23.52490498352026" CI_START="0.32987185653114676" EFFECT_SIZE="2.7857142857142856" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3715278779987132" LOG_CI_START="-0.4816547353021907" LOG_EFFECT_SIZE="0.44493657134826115" ORDER="11226" O_E="0.0" SE="1.0885686404548336" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="1.184981684981685" WEIGHT="64.68233373879232"/>
<DICH_DATA CI_END="3.919915520931636" CI_START="0.0102043015433387" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5932767075335775" LOG_CI_START="-1.991216716205615" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="11227" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="35.31766626120769"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4105442564881251" CI_END="3.975340135622865" CI_START="0.7299751201556305" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.703496226341814" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.5993742934212706" LOG_CI_START="-0.13669194174701726" LOG_EFFECT_SIZE="0.23134117583712663" METHOD="MH" NO="16" P_CHI2="0.5216934066378229" P_Q="0.0" P_Z="0.21794548205593234" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="26" WEIGHT="200.0" Z="1.2320097054261696">
<NAME>Adverse events: 7. Weight</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.509705792100631" CI_START="0.33990683411746153" DF="0.0" EFFECT_SIZE="1.2380952380952381" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.6541482099411504" LOG_CI_START="-0.46864010346735296" LOG_EFFECT_SIZE="0.09275405323689871" NO="1" P_CHI2="1.0" P_Z="0.7460689896556336" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0" Z="0.32382703238609517">
<NAME>gain &gt;10 lb</NAME>
<DICH_DATA CI_END="4.509705792100631" CI_START="0.33990683411746153" EFFECT_SIZE="1.2380952380952381" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6541482099411504" LOG_CI_START="-0.46864010346735296" LOG_EFFECT_SIZE="0.09275405323689871" ORDER="11228" O_E="0.0" SE="0.6595314131879428" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="0.43498168498168494" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.65528059393854" CI_START="0.7053713781384399" DF="0.0" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="0.8231663705289874" LOG_CI_START="-0.15158216668260133" LOG_EFFECT_SIZE="0.3357921019231931" NO="2" P_CHI2="1.0" P_Z="0.1768941483240135" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="99.99999999999999" Z="1.3503799204360312">
<NAME>loss &gt;10 lb</NAME>
<DICH_DATA CI_END="6.65528059393854" CI_START="0.7053713781384399" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8231663705289874" LOG_CI_START="-0.15158216668260133" LOG_EFFECT_SIZE="0.3357921019231931" ORDER="11229" O_E="0.0" SE="0.5725721158411644" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="0.32783882783882784" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.327641147053461" CI_END="1.9386699659222175" CI_START="0.6485241188894477" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.121282404868257" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.2875038822203463" LOG_CI_START="-0.1880738676819596" LOG_EFFECT_SIZE="0.04971500726919335" METHOD="MH" NO="17" P_CHI2="0.804863069920251" P_Q="0.0" P_Z="0.6819719720610042" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="212" TOTAL_2="209" WEIGHT="600.0" Z="0.4097736858327886">
<NAME>Adverse events: 8. Miscellaneous</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6485250618561182" CI_START="0.24164392824415276" DF="0.0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="0.4230040868333767" LOG_CI_START="-0.6168241128494895" LOG_EFFECT_SIZE="-0.09691001300805639" NO="1" P_CHI2="1.0" P_Z="0.7148652066631331" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.00000000000001" Z="0.3653298406314196">
<NAME>anorexia</NAME>
<DICH_DATA CI_END="2.6485250618561182" CI_START="0.24164392824415276" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4230040868333767" LOG_CI_START="-0.6168241128494895" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="11230" O_E="0.0" SE="0.6108002317263175" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.3730769230769231" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.244322087550606" CI_END="6.258204673626299" CI_START="0.47444542342813195" DF="2.0" EFFECT_SIZE="1.7231298750467254" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="10.886231031894914" ID="CMP-001.17.02" LOG_CI_END="0.7964497625770222" LOG_CI_START="-0.3238137382782419" LOG_EFFECT_SIZE="0.2363180121493901" NO="2" P_CHI2="0.3255757670610777" P_Z="0.4082918809176943" STUDIES="3" TAU2="0.15012343321101232" TOTAL_1="60" TOTAL_2="59" WEIGHT="99.99999999999999" Z="0.8269032997277753">
<NAME>blurred vision</NAME>
<DICH_DATA CI_END="29.059735666850496" CI_START="0.4747434224972819" EFFECT_SIZE="3.7142857142857144" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4632916595507734" LOG_CI_START="-0.32354104363765107" LOG_EFFECT_SIZE="0.5698753079565612" ORDER="11231" O_E="0.0" SE="1.049594374817411" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="1.1016483516483517" WEIGHT="34.07846596570916"/>
<DICH_DATA CI_END="3.6661857415089174" CI_START="0.12122802164996731" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5642144640274329" LOG_CI_START="-0.9163969821387954" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="11232" O_E="0.0" SE="0.869718492622904" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.7564102564102564" WEIGHT="49.6324389306878"/>
<DICH_DATA CI_END="97.99788802329087" CI_START="0.2551075385834674" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.991216716205615" LOG_CI_START="-0.5932767075335774" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="11233" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="16.28909510360303"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.053290790329684" CI_START="0.27505615152972895" DF="0.0" EFFECT_SIZE="1.3928571428571428" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.17.03" LOG_CI_END="0.8483917891377037" LOG_CI_START="-0.5605786377691437" LOG_EFFECT_SIZE="0.14390657568427995" NO="3" P_CHI2="1.0" P_Z="0.6888871952820483" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0" Z="0.400365685600474">
<NAME>nausea</NAME>
<DICH_DATA CI_END="7.053290790329684" CI_START="0.27505615152972895" EFFECT_SIZE="1.3928571428571428" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8483917891377037" LOG_CI_START="-0.5605786377691437" LOG_EFFECT_SIZE="0.14390657568427995" ORDER="11234" O_E="0.0" SE="0.8276362032811789" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="0.684981684981685" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.504828095259613" CI_START="0.22198405329879073" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-001.17.04" LOG_CI_END="0.6536782229056234" LOG_CI_START="-0.6536782229056235" LOG_EFFECT_SIZE="0.0" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="0.0">
<NAME>oedema - face</NAME>
<DICH_DATA CI_END="4.504828095259613" CI_START="0.22198405329879073" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6536782229056234" LOG_CI_START="-0.6536782229056235" LOG_EFFECT_SIZE="0.0" ORDER="11235" O_E="0.0" SE="0.7679476477883045" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.5897435897435898" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2364727520236105" CI_END="4.006023442027393" CI_START="0.2970381646479849" DF="2.0" EFFECT_SIZE="1.0908445584759634" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="10.57346895058948" ID="CMP-001.17.05" LOG_CI_END="0.6027134863238466" LOG_CI_START="-0.5271877472107793" LOG_EFFECT_SIZE="0.037762869556533546" NO="5" P_CHI2="0.32685604344428365" P_Z="0.8957678392635277" STUDIES="3" TAU2="0.14977887140872106" TOTAL_1="60" TOTAL_2="59" WEIGHT="100.00000000000001" Z="0.13100944062545222">
<NAME>rashes</NAME>
<DICH_DATA CI_END="29.059735666850496" CI_START="0.4747434224972819" EFFECT_SIZE="3.7142857142857144" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4632916595507734" LOG_CI_START="-0.32354104363765107" LOG_EFFECT_SIZE="0.5698753079565612" ORDER="11236" O_E="0.0" SE="1.049594374817411" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="13" VAR="1.1016483516483517" WEIGHT="34.664024354703486"/>
<DICH_DATA CI_END="3.6661857415089174" CI_START="0.12122802164996731" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5642144640274329" LOG_CI_START="-0.9163969821387954" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="11237" O_E="0.0" SE="0.869718492622904" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.7564102564102564" WEIGHT="50.485255809574205"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11238" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="14.850719835722325"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.504828095259613" CI_START="0.22198405329879073" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-001.17.06" LOG_CI_END="0.6536782229056234" LOG_CI_START="-0.6536782229056235" LOG_EFFECT_SIZE="0.0" NO="6" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="0.0">
<NAME>swallowing - difficulties</NAME>
<DICH_DATA CI_END="4.504828095259613" CI_START="0.22198405329879073" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6536782229056234" LOG_CI_START="-0.6536782229056235" LOG_EFFECT_SIZE="0.0" ORDER="11239" O_E="0.0" SE="0.7679476477883045" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.5897435897435898" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>TRIFLUOPERAZINE versus TYPICAL ANTIPSYCHOTICS</NAME>
<DICH_OUTCOME CHI2="18.296457606069026" CI_END="1.1405230496938004" CI_START="0.9754276280645885" CI_STUDY="95" CI_TOTAL="95" DF="26.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0547500619179002" ESTIMABLE="YES" EVENTS_1="290" EVENTS_2="279" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.057104066687347736" LOG_CI_START="-0.01080494758998384" LOG_EFFECT_SIZE="0.02314955954868192" METHOD="MH" NO="1" P_CHI2="0.8647227064164045" P_Q="0.0" P_Z="0.18146186870378703" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="28" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="506" TOTAL_2="510" WEIGHT="100.0" Z="1.3362674589293053">
<NAME>Global state: 1a. No substantial improvement (defined as slight improvement or worse) - by time period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="15.458951606520369" CI_END="1.1516412143292385" CI_START="0.9387008229969388" DF="20.0" EFFECT_SIZE="1.0397338869576438" ESTIMABLE="YES" EVENTS_1="209" EVENTS_2="203" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.06131719878634747" LOG_CI_START="-0.02747280137045782" LOG_EFFECT_SIZE="0.016922198707944876" NO="1" P_CHI2="0.7495719306139473" P_Z="0.455011425533264" STUDIES="22" TAU2="0.0" TOTAL_1="406" TOTAL_2="410" WEIGHT="58.4960767649944" Z="0.7470863824356024">
<NAME>by 3 months</NAME>
<DICH_DATA CI_END="1.7333352857794935" CI_START="0.7596662116111281" EFFECT_SIZE="1.1475" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.23888257810904975" LOG_CI_START="-0.11937718969045212" LOG_EFFECT_SIZE="0.05975269420929884" ORDER="11240" O_E="0.0" SE="0.21044356101987932" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="0.044286492374727676" WEIGHT="3.593012871321773"/>
<DICH_DATA CI_END="3.0274540218576087" CI_START="0.3930968516898826" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.48107755620645043" LOG_CI_START="-0.4055004344276508" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="11241" O_E="0.0" SE="0.5207803003303036" STUDY_ID="STD-Angus-1969" TOTAL_1="22" TOTAL_2="20" VAR="0.27121212121212124" WEIGHT="0.5867065838242427"/>
<DICH_DATA CI_END="1.4302350891163809" CI_START="0.6991857545725675" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.15540742873399502" LOG_CI_START="-0.155407428733995" LOG_EFFECT_SIZE="0.0" ORDER="11242" O_E="0.0" SE="0.18257418583505536" STUDY_ID="STD-Bishop-1963" TOTAL_1="20" TOTAL_2="20" VAR="0.033333333333333326" WEIGHT="4.773658113842703"/>
<DICH_DATA CI_END="1.5018371111820334" CI_START="0.5393394489782468" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.17662283176869495" LOG_CI_START="-0.26813781289004524" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="11243" O_E="0.0" SE="0.261254604273242" STUDY_ID="STD-Bishop-1964" TOTAL_1="14" TOTAL_2="14" VAR="0.06825396825396826" WEIGHT="2.331321404434808"/>
<DICH_DATA CI_END="2.2014833500781594" CI_START="0.6610444760382554" EFFECT_SIZE="1.2063492063492063" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.34271540521842736" LOG_CI_START="-0.17976931956400805" LOG_EFFECT_SIZE="0.08147304282720963" ORDER="11244" O_E="0.0" SE="0.30691011367830223" STUDY_ID="STD-Bishop-1966" TOTAL_1="21" TOTAL_2="19" VAR="0.09419381787802839" WEIGHT="1.6893034034795908"/>
<DICH_DATA CI_END="1.907279467152222" CI_START="0.34415514118317986" EFFECT_SIZE="0.8101851851851852" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.28041433339713645" LOG_CI_START="-0.46324573832640925" LOG_EFFECT_SIZE="-0.09141570246463643" ORDER="11245" O_E="0.0" SE="0.43682960730713505" STUDY_ID="STD-Bishop-1967" TOTAL_1="27" TOTAL_2="25" VAR="0.1908201058201058" WEIGHT="0.833884545049467"/>
<DICH_DATA CI_END="1.5871944192581473" CI_START="0.6300425378684225" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.20063012778789294" LOG_CI_START="-0.20063012778789288" LOG_EFFECT_SIZE="0.0" ORDER="11246" O_E="0.0" SE="0.23570226039551587" STUDY_ID="STD-Bishop-1970" TOTAL_1="12" TOTAL_2="12" VAR="0.055555555555555566" WEIGHT="2.864194868305621"/>
<DICH_DATA CI_END="1.7570591839122245" CI_START="0.7746529676254246" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.24478639030212707" LOG_CI_START="-0.11089281104090057" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="11247" O_E="0.0" SE="0.20892772350933628" STUDY_ID="STD-Brauzer-1968" TOTAL_1="18" TOTAL_2="18" VAR="0.04365079365079366" WEIGHT="3.6453389232980626"/>
<DICH_DATA CI_END="1.52751026146968" CI_START="0.4809747574750439" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.18398413641684347" LOG_CI_START="-0.31787771567806994" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="11248" O_E="0.0" SE="0.2947961361767856" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.08690476190476192" WEIGHT="1.8309921532547349"/>
<DICH_DATA CI_END="2.3164128684582366" CI_START="0.4911809087535689" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3648159689210148" LOG_CI_START="-0.3087585217205277" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="11249" O_E="0.0" SE="0.3956609900503448" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="0.15654761904761905" WEIGHT="1.0164443132136554"/>
<DICH_DATA CI_END="1.6709380022245195" CI_START="0.25773790644934585" EFFECT_SIZE="0.65625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2229603363139254" LOG_CI_START="-0.5888217034858987" LOG_EFFECT_SIZE="-0.1829306835859867" ORDER="11250" O_E="0.0" SE="0.47684478856432144" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.2273809523809524" WEIGHT="0.6998032837046894"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11251" O_E="0.0" SE="0.0" STUDY_ID="STD-Gallant-1968" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.169905185140503" CI_START="0.8547701238540133" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.0681506658155179" LOG_CI_START="-0.0681506658155179" LOG_EFFECT_SIZE="0.0" ORDER="11252" O_E="0.0" SE="0.08006407690254351" STUDY_ID="STD-Gallant-1968-II" TOTAL_1="26" TOTAL_2="26" VAR="0.006410256410256401" WEIGHT="24.82302219198209"/>
<DICH_DATA CI_END="2.2163391247603808" CI_START="0.9757666295852986" EFFECT_SIZE="1.4705882352941178" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.3456362130707369" LOG_CI_START="-0.010654038483209498" LOG_EFFECT_SIZE="0.1674910872937637" ORDER="11253" O_E="0.0" SE="0.20928665742797734" STUDY_ID="STD-Gallant-1972" TOTAL_1="12" TOTAL_2="12" VAR="0.04380090497737554" WEIGHT="3.632845878647513"/>
<DICH_DATA CI_END="2.562295143629686" CI_START="0.7804705652905448" EFFECT_SIZE="1.4141414141414141" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.4086291534598592" LOG_CI_START="-0.10764347129848287" LOG_EFFECT_SIZE="0.1504928410806881" ORDER="11254" O_E="0.0" SE="0.3032610953737587" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.09196729196729198" WEIGHT="1.730201397956586"/>
<DICH_DATA CI_END="3.037380083063955" CI_START="0.18519249636765195" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.48249914083133905" LOG_CI_START="-0.7323766140479391" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="11255" O_E="0.0" SE="0.7136240321480628" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.5092592592592593" WEIGHT="0.31245762199697685"/>
<DICH_DATA CI_END="2.8592753848835426" CI_START="0.7869126604227532" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.45625598549989865" LOG_CI_START="-0.10407346738853616" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="11256" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Menon-1972" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="1.4688178811823702"/>
<DICH_DATA CI_END="3.0927915802339063" CI_START="0.4655987843484408" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4903506543697692" LOG_CI_START="-0.3319881622745195" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="11257" O_E="0.0" SE="0.483045891539648" STUDY_ID="STD-O_x0027_Brien-1974" TOTAL_1="15" TOTAL_2="15" VAR="0.2333333333333334" WEIGHT="0.681951159120386"/>
<DICH_DATA CI_END="182.87437826478745" CI_START="0.6616563848261" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2621528626241068" LOG_CI_START="-0.17936749230765672" LOG_EFFECT_SIZE="1.041392685158225" ORDER="11258" O_E="0.0" SE="1.4341611422075908" STUDY_ID="STD-Perales-1974" TOTAL_1="15" TOTAL_2="15" VAR="2.0568181818181817" WEIGHT="0.07736315175288358"/>
<DICH_DATA CI_END="2.226970712817951" CI_START="0.25258527054818203" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.34771450560826794" LOG_CI_START="-0.5975919788248678" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="11259" O_E="0.0" SE="0.5552777082985894" STUDY_ID="STD-Rubin-1971" TOTAL_1="8" TOTAL_2="10" VAR="0.30833333333333335" WEIGHT="0.5160711474424543"/>
<DICH_DATA CI_END="1.1218360489653505" CI_START="0.222848962850294" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.049929391472379465" LOG_CI_START="-0.6519893828003418" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11260" O_E="0.0" SE="0.412310562561766" STUDY_ID="STD-Stewart-1969" TOTAL_1="25" TOTAL_2="25" VAR="0.16999999999999998" WEIGHT="0.9360113948711182"/>
<DICH_DATA CI_END="1.917863492666026" CI_START="0.18770887572376865" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.28281769225504644" LOG_CI_START="-0.7265151914877592" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="11261" O_E="0.0" SE="0.5928871321888775" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="0.35151515151515145" WEIGHT="0.45267447631267016"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6582227305042463" CI_END="1.2377528371282354" CI_START="0.9256132435904418" DF="4.0" EFFECT_SIZE="1.0703646193412495" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="65" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.0926339304773451" LOG_CI_START="-0.03357044016574672" LOG_EFFECT_SIZE="0.029531745155799212" NO="2" P_CHI2="0.6165448050919822" P_Z="0.3590060379501582" STUDIES="5" TAU2="0.0" TOTAL_1="87" TOTAL_2="88" WEIGHT="28.953832810657374" Z="0.9172607352826242">
<NAME>3 months to 1 year</NAME>
<DICH_DATA CI_END="2.671054939630425" CI_START="0.53911283464624" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.42668282090529175" LOG_CI_START="-0.26832032881004214" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="11262" O_E="0.0" SE="0.4082482904638631" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.1666666666666667" WEIGHT="0.9547316227685402"/>
<DICH_DATA CI_END="1.3557353984025478" CI_START="0.9060785601860033" EFFECT_SIZE="1.1083333333333334" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.13217493567629254" LOG_CI_START="-0.04283414583737055" LOG_EFFECT_SIZE="0.04467039491946099" ORDER="11263" O_E="0.0" SE="0.10280120079005085" STUDY_ID="STD-Gross-1974" TOTAL_1="20" TOTAL_2="21" VAR="0.010568086883876351" WEIGHT="15.056834683187663"/>
<DICH_DATA CI_END="1.6859747462351278" CI_START="0.8860317533400923" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.2268510651565343" LOG_CI_START="-0.05255071371873387" LOG_EFFECT_SIZE="0.0871501757189002" ORDER="11264" O_E="0.0" SE="0.16412198797244365" STUDY_ID="STD-Needham-1969" TOTAL_1="27" TOTAL_2="27" VAR="0.02693602693602694" WEIGHT="5.907401915880344"/>
<DICH_DATA CI_END="1.2554427362523732" CI_START="0.6098446212572547" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.09879690829006142" LOG_CI_START="-0.2147808022454349" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="11265" O_E="0.0" SE="0.1841970994032518" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="0.03392857142857142" WEIGHT="4.689909725880551"/>
<DICH_DATA CI_END="1.457944455315932" CI_START="0.525140033427468" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.16374097857091496" LOG_CI_START="-0.27972487252628847" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="11266" O_E="0.0" SE="0.2604940361258638" STUDY_ID="STD-Vergara-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.06785714285714284" WEIGHT="2.3449548629402757"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.359243444419585" CI_START="0.8741888088281169" DF="0.0" EFFECT_SIZE="1.0900621118012421" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.133297247092718" LOG_CI_START="-0.058394757552731755" LOG_EFFECT_SIZE="0.03745124476999313" NO="3" P_CHI2="1.0" P_Z="0.44376910457776353" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="12.550090424348225" Z="0.7658440534454809">
<NAME>1 year to 2 years</NAME>
<DICH_DATA CI_END="1.359243444419585" CI_START="0.8741888088281169" EFFECT_SIZE="1.0900621118012421" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.133297247092718" LOG_CI_START="-0.058394757552731755" LOG_EFFECT_SIZE="0.03745124476999313" ORDER="11267" O_E="0.0" SE="0.11260083241946371" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="0.01267894746155615" WEIGHT="12.550090424348225"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.648252770236906" CI_END="1.1642875370701296" CI_START="0.7429357543151882" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9300488372085465" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.0660602486486836" LOG_CI_START="-0.12904874041541947" LOG_EFFECT_SIZE="-0.031494245883367945" METHOD="MH" NO="2" P_CHI2="0.6182997544776037" P_Q="0.0" P_Z="0.5268970421183423" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="94" TOTAL_2="95" WEIGHT="300.0" Z="0.6327498076612905">
<NAME>Global state: 1b. No substantial improvement (short term) - by rater's role</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.2161385661442162E-31" CI_END="1.52751026146968" CI_START="0.4809747574750439" DF="0.0" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="100.0" ID="CMP-002.02.01" LOG_CI_END="0.18398413641684347" LOG_CI_START="-0.31787771567806994" LOG_EFFECT_SIZE="-0.06694678963061322" NO="1" P_CHI2="0.0" P_Z="0.6010396441359775" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.0" Z="0.522906038818691">
<NAME>doctor rated</NAME>
<DICH_DATA CI_END="1.52751026146968" CI_START="0.4809747574750439" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.18398413641684347" LOG_CI_START="-0.31787771567806994" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="11268" O_E="0.0" SE="0.2947961361767856" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.08690476190476192" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3240864233557095" CI_START="0.738730281597126" DF="0.0" EFFECT_SIZE="0.989010989010989" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.1219163325066771" LOG_CI_START="-0.13151409827021457" LOG_EFFECT_SIZE="-0.004798882881768708" NO="2" P_CHI2="1.0" P_Z="0.9408300929998126" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.0" Z="0.07422658427766113">
<NAME>nurse rated</NAME>
<DICH_DATA CI_END="1.3240864233557095" CI_START="0.738730281597126" EFFECT_SIZE="0.989010989010989" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.1219163325066771" LOG_CI_START="-0.13151409827021457" LOG_EFFECT_SIZE="-0.004798882881768708" ORDER="11269" O_E="0.0" SE="0.14886628953921083" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.022161172161172152" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0145716932599926" CI_END="1.321446881555808" CI_START="0.5416909595966231" DF="2.0" EFFECT_SIZE="0.8460589987264072" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="27" I2="0.723314703008292" ID="CMP-002.02.03" LOG_CI_END="0.12104971040314419" LOG_CI_START="-0.2662484123914999" LOG_EFFECT_SIZE="-0.07259935099417786" NO="3" P_CHI2="0.36520898752043407" P_Z="0.4624651409821978" STUDIES="3" TAU2="0.0012267854798156627" TOTAL_1="66" TOTAL_2="65" WEIGHT="100.0" Z="0.7347937150989907">
<NAME>patent rated</NAME>
<DICH_DATA CI_END="2.3954941891267496" CI_START="0.4912712947622544" EFFECT_SIZE="1.0848214285714286" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3793951217050185" LOG_CI_START="-0.30867861117671974" LOG_EFFECT_SIZE="0.035358255264149395" ORDER="11270" O_E="0.0" SE="0.40417791671464237" STUDY_ID="STD-Bagadia-1980" TOTAL_1="28" TOTAL_2="27" VAR="0.16335978835978837" WEIGHT="31.38933774704462"/>
<DICH_DATA CI_END="1.704556822700689" CI_START="0.4929596752582568" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.23161148334374548" LOG_CI_START="-0.3071886051225451" LOG_EFFECT_SIZE="-0.0377885608893998" ORDER="11271" O_E="0.0" SE="0.3164938390685515" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.10016835016835018" WEIGHT="51.19137494521022"/>
<DICH_DATA CI_END="1.2412288516716943" CI_START="0.1479771189175812" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.09385186196222604" LOG_CI_START="-0.8298054325514149" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="11272" O_E="0.0" SE="0.5425608669746597" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="0.2943722943722943" WEIGHT="17.419287307745154"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.12136853256038" CI_END="1.1360472090769236" CI_START="0.969023495064312" CI_STUDY="95" CI_TOTAL="95" DF="22.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0492170590958658" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="254" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.055396379099998644" LOG_CI_START="-0.013665692863496155" LOG_EFFECT_SIZE="0.02086534311825124" METHOD="MH" NO="3" P_CHI2="0.756627833415864" P_Q="0.0" P_Z="0.23629188471690954" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="415" TOTAL_2="418" WEIGHT="100.00000000000001" Z="1.1843062298640497">
<NAME>Global state: 1d. No substantial improvement - subgroup analysis - acute vs chronic</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.358556544045258" CI_END="1.2720527982064738" CI_START="0.8419149059555538" DF="9.0" EFFECT_SIZE="1.0348720751728218" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="80" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.10450513764403833" LOG_CI_START="-0.07473180130496496" LOG_EFFECT_SIZE="0.014886668169536684" NO="1" P_CHI2="0.7035650640154107" P_Z="0.7447476165881397" STUDIES="10" TAU2="0.0" TOTAL_1="174" TOTAL_2="177" WEIGHT="14.846503011762664" Z="0.32557277125104517">
<NAME>acutely ill people</NAME>
<DICH_DATA CI_END="1.7333352857794935" CI_START="0.7596662116111281" EFFECT_SIZE="1.1475" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.23888257810904975" LOG_CI_START="-0.11937718969045212" LOG_EFFECT_SIZE="0.05975269420929884" ORDER="11273" O_E="0.0" SE="0.21044356101987932" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="0.044286492374727676" WEIGHT="3.7160635050856152"/>
<DICH_DATA CI_END="2.2014833500781594" CI_START="0.6610444760382554" EFFECT_SIZE="1.2063492063492063" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.34271540521842736" LOG_CI_START="-0.17976931956400805" LOG_EFFECT_SIZE="0.08147304282720963" ORDER="11274" O_E="0.0" SE="0.30691011367830223" STUDY_ID="STD-Bishop-1966" TOTAL_1="21" TOTAL_2="19" VAR="0.09419381787802839" WEIGHT="1.7471573165776282"/>
<DICH_DATA CI_END="1.907279467152222" CI_START="0.34415514118317986" EFFECT_SIZE="0.8101851851851852" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.28041433339713645" LOG_CI_START="-0.46324573832640925" LOG_EFFECT_SIZE="-0.09141570246463643" ORDER="11275" O_E="0.0" SE="0.43682960730713505" STUDY_ID="STD-Bishop-1967" TOTAL_1="27" TOTAL_2="25" VAR="0.1908201058201058" WEIGHT="0.8624427566198204"/>
<DICH_DATA CI_END="1.7570591839122245" CI_START="0.7746529676254246" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.24478639030212707" LOG_CI_START="-0.11089281104090057" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="11276" O_E="0.0" SE="0.20892772350933628" STUDY_ID="STD-Brauzer-1968" TOTAL_1="18" TOTAL_2="18" VAR="0.04365079365079366" WEIGHT="3.770181577878038"/>
<DICH_DATA CI_END="1.52751026146968" CI_START="0.4809747574750439" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.18398413641684347" LOG_CI_START="-0.31787771567806994" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="11277" O_E="0.0" SE="0.2947961361767856" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.08690476190476192" WEIGHT="1.8936985094364576"/>
<DICH_DATA CI_END="2.3164128684582366" CI_START="0.4911809087535689" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3648159689210148" LOG_CI_START="-0.3087585217205277" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="11278" O_E="0.0" SE="0.3956609900503448" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="0.15654761904761905" WEIGHT="1.051254685846855"/>
<DICH_DATA CI_END="1.6709380022245195" CI_START="0.25773790644934585" EFFECT_SIZE="0.65625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2229603363139254" LOG_CI_START="-0.5888217034858987" LOG_EFFECT_SIZE="-0.1829306835859867" ORDER="11279" O_E="0.0" SE="0.47684478856432144" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.2273809523809524" WEIGHT="0.7237695873762379"/>
<DICH_DATA CI_END="182.87437826478745" CI_START="0.6616563848261" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2621528626241068" LOG_CI_START="-0.17936749230765672" LOG_EFFECT_SIZE="1.041392685158225" ORDER="11280" O_E="0.0" SE="1.4341611422075908" STUDY_ID="STD-Perales-1974" TOTAL_1="15" TOTAL_2="15" VAR="2.0568181818181817" WEIGHT="0.08001262315587876"/>
<DICH_DATA CI_END="2.226970712817951" CI_START="0.25258527054818203" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.34771450560826794" LOG_CI_START="-0.5975919788248678" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="11281" O_E="0.0" SE="0.5552777082985894" STUDY_ID="STD-Rubin-1971" TOTAL_1="8" TOTAL_2="10" VAR="0.30833333333333335" WEIGHT="0.5337451397253337"/>
<DICH_DATA CI_END="1.917863492666026" CI_START="0.18770887572376865" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.28281769225504644" LOG_CI_START="-0.7265151914877592" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="11282" O_E="0.0" SE="0.5928871321888775" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="0.35151515151515145" WEIGHT="0.46817731006079927"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.763555257003953" CI_END="1.1463787290237966" CI_START="0.9649111607378258" DF="12.0" EFFECT_SIZE="1.0517383848027535" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="174" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.05932811916066515" LOG_CI_START="-0.015512670259754365" LOG_EFFECT_SIZE="0.021907724450455354" NO="2" P_CHI2="0.5492834793430263" P_Z="0.2511921846201921" STUDIES="14" TAU2="0.0" TOTAL_1="241" TOTAL_2="241" WEIGHT="85.15349698823735" Z="1.1474585246532643">
<NAME>chronically ill people</NAME>
<DICH_DATA CI_END="2.671054939630425" CI_START="0.53911283464624" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.42668282090529175" LOG_CI_START="-0.26832032881004214" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="11283" O_E="0.0" SE="0.4082482904638631" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.1666666666666667" WEIGHT="0.987428508491867"/>
<DICH_DATA CI_END="1.4302350891163809" CI_START="0.6991857545725675" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.15540742873399502" LOG_CI_START="-0.155407428733995" LOG_EFFECT_SIZE="0.0" ORDER="11284" O_E="0.0" SE="0.18257418583505536" STUDY_ID="STD-Bishop-1963" TOTAL_1="20" TOTAL_2="20" VAR="0.033333333333333326" WEIGHT="4.937142542459338"/>
<DICH_DATA CI_END="1.5018371111820334" CI_START="0.5393394489782468" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.17662283176869495" LOG_CI_START="-0.26813781289004524" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="11285" O_E="0.0" SE="0.261254604273242" STUDY_ID="STD-Bishop-1964" TOTAL_1="14" TOTAL_2="14" VAR="0.06825396825396826" WEIGHT="2.4111626370150248"/>
<DICH_DATA CI_END="1.5871944192581473" CI_START="0.6300425378684225" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.20063012778789294" LOG_CI_START="-0.20063012778789288" LOG_EFFECT_SIZE="0.0" ORDER="11286" O_E="0.0" SE="0.23570226039551587" STUDY_ID="STD-Bishop-1970" TOTAL_1="12" TOTAL_2="12" VAR="0.055555555555555566" WEIGHT="2.9622855254756013"/>
<DICH_DATA CI_END="1.359243444419585" CI_START="0.8741888088281169" EFFECT_SIZE="1.0900621118012421" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.133297247092718" LOG_CI_START="-0.058394757552731755" LOG_EFFECT_SIZE="0.03745124476999313" ORDER="11287" O_E="0.0" SE="0.11260083241946371" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="0.01267894746155615" WEIGHT="12.979895892855069"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11288" O_E="0.0" SE="0.0" STUDY_ID="STD-Gallant-1968" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.169905185140503" CI_START="0.8547701238540133" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.0681506658155179" LOG_CI_START="-0.0681506658155179" LOG_EFFECT_SIZE="0.0" ORDER="11289" O_E="0.0" SE="0.08006407690254351" STUDY_ID="STD-Gallant-1968-II" TOTAL_1="26" TOTAL_2="26" VAR="0.006410256410256401" WEIGHT="25.67314122078859"/>
<DICH_DATA CI_END="2.2163391247603808" CI_START="0.9757666295852986" EFFECT_SIZE="1.4705882352941178" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.3456362130707369" LOG_CI_START="-0.010654038483209498" LOG_EFFECT_SIZE="0.1674910872937637" ORDER="11290" O_E="0.0" SE="0.20928665742797734" STUDY_ID="STD-Gallant-1972" TOTAL_1="12" TOTAL_2="12" VAR="0.04380090497737554" WEIGHT="3.7572606814170593"/>
<DICH_DATA CI_END="1.3557353984025478" CI_START="0.9060785601860033" EFFECT_SIZE="1.1083333333333334" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.13217493567629254" LOG_CI_START="-0.04283414583737055" LOG_EFFECT_SIZE="0.04467039491946099" ORDER="11291" O_E="0.0" SE="0.10280120079005085" STUDY_ID="STD-Gross-1974" TOTAL_1="20" TOTAL_2="21" VAR="0.010568086883876351" WEIGHT="15.572489126017995"/>
<DICH_DATA CI_END="2.8592753848835426" CI_START="0.7869126604227532" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.45625598549989865" LOG_CI_START="-0.10407346738853616" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="11292" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Menon-1972" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="1.5191207822951807"/>
<DICH_DATA CI_END="1.6859747462351278" CI_START="0.8860317533400923" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.2268510651565343" LOG_CI_START="-0.05255071371873387" LOG_EFFECT_SIZE="0.0871501757189002" ORDER="11293" O_E="0.0" SE="0.16412198797244365" STUDY_ID="STD-Needham-1969" TOTAL_1="27" TOTAL_2="27" VAR="0.02693602693602694" WEIGHT="6.109713896293429"/>
<DICH_DATA CI_END="1.2554427362523732" CI_START="0.6098446212572547" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.09879690829006142" LOG_CI_START="-0.2147808022454349" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="11294" O_E="0.0" SE="0.1841970994032518" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="0.03392857142857142" WEIGHT="4.850526006626718"/>
<DICH_DATA CI_END="1.1218360489653505" CI_START="0.222848962850294" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.049929391472379465" LOG_CI_START="-0.6519893828003418" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11295" O_E="0.0" SE="0.412310562561766" STUDY_ID="STD-Stewart-1969" TOTAL_1="25" TOTAL_2="25" VAR="0.16999999999999998" WEIGHT="0.9680671651881053"/>
<DICH_DATA CI_END="1.457944455315932" CI_START="0.525140033427468" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.16374097857091496" LOG_CI_START="-0.27972487252628847" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="11296" O_E="0.0" SE="0.2604940361258638" STUDY_ID="STD-Vergara-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.06785714285714284" WEIGHT="2.425263003313359"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.552326097426192" CI_END="1.129258449741302" CI_START="0.9143464598312575" CI_STUDY="95" CI_TOTAL="95" DF="19.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0161365389333727" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="195" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.05279334887902994" LOG_CI_START="-0.03888921227222984" LOG_EFFECT_SIZE="0.0069520683034000825" METHOD="MH" NO="4" P_CHI2="0.8606800895990848" P_Q="0.0" P_Z="0.7662842642106004" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="394" TOTAL_2="398" WEIGHT="100.00000000000001" Z="0.2972387185005974">
<NAME>Global state: 1e. No substantial improvement - subgroup analysis - mixed diagnoses vs schizophrenia only</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6113564571732227" CI_END="1.5310440032147123" CI_START="0.8025155677279285" DF="3.0" EFFECT_SIZE="1.10846138744491" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.18498767278755615" LOG_CI_START="-0.09554653410968503" LOG_EFFECT_SIZE="0.04472056933893552" NO="1" P_CHI2="0.8938277293377761" P_Z="0.532047026488052" STUDIES="4" TAU2="0.0" TOTAL_1="56" TOTAL_2="59" WEIGHT="10.680751841271553" Z="0.624884260938247">
<NAME>mixed diagnoses - short term studies only</NAME>
<DICH_DATA CI_END="1.7570591839122245" CI_START="0.7746529676254246" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.24478639030212707" LOG_CI_START="-0.11089281104090057" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="11297" O_E="0.0" SE="0.20892772350933628" STUDY_ID="STD-Brauzer-1968" TOTAL_1="18" TOTAL_2="18" VAR="0.04365079365079366" WEIGHT="6.644411684119813"/>
<DICH_DATA CI_END="2.3164128684582366" CI_START="0.4911809087535689" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3648159689210148" LOG_CI_START="-0.3087585217205277" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="11298" O_E="0.0" SE="0.3956609900503448" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="0.15654761904761905" WEIGHT="1.8526876685758675"/>
<DICH_DATA CI_END="3.0927915802339063" CI_START="0.4655987843484408" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4903506543697692" LOG_CI_START="-0.3319881622745195" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="11299" O_E="0.0" SE="0.483045891539648" STUDY_ID="STD-O_x0027_Brien-1974" TOTAL_1="15" TOTAL_2="15" VAR="0.2333333333333334" WEIGHT="1.243002185804727"/>
<DICH_DATA CI_END="2.226970712817951" CI_START="0.25258527054818203" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.34771450560826794" LOG_CI_START="-0.5975919788248678" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="11300" O_E="0.0" SE="0.5552777082985894" STUDY_ID="STD-Rubin-1971" TOTAL_1="8" TOTAL_2="10" VAR="0.30833333333333335" WEIGHT="0.9406503027711449"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.6466087139917" CI_END="1.1244508392655925" CI_START="0.8993546532934531" DF="15.0" EFFECT_SIZE="1.0056242313574386" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="166" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.05094047293093387" LOG_CI_START="-0.0460690139449864" LOG_EFFECT_SIZE="0.0024357294929737146" NO="2" P_CHI2="0.70555710409105" P_Z="0.9215970714009086" STUDIES="17" TAU2="0.0" TOTAL_1="338" TOTAL_2="339" WEIGHT="89.31924815872846" Z="0.09842216954341065">
<NAME>schizophrenia only - short term studies</NAME>
<DICH_DATA CI_END="1.7333352857794935" CI_START="0.7596662116111281" EFFECT_SIZE="1.1475" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.23888257810904975" LOG_CI_START="-0.11937718969045212" LOG_EFFECT_SIZE="0.05975269420929884" ORDER="11301" O_E="0.0" SE="0.21044356101987932" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="0.044286492374727676" WEIGHT="6.549036236609828"/>
<DICH_DATA CI_END="3.0274540218576087" CI_START="0.3930968516898826" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.48107755620645043" LOG_CI_START="-0.4055004344276508" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="11302" O_E="0.0" SE="0.5207803003303036" STUDY_ID="STD-Angus-1969" TOTAL_1="22" TOTAL_2="20" VAR="0.27121212121212124" WEIGHT="1.06939852856943"/>
<DICH_DATA CI_END="1.4302350891163809" CI_START="0.6991857545725675" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.15540742873399502" LOG_CI_START="-0.155407428733995" LOG_EFFECT_SIZE="0.0" ORDER="11303" O_E="0.0" SE="0.18257418583505536" STUDY_ID="STD-Bishop-1963" TOTAL_1="20" TOTAL_2="20" VAR="0.033333333333333326" WEIGHT="8.701015300633093"/>
<DICH_DATA CI_END="1.5018371111820334" CI_START="0.5393394489782468" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.17662283176869495" LOG_CI_START="-0.26813781289004524" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="11304" O_E="0.0" SE="0.261254604273242" STUDY_ID="STD-Bishop-1964" TOTAL_1="14" TOTAL_2="14" VAR="0.06825396825396826" WEIGHT="4.249333053797556"/>
<DICH_DATA CI_END="2.2014833500781594" CI_START="0.6610444760382554" EFFECT_SIZE="1.2063492063492063" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.34271540521842736" LOG_CI_START="-0.17976931956400805" LOG_EFFECT_SIZE="0.08147304282720963" ORDER="11305" O_E="0.0" SE="0.30691011367830223" STUDY_ID="STD-Bishop-1966" TOTAL_1="21" TOTAL_2="19" VAR="0.09419381787802839" WEIGHT="3.0791176097140616"/>
<DICH_DATA CI_END="1.907279467152222" CI_START="0.34415514118317986" EFFECT_SIZE="0.8101851851851852" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.28041433339713645" LOG_CI_START="-0.46324573832640925" LOG_EFFECT_SIZE="-0.09141570246463643" ORDER="11306" O_E="0.0" SE="0.43682960730713505" STUDY_ID="STD-Bishop-1967" TOTAL_1="27" TOTAL_2="25" VAR="0.1908201058201058" WEIGHT="1.5199333535003043"/>
<DICH_DATA CI_END="1.5871944192581473" CI_START="0.6300425378684225" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.20063012778789294" LOG_CI_START="-0.20063012778789288" LOG_EFFECT_SIZE="0.0" ORDER="11307" O_E="0.0" SE="0.23570226039551587" STUDY_ID="STD-Bishop-1970" TOTAL_1="12" TOTAL_2="12" VAR="0.055555555555555566" WEIGHT="5.220609180379854"/>
<DICH_DATA CI_END="1.52751026146968" CI_START="0.4809747574750439" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.18398413641684347" LOG_CI_START="-0.31787771567806994" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="11308" O_E="0.0" SE="0.2947961361767856" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.08690476190476192" WEIGHT="3.3373757317496784"/>
<DICH_DATA CI_END="1.6709380022245195" CI_START="0.25773790644934585" EFFECT_SIZE="0.65625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2229603363139254" LOG_CI_START="-0.5888217034858987" LOG_EFFECT_SIZE="-0.1829306835859867" ORDER="11309" O_E="0.0" SE="0.47684478856432144" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.2273809523809524" WEIGHT="1.275541510040453"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11310" O_E="0.0" SE="0.0" STUDY_ID="STD-Gallant-1968" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.169905185140503" CI_START="0.8547701238540133" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.0681506658155179" LOG_CI_START="-0.0681506658155179" LOG_EFFECT_SIZE="0.0" ORDER="11311" O_E="0.0" SE="0.08006407690254351" STUDY_ID="STD-Gallant-1968-II" TOTAL_1="26" TOTAL_2="26" VAR="0.006410256410256401" WEIGHT="45.245279563292144"/>
<DICH_DATA CI_END="2.562295143629686" CI_START="0.7804705652905448" EFFECT_SIZE="1.4141414141414141" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.4086291534598592" LOG_CI_START="-0.10764347129848287" LOG_EFFECT_SIZE="0.1504928410806881" ORDER="11312" O_E="0.0" SE="0.3032610953737587" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.09196729196729198" WEIGHT="3.1536629724574956"/>
<DICH_DATA CI_END="3.037380083063955" CI_START="0.18519249636765195" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.48249914083133905" LOG_CI_START="-0.7323766140479391" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="11313" O_E="0.0" SE="0.7136240321480628" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.5092592592592593" WEIGHT="0.5695210014959841"/>
<DICH_DATA CI_END="2.8592753848835426" CI_START="0.7869126604227532" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.45625598549989865" LOG_CI_START="-0.10407346738853616" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="11314" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Menon-1972" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="2.6772354771178746"/>
<DICH_DATA CI_END="182.87437826478745" CI_START="0.6616563848261" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2621528626241068" LOG_CI_START="-0.17936749230765672" LOG_EFFECT_SIZE="1.041392685158225" ORDER="11315" O_E="0.0" SE="1.4341611422075908" STUDY_ID="STD-Perales-1974" TOTAL_1="15" TOTAL_2="15" VAR="2.0568181818181817" WEIGHT="0.14101092936569284"/>
<DICH_DATA CI_END="1.1218360489653505" CI_START="0.222848962850294" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.049929391472379465" LOG_CI_START="-0.6519893828003418" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11316" O_E="0.0" SE="0.412310562561766" STUDY_ID="STD-Stewart-1969" TOTAL_1="25" TOTAL_2="25" VAR="0.16999999999999998" WEIGHT="1.7060814314966848"/>
<DICH_DATA CI_END="1.917863492666026" CI_START="0.18770887572376865" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.28281769225504644" LOG_CI_START="-0.7265151914877592" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="11317" O_E="0.0" SE="0.5928871321888775" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="0.35151515151515145" WEIGHT="0.8250962785083106"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.16222234447209904" CI_END="1.4678314134494146" CI_START="0.821933656401889" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.09838974896802" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.16667617791446956" LOG_CI_START="-0.08516323577061412" LOG_EFFECT_SIZE="0.04075647107192772" METHOD="MH" NO="5" P_CHI2="0.9220912021545736" P_Q="0.0" P_Z="0.5258314539672817" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="64" WEIGHT="100.0" Z="0.6343821586069568">
<NAME>Global state: 2. Not discharged from hospital - by time period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5755520368238292" CI_START="0.7884373787100187" DF="0.0" EFFECT_SIZE="1.1145510835913313" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="0.19743275148478162" LOG_CI_START="-0.10323279461241286" LOG_EFFECT_SIZE="0.047099978436184374" NO="1" P_CHI2="1.0" P_Z="0.5391716442190144" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="24" WEIGHT="70.15846374092905" Z="0.6140661117033519">
<NAME>by 3 months</NAME>
<DICH_DATA CI_END="1.5755520368238292" CI_START="0.7884373787100187" EFFECT_SIZE="1.1145510835913313" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.19743275148478162" LOG_CI_START="-0.10323279461241286" LOG_EFFECT_SIZE="0.047099978436184374" ORDER="11318" O_E="0.0" SE="0.17661243009594849" STUDY_ID="STD-Simpson-1976" TOTAL_1="19" TOTAL_2="24" VAR="0.03119195046439629" WEIGHT="70.15846374092905"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1329926107922679" CI_END="1.8044678043741111" CI_START="0.6242178774016529" DF="1.0" EFFECT_SIZE="1.061311011290295" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.25634913770757795" LOG_CI_START="-0.20466379743661448" LOG_EFFECT_SIZE="0.025842670135481728" NO="2" P_CHI2="0.7153492463448061" P_Z="0.8260763146925889" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="40" WEIGHT="29.841536259070942" Z="0.21973657946951455">
<NAME>3 months to 1 year</NAME>
<DICH_DATA CI_END="1.8585470606953671" CI_START="0.5380547101270895" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.26917356244091883" LOG_CI_START="-0.26917356244091883" LOG_EFFECT_SIZE="0.0" ORDER="11319" O_E="0.0" SE="0.31622776601683794" STUDY_ID="STD-_x002a_Itil-1971" TOTAL_1="30" TOTAL_2="30" VAR="0.1" WEIGHT="21.883793256652023"/>
<DICH_DATA CI_END="3.4936859878653794" CI_START="0.447235385614801" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5432838680579707" LOG_CI_START="-0.3494638420418579" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="11320" O_E="0.0" SE="0.5244044240850758" STUDY_ID="STD-Rubin-1971" TOTAL_1="8" TOTAL_2="10" VAR="0.275" WEIGHT="7.957743002418917"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.123454892303467" CI_END="1.905748063183088" CI_START="0.3280633526686153" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7906997527187953" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" I2="51.496983664522425" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.2800654870676369" LOG_CI_START="-0.48404228111264747" LOG_EFFECT_SIZE="-0.10198839702250526" METHOD="MH" NO="6" P_CHI2="0.1272342809457061" P_Q="0.0" P_Z="0.6008296327954686" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2908721401405855" TOTALS="YES" TOTAL_1="43" TOTAL_2="35" WEIGHT="100.0" Z="0.5232078335785728">
<NAME>Global state: 3. Use of additional antipsychotics or sedatives</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2264121156385457" CI_START="0.6525682427038176" EFFECT_SIZE="1.2053571428571428" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.34760555666619875" LOG_CI_START="-0.18537406501654977" LOG_EFFECT_SIZE="0.08111574582482449" ORDER="11321" O_E="0.0" SE="0.3130748680681236" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.09801587301587301" WEIGHT="51.80359231345964"/>
<DICH_DATA CI_END="0.9874993221758223" CI_START="0.17044094955490882" EFFECT_SIZE="0.41025641025641024" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="-0.0054631938031741815" LOG_CI_START="-0.7684260549379748" LOG_EFFECT_SIZE="-0.3869446243705744" ORDER="11322" O_E="0.0" SE="0.44816816135765475" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="0.20085470085470086" WEIGHT="40.969486327759"/>
<DICH_DATA CI_END="35.1481697484832" CI_START="0.07176735993742109" EFFECT_SIZE="1.588235294117647" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.545902715164399" LOG_CI_START="-1.1440730296029722" LOG_EFFECT_SIZE="0.20091484278071337" ORDER="11323" O_E="0.0" SE="1.5801050680710416" STUDY_ID="STD-Marjerrison-1964" TOTAL_1="16" TOTAL_2="8" VAR="2.496732026143791" WEIGHT="7.226921358781374"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.616411291471565" CI_START="0.38509952115013524" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.664304494614599" LOG_CI_START="-0.41442702139799914" LOG_EFFECT_SIZE="0.12493873660829992" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.6498243312892176" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="11" WEIGHT="100.0" Z="0.4540062478777973">
<NAME>Mental state: 1. Delusions and hallucinations by the end of the study</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.616411291471565" CI_START="0.38509952115013524" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.664304494614599" LOG_CI_START="-0.41442702139799914" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="11324" O_E="0.0" SE="0.6336522323129237" STUDY_ID="STD-Reardon-1966" TOTAL_1="11" TOTAL_2="11" VAR="0.4015151515151514" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.671827271128347" CI_END="1.0320753383775418" CI_START="0.3462073851454764" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5977558901197223" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.013711400631713262" LOG_CI_START="-0.4606636721806725" LOG_EFFECT_SIZE="-0.22347613577447956" METHOD="MH" NO="8" P_CHI2="0.4697414108516397" P_Q="0.0" P_Z="0.06479616241780313" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="269" TOTAL_2="279" WEIGHT="300.0" Z="1.8466618615746413">
<NAME>Mental state: 2. Other specific effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9370200368931922E-32" CI_END="8.076548849507702" CI_START="0.015530646828864726" DF="0.0" EFFECT_SIZE="0.35416666666666674" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="100.0" ID="CMP-002.08.01" LOG_CI_END="0.9072258241662697" LOG_CI_START="-1.808810456160896" LOG_EFFECT_SIZE="-0.4507923159973132" NO="1" P_CHI2="0.0" P_Z="0.5152999312716893" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0" Z="0.6506074386868684">
<NAME>anxious</NAME>
<DICH_DATA CI_END="8.076548849507702" CI_START="0.015530646828864726" EFFECT_SIZE="0.3541666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9072258241662697" LOG_CI_START="-1.808810456160896" LOG_EFFECT_SIZE="-0.4507923159973133" ORDER="11325" O_E="0.0" SE="1.5954131556605964" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="2.545343137254902" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.248642556799868" CI_END="1.4006573321891445" CI_START="0.3264944717632554" DF="4.0" EFFECT_SIZE="0.6762446863335972" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" I2="5.8522823107799535" ID="CMP-002.08.02" LOG_CI_END="0.14633189906736724" LOG_CI_START="-0.4861241678438497" LOG_EFFECT_SIZE="-0.16989613438824122" NO="2" P_CHI2="0.37340037374190593" P_Z="0.29233784032158394" STUDIES="5" TAU2="0.04781763652217487" TOTAL_1="119" TOTAL_2="125" WEIGHT="100.0" Z="1.0530069104713777">
<NAME>depressed</NAME>
<DICH_DATA CI_END="5.083060192649951" CI_START="0.04918297059741634" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7061252525673394" LOG_CI_START="-1.3081852438953019" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11326" O_E="0.0" SE="1.1832159566199232" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="1.4" WEIGHT="8.639585856608333"/>
<DICH_DATA CI_END="75.8304681762221" CI_START="0.13764744005310217" EFFECT_SIZE="3.230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8798437373227375" LOG_CI_START="-0.8612318611406102" LOG_EFFECT_SIZE="0.5093059380910637" ORDER="11327" O_E="0.0" SE="1.6101213750804138" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="2.5924908424908426" WEIGHT="4.6655594692980635"/>
<DICH_DATA CI_END="0.9504600255608264" CI_START="0.05728220333340065" EFFECT_SIZE="0.23333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.022066143967841338" LOG_CI_START="-1.24198028544297" LOG_EFFECT_SIZE="-0.6320232147054056" ORDER="11328" O_E="0.0" SE="0.7165836053748812" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.5134920634920634" WEIGHT="23.555223262839412"/>
<DICH_DATA CI_END="2.0952805331041575" CI_START="0.3314326809573443" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3212421780530079" LOG_CI_START="-0.47960467014825753" LOG_EFFECT_SIZE="-0.07918124604762482" ORDER="11329" O_E="0.0" SE="0.4704214028892566" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.22129629629629627" WEIGHT="54.6571289338569"/>
<DICH_DATA CI_END="20.771505597011338" CI_START="0.1925715004778244" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.317467976976883" LOG_CI_START="-0.7154079856489205" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11330" O_E="0.0" SE="1.1941214033447043" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.425925925925926" WEIGHT="8.48250247739727"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.043598273811882" CI_END="1.5771500122924025" CI_START="0.16843064555298926" DF="4.0" EFFECT_SIZE="0.5154031380427503" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" I2="20.69154237026782" ID="CMP-002.08.03" LOG_CI_END="0.19787300367280106" LOG_CI_START="-0.7735788868049167" LOG_EFFECT_SIZE="-0.2878529415660578" NO="3" P_CHI2="0.2828533010692602" P_Z="0.2454296792196824" STUDIES="5" TAU2="0.34329240785217957" TOTAL_1="135" TOTAL_2="138" WEIGHT="100.0" Z="1.1615220554791368">
<NAME>excitement</NAME>
<DICH_DATA CI_END="4.021183978262525" CI_START="0.009947319052356126" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6043539435123508" LOG_CI_START="-2.002293952184388" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="11331" O_E="0.0" SE="1.531157877047447" STUDY_ID="STD-Bankier-1968" TOTAL_1="35" TOTAL_2="35" VAR="2.3444444444444446" WEIGHT="10.111179002922192"/>
<DICH_DATA CI_END="33.41835823950553" CI_START="0.4787787564347068" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5239851102779827" LOG_CI_START="-0.31986512762205804" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="11332" O_E="0.0" SE="1.0830867569483633" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="1.173076923076923" WEIGHT="20.20762404737019"/>
<DICH_DATA CI_END="1.0434620982929599" CI_START="0.05842695792217673" EFFECT_SIZE="0.24691358024691357" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="0.018476678795659427" LOG_CI_START="-1.2333867252249968" LOG_EFFECT_SIZE="-0.6074550232146686" ORDER="11333" O_E="0.0" SE="0.7353507603455244" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.5407407407407409" WEIGHT="43.83819389623115"/>
<DICH_DATA CI_END="5.1928763992528335" CI_START="0.048142875119456086" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7154079856489205" LOG_CI_START="-1.317467976976883" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11334" O_E="0.0" SE="1.1941214033447043" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.425925925925926" WEIGHT="16.624354048960384"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11335" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="9.218649004516097"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.1363329557898925" CI_START="0.46809182870572613" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.32966894011371894" LOG_CI_START="-0.329668940113719" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.0">
<NAME>Behaviour: 1. No improvement (Wings Behaviour Rating Scale)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1363329557898925" CI_START="0.46809182870572613" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.32966894011371894" LOG_CI_START="-0.329668940113719" LOG_EFFECT_SIZE="0.0" ORDER="11336" O_E="0.0" SE="0.3872983346207417" STUDY_ID="STD-Menon-1972" TOTAL_1="20" TOTAL_2="20" VAR="0.15000000000000002" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.596956644327971" CI_END="1.2929738448223924" CI_START="0.4557256609389597" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7676205833668563" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="33" I2="10.665736439694145" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.11158973975727199" LOG_CI_START="-0.34129651653401827" LOG_EFFECT_SIZE="-0.11485338838837308" METHOD="MH" NO="10" P_CHI2="0.3474314389537557" P_Q="0.0" P_Z="0.32017120813590305" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.049167431971853304" TOTALS="SUB" TOTAL_1="159" TOTAL_2="163" WEIGHT="400.0" Z="0.9941061430612964">
<NAME>Behaviour: 2. Specific effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.22991724401180108" CI_END="2.2116152436615364" CI_START="0.23463409782392824" DF="1.0" EFFECT_SIZE="0.7203612617500832" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="0.34470957467204955" LOG_CI_START="-0.6296088744851345" LOG_EFFECT_SIZE="-0.14244964990654244" NO="1" P_CHI2="0.6315852190493046" P_Z="0.5665697189133646" STUDIES="2" TAU2="0.0" TOTAL_1="42" TOTAL_2="43" WEIGHT="100.0" Z="0.5731107394480237">
<NAME>lethargy</NAME>
<DICH_DATA CI_END="8.076548849507702" CI_START="0.015530646828864726" EFFECT_SIZE="0.3541666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9072258241662697" LOG_CI_START="-1.808810456160896" LOG_EFFECT_SIZE="-0.4507923159973133" ORDER="11337" O_E="0.0" SE="1.5954131556605964" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="2.545343137254902" WEIGHT="14.077785304199852"/>
<DICH_DATA CI_END="2.6606360668832783" CI_START="0.2405439841871003" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4249854739675706" LOG_CI_START="-0.6188054999836834" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="11338" O_E="0.0" SE="0.6131279849476176" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.37592592592592594" WEIGHT="85.92221469580015"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6606360668832783" CI_START="0.2405439841871003" DF="0.0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-002.10.02" LOG_CI_END="0.4249854739675706" LOG_CI_START="-0.6188054999836834" LOG_EFFECT_SIZE="-0.09691001300805639" NO="2" P_CHI2="1.0" P_Z="0.7159006805416287" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.36394285824887596">
<NAME>restlessness</NAME>
<DICH_DATA CI_END="2.6606360668832783" CI_START="0.2405439841871003" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4249854739675706" LOG_CI_START="-0.6188054999836834" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="11339" O_E="0.0" SE="0.6131279849476176" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.37592592592592594" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.1928763992528335" CI_START="0.048142875119456086" DF="0.0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.10.03" LOG_CI_END="0.7154079856489205" LOG_CI_START="-1.317467976976883" LOG_EFFECT_SIZE="-0.3010299956639812" NO="3" P_CHI2="1.0" P_Z="0.5616002386525207" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.5804662562939223">
<NAME>violent and aggressive</NAME>
<DICH_DATA CI_END="5.1928763992528335" CI_START="0.048142875119456086" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7154079856489205" LOG_CI_START="-1.317467976976883" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11340" O_E="0.0" SE="1.1941214033447043" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.425925925925926" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.3600444996598835" CI_END="5.486183392105672" CI_START="0.2143444142633404" DF="1.0" EFFECT_SIZE="1.0844043368237495" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" I2="81.3434384721348" ID="CMP-002.10.04" LOG_CI_END="0.7392703211045109" LOG_CI_START="-0.6688878295604714" LOG_EFFECT_SIZE="0.035191245772019646" NO="4" P_CHI2="0.0206033160223007" P_Z="0.9219618137775532" STUDIES="2" TAU2="1.1253949283163502" TOTAL_1="63" TOTAL_2="66" WEIGHT="100.0" Z="0.09796282363835934">
<NAME>unspecified behavioural problems</NAME>
<DICH_DATA CI_END="1.0118290457137196" CI_START="0.2702028778030715" EFFECT_SIZE="0.5228758169934641" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.005107142172898727" LOG_CI_START="-0.568310029824209" LOG_EFFECT_SIZE="-0.28160144382565516" ORDER="11341" O_E="0.0" SE="0.3368280852918806" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.11345315904139436" WEIGHT="73.53894557565977"/>
<DICH_DATA CI_END="9.250855217272443" CI_START="0.7686976981148537" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9661818839794107" LOG_CI_START="-0.11424441943484842" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="11342" O_E="0.0" SE="0.6346477588219923" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.40277777777777773" WEIGHT="26.461054424340226"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.37516617090773" CI_END="1.6195704768920627" CI_START="0.9223411831927778" CI_STUDY="95" CI_TOTAL="95" DF="29.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.222209699650889" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="76" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.2093998514257605" LOG_CI_START="-0.035108399370398446" LOG_EFFECT_SIZE="0.08714572602768103" METHOD="MH" NO="11" P_CHI2="0.9560284521109081" P_Q="0.0" P_Z="0.1623804378637159" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="32" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="650" TOTAL_2="650" WEIGHT="100.0" Z="1.3971101904715997">
<NAME>Leaving the study early: 1. Any reason - by time period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.761537110624108" CI_END="1.5826867338143549" CI_START="0.8285372887572173" DF="20.0" EFFECT_SIZE="1.1451266198052341" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="59" I2="0.0" ID="CMP-002.11.01" LOG_CI_END="0.19939496208959198" LOG_CI_START="-0.08168794115282246" LOG_EFFECT_SIZE="0.05885351046838474" NO="1" P_CHI2="0.952173641757538" P_Z="0.41178316068102494" STUDIES="22" TAU2="0.0" TOTAL_1="460" TOTAL_2="470" WEIGHT="75.66903164515395" Z="0.8207597086209346">
<NAME>by 3 months</NAME>
<DICH_DATA CI_END="2.2928589592378805" CI_START="0.3028727264913275" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.36037734077066724" LOG_CI_START="-0.5187398328659169" LOG_EFFECT_SIZE="-0.07918124604762482" ORDER="11343" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.2666666666666667" WEIGHT="7.735591174184566"/>
<DICH_DATA CI_END="3.252327169601902" CI_START="0.627494166517207" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5121942272067187" LOG_CI_START="-0.2023903072352323" LOG_EFFECT_SIZE="0.15490195998574316" ORDER="11344" O_E="0.0" SE="0.4197504927816955" STUDY_ID="STD-_x002a_Itil-1971" TOTAL_1="30" TOTAL_2="30" VAR="0.1761904761904762" WEIGHT="11.707921777144211"/>
<DICH_DATA CI_END="27.33325429307962" CI_START="0.3292692448362676" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4366913418056761" LOG_CI_START="-0.4824488323663515" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="11345" O_E="0.0" SE="1.1273124382057236" STUDY_ID="STD-_x002a_Pinard-1972" TOTAL_1="32" TOTAL_2="32" VAR="1.2708333333333333" WEIGHT="1.6232060168780735"/>
<DICH_DATA CI_END="2.224650770486351" CI_START="0.40142255667606086" EFFECT_SIZE="0.945" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3472618443710358" LOG_CI_START="-0.39639822735251" LOG_EFFECT_SIZE="-0.024568191490737076" ORDER="11346" O_E="0.0" SE="0.43682960730713505" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="0.1908201058201058" WEIGHT="10.810309030331409"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11347" O_E="0.0" SE="0.0" STUDY_ID="STD-_x002a_Vestre-1970" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528004" LOG_EFFECT_SIZE="0.0" ORDER="11348" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Andersen-1974" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="1.0856970069030971"/>
<DICH_DATA CI_END="7.991740530856307" CI_START="0.26178973205737016" EFFECT_SIZE="1.4464285714285714" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.902641375137019" LOG_CI_START="-0.5820473913921204" LOG_EFFECT_SIZE="0.1602969918724493" ORDER="11349" O_E="0.0" SE="0.8721135307871393" STUDY_ID="STD-Bagadia-1980" TOTAL_1="28" TOTAL_2="27" VAR="0.7605820105820105" WEIGHT="2.7121655316793203"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528004" LOG_EFFECT_SIZE="0.0" ORDER="11350" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Bishop-1963" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="1.0856970069030971"/>
<DICH_DATA CI_END="4.796535261780003" CI_START="0.04468531833453172" EFFECT_SIZE="0.46296296296296297" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6809276415382318" LOG_CI_START="-1.3498351438400935" LOG_EFFECT_SIZE="-0.3344537511509309" ORDER="11351" O_E="0.0" SE="1.1928801125691395" STUDY_ID="STD-Bishop-1967" TOTAL_1="27" TOTAL_2="25" VAR="1.422962962962963" WEIGHT="1.4496683095816993"/>
<DICH_DATA CI_END="2.07915142858136" CI_START="0.10245417844559572" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3178861209824303" LOG_CI_START="-0.9894703248288166" LOG_EFFECT_SIZE="-0.3357921019231931" ORDER="11352" O_E="0.0" SE="0.7679476477883045" STUDY_ID="STD-Brauzer-1971" TOTAL_1="13" TOTAL_2="12" VAR="0.5897435897435898" WEIGHT="3.497832530935631"/>
<DICH_DATA CI_END="8.237478993496916" CI_START="0.31355566008779934" EFFECT_SIZE="1.6071428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9157943201034313" LOG_CI_START="-0.5036853552371823" LOG_EFFECT_SIZE="0.20605448243312446" ORDER="11353" O_E="0.0" SE="0.8338093878327919" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.6952380952380952" WEIGHT="2.967076066810519"/>
<DICH_DATA CI_END="102.37925903707298" CI_START="0.27566771351392755" EFFECT_SIZE="5.3125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.010211982048814" LOG_CI_START="-0.5596140959320774" LOG_EFFECT_SIZE="0.725298943058368" ORDER="11354" O_E="0.0" SE="1.5095285590502205" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="2.2786764705882354" WEIGHT="0.9052730125323017"/>
<DICH_DATA CI_END="2.7260123373687333" CI_START="0.008216424617442705" EFFECT_SIZE="0.14965986394557823" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4355278170302165" LOG_CI_START="-2.085317124882156" LOG_EFFECT_SIZE="-0.8248946539259698" ORDER="11355" O_E="0.0" SE="1.4807567972630389" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="2.1926406926406927" WEIGHT="0.9407945041061587"/>
<DICH_DATA CI_END="3.8750219754150135" CI_START="0.458778760238483" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5882741697518559" LOG_CI_START="-0.33839669653525606" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="11356" O_E="0.0" SE="0.5443310539518174" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.29629629629629634" WEIGHT="6.96203205676611"/>
<DICH_DATA CI_END="15.180224957567825" CI_START="0.06587517660609293" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1812782074689785" LOG_CI_START="-1.1812782074689785" LOG_EFFECT_SIZE="0.0" ORDER="11357" O_E="0.0" SE="1.387777332977422" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.925925925925926" WEIGHT="1.071081854887094"/>
<DICH_DATA CI_END="4.1843664851249125" CI_START="0.23898480296955818" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.62162971493598" LOG_CI_START="-0.6216297149359801" LOG_EFFECT_SIZE="0.0" ORDER="11358" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-O_x0027_Brien-1974" TOTAL_1="15" TOTAL_2="15" VAR="0.5333333333333333" WEIGHT="3.8677955870922838"/>
<DICH_DATA CI_END="92.62160011346378" CI_START="0.2699154405600246" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9667122795130358" LOG_CI_START="-0.5687722708409984" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="11359" O_E="0.0" SE="1.4893561757289013" STUDY_ID="STD-Ramsay-1970" TOTAL_1="10" TOTAL_2="10" VAR="2.2181818181818183" WEIGHT="0.9299617805030628"/>
<DICH_DATA CI_END="7.29711607747592" CI_START="0.3083409906202667" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8631512547638782" LOG_CI_START="-0.5109687366525157" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="11360" O_E="0.0" SE="0.8071648849616486" STUDY_ID="STD-Reardon-1966" TOTAL_1="11" TOTAL_2="11" VAR="0.6515151515151514" WEIGHT="3.166195457340661"/>
<DICH_DATA CI_END="3.52818330812873" CI_START="0.15242342327814115" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5475511409837852" LOG_CI_START="-0.8169482887786976" LOG_EFFECT_SIZE="-0.13469857389745624" ORDER="11361" O_E="0.0" SE="0.8015137194235931" STUDY_ID="STD-Schiele-1969" TOTAL_1="10" TOTAL_2="11" VAR="0.6424242424242423" WEIGHT="3.211000110038878"/>
<DICH_DATA CI_END="6.459691520658577" CI_START="0.4300170942984254" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8102117789742533" LOG_CI_START="-0.3665142797415406" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="11362" O_E="0.0" SE="0.6912147117775906" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.47777777777777775" WEIGHT="4.317539260009991"/>
<DICH_DATA CI_END="7.714542467723204" CI_START="0.5745166330385083" EFFECT_SIZE="2.1052631578947367" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8873101741275758" LOG_CI_START="-0.24069739337730894" LOG_EFFECT_SIZE="0.3233063903751334" ORDER="11363" O_E="0.0" SE="0.6625972288798816" STUDY_ID="STD-Simpson-1976" TOTAL_1="19" TOTAL_2="24" VAR="0.4390350877192982" WEIGHT="4.698540893011207"/>
<DICH_DATA CI_END="3.7419210762620905" CI_START="0.01068969633105066" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5730946232213574" LOG_CI_START="-1.9710346318933951" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="11364" O_E="0.0" SE="1.4944341180973262" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="2.233333333333333" WEIGHT="0.9236526775145755"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3941431119349343" CI_END="3.269179850758979" CI_START="0.9935929745822668" DF="7.0" EFFECT_SIZE="1.802285807623204" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" I2="0.0" ID="CMP-002.11.02" LOG_CI_END="0.5144388135273339" LOG_CI_START="-0.002791487931324842" LOG_EFFECT_SIZE="0.25582366279800445" NO="2" P_CHI2="0.9857499810139301" P_Z="0.05252470170395179" STUDIES="9" TAU2="0.0" TOTAL_1="177" TOTAL_2="168" WEIGHT="22.34699429290968" Z="1.9388081636484888">
<NAME>by 3 months to 1 year</NAME>
<DICH_DATA CI_END="12.011998353083218" CI_START="0.05960509736310207" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0796152639825778" LOG_CI_START="-1.2247165982798012" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="11365" O_E="0.0" SE="1.3535759425196032" STUDY_ID="STD-_x002a_Bankier-1973" TOTAL_1="13" TOTAL_2="11" VAR="1.8321678321678323" WEIGHT="1.1258926594487462"/>
<DICH_DATA CI_END="7.136685127407792" CI_START="0.3152724212756815" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8534965359826647" LOG_CI_START="-0.5013140178713023" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="11366" O_E="0.0" SE="0.7958224257542215" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.6333333333333333" WEIGHT="3.2570910207092916"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11367" O_E="0.0" SE="0.0" STUDY_ID="STD-Bankier-1968" TOTAL_1="35" TOTAL_2="35" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.674780151318313" CI_START="0.764121495423191" EFFECT_SIZE="1.89" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6697611913979693" LOG_CI_START="-0.11683758305148102" LOG_EFFECT_SIZE="0.2764618041732441" ORDER="11368" O_E="0.0" SE="0.4620520138383378" STUDY_ID="STD-Gross-1974" TOTAL_1="20" TOTAL_2="21" VAR="0.2134920634920635" WEIGHT="9.662299756602284"/>
<DICH_DATA CI_END="99.34278665287792" CI_START="0.2516539030393281" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9971363381737377" LOG_CI_START="-0.5991963295017" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="11369" O_E="0.0" SE="1.5250986610465322" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="2.3259259259259255" WEIGHT="0.8868830645561926"/>
<DICH_DATA CI_END="64.12472892455663" CI_START="0.21416954495041227" EFFECT_SIZE="3.7058823529411766" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8070255422240744" LOG_CI_START="-0.6692422860734587" LOG_EFFECT_SIZE="0.5688916280753078" ORDER="11370" O_E="0.0" SE="1.4545719800654109" STUDY_ID="STD-Marjerrison-1964" TOTAL_1="16" TOTAL_2="8" VAR="2.11577964519141" WEIGHT="0.9749712441955484"/>
<DICH_DATA CI_END="6.290667227826043" CI_START="0.44157124787822144" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7986967118991457" LOG_CI_START="-0.3549992126664329" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="11371" O_E="0.0" SE="0.6776866969767514" STUDY_ID="STD-Needham-1969" TOTAL_1="27" TOTAL_2="27" VAR="0.45925925925925926" WEIGHT="4.491633585010394"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="11372" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.8022094551006218"/>
<DICH_DATA CI_END="13.867772482168174" CI_START="0.07210963413813187" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1420067079086857" LOG_CI_START="-1.1420067079086857" LOG_EFFECT_SIZE="0.0" ORDER="11373" O_E="0.0" SE="1.3416407864998738" STUDY_ID="STD-Vergara-1977" TOTAL_1="10" TOTAL_2="10" VAR="1.7999999999999998" WEIGHT="1.1460135072866027"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.362133046387858" CI_START="0.02502166754346663" DF="0.0" EFFECT_SIZE="0.18461538461538463" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-002.11.03" LOG_CI_END="0.13421952937566228" LOG_CI_START="-1.6016837505661239" LOG_EFFECT_SIZE="-0.7337321105952308" NO="3" P_CHI2="1.0" P_Z="0.09754448468983705" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="1.9839740619363624" Z="1.6568763106610858">
<NAME>by 1 year to 2 years</NAME>
<DICH_DATA CI_END="1.3621330463878576" CI_START="0.02502166754346663" EFFECT_SIZE="0.18461538461538463" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.13421952937566217" LOG_CI_START="-1.6016837505661239" LOG_EFFECT_SIZE="-0.7337321105952308" ORDER="11374" O_E="0.0" SE="1.0196781794976246" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="1.0397435897435898" WEIGHT="1.9839740619363624"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.608652891010855" CI_END="3.108659643246334" CI_START="0.4918992233301286" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2365869415898691" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.4925731751948197" LOG_CI_START="-0.30812386315667945" LOG_EFFECT_SIZE="0.09222465601907016" METHOD="MH" NO="12" P_CHI2="0.8561150121916928" P_Q="0.0" P_Z="0.651629860199858" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="155" WEIGHT="100.0" Z="0.45149912045664853">
<NAME>Leaving the study early: 2. Due to adverse events - by time period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2520880358856792" CI_END="4.053127437381711" CI_START="0.10826831506937226" DF="2.0" EFFECT_SIZE="0.6624388865448348" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.12.01" LOG_CI_END="0.6077902589308317" LOG_CI_START="-0.965498621896068" LOG_EFFECT_SIZE="-0.1788541814826181" NO="1" P_CHI2="0.534703233721938" P_Z="0.6558687696468873" STUDIES="3" TAU2="0.0" TOTAL_1="66" TOTAL_2="63" WEIGHT="25.90117687550925" Z="0.44562414247290544">
<NAME>by 3 months</NAME>
<DICH_DATA CI_END="68.15071061090849" CI_START="0.12310967582579363" EFFECT_SIZE="2.896551724137931" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.833470388604843" LOG_CI_START="-0.9097078122789919" LOG_EFFECT_SIZE="0.46188128816292556" ORDER="11375" O_E="0.0" SE="1.6113564541502576" STUDY_ID="STD-Bagadia-1980" TOTAL_1="28" TOTAL_2="27" VAR="2.5964696223316914" WEIGHT="8.519780430586515"/>
<DICH_DATA CI_END="7.264937143867087" CI_START="0.013187311433658885" EFFECT_SIZE="0.30952380952380953" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8612318611406103" LOG_CI_START="-1.8798437373227375" LOG_EFFECT_SIZE="-0.5093059380910636" ORDER="11376" O_E="0.0" SE="1.6101213750804138" STUDY_ID="STD-Bishop-1967" TOTAL_1="27" TOTAL_2="25" VAR="2.5924908424908426" WEIGHT="8.532856014141174"/>
<DICH_DATA CI_END="7.391737873352934" CI_START="0.015031798071690874" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8687465574849313" LOG_CI_START="-1.8229890669242566" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11377" O_E="0.0" SE="1.5811388300841895" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="2.4999999999999996" WEIGHT="8.848540430781563"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7594847243048085" CI_END="4.488128418676873" CI_START="0.5271021213798261" DF="3.0" EFFECT_SIZE="1.538083876292078" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-002.12.02" LOG_CI_END="0.6520652748801988" LOG_CI_START="-0.27810523591613995" LOG_EFFECT_SIZE="0.18698001948202944" NO="2" P_CHI2="0.8591311752512981" P_Z="0.4307131600017131" STUDIES="5" TAU2="0.0" TOTAL_1="99" TOTAL_2="92" WEIGHT="74.09882312449075" Z="0.7879718820576866">
<NAME>by 3 months to 1 year</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11378" O_E="0.0" SE="0.0" STUDY_ID="STD-Gross-1974" TOTAL_1="20" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="99.34278665287792" CI_START="0.2516539030393281" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9971363381737377" LOG_CI_START="-0.5991963295017" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="11379" O_E="0.0" SE="1.5250986610465322" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="2.3259259259259255" WEIGHT="9.510771959836871"/>
<DICH_DATA CI_END="35.1481697484832" CI_START="0.07176735993742109" EFFECT_SIZE="1.588235294117647" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.545902715164399" LOG_CI_START="-1.1440730296029722" LOG_EFFECT_SIZE="0.20091484278071337" ORDER="11380" O_E="0.0" SE="1.5801050680710416" STUDY_ID="STD-Marjerrison-1964" TOTAL_1="16" TOTAL_2="8" VAR="2.496732026143791" WEIGHT="8.860122289984155"/>
<DICH_DATA CI_END="5.39978681433592" CI_START="0.32923110465360345" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.732376614047939" LOG_CI_START="-0.48249914083133916" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="11381" O_E="0.0" SE="0.7136240321480628" STUDY_ID="STD-Needham-1969" TOTAL_1="27" TOTAL_2="27" VAR="0.5092592592592593" WEIGHT="43.43828938747311"/>
<DICH_DATA CI_END="13.867772482168174" CI_START="0.07210963413813187" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1420067079086857" LOG_CI_START="-1.1420067079086857" LOG_EFFECT_SIZE="0.0" ORDER="11382" O_E="0.0" SE="1.3416407864998738" STUDY_ID="STD-Vergara-1977" TOTAL_1="10" TOTAL_2="10" VAR="1.7999999999999998" WEIGHT="12.289639487196613"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.576927610761759" CI_END="2.3825340260989325" CI_START="0.7191223244256106" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3089436224953972" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="0.3770391117202215" LOG_CI_START="-0.14319722880424005" LOG_EFFECT_SIZE="0.11692094145799072" METHOD="MH" NO="13" P_CHI2="0.8842604105204735" P_Q="0.0" P_Z="0.37832464137269795" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="221" TOTAL_2="210" WEIGHT="100.0" Z="0.8809874145476111">
<NAME>Leaving the study early: 3. Due to relapse or worsening - by time period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.231217251263848" CI_END="2.782570405519715" CI_START="0.41026410019421755" DF="5.0" EFFECT_SIZE="1.0684515635477374" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-002.13.01" LOG_CI_END="0.44444616180885665" LOG_CI_START="-0.3869364839340748" LOG_EFFECT_SIZE="0.02875483893739092" NO="1" P_CHI2="0.8163143324150555" P_Z="0.8921551826062316" STUDIES="6" TAU2="0.0" TOTAL_1="102" TOTAL_2="101" WEIGHT="39.156103024161396" Z="0.13557764042133405">
<NAME>by 3 months</NAME>
<DICH_DATA CI_END="14.651750998933705" CI_START="0.06346319554865361" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1658895293818077" LOG_CI_START="-1.1974780637482711" LOG_EFFECT_SIZE="-0.015794267183231903" ORDER="11383" O_E="0.0" SE="1.388253823062871" STUDY_ID="STD-Bagadia-1980" TOTAL_1="28" TOTAL_2="27" VAR="1.9272486772486772" WEIGHT="4.84550247689106"/>
<DICH_DATA CI_END="14.02637438463267" CI_START="0.06112333784852386" EFFECT_SIZE="0.9259259259259259" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1469454266781303" LOG_CI_START="-1.2137929376520296" LOG_EFFECT_SIZE="-0.0334237554869497" ORDER="11384" O_E="0.0" SE="1.3867094010509062" STUDY_ID="STD-Bishop-1967" TOTAL_1="27" TOTAL_2="25" VAR="1.922962962962963" WEIGHT="4.856301665220032"/>
<DICH_DATA CI_END="102.37925903707298" CI_START="0.27566771351392755" EFFECT_SIZE="5.3125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.010211982048814" LOG_CI_START="-0.5596140959320774" LOG_EFFECT_SIZE="0.725298943058368" ORDER="11385" O_E="0.0" SE="1.5095285590502205" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="2.2786764705882354" WEIGHT="4.098207165312402"/>
<DICH_DATA CI_END="18.980705815507015" CI_START="0.2107403190840273" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2783123580428297" LOG_CI_START="-0.6762523667148672" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11386" O_E="0.0" SE="1.148120994574099" STUDY_ID="STD-Reardon-1966" TOTAL_1="11" TOTAL_2="11" VAR="1.3181818181818183" WEIGHT="7.084370388353676"/>
<DICH_DATA CI_END="3.52818330812873" CI_START="0.15242342327814115" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5475511409837852" LOG_CI_START="-0.8169482887786976" LOG_EFFECT_SIZE="-0.13469857389745624" ORDER="11387" O_E="0.0" SE="0.8015137194235931" STUDY_ID="STD-Schiele-1969" TOTAL_1="10" TOTAL_2="11" VAR="0.6424242424242423" WEIGHT="14.536326032706839"/>
<DICH_DATA CI_END="7.391737873352934" CI_START="0.015031798071690874" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8687465574849313" LOG_CI_START="-1.8229890669242566" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11388" O_E="0.0" SE="1.5811388300841895" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="2.4999999999999996" WEIGHT="3.7353952956773937"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.008563164818787" CI_END="3.848612391149256" CI_START="0.7841378688095173" DF="5.0" EFFECT_SIZE="1.7371939207439329" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" I2="0.0" ID="CMP-002.13.02" LOG_CI_END="0.5853041737961655" LOG_CI_START="-0.1056075720105139" LOG_EFFECT_SIZE="0.23984830089282583" NO="2" P_CHI2="0.8479589295972936" P_Z="0.17357902514534365" STUDIES="6" TAU2="0.0" TOTAL_1="106" TOTAL_2="97" WEIGHT="56.69649614730466" Z="1.3607932832411258">
<NAME>by 3 months to 1 year</NAME>
<DICH_DATA CI_END="12.011998353083218" CI_START="0.05960509736310207" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0796152639825778" LOG_CI_START="-1.2247165982798012" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="11389" O_E="0.0" SE="1.3535759425196032" STUDY_ID="STD-_x002a_Bankier-1973" TOTAL_1="13" TOTAL_2="11" VAR="1.8321678321678323" WEIGHT="5.096961138185756"/>
<DICH_DATA CI_END="6.461095349438592" CI_START="0.8638483025149861" EFFECT_SIZE="2.3625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.810306150176445" LOG_CI_START="-0.06356251581384399" LOG_EFFECT_SIZE="0.3733718171813005" ORDER="11390" O_E="0.0" SE="0.5133147801223568" STUDY_ID="STD-Gross-1974" TOTAL_1="20" TOTAL_2="21" VAR="0.2634920634920635" WEIGHT="35.44125054633671"/>
<DICH_DATA CI_END="35.1481697484832" CI_START="0.07176735993742109" EFFECT_SIZE="1.588235294117647" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.545902715164399" LOG_CI_START="-1.1440730296029722" LOG_EFFECT_SIZE="0.20091484278071337" ORDER="11391" O_E="0.0" SE="1.5801050680710416" STUDY_ID="STD-Marjerrison-1964" TOTAL_1="16" TOTAL_2="8" VAR="2.496732026143791" WEIGHT="3.7402845565356095"/>
<DICH_DATA CI_END="70.53181155968163" CI_START="0.1276019969001435" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8483850385343752" LOG_CI_START="-0.8941425290950502" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="11392" O_E="0.0" SE="1.6109742689559308" STUDY_ID="STD-Needham-1969" TOTAL_1="27" TOTAL_2="27" VAR="2.5952380952380953" WEIGHT="3.598316569230516"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11393" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="3.6316343152419095"/>
<DICH_DATA CI_END="13.867772482168174" CI_START="0.07210963413813187" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1420067079086857" LOG_CI_START="-1.1420067079086857" LOG_EFFECT_SIZE="0.0" ORDER="11394" O_E="0.0" SE="1.3416407864998738" STUDY_ID="STD-Vergara-1977" TOTAL_1="10" TOTAL_2="10" VAR="1.7999999999999998" WEIGHT="5.188049021774157"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5165373509904523" CI_START="0.009807885563522621" DF="0.0" EFFECT_SIZE="0.18571428571428572" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-002.13.03" LOG_CI_END="0.5461152346437514" LOG_CI_START="-2.008424610058592" LOG_EFFECT_SIZE="-0.73115468770742" NO="3" P_CHI2="1.0" P_Z="0.2618824310819907" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="4.147400828533954" Z="1.1219530264959736">
<NAME>by 1 year to 2 years</NAME>
<DICH_DATA CI_END="3.5165373509904523" CI_START="0.009807885563522621" EFFECT_SIZE="0.18571428571428572" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5461152346437514" LOG_CI_START="-2.008424610058592" LOG_EFFECT_SIZE="-0.73115468770742" ORDER="11395" O_E="0.0" SE="1.5005493499543263" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="2.251648351648351" WEIGHT="4.147400828533954"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.33511242496627" CI_END="2.4998568868492086" CI_START="0.2736763295674" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8271346064799119" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.39791514665974403" LOG_CI_START="-0.5627627633600945" LOG_EFFECT_SIZE="-0.08242380835017517" METHOD="MH" NO="14" P_CHI2="0.8457291020500481" P_Q="0.0" P_Z="0.7366294156173596" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="54" WEIGHT="100.0" Z="0.33632020503446175">
<NAME>Leaving the study early: 4. Due to refusal of treatment - by time period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.410121140773718E-4" CI_END="3.521497178761942" CI_START="0.27952831871604494" DF="1.0" EFFECT_SIZE="0.9921482680237976" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-002.14.01" LOG_CI_END="0.5467273447946254" LOG_CI_START="-0.5535741876376306" LOG_EFFECT_SIZE="-0.00342342142150256" NO="1" P_CHI2="0.9814431443478203" P_Z="0.990269032376925" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="42" WEIGHT="76.23109770468557" Z="0.012196261646961016">
<NAME>by 3 months</NAME>
<DICH_DATA CI_END="14.651750998933705" CI_START="0.06346319554865361" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1658895293818077" LOG_CI_START="-1.1974780637482711" LOG_EFFECT_SIZE="-0.015794267183231903" ORDER="11396" O_E="0.0" SE="1.388253823062871" STUDY_ID="STD-Bagadia-1980" TOTAL_1="28" TOTAL_2="27" VAR="1.9272486772486772" WEIGHT="16.52315804458081"/>
<DICH_DATA CI_END="4.1843664851249125" CI_START="0.23898480296955818" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.62162971493598" LOG_CI_START="-0.6216297149359801" LOG_EFFECT_SIZE="0.0" ORDER="11397" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-O_x0027_Brien-1974" TOTAL_1="15" TOTAL_2="15" VAR="0.5333333333333333" WEIGHT="59.707939660104756"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.461189224607842" CI_START="0.04774909575776068" DF="0.0" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.14.02" LOG_CI_END="0.6494506445507751" LOG_CI_START="-1.3210348483971615" LOG_EFFECT_SIZE="-0.3357921019231931" NO="2" P_CHI2="1.0" P_Z="0.504134716733027" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="23.768902295314426" Z="0.6679982455266427">
<NAME>by 1 year to 2 years</NAME>
<DICH_DATA CI_END="4.461189224607842" CI_START="0.04774909575776068" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6494506445507751" LOG_CI_START="-1.3210348483971615" LOG_EFFECT_SIZE="-0.3357921019231931" ORDER="11398" O_E="0.0" SE="1.1574729326181195" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="1.3397435897435899" WEIGHT="23.768902295314426"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.98563037195528" CI_END="1.1295234560181149" CI_START="0.880753039705331" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.997412260455237" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="175" I2="33.280069967903835" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="0.05289525403766799" LOG_CI_START="-0.055145849282145575" LOG_EFFECT_SIZE="-0.0011252976222387743" METHOD="MH" NO="15" P_CHI2="0.11612762119655418" P_Q="0.0" P_Z="0.967433139261252" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.015519753782990038" TOTALS="YES" TOTAL_1="293" TOTAL_2="292" WEIGHT="100.00000000000001" Z="0.04082784687875574">
<NAME>Adverse events: 1. Reporting at least one adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1827192555393649" CI_START="0.6921288382466387" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.07288166750213396" LOG_CI_START="-0.15981305506431456" LOG_EFFECT_SIZE="-0.0434656937810903" ORDER="11399" O_E="0.0" SE="0.13668603189298548" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.018683071314650246" WEIGHT="11.775822359142001"/>
<DICH_DATA CI_END="1.08680917961515" CI_START="0.7241588162314605" EFFECT_SIZE="0.8871428571428571" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="25" LOG_CI_END="0.03615329798229884" LOG_CI_START="-0.14016617765765216" LOG_EFFECT_SIZE="-0.052006439837676645" ORDER="11400" O_E="0.0" SE="0.10357093278638789" STUDY_ID="STD-Bagadia-1980" TOTAL_1="28" TOTAL_2="27" VAR="0.010726938118242477" WEIGHT="15.345415492597839"/>
<DICH_DATA CI_END="4.0876696757036886" CI_START="0.6795504524957944" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6114757932383523" LOG_CI_START="-0.16777829400563948" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="11401" O_E="0.0" SE="0.45773770821706344" STUDY_ID="STD-Bankier-1968" TOTAL_1="35" TOTAL_2="35" VAR="0.2095238095238095" WEIGHT="1.7897263383691115"/>
<DICH_DATA CI_END="3.9914694376995405" CI_START="0.8420736181430634" EFFECT_SIZE="1.8333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.6011328082684106" LOG_CI_START="-0.07464993871924794" LOG_EFFECT_SIZE="0.2632414347745814" ORDER="11402" O_E="0.0" SE="0.3969581307590986" STUDY_ID="STD-Bishop-1963" TOTAL_1="20" TOTAL_2="20" VAR="0.1575757575757576" WEIGHT="2.3268448116824105"/>
<DICH_DATA CI_END="1.5500603737061573" CI_START="0.4128871435309164" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.1903486139488756" LOG_CI_START="-0.3841686399649884" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="11403" O_E="0.0" SE="0.3374742788552765" STUDY_ID="STD-Brauzer-1968" TOTAL_1="18" TOTAL_2="18" VAR="0.1138888888888889" WEIGHT="3.112360845572322"/>
<DICH_DATA CI_END="1.8956320879861766" CI_START="0.9752630970171873" EFFECT_SIZE="1.359683794466403" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="23" LOG_CI_END="0.277754051534741" LOG_CI_START="-0.010878208743316653" LOG_EFFECT_SIZE="0.13343792139571217" ORDER="11404" O_E="0.0" SE="0.1695440184400621" STUDY_ID="STD-Claghorn-1974" TOTAL_1="44" TOTAL_2="43" VAR="0.028745174188804117" WEIGHT="9.098995773522109"/>
<DICH_DATA CI_END="1.3546470417132461" CI_START="0.588488257828988" EFFECT_SIZE="0.8928571428571429" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.13182615291935382" LOG_CI_START="-0.23026219825971694" LOG_EFFECT_SIZE="-0.049218022670181584" ORDER="11405" O_E="0.0" SE="0.21269248984883143" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.04523809523809526" WEIGHT="6.629042979958694"/>
<DICH_DATA CI_END="1.3416050174776506" CI_START="0.8480720949575099" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.12762467382192763" LOG_CI_START="-0.07156722662144054" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="11406" O_E="0.0" SE="0.11700630833624392" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="0.013690476190476183" WEIGHT="13.788538909021861"/>
<DICH_DATA CI_END="1.1161093958607873" CI_START="0.6538822129257317" EFFECT_SIZE="0.8542857142857143" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.04770676421648035" LOG_CI_START="-0.18450047626817234" LOG_EFFECT_SIZE="-0.06839685602584597" ORDER="11407" O_E="0.0" SE="0.1363996825050634" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="0.018604873387482096" WEIGHT="11.802807119871696"/>
<DICH_DATA CI_END="1.3355274698152124" CI_START="0.26955641732312" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.12565282524131058" LOG_CI_START="-0.5693503244740233" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="11408" O_E="0.0" SE="0.408248290463863" STUDY_ID="STD-Menon-1972" TOTAL_1="20" TOTAL_2="20" VAR="0.16666666666666669" WEIGHT="2.2107377242307225"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11409" O_E="0.0" SE="0.0" STUDY_ID="STD-Ramsay-1970" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.113012012857777" CI_START="0.681491629596771" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.3249019661024858" LOG_CI_START="-0.16653947400723618" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="11410" O_E="0.0" SE="0.2886751345948129" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="0.08333333333333336" WEIGHT="4.074393671253467"/>
<DICH_DATA CI_END="1.9946237798880408" CI_START="0.839627252675725" EFFECT_SIZE="1.2941176470588236" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.2998609923903166" LOG_CI_START="-0.07591347350245202" LOG_EFFECT_SIZE="0.11197375944393231" ORDER="11411" O_E="0.0" SE="0.22073178137901803" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.04872251931075461" WEIGHT="6.269491615635773"/>
<DICH_DATA CI_END="1.1827192555393649" CI_START="0.6921288382466387" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.07288166750213396" LOG_CI_START="-0.15981305506431456" LOG_EFFECT_SIZE="-0.0434656937810903" ORDER="11412" O_E="0.0" SE="0.13668603189298548" STUDY_ID="STD-Vergara-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.018683071314650246" WEIGHT="11.775822359142001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.248126239277397" CI_END="1.1492012466608714" CI_START="0.8803018453885797" CI_STUDY="95" CI_TOTAL="95" DF="37.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0058051392583067" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="180" I2="0.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="0.06039608844560042" LOG_CI_START="-0.055368387725413123" LOG_EFFECT_SIZE="0.0025138503600937155" METHOD="MH" NO="16" P_CHI2="0.9620421055789328" P_Q="0.0" P_Z="0.9321643412820739" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="819" TOTAL_2="847" WEIGHT="600.0" Z="0.08512207425407635">
<NAME>Adverse events: 2. Anticholinergic</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.344308159650411" CI_END="1.548450214469117" CI_START="0.9053571174870544" DF="13.0" EFFECT_SIZE="1.1840187594561038" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="56" I2="0.0" ID="CMP-002.16.01" LOG_CI_END="0.18989724654852128" LOG_CI_START="-0.043180079842746424" LOG_EFFECT_SIZE="0.07335858335288742" NO="1" P_CHI2="0.9327195386764425" P_Z="0.21729416255144496" STUDIES="14" TAU2="0.0" TOTAL_1="299" TOTAL_2="307" WEIGHT="100.0" Z="1.233755196652416">
<NAME>blurred vision</NAME>
<DICH_DATA CI_END="6.41978801003991" CI_START="0.15576838338526122" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8075206873227565" LOG_CI_START="-0.8075206873227565" LOG_EFFECT_SIZE="0.0" ORDER="11413" O_E="0.0" SE="0.9486832980505138" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.8999999999999999" WEIGHT="2.0827289317799154"/>
<DICH_DATA CI_END="74.77836033541826" CI_START="0.2238018741654057" EFFECT_SIZE="4.090909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8737759381505485" LOG_CI_START="-0.6501362809163113" LOG_EFFECT_SIZE="0.6118198286171186" ORDER="11414" O_E="0.0" SE="1.4825585310468514" STUDY_ID="STD-_x002a_Goldstein-1966" TOTAL_1="10" TOTAL_2="8" VAR="2.197979797979798" WEIGHT="0.8528085837389267"/>
<DICH_DATA CI_END="2.45956487523887" CI_START="0.585469411478788" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.3908582823076977" LOG_CI_START="-0.23249579021244807" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="11415" O_E="0.0" SE="0.36616126785075737" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="0.13407407407407407" WEIGHT="13.980749459185619"/>
<DICH_DATA CI_END="2.523907854293063" CI_START="0.22286867527402432" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.40207349514318896" LOG_CI_START="-0.6519509683597887" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="11416" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.3833333333333333" WEIGHT="4.889885318091975"/>
<DICH_DATA CI_END="63.6312363433901" CI_START="0.11791120163472589" EFFECT_SIZE="2.739130434782609" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8036703615812775" LOG_CI_START="-0.9284449347092995" LOG_EFFECT_SIZE="0.43761271343598884" ORDER="11417" O_E="0.0" SE="1.6048580492299167" STUDY_ID="STD-Angus-1969" TOTAL_1="22" TOTAL_2="20" VAR="2.5755693581780537" WEIGHT="0.7277831725439945"/>
<DICH_DATA CI_END="5.192624726175789" CI_START="0.045981658305512124" EFFECT_SIZE="0.48863636363636365" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7153869370298302" LOG_CI_START="-1.3374153701709945" LOG_EFFECT_SIZE="-0.3110142165705821" ORDER="11418" O_E="0.0" SE="1.205826236785068" STUDY_ID="STD-Claghorn-1974" TOTAL_1="44" TOTAL_2="43" VAR="1.4540169133192389" WEIGHT="1.2891569702053216"/>
<DICH_DATA CI_END="9.92750288457511" CI_START="0.4625369328100079" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9968400219262878" LOG_CI_START="-0.334853583843439" LOG_EFFECT_SIZE="0.3309932190414244" ORDER="11419" O_E="0.0" SE="0.7822434160188003" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.611904761904762" WEIGHT="3.0633133704778515"/>
<DICH_DATA CI_END="5.1069967647477466" CI_START="0.6822883594711957" EFFECT_SIZE="1.8666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7081655827326409" LOG_CI_START="-0.16603203815956497" LOG_EFFECT_SIZE="0.27106677228653797" ORDER="11420" O_E="0.0" SE="0.5135080098600957" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="0.2636904761904762" WEIGHT="7.108546602372983"/>
<DICH_DATA CI_END="2.6417829236282904" CI_START="0.6520809240579316" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4218971285913058" LOG_CI_START="-0.18569850443531688" LOG_EFFECT_SIZE="0.11809931207799448" ORDER="11421" O_E="0.0" SE="0.35690468248672835" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.12738095238095237" WEIGHT="14.715355817061832"/>
<DICH_DATA CI_END="20.722972310630787" CI_START="0.19302250372394794" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3164520467067224" LOG_CI_START="-0.7143920553787599" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11422" O_E="0.0" SE="1.1929278784054478" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="1.423076923076923" WEIGHT="1.3171853244229734"/>
<DICH_DATA CI_END="1.932409141494781" CI_START="0.20861224675028836" EFFECT_SIZE="0.6349206349206349" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2860990833018291" LOG_CI_START="-0.6806601995530678" LOG_EFFECT_SIZE="-0.19728055812561934" ORDER="11423" O_E="0.0" SE="0.5678791882845967" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.3224867724867725" WEIGHT="5.812505189430083"/>
<DICH_DATA CI_END="1.6969321855075357" CI_START="0.7458312187186573" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.22966448695624578" LOG_CI_START="-0.12735944206148317" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="11424" O_E="0.0" SE="0.20971762320196527" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.04398148148148148" WEIGHT="42.619210982949"/>
<DICH_DATA CI_END="97.99788802329087" CI_START="0.2551075385834674" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.991216716205615" LOG_CI_START="-0.5932767075335774" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="11425" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="0.8132970415421568"/>
<DICH_DATA CI_END="9.685841913440106" CI_START="0.017924214814017136" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9861373764717322" LOG_CI_START="-1.746559859894944" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="11426" O_E="0.0" SE="1.6051998837112675" STUDY_ID="STD-Simpson-1976" TOTAL_1="19" TOTAL_2="24" VAR="2.5766666666666667" WEIGHT="0.727473236197383"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.541236378864294" CI_END="1.1026621939668213" CI_START="0.7503713119232167" DF="6.0" EFFECT_SIZE="0.9096186437705728" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="47" I2="0.0" ID="CMP-002.16.02" LOG_CI_END="0.04244248454706037" LOG_CI_START="-0.12472377818923586" LOG_EFFECT_SIZE="-0.041140646821087735" NO="2" P_CHI2="0.8638244239653631" P_Z="0.33468588091828355" STUDIES="7" TAU2="0.0" TOTAL_1="135" TOTAL_2="141" WEIGHT="100.0" Z="0.9647184156675702">
<NAME>constipation</NAME>
<DICH_DATA CI_END="2.55112882921191" CI_START="0.5119782403866592" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4067323905592665" LOG_CI_START="-0.29074849660389307" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="11427" O_E="0.0" SE="0.40970372570571395" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.16785714285714287" WEIGHT="5.744240886760144"/>
<DICH_DATA CI_END="75.8304681762221" CI_START="0.13764744005310217" EFFECT_SIZE="3.230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8798437373227375" LOG_CI_START="-0.8612318611406102" LOG_EFFECT_SIZE="0.5093059380910637" ORDER="11428" O_E="0.0" SE="1.6101213750804138" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="2.5924908424908426" WEIGHT="0.3719248868043569"/>
<DICH_DATA CI_END="4.4869472965209996" CI_START="0.396210978264932" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6519509683597887" LOG_CI_START="-0.40207349514318896" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="11429" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.3833333333333333" WEIGHT="2.5153352951341006"/>
<DICH_DATA CI_END="5.291850388505473" CI_START="0.05375141463981889" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7236075572907867" LOG_CI_START="-1.2696101014182621" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="11430" O_E="0.0" SE="1.1708259193122321" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="1.3708333333333333" WEIGHT="0.703376435113487"/>
<DICH_DATA CI_END="2.2077958919665197" CI_START="0.28529882882492763" EFFECT_SIZE="0.7936507936507936" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3439589209185768" LOG_CI_START="-0.5447000111537027" LOG_EFFECT_SIZE="-0.10037054511756292" ORDER="11431" O_E="0.0" SE="0.5220026556319158" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.2724867724867725" WEIGHT="3.538563924902244"/>
<DICH_DATA CI_END="1.0846465776703202" CI_START="0.7139652822796072" EFFECT_SIZE="0.88" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="25" LOG_CI_END="0.035288250284630805" LOG_CI_START="-0.14632290598429348" LOG_EFFECT_SIZE="-0.05551732784983137" ORDER="11432" O_E="0.0" SE="0.10667929218208837" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.01138047138047138" WEIGHT="84.72512525178028"/>
<DICH_DATA CI_END="4.616411291471565" CI_START="0.38509952115013524" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.664304494614599" LOG_CI_START="-0.41442702139799914" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="11433" O_E="0.0" SE="0.6336522323129237" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="0.4015151515151514" WEIGHT="2.4014333195053874"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.00465326781127" CI_END="1.4418330959625447" CI_START="0.7743317169108697" DF="10.0" EFFECT_SIZE="1.056625334115926" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="52" I2="0.0" ID="CMP-002.16.03" LOG_CI_END="0.15891499013534585" LOG_CI_START="-0.1110729515110186" LOG_EFFECT_SIZE="0.02392101931216367" NO="3" P_CHI2="0.6283824402740869" P_Z="0.7283607749146864" STUDIES="11" TAU2="0.0" TOTAL_1="230" TOTAL_2="236" WEIGHT="100.00000000000001" Z="0.34730689111099555">
<NAME>dry mouth</NAME>
<DICH_DATA CI_END="2.4351651446763345" CI_START="0.7300440307567179" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.3865284189344891" LOG_CI_START="-0.1366509457178893" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="11434" O_E="0.0" SE="0.30731814857642953" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.09444444444444443" WEIGHT="26.63100300040195"/>
<DICH_DATA CI_END="10.892770737658854" CI_START="0.05875456441834129" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.037138363045254" LOG_CI_START="-1.2309583890613667" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="11435" O_E="0.0" SE="1.3322912594474228" STUDY_ID="STD-_x002a_Goldstein-1966" TOTAL_1="10" TOTAL_2="8" VAR="1.775" WEIGHT="1.416986075138758"/>
<DICH_DATA CI_END="8.907687416524878" CI_START="0.29462192343339405" EFFECT_SIZE="1.62" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9497649686156782" LOG_CI_START="-0.5307349395304162" LOG_EFFECT_SIZE="0.20951501454263097" ORDER="11436" O_E="0.0" SE="0.8696529746377553" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="0.7562962962962962" WEIGHT="3.325614968218657"/>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" ORDER="11437" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="5.389607750081346"/>
<DICH_DATA CI_END="8.877552852285127" CI_START="0.37237571873379677" EFFECT_SIZE="1.8181818181818181" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9482932665425025" LOG_CI_START="-0.42901864553099023" LOG_EFFECT_SIZE="0.2596373105057561" ORDER="11438" O_E="0.0" SE="0.8090398349558905" STUDY_ID="STD-Angus-1969" TOTAL_1="22" TOTAL_2="20" VAR="0.6545454545454545" WEIGHT="3.842590710706145"/>
<DICH_DATA CI_END="70.08142337334066" CI_START="0.12277782085855314" EFFECT_SIZE="2.933333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.845602913892187" LOG_CI_START="-0.910880079031175" LOG_EFFECT_SIZE="0.4673614174305062" ORDER="11439" O_E="0.0" SE="1.6191717548540585" STUDY_ID="STD-Claghorn-1974" TOTAL_1="44" TOTAL_2="43" VAR="2.6217171717171714" WEIGHT="0.9593522560345145"/>
<DICH_DATA CI_END="3.3268581893891853" CI_START="0.4924766571732991" EFFECT_SIZE="1.28" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5220342890328294" LOG_CI_START="-0.3076143497370926" LOG_EFFECT_SIZE="0.10720996964786837" ORDER="11440" O_E="0.0" SE="0.4873397172404482" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="0.23750000000000004" WEIGHT="10.590106456300187"/>
<DICH_DATA CI_END="1.4050055965782204" CI_START="0.298999536351303" EFFECT_SIZE="0.6481481481481481" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.14767805417575908" LOG_CI_START="-0.5243294851211449" LOG_EFFECT_SIZE="-0.1883257154726929" ORDER="11441" O_E="0.0" SE="0.3947405550739698" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.1558201058201058" WEIGHT="16.14137193742529"/>
<DICH_DATA CI_END="1.3416758250159642" CI_START="0.3572323000026474" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.12764759451117258" LOG_CI_START="-0.4470492802461964" LOG_EFFECT_SIZE="-0.1597008428675119" ORDER="11442" O_E="0.0" SE="0.3375797890278889" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.11396011396011396" WEIGHT="22.070443736583115"/>
<DICH_DATA CI_END="4.916480820681672" CI_START="0.012712344923036707" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6916543493074901" LOG_CI_START="-1.8957743319634148" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="11443" O_E="0.0" SE="1.5198684153570663" STUDY_ID="STD-Simpson-1976" TOTAL_1="19" TOTAL_2="24" VAR="2.31" WEIGHT="1.0888096464810801"/>
<DICH_DATA CI_END="6.757801525768114" CI_START="0.80565320299572" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8298054325514148" LOG_CI_START="-0.09385186196222609" LOG_EFFECT_SIZE="0.36797678529459443" ORDER="11444" O_E="0.0" SE="0.5425608669746597" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="0.2943722943722943" WEIGHT="8.54411346262896"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.11806003056251353" CI_END="5.484500468909817" CI_START="0.469897767006537" DF="2.0" EFFECT_SIZE="1.605351837911873" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-002.16.04" LOG_CI_END="0.7391370779498599" LOG_CI_START="-0.3279966187758209" LOG_EFFECT_SIZE="0.2055702295870195" NO="4" P_CHI2="0.9426784796592904" P_Z="0.45017333818101524" STUDIES="3" TAU2="0.0" TOTAL_1="72" TOTAL_2="77" WEIGHT="100.0" Z="0.7551260868632496">
<NAME>nasal congestion</NAME>
<DICH_DATA CI_END="20.332240770599807" CI_START="0.19673188238966538" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3081852438953019" LOG_CI_START="-0.7061252525673394" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11445" O_E="0.0" SE="1.1832159566199232" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="1.4" WEIGHT="28.066278857397172"/>
<DICH_DATA CI_END="16.360363082235548" CI_START="0.07129426126651824" EFFECT_SIZE="1.08" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2137929376520298" LOG_CI_START="-1.1469454266781303" LOG_EFFECT_SIZE="0.03342375548694973" ORDER="11446" O_E="0.0" SE="1.3867094010509062" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="1.922962962962963" WEIGHT="20.43346188000025"/>
<DICH_DATA CI_END="9.233240658249684" CI_START="0.300845378192964" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9653541553036931" LOG_CI_START="-0.5216566560709803" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="11447" O_E="0.0" SE="0.8734775114237132" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.762962962962963" WEIGHT="51.50025926260258"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.332240770599807" CI_START="0.19673188238966538" DF="0.0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.16.05" LOG_CI_END="1.3081852438953019" LOG_CI_START="-0.7061252525673394" LOG_EFFECT_SIZE="0.3010299956639812" NO="5" P_CHI2="1.0" P_Z="0.5579989793003175" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.585816288803313">
<NAME>urinary difficulties</NAME>
<DICH_DATA CI_END="20.332240770599807" CI_START="0.19673188238966538" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3081852438953019" LOG_CI_START="-0.7061252525673394" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11448" O_E="0.0" SE="1.1832159566199232" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="1.4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8217957594145173" CI_END="2.489815878877665" CI_START="0.4347724285980568" DF="1.0" EFFECT_SIZE="1.0404341864921816" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" I2="45.10910485808921" ID="CMP-002.16.06" LOG_CI_END="0.39616723233912154" LOG_CI_START="-0.3617380048051256" LOG_EFFECT_SIZE="0.01721461376699798" NO="6" P_CHI2="0.17709983120563655" P_Z="0.929054143672403" STUDIES="2" TAU2="0.2121181973782896" TOTAL_1="63" TOTAL_2="66" WEIGHT="99.99999999999999" Z="0.0890349382416577">
<NAME>unspecified</NAME>
<DICH_DATA CI_END="1.3260266626053434" CI_START="0.4639032059760273" EFFECT_SIZE="0.7843137254901961" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.12255225657701865" LOG_CI_START="-0.3335726261169666" LOG_EFFECT_SIZE="-0.10551018476997398" ORDER="11449" O_E="0.0" SE="0.2679300139490305" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.07178649237472767" WEIGHT="86.09411268200041"/>
<DICH_DATA CI_END="7.387503355312876" CI_START="0.5414549148222474" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8684976911405518" LOG_CI_START="-0.26643769981258947" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11450" O_E="0.0" SE="0.6666666666666666" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.4444444444444444" WEIGHT="13.905887317999577"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.36767392107769" CI_END="1.1940666755867402" CI_START="0.5882375762590468" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8380900232903632" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="0.07702857807552968" LOG_CI_START="-0.2304472364751337" LOG_EFFECT_SIZE="-0.07670932919980203" METHOD="MH" NO="17" P_CHI2="0.656941573008879" P_Q="0.0" P_Z="0.3281005591268744" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="352" TOTAL_2="363" WEIGHT="700.0" Z="0.9779469824613837">
<NAME>Adverse events: 3. Cardiovascular</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4164108810178448" CI_END="2.733657965302107" CI_START="0.5387904105955776" DF="1.0" EFFECT_SIZE="1.2136180196227286" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" I2="29.39901737542488" ID="CMP-002.17.01" LOG_CI_END="0.43674417479858846" LOG_CI_START="-0.2685801424636886" LOG_EFFECT_SIZE="0.08408201616744995" NO="1" P_CHI2="0.23399529638469874" P_Z="0.6402879016432748" STUDIES="2" TAU2="0.10473614950468675" TOTAL_1="63" TOTAL_2="66" WEIGHT="100.0" Z="0.4672963044160461">
<NAME>any unspecified cardiovascular problem</NAME>
<DICH_DATA CI_END="2.0014217401058216" CI_START="0.3731534225826326" EFFECT_SIZE="0.8641975308641975" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.301338612924918" LOG_CI_START="-0.4281125706537039" LOG_EFFECT_SIZE="-0.06338697886439294" ORDER="11451" O_E="0.0" SE="0.4284832360756761" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.1835978835978836" WEIGHT="63.50249802787273"/>
<DICH_DATA CI_END="6.055139337673937" CI_START="0.660595863601809" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7821241413496992" LOG_CI_START="-0.18006415002173679" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11452" O_E="0.0" SE="0.565194165260439" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.3194444444444444" WEIGHT="36.49750197212727"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5472586901276815" CI_START="0.45066454699814096" DF="0.0" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-002.17.02" LOG_CI_END="0.40607305253722115" LOG_CI_START="-0.3461466057823347" LOG_EFFECT_SIZE="0.029963223377443202" NO="2" P_CHI2="1.0" P_Z="0.8759204692124657" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="99.99999999999999" Z="0.1561427916194371">
<NAME>ECG abnormalities - minor</NAME>
<DICH_DATA CI_END="2.5472586901276815" CI_START="0.45066454699814096" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.40607305253722115" LOG_CI_START="-0.3461466057823347" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="11453" O_E="0.0" SE="0.44185755084426837" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.1952380952380952" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3067794472250085" CI_END="7.657740324122071" CI_START="0.20830297947406975" DF="1.0" EFFECT_SIZE="1.2629846101807243" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="23.475992668576577" ID="CMP-002.17.03" LOG_CI_END="0.8841006352275249" LOG_CI_START="-0.6813045180508464" LOG_EFFECT_SIZE="0.10139805858833927" NO="3" P_CHI2="0.252978708523538" P_Z="0.7995645644597179" STUDIES="2" TAU2="0.4724646963016897" TOTAL_1="55" TOTAL_2="56" WEIGHT="100.0" Z="0.2539106793141962">
<NAME>hypertension</NAME>
<DICH_DATA CI_END="100.52959945656309" CI_START="0.24868297630890304" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.002293952184388" LOG_CI_START="-0.6043539435123508" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="11454" O_E="0.0" SE="1.531157877047447" STUDY_ID="STD-Bankier-1968" TOTAL_1="35" TOTAL_2="35" VAR="2.3444444444444446" WEIGHT="23.885596495748512"/>
<DICH_DATA CI_END="3.7601559255075196" CI_START="0.13031374488382766" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5752058545509147" LOG_CI_START="-0.8850097745224011" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="11455" O_E="0.0" SE="0.8577378887016042" STUDY_ID="STD-Gross-1974" TOTAL_1="20" TOTAL_2="21" VAR="0.7357142857142855" WEIGHT="76.11440350425148"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.201702101632225" CI_END="1.0955510294115063" CI_START="0.2767235017512394" DF="5.0" EFFECT_SIZE="0.5506039567655931" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" I2="0.0" ID="CMP-002.17.04" LOG_CI_END="0.03963261126750414" LOG_CI_START="-0.5579539552520864" LOG_EFFECT_SIZE="-0.25916067199229104" NO="4" P_CHI2="0.520756543973401" P_Z="0.08913281299426268" STUDIES="6" TAU2="0.0" TOTAL_1="126" TOTAL_2="126" WEIGHT="99.99999999999999" Z="1.6999899655456432">
<NAME>hypotension</NAME>
<DICH_DATA CI_END="3.05118976192878" CI_START="0.03641566725790049" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48446921845714286" LOG_CI_START="-1.4387117278964678" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11456" O_E="0.0" SE="1.1296860077873303" STUDY_ID="STD-Bankier-1968" TOTAL_1="35" TOTAL_2="35" VAR="1.2761904761904763" WEIGHT="9.655201840653014"/>
<DICH_DATA CI_END="2.446581639137676" CI_START="0.007192416705305787" EFFECT_SIZE="0.1326530612244898" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3885597121603116" LOG_CI_START="-2.143125158931628" LOG_EFFECT_SIZE="-0.8772827233856582" ORDER="11457" O_E="0.0" SE="1.4871242253216312" STUDY_ID="STD-Bishop-1967" TOTAL_1="27" TOTAL_2="25" VAR="2.2115384615384617" WEIGHT="5.571631173968546"/>
<DICH_DATA CI_END="2.768735649211788" CI_START="0.0401306318798411" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4422814925570199" LOG_CI_START="-1.3965240019963447" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11458" O_E="0.0" SE="1.0801234497346435" STUDY_ID="STD-Bishop-1970" TOTAL_1="12" TOTAL_2="12" VAR="1.1666666666666667" WEIGHT="10.561608544061256"/>
<DICH_DATA CI_END="1.4466125692141263" CI_START="0.14725280010183517" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.1603522342414112" LOG_CI_START="-0.8319364380877975" LOG_EFFECT_SIZE="-0.3357921019231931" ORDER="11459" O_E="0.0" SE="0.5828752780343234" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="0.33974358974358976" WEIGHT="36.26816518904054"/>
<DICH_DATA CI_END="3.773467029338969" CI_START="0.010600331124930263" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5767405596967805" LOG_CI_START="-1.974680568368818" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="11460" O_E="0.0" SE="1.4987174003640065" STUDY_ID="STD-Gallant-1972" TOTAL_1="12" TOTAL_2="12" VAR="2.2461538461538457" WEIGHT="5.485766994917662"/>
<DICH_DATA CI_END="4.646517776255189" CI_START="0.41515225779114073" EFFECT_SIZE="1.3888888888888888" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6671276029763089" LOG_CI_START="-0.38179259583884584" LOG_EFFECT_SIZE="0.14266750356873154" ORDER="11461" O_E="0.0" SE="0.6161409170227454" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.37962962962962965" WEIGHT="32.457626257358974"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.577326316861588" CI_START="0.38799898695703405" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-002.17.05" LOG_CI_END="0.4111694083221442" LOG_CI_START="-0.4111694083221443" LOG_EFFECT_SIZE="0.0" NO="5" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001" Z="0.0">
<NAME>palpitations</NAME>
<DICH_DATA CI_END="2.577326316861588" CI_START="0.38799898695703405" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4111694083221442" LOG_CI_START="-0.4111694083221443" LOG_EFFECT_SIZE="0.0" ORDER="11462" O_E="0.0" SE="0.48304589153964794" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.23333333333333334" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0028953137898344635" CI_END="2.172372715593736" CI_START="0.05891082986159731" DF="1.0" EFFECT_SIZE="0.3577377243796336" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-002.17.06" LOG_CI_END="0.33693433953511065" LOG_CI_START="-1.2298048594270692" LOG_EFFECT_SIZE="-0.4464352599459793" NO="6" P_CHI2="0.9570880639497399" P_Z="0.26400897760447606" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="50" WEIGHT="100.0" Z="1.1169657738856618">
<NAME>syncope</NAME>
<DICH_DATA CI_END="3.3514316123888594" CI_START="0.04093003441908493" EFFECT_SIZE="0.37037037037037035" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5252303618275603" LOG_CI_START="-1.387957890145535" LOG_EFFECT_SIZE="-0.43136376415898736" ORDER="11463" O_E="0.0" SE="1.1238162496435806" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="1.2629629629629628" WEIGHT="67.06223264799227"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11464" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="32.93776735200772"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9576511434712608E-32" CI_END="2.104937170887937" CI_START="0.09384169130055571" DF="0.0" EFFECT_SIZE="0.4444444444444445" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="100.0" ID="CMP-002.17.07" LOG_CI_END="0.32323913734798393" LOG_CI_START="-1.0276041735707089" LOG_EFFECT_SIZE="-0.3521825181113625" NO="7" P_CHI2="0.0" P_Z="0.3067920428209816" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="30" WEIGHT="100.0" Z="1.0219764881738276">
<NAME>tachycardia</NAME>
<DICH_DATA CI_END="2.104937170887937" CI_START="0.09384169130055571" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.32323913734798393" LOG_CI_START="-1.0276041735707089" LOG_EFFECT_SIZE="-0.35218251811136253" ORDER="11465" O_E="0.0" SE="0.7934920476158722" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.6296296296296297" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.770620501341526" CI_END="1.6703042648028021" CI_START="0.9436666609293402" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2554722013260575" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-002.18" LOG_CI_END="0.22279559000310326" LOG_CI_START="-0.025181387994993122" LOG_EFFECT_SIZE="0.09880710100405506" METHOD="MH" NO="18" P_CHI2="0.6512312165462109" P_Q="0.0" P_Z="0.11831014528666653" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="228" TOTAL_2="228" WEIGHT="400.0" Z="1.5619059555298396">
<NAME>Adverse events: 4. Endocrine</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4858346286183267" CI_END="2.8561329043789137" CI_START="0.24306574415201393" DF="1.0" EFFECT_SIZE="0.8332034984323539" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-002.18.01" LOG_CI_END="0.4557784125913317" LOG_CI_START="-0.6142762430243682" LOG_EFFECT_SIZE="-0.07924891521651824" NO="1" P_CHI2="0.48579133226720617" P_Z="0.7715773222766891" STUDIES="2" TAU2="0.0" TOTAL_1="32" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.290312310353664">
<NAME>amenorrhoea</NAME>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" ORDER="11466" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="84.66040560773104"/>
<DICH_DATA CI_END="7.070137371487788" CI_START="0.013101244626080647" EFFECT_SIZE="0.30434782608695654" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8494278521419525" LOG_CI_START="-1.8826874441486245" LOG_EFFECT_SIZE="-0.516629796003336" ORDER="11467" O_E="0.0" SE="1.6048580492299167" STUDY_ID="STD-Angus-1969" TOTAL_1="22" TOTAL_2="20" VAR="2.5755693581780537" WEIGHT="15.339594392268953"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.39906951804930035" CI_END="3.8616544449886625" CI_START="0.16356690825749856" DF="1.0" EFFECT_SIZE="0.7947571190782892" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-002.18.02" LOG_CI_END="0.5867734089180152" LOG_CI_START="-0.7863045552786633" LOG_EFFECT_SIZE="-0.09976557318032406" NO="2" P_CHI2="0.527570602751785" P_Z="0.7757855115626435" STUDIES="2" TAU2="0.0" TOTAL_1="35" TOTAL_2="36" WEIGHT="100.00000000000001" Z="0.28481548088178593">
<NAME>galactorrhoea</NAME>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11468" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="25.298288085768633"/>
<DICH_DATA CI_END="6.642886317962055" CI_START="0.1712776229063682" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.822356820271713" LOG_CI_START="-0.766299373071226" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="11469" O_E="0.0" SE="0.9331845119446279" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="0.8708333333333333" WEIGHT="74.70171191423138"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.7317468105557783" CI_END="1.7140927059276376" CI_START="0.9184578618388752" DF="4.0" EFFECT_SIZE="1.254719857848719" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="24" I2="0.0" ID="CMP-002.18.03" LOG_CI_END="0.2340343068427371" LOG_CI_START="-0.036940764007766004" LOG_EFFECT_SIZE="0.09854677141748552" NO="3" P_CHI2="0.44352547698876044" P_Z="0.15399003475170275" STUDIES="5" TAU2="0.0" TOTAL_1="103" TOTAL_2="104" WEIGHT="99.99999999999997" Z="1.4255785387544573">
<NAME>weight gain &gt;10 lb</NAME>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" ORDER="11470" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="5.429090736608648"/>
<DICH_DATA CI_END="1.7075423580094018" CI_START="0.8635157944996927" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.23237148577762767" LOG_CI_START="-0.06372971437755585" LOG_EFFECT_SIZE="0.08432088570003587" ORDER="11471" O_E="0.0" SE="0.17393131069573445" STUDY_ID="STD-Bishop-1963" TOTAL_1="20" TOTAL_2="20" VAR="0.03025210084033611" WEIGHT="83.74875154805571"/>
<DICH_DATA CI_END="3.0107882078094432" CI_START="0.03524591928724901" EFFECT_SIZE="0.32575757575757575" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.47868020638797026" LOG_CI_START="-1.4528911576404968" LOG_EFFECT_SIZE="-0.4871054756262634" ORDER="11472" O_E="0.0" SE="1.1346145806627783" STUDY_ID="STD-Claghorn-1974" TOTAL_1="44" TOTAL_2="43" VAR="1.2873502466525721" WEIGHT="1.9680546795030776"/>
<DICH_DATA CI_END="9.92750288457511" CI_START="0.4625369328100079" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9968400219262878" LOG_CI_START="-0.334853583843439" LOG_EFFECT_SIZE="0.3309932190414244" ORDER="11473" O_E="0.0" SE="0.7822434160188003" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.611904761904762" WEIGHT="4.140473869164572"/>
<DICH_DATA CI_END="13.464902409953368" CI_START="0.7604956715044967" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1292032101075493" LOG_CI_START="-0.11890325346773721" LOG_EFFECT_SIZE="0.505149978319906" ORDER="11474" O_E="0.0" SE="0.733143914930759" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="0.5375" WEIGHT="4.713629166667974"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.606790220426132" CI_END="7.445469264926169" CI_START="0.5365279424558538" DF="1.0" EFFECT_SIZE="1.998675137517134" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="37.76412208092771" ID="CMP-002.18.04" LOG_CI_END="0.8718920751903353" LOG_CI_START="-0.2704076549871639" LOG_EFFECT_SIZE="0.30074221010158564" NO="4" P_CHI2="0.20494363918626224" P_Z="0.30205799224763963" STUDIES="2" TAU2="0.34145465688385934" TOTAL_1="58" TOTAL_2="58" WEIGHT="100.0" Z="1.0320301841242556">
<NAME>weight loss &gt;10 lb</NAME>
<DICH_DATA CI_END="4.577432269097445" CI_START="0.20864579251532847" EFFECT_SIZE="0.9772727272727273" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6606219268951198" LOG_CI_START="-0.6805903687083216" LOG_EFFECT_SIZE="-0.009984220906600895" ORDER="11475" O_E="0.0" SE="0.7878347415453989" STUDY_ID="STD-Claghorn-1974" TOTAL_1="44" TOTAL_2="43" VAR="0.6206835799859055" WEIGHT="44.84996488968204"/>
<DICH_DATA CI_END="15.093188774801751" CI_START="0.9317116621159276" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1787810039238988" LOG_CI_START="-0.030718468468461137" LOG_EFFECT_SIZE="0.5740312677277188" ORDER="11476" O_E="0.0" SE="0.7104659772022196" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.5047619047619047" WEIGHT="55.15003511031796"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="56.40613689703406" CI_END="1.2325416712221393" CI_START="0.9228876801903887" CI_STUDY="95" CI_TOTAL="95" DF="30.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0665352894734355" ESTIMABLE="YES" EVENTS_1="316" EVENTS_2="284" I2="46.814297786846915" I2_Q="0.0" ID="CMP-002.19" LOG_CI_END="0.09080161133741661" LOG_CI_START="-0.03485115145704919" LOG_EFFECT_SIZE="0.027975229940183685" METHOD="MH" NO="19" P_CHI2="0.002451537368042378" P_Q="0.0" P_Z="0.3828104852902011" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="28" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.06155658355598673" TOTALS="SUB" TOTAL_1="594" TOTAL_2="598" WEIGHT="200.0" Z="0.8727296069354974">
<NAME>Adverse events: 5a. Extrapyramidal - non specific</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="19.647346764915035" CI_END="1.4247284553782493" CI_START="0.8757913979245656" DF="11.0" EFFECT_SIZE="1.1170339858744782" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="113" I2="44.01279657952039" ID="CMP-002.19.01" LOG_CI_END="0.15373209833154192" LOG_CI_START="-0.05759932478929268" LOG_EFFECT_SIZE="0.0480663867711246" NO="1" P_CHI2="0.05041809631646166" P_Z="0.3726234228078811" STUDIES="12" TAU2="0.07520129349260604" TOTAL_1="240" TOTAL_2="245" WEIGHT="100.0" Z="0.8915700802763297">
<NAME>any unspecifed extrapramidal effect</NAME>
<DICH_DATA CI_END="46.0587303773455" CI_START="0.9948707841421282" EFFECT_SIZE="6.769230769230769" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.6633119623361476" LOG_CI_START="-0.0022333226494841603" LOG_EFFECT_SIZE="0.8305393198433318" ORDER="11477" O_E="0.0" SE="0.9783495449826878" STUDY_ID="STD-_x002a_Bankier-1973" TOTAL_1="13" TOTAL_2="11" VAR="0.9571678321678322" WEIGHT="1.3832460306876941"/>
<DICH_DATA CI_END="1.2093969629453483" CI_START="0.44466605610459053" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.0825688736648852" LOG_CI_START="-0.3519660214597977" LOG_EFFECT_SIZE="-0.13469857389745624" ORDER="11478" O_E="0.0" SE="0.2552479483786602" STUDY_ID="STD-Bishop-1964" TOTAL_1="7" TOTAL_2="7" VAR="0.06515151515151518" WEIGHT="11.121203133728205"/>
<DICH_DATA CI_END="1.5835717949838224" CI_START="0.5169289494176377" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.1996377579248416" LOG_CI_START="-0.2865691454870222" LOG_EFFECT_SIZE="-0.0434656937810903" ORDER="11479" O_E="0.0" SE="0.2856003418271165" STUDY_ID="STD-Bishop-1966" TOTAL_1="21" TOTAL_2="19" VAR="0.08156755525176579" WEIGHT="9.845624338095822"/>
<DICH_DATA CI_END="2.4472071470738177" CI_START="0.5561895782866699" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.38867073233645727" LOG_CI_START="-0.2547771530752308" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="11480" O_E="0.0" SE="0.3779644730092273" STUDY_ID="STD-Bishop-1970" TOTAL_1="12" TOTAL_2="12" VAR="0.1428571428571429" WEIGHT="6.893600195745478"/>
<DICH_DATA CI_END="2.4807275736590495" CI_START="0.6044094789887149" EFFECT_SIZE="1.2244897959183674" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.3945790739244573" LOG_CI_START="-0.21866873321419733" LOG_EFFECT_SIZE="0.08795517035512998" ORDER="11481" O_E="0.0" SE="0.360224797538849" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.12976190476190474" WEIGHT="7.365448665228839"/>
<DICH_DATA CI_END="1.034668171367047" CI_START="0.3058045649379075" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.014801089454049815" LOG_CI_START="-0.5145560358872495" LOG_EFFECT_SIZE="-0.24987747321659987" ORDER="11482" O_E="0.0" SE="0.3109469957855103" STUDY_ID="STD-Gallant-1968-II" TOTAL_1="26" TOTAL_2="26" VAR="0.09668803418803418" WEIGHT="8.904862133725594"/>
<DICH_DATA CI_END="3.5481063888087543" CI_START="0.44037574660341444" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5499966335328185" LOG_CI_START="-0.35617660751670577" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="11483" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Gallant-1972" TOTAL_1="12" TOTAL_2="12" VAR="0.2833333333333334" WEIGHT="4.085786320238603"/>
<DICH_DATA CI_END="3.895554234117505" CI_START="0.8853630021706176" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.5905692549984239" LOG_CI_START="-0.052878630413264" LOG_EFFECT_SIZE="0.26884531229257996" ORDER="11484" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.14285714285714285" WEIGHT="6.89360019574548"/>
<DICH_DATA CI_END="1.3051281027257766" CI_START="0.6198992246855172" EFFECT_SIZE="0.8994708994708994" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="21" LOG_CI_END="0.11565314123482448" LOG_CI_START="-0.20767890682476492" LOG_EFFECT_SIZE="-0.046012882794970233" ORDER="11485" O_E="0.0" SE="0.18992684554965356" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.036072206660441954" WEIGHT="14.433718796379043"/>
<DICH_DATA CI_END="3.681880652108193" CI_START="0.7981723982610299" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.566069706772315" LOG_CI_START="-0.09790329470557912" LOG_EFFECT_SIZE="0.23408320603336794" ORDER="11486" O_E="0.0" SE="0.3900210277874798" STUDY_ID="STD-Needham-1969" TOTAL_1="27" TOTAL_2="27" VAR="0.1521164021164021" WEIGHT="6.594874405766799"/>
<DICH_DATA CI_END="2.997540601817565" CI_START="1.021670898516953" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" LOG_CI_END="0.4767650743483349" LOG_CI_START="0.009311023024253864" LOG_EFFECT_SIZE="0.24303804868629442" ORDER="11487" O_E="0.0" SE="0.274584823682638" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.07539682539682538" WEIGHT="10.289240079450234"/>
<DICH_DATA CI_END="1.8500016003275888" CI_START="0.7436589527575561" EFFECT_SIZE="1.1729323308270676" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.2671721040857924" LOG_CI_START="-0.12862618931104086" LOG_EFFECT_SIZE="0.06927295738737577" ORDER="11488" O_E="0.0" SE="0.23249387677445027" STUDY_ID="STD-Simpson-1976" TOTAL_1="19" TOTAL_2="24" VAR="0.05405340273761327" WEIGHT="12.188795705208221"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="35.432816380220856" CI_END="1.2500900497494998" CI_START="0.8640186694711104" DF="18.0" EFFECT_SIZE="1.0392791451307184" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="171" I2="49.199635143742405" ID="CMP-002.19.02" LOG_CI_END="0.096941298368618" LOG_CI_START="-0.06347687330735156" LOG_EFFECT_SIZE="0.016732212530633197" NO="2" P_CHI2="0.008334108887388947" P_Z="0.682640145058511" STUDIES="19" TAU2="0.061529954327820074" TOTAL_1="354" TOTAL_2="353" WEIGHT="100.0" Z="0.4088630807730805">
<NAME>use of antiparkinson agents</NAME>
<DICH_DATA CI_END="1.4317045869649099" CI_START="0.5378248117737379" EFFECT_SIZE="0.8775" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.15585341637531663" LOG_CI_START="-0.2693591660995934" LOG_EFFECT_SIZE="-0.056752874862138335" ORDER="11489" O_E="0.0" SE="0.24977197578199178" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="0.062386039886039885" WEIGHT="7.165650892980709"/>
<DICH_DATA CI_END="3.9855442667258254" CI_START="0.39204181297015506" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6004876371237167" LOG_CI_START="-0.40666761110760397" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="11490" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Andersen-1974" TOTAL_1="20" TOTAL_2="20" VAR="0.35000000000000003" WEIGHT="2.1579768270792625"/>
<DICH_DATA CI_END="3.1656512741937846" CI_START="0.7672165632635247" EFFECT_SIZE="1.5584415584415585" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.5004630716018824" LOG_CI_START="-0.11508202985159653" LOG_EFFECT_SIZE="0.19269052087514296" ORDER="11491" O_E="0.0" SE="0.3615742395911671" STUDY_ID="STD-Angus-1969" TOTAL_1="22" TOTAL_2="20" VAR="0.1307359307359307" WEIGHT="4.6186382949752725"/>
<DICH_DATA CI_END="2.886458130067041" CI_START="0.9623481972050159" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.46036526215935947" LOG_CI_START="-0.016667762926646703" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="11492" O_E="0.0" SE="0.2802115602870776" STUDY_ID="STD-Bishop-1967" TOTAL_1="27" TOTAL_2="25" VAR="0.07851851851851852" WEIGHT="6.340381389644379"/>
<DICH_DATA CI_END="3.066407321427068" CI_START="0.5797591746390763" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.48662984317937014" LOG_CI_START="-0.23675236996277021" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="11493" O_E="0.0" SE="0.4249182927993987" STUDY_ID="STD-Brauzer-1968" TOTAL_1="18" TOTAL_2="18" VAR="0.18055555555555552" WEIGHT="3.6682570878305456"/>
<DICH_DATA CI_END="1.359243444419585" CI_START="0.8741888088281169" EFFECT_SIZE="1.0900621118012421" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.133297247092718" LOG_CI_START="-0.058394757552731755" LOG_EFFECT_SIZE="0.03745124476999313" ORDER="11494" O_E="0.0" SE="0.11260083241946371" STUDY_ID="STD-Brauzer-1971" TOTAL_1="13" TOTAL_2="12" VAR="0.01267894746155615" WEIGHT="11.96367235705302"/>
<DICH_DATA CI_END="1.7321877791583402" CI_START="0.3727812010832229" EFFECT_SIZE="0.8035714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2385949702631983" LOG_CI_START="-0.4285459967249118" LOG_EFFECT_SIZE="-0.09497551323085672" ORDER="11495" O_E="0.0" SE="0.39188190640986287" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.15357142857142853" WEIGHT="4.1283771535048235"/>
<DICH_DATA CI_END="5.742492463333628" CI_START="0.8428395911538189" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7591004338827771" LOG_CI_START="-0.07425507223836458" LOG_EFFECT_SIZE="0.3424226808222063" ORDER="11496" O_E="0.0" SE="0.48951714947184394" STUDY_ID="STD-Coons-1962" TOTAL_1="39" TOTAL_2="39" VAR="0.2396270396270396" WEIGHT="2.948797683485009"/>
<DICH_DATA CI_END="1.7970991296816015" CI_START="0.6331190967631051" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.25457203386262467" LOG_CI_START="-0.1985145866621376" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="11497" O_E="0.0" SE="0.2661453237111886" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="0.07083333333333336" WEIGHT="6.708438159140315"/>
<DICH_DATA CI_END="0.8564563908028242" CI_START="0.27222754469683214" EFFECT_SIZE="0.4828571428571429" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="-0.0672947456183319" LOG_CI_START="-0.5650679338548721" LOG_EFFECT_SIZE="-0.31618133973660206" ORDER="11498" O_E="0.0" SE="0.2923944347871647" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="0.08549450549450552" WEIGHT="6.03959872776445"/>
<DICH_DATA CI_END="1.0681050830389196" CI_START="0.7607804209617868" EFFECT_SIZE="0.9014396456256921" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" LOG_CI_END="0.028613981848835762" LOG_CI_START="-0.11874067269744486" LOG_EFFECT_SIZE="-0.04506334542430457" ORDER="11499" O_E="0.0" SE="0.08655685349778912" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.007492088887437728" WEIGHT="12.862369961905138"/>
<DICH_DATA CI_END="13.534833367737306" CI_START="0.9050720956195932" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1314529133819102" LOG_CI_START="-0.043316824681358924" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="11500" O_E="0.0" SE="0.6900655593423541" STUDY_ID="STD-Gallant-1968" TOTAL_1="12" TOTAL_2="12" VAR="0.4761904761904761" WEIGHT="1.6515749444812686"/>
<DICH_DATA CI_END="1.8374964386018324" CI_START="0.7584838753829498" EFFECT_SIZE="1.1805555555555556" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.26422650601632997" LOG_CI_START="-0.12005364745028142" LOG_EFFECT_SIZE="0.07208642928302428" ORDER="11501" O_E="0.0" SE="0.2257280643637258" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.05095315904139434" WEIGHT="7.893801459700462"/>
<DICH_DATA CI_END="153.71117891430487" CI_START="0.6582470547067777" EFFECT_SIZE="10.058823529411764" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.1867054534740453" LOG_CI_START="-0.18161107544628577" LOG_EFFECT_SIZE="1.00254718901388" ORDER="11502" O_E="0.0" SE="1.3911608524436925" STUDY_ID="STD-Marjerrison-1964" TOTAL_1="16" TOTAL_2="8" VAR="1.935328517371861" WEIGHT="0.44475747249206404"/>
<DICH_DATA CI_END="1.4839194109057914" CI_START="0.29950713035902227" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.17141031580198565" LOG_CI_START="-0.5235928339133482" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="11503" O_E="0.0" SE="0.40824829046386296" STUDY_ID="STD-Marjerrison-1966" TOTAL_1="8" TOTAL_2="8" VAR="0.16666666666666663" WEIGHT="3.8914947073940778"/>
<DICH_DATA CI_END="1.4741237394803681" CI_START="0.26498793116085095" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.16853394018380938" LOG_CI_START="-0.576773905495659" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="11504" O_E="0.0" SE="0.4377975178854566" STUDY_ID="STD-O_x0027_Brien-1974" TOTAL_1="15" TOTAL_2="15" VAR="0.1916666666666667" WEIGHT="3.507298676424134"/>
<DICH_DATA CI_END="4.429682755520869" CI_START="0.7314293548362745" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6463726240875729" LOG_CI_START="-0.13582761388096082" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="11505" O_E="0.0" SE="0.45946829173634074" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="0.21111111111111114" WEIGHT="3.2571866330921755"/>
<DICH_DATA CI_END="1.6915734129893172" CI_START="0.7084816681675834" EFFECT_SIZE="1.0947368421052632" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.22829085058057919" LOG_CI_START="-0.14967138256071397" LOG_EFFECT_SIZE="0.039309734009932616" ORDER="11506" O_E="0.0" SE="0.22201688669042383" STUDY_ID="STD-Simpson-1976" TOTAL_1="19" TOTAL_2="24" VAR="0.0492914979757085" WEIGHT="8.012132984834594"/>
<DICH_DATA CI_END="0.9101115642724511" CI_START="0.12208515469192392" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="-0.04090536726341229" LOG_CI_START="-0.9133371421759128" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11507" O_E="0.0" SE="0.5124707431905382" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="0.26262626262626254" WEIGHT="2.7395945862183"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="79.33373096910658" CI_END="1.0451472256711465" CI_START="0.8637558863186197" CI_STUDY="95" CI_TOTAL="95" DF="80.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9501326582341161" ESTIMABLE="YES" EVENTS_1="379" EVENTS_2="379" I2="0.0" I2_Q="0.0" ID="CMP-002.20" LOG_CI_END="0.01917747206709829" LOG_CI_START="-0.06360897998013641" LOG_EFFECT_SIZE="-0.02221575395651904" METHOD="MH" NO="20" P_CHI2="0.5000190844775734" P_Q="0.0" P_Z="0.2928394260392" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1631" TOTAL_2="1641" WEIGHT="1000.0" Z="1.051913122677057">
<NAME>Adverse events: 5b. Extrapyramidal - specific problems</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="19.18427839056289" CI_END="1.1733088301320984" CI_START="0.699640284097131" DF="17.0" EFFECT_SIZE="0.9060320762794735" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="89" I2="11.385773006908506" ID="CMP-002.20.01" LOG_CI_END="0.0694123391139771" LOG_CI_START="-0.15512519253611126" LOG_EFFECT_SIZE="-0.04285642671106712" NO="1" P_CHI2="0.31805795057497555" P_Z="0.4543526321368191" STUDIES="18" TAU2="0.03379794016507081" TOTAL_1="360" TOTAL_2="359" WEIGHT="100.00000000000001" Z="0.748178286654278">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="1.5233750002077708" CI_START="0.29174986092316557" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.1828068241988772" LOG_CI_START="-0.5349893423102396" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="11508" O_E="0.0" SE="0.42163702135578396" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.1777777777777778" WEIGHT="7.416026454528062"/>
<DICH_DATA CI_END="1.4252612562034885" CI_START="0.16165457315083653" EFFECT_SIZE="0.48" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.15389447959215508" LOG_CI_START="-0.7914120048409806" LOG_EFFECT_SIZE="-0.3187587626244128" ORDER="11509" O_E="0.0" SE="0.5552777082985894" STUDY_ID="STD-_x002a_Goldstein-1966" TOTAL_1="10" TOTAL_2="8" VAR="0.30833333333333335" WEIGHT="4.275907144953117"/>
<DICH_DATA CI_END="4.864506835888262" CI_START="0.2397776463987669" EFFECT_SIZE="1.08" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6870388180249775" LOG_CI_START="-0.620191307051078" LOG_EFFECT_SIZE="0.03342375548694973" ORDER="11510" O_E="0.0" SE="0.7678734463631552" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="0.5896296296296295" WEIGHT="2.235987875737105"/>
<DICH_DATA CI_END="1.6600512529016966" CI_START="0.26772935092671085" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.22012149678027904" LOG_CI_START="-0.5723040148916416" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="11511" O_E="0.0" SE="0.4654746681256314" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.21666666666666665" WEIGHT="6.084944783202514"/>
<DICH_DATA CI_END="10.432249938398574" CI_START="0.49512706143917956" EFFECT_SIZE="2.272727272727273" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0183779834460323" LOG_CI_START="-0.30528333641840705" LOG_EFFECT_SIZE="0.35654732351381263" ORDER="11512" O_E="0.0" SE="0.777525211517578" STUDY_ID="STD-Angus-1969" TOTAL_1="22" TOTAL_2="20" VAR="0.6045454545454545" WEIGHT="2.1808198095186953"/>
<DICH_DATA CI_END="71.21510406800243" CI_START="0.12637768515238015" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.85257211326778" LOG_CI_START="-0.8983296038284552" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="11513" O_E="0.0" SE="1.6158932858054431" STUDY_ID="STD-Bankier-1968" TOTAL_1="35" TOTAL_2="35" VAR="2.611111111111111" WEIGHT="0.5049209500955277"/>
<DICH_DATA CI_END="1.3183556381700692" CI_START="0.0689911719154621" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.12003258086541281" LOG_CI_START="-1.1612064778669184" LOG_EFFECT_SIZE="-0.5205869485007527" ORDER="11514" O_E="0.0" SE="0.7526061653349982" STUDY_ID="STD-Bishop-1966" TOTAL_1="21" TOTAL_2="19" VAR="0.5664160401002507" WEIGHT="2.3276260022471558"/>
<DICH_DATA CI_END="6.789650498839116" CI_START="0.5891319443738545" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8318474192978551" LOG_CI_START="-0.2297874279698927" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11515" O_E="0.0" SE="0.6236095644623235" STUDY_ID="STD-Brauzer-1968" TOTAL_1="18" TOTAL_2="18" VAR="0.38888888888888884" WEIGHT="3.390183522069972"/>
<DICH_DATA CI_END="128.68190505687764" CI_START="0.3640482298764554" EFFECT_SIZE="6.844444444444444" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.109517481741631" LOG_CI_START="-0.43884107629142993" LOG_EFFECT_SIZE="0.8353382027251006" ORDER="11516" O_E="0.0" SE="1.4969184315669275" STUDY_ID="STD-Claghorn-1974" TOTAL_1="44" TOTAL_2="43" VAR="2.2407647907647905" WEIGHT="0.5883726433318462"/>
<DICH_DATA CI_END="2.7408132456560583" CI_START="0.6862256410616581" EFFECT_SIZE="1.3714285714285714" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.4378794444617137" LOG_CI_START="-0.16353305841109048" LOG_EFFECT_SIZE="0.13717319302531158" ORDER="11517" O_E="0.0" SE="0.3532726812273874" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="0.1248015873015873" WEIGHT="10.56400588753123"/>
<DICH_DATA CI_END="0.6772150111791904" CI_START="0.050327945591962214" EFFECT_SIZE="0.18461538461538463" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.1692734238648811" LOG_CI_START="-1.2981907973255806" LOG_EFFECT_SIZE="-0.7337321105952308" ORDER="11518" O_E="0.0" SE="0.6631316534019392" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="0.4397435897435897" WEIGHT="2.9981214821026967"/>
<DICH_DATA CI_END="1.2736486009691999" CI_START="0.5714466808750499" EFFECT_SIZE="0.853125" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.10504962288889967" LOG_CI_START="-0.24302428544719948" LOG_EFFECT_SIZE="-0.06898733127914992" ORDER="11519" O_E="0.0" SE="0.204460336750259" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.04180402930402931" WEIGHT="31.537742293662973"/>
<DICH_DATA CI_END="14.207980025005401" CI_START="0.07038298183415555" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.152532337860481" LOG_CI_START="-1.152532337860481" LOG_EFFECT_SIZE="0.0" ORDER="11520" O_E="0.0" SE="1.3540064007726602" STUDY_ID="STD-Gallant-1968" TOTAL_1="12" TOTAL_2="12" VAR="1.8333333333333335" WEIGHT="0.7191298380148424"/>
<DICH_DATA CI_END="3.3084726724198283" CI_START="0.6168454536570049" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5196275517750542" LOG_CI_START="-0.20982363180356778" LOG_EFFECT_SIZE="0.15490195998574316" ORDER="11521" O_E="0.0" SE="0.4284832360756761" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.1835978835978836" WEIGHT="7.180936278736107"/>
<DICH_DATA CI_END="5.1928763992528335" CI_START="0.048142875119456086" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7154079856489205" LOG_CI_START="-1.317467976976883" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11522" O_E="0.0" SE="1.1941214033447043" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.425925925925926" WEIGHT="0.924595506019083"/>
<DICH_DATA CI_END="4.4869472965209996" CI_START="0.396210978264932" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6519509683597887" LOG_CI_START="-0.40207349514318896" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="11523" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Ramsay-1970" TOTAL_1="10" TOTAL_2="10" VAR="0.3833333333333333" WEIGHT="3.439316616592725"/>
<DICH_DATA CI_END="5.083060192649951" CI_START="0.04918297059741634" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7061252525673394" LOG_CI_START="-1.3081852438953019" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11524" O_E="0.0" SE="1.1832159566199232" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="1.4" WEIGHT="0.9417176450194367"/>
<DICH_DATA CI_END="1.8809060363207437" CI_START="0.531658669114651" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.2743671002145492" LOG_CI_START="-0.2743671002145492" LOG_EFFECT_SIZE="0.0" ORDER="11525" O_E="0.0" SE="0.3223291856101521" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="0.10389610389610388" WEIGHT="12.68964526663691"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.002767703877352466" CI_END="9.019579292717523" CI_START="0.7138271148308115" DF="1.0" EFFECT_SIZE="2.537404237307938" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-002.20.02" LOG_CI_END="0.9551862808775989" LOG_CI_START="-0.14640695932552064" LOG_EFFECT_SIZE="0.40438966077603905" NO="2" P_CHI2="0.9580434901007322" P_Z="0.15015420868215695" STUDIES="2" TAU2="0.0" TOTAL_1="32" TOTAL_2="30" WEIGHT="99.99999999999999" Z="1.43898699068862">
<NAME>dyskinesia, tardive</NAME>
<DICH_DATA CI_END="9.996095394793457" CI_START="0.6252441331497659" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.9998303920357164" LOG_CI_START="-0.2039503746916411" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="11526" O_E="0.0" SE="0.7071067811865476" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.5" WEIGHT="83.74284752608548"/>
<DICH_DATA CI_END="63.6312363433901" CI_START="0.11791120163472589" EFFECT_SIZE="2.739130434782609" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8036703615812775" LOG_CI_START="-0.9284449347092995" LOG_EFFECT_SIZE="0.43761271343598884" ORDER="11527" O_E="0.0" SE="1.6048580492299167" STUDY_ID="STD-Angus-1969" TOTAL_1="22" TOTAL_2="20" VAR="2.5755693581780537" WEIGHT="16.257152473914505"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.516425663712734" CI_END="1.653448912311121" CI_START="0.7222832840591409" DF="12.0" EFFECT_SIZE="1.0928213533821944" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="39" I2="0.0" ID="CMP-002.20.03" LOG_CI_END="0.21839078077730886" LOG_CI_START="-0.14129243598406654" LOG_EFFECT_SIZE="0.038549172396621215" NO="3" P_CHI2="0.5707508942848694" P_Z="0.6743980660551034" STUDIES="14" TAU2="0.0" TOTAL_1="261" TOTAL_2="259" WEIGHT="100.0" Z="0.4201196275517553">
<NAME>dystonic symptoms - unspecified</NAME>
<DICH_DATA CI_END="6.41978801003991" CI_START="0.15576838338526122" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8075206873227565" LOG_CI_START="-0.8075206873227565" LOG_EFFECT_SIZE="0.0" ORDER="11528" O_E="0.0" SE="0.9486832980505138" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.8999999999999999" WEIGHT="4.959901385711888"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11529" O_E="0.0" SE="0.0" STUDY_ID="STD-_x002a_Goldstein-1966" TOTAL_1="10" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="29.148154334812613" CI_START="0.36014630221243094" EFFECT_SIZE="3.24" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4646110603786244" LOG_CI_START="-0.4435210399654002" LOG_EFFECT_SIZE="0.5105450102066121" ORDER="11530" O_E="0.0" SE="1.1208462411483104" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="1.2562962962962962" WEIGHT="3.5532312403537403"/>
<DICH_DATA CI_END="3.330510326941122" CI_START="0.4691473217664706" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5225107846154844" LOG_CI_START="-0.3286907585993715" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="11531" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.24999999999999997" WEIGHT="17.855644988562798"/>
<DICH_DATA CI_END="18.55351612686302" CI_START="0.17817566769355403" EFFECT_SIZE="1.8181818181818181" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2684262260690662" LOG_CI_START="-0.749151605057554" LOG_EFFECT_SIZE="0.2596373105057561" ORDER="11532" O_E="0.0" SE="1.1851352051751118" STUDY_ID="STD-Angus-1969" TOTAL_1="22" TOTAL_2="20" VAR="1.4045454545454545" WEIGHT="3.178189237446452"/>
<DICH_DATA CI_END="1.8500642186633196" CI_START="0.027654246270564203" EFFECT_SIZE="0.2261904761904762" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2671868037149378" LOG_CI_START="-1.558238173933043" LOG_EFFECT_SIZE="-0.6455256851090527" ORDER="11533" O_E="0.0" SE="1.072263667869794" STUDY_ID="STD-Bishop-1966" TOTAL_1="21" TOTAL_2="19" VAR="1.149749373433584" WEIGHT="3.8825080928809563"/>
<DICH_DATA CI_END="19.186141047120007" CI_START="0.17874127333812684" EFFECT_SIZE="1.8518518518518519" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2829876328661942" LOG_CI_START="-0.7477751525121312" LOG_EFFECT_SIZE="0.2676062401770315" ORDER="11534" O_E="0.0" SE="1.1928801125691395" STUDY_ID="STD-Bishop-1967" TOTAL_1="27" TOTAL_2="25" VAR="1.422962962962963" WEIGHT="3.137053713503354"/>
<DICH_DATA CI_END="11.249789078271847" CI_START="0.5555659716386525" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0511443799583708" LOG_CI_START="-0.2552643626142957" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="11535" O_E="0.0" SE="0.7673909622147558" STUDY_ID="STD-Brauzer-1968" TOTAL_1="18" TOTAL_2="18" VAR="0.5888888888888888" WEIGHT="7.58022664608798"/>
<DICH_DATA CI_END="3.4836416990053385" CI_START="0.32952848853578676" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.542033480392197" LOG_CI_START="-0.4821070336373106" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="11536" O_E="0.0" SE="0.6015852075182384" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.36190476190476195" WEIGHT="12.334491603941402"/>
<DICH_DATA CI_END="3.054706337101762" CI_START="0.04138523940941702" EFFECT_SIZE="0.35555555555555557" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48496946586945155" LOG_CI_START="-1.3831545281082893" LOG_EFFECT_SIZE="-0.4490925311194189" ORDER="11537" O_E="0.0" SE="1.0973452814254347" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="1.2041666666666666" WEIGHT="3.7070543228850092"/>
<DICH_DATA CI_END="1.0990363038643731" CI_START="0.021535811847190146" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.04101203847222755" LOG_CI_START="-1.6668387517579386" LOG_EFFECT_SIZE="-0.8129133566428556" ORDER="11538" O_E="0.0" SE="1.0032000081789556" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="1.0064102564102566" WEIGHT="4.435478691426425"/>
<DICH_DATA CI_END="14.207980025005401" CI_START="0.07038298183415555" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.152532337860481" LOG_CI_START="-1.152532337860481" LOG_EFFECT_SIZE="0.0" ORDER="11539" O_E="0.0" SE="1.3540064007726602" STUDY_ID="STD-Gallant-1968" TOTAL_1="12" TOTAL_2="12" VAR="1.8333333333333335" WEIGHT="2.434860680258563"/>
<DICH_DATA CI_END="2.384817674811927" CI_START="0.5176781077538471" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.37745518176192905" LOG_CI_START="-0.2859402006405787" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="11540" O_E="0.0" SE="0.38968173148333735" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.15185185185185185" WEIGHT="29.396488700682653"/>
<DICH_DATA CI_END="27.058998600700928" CI_START="0.33260654367922043" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.432311720190758" LOG_CI_START="-0.47806921075143316" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="11541" O_E="0.0" SE="1.1221672153735642" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.2592592592592593" WEIGHT="3.5448706962587897"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.148400614551641" CI_END="1.1555536070181482" CI_START="0.3289344134148183" DF="3.0" EFFECT_SIZE="0.6165235988134534" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" I2="0.0" ID="CMP-002.20.04" LOG_CI_END="0.06279009753658861" LOG_CI_START="-0.48289068786023676" LOG_EFFECT_SIZE="-0.21005029516182408" NO="4" P_CHI2="0.7654047117657756" P_Z="0.13132233055302514" STUDIES="4" TAU2="0.0" TOTAL_1="73" TOTAL_2="74" WEIGHT="100.00000000000001" Z="1.5089078614332982">
<NAME>facial expression abnormal</NAME>
<DICH_DATA CI_END="1.6504430213009715" CI_START="0.19784422002494106" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.21760053565711035" LOG_CI_START="-0.7036766330296993" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="11542" O_E="0.0" SE="0.541162769282166" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.29285714285714287" WEIGHT="35.08299860561806"/>
<DICH_DATA CI_END="2.2249677791209805" CI_START="0.18409255353882967" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.34732372612536294" LOG_CI_START="-0.7349637781575885" LOG_EFFECT_SIZE="-0.1938200260161128" ORDER="11543" O_E="0.0" SE="0.635741037425355" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="0.4041666666666667" WEIGHT="25.420965116294678"/>
<DICH_DATA CI_END="20.771505597011338" CI_START="0.1925715004778244" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.317467976976883" LOG_CI_START="-0.7154079856489205" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11544" O_E="0.0" SE="1.1941214033447043" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.425925925925926" WEIGHT="7.205357969651055"/>
<DICH_DATA CI_END="1.5104711327765359" CI_START="0.1655112729896744" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.17911242971147984" LOG_CI_START="-0.7811724210394423" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11545" O_E="0.0" SE="0.5640760748177661" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="0.3181818181818181" WEIGHT="32.29067830843622"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.052626919662956" CI_END="1.5742685054365748" CI_START="0.6726717988998534" DF="4.0" EFFECT_SIZE="1.0290607501520037" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" I2="1.2985878223237102" ID="CMP-002.20.05" LOG_CI_END="0.1970788071109932" LOG_CI_START="-0.1721967793023436" LOG_EFFECT_SIZE="0.01244101390432484" NO="5" P_CHI2="0.3989306607885269" P_Z="0.8949339545036076" STUDIES="5" TAU2="0.0038021855427753564" TOTAL_1="76" TOTAL_2="76" WEIGHT="100.0" Z="0.13206364071057375">
<NAME>gait, Parkinsonian</NAME>
<DICH_DATA CI_END="1.3671860356545893" CI_START="0.22574980087539337" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.13582761388096082" LOG_CI_START="-0.6463726240875729" LOG_EFFECT_SIZE="-0.255272505103306" ORDER="11546" O_E="0.0" SE="0.45946829173634074" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.21111111111111114" WEIGHT="21.629575145525415"/>
<DICH_DATA CI_END="53.24621860927151" CI_START="0.11314969486641972" EFFECT_SIZE="2.4545454545454546" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.726288770881867" LOG_CI_START="-0.9463466128803427" LOG_EFFECT_SIZE="0.3899710790007623" ORDER="11547" O_E="0.0" SE="1.5699192541804385" STUDY_ID="STD-_x002a_Goldstein-1966" TOTAL_1="10" TOTAL_2="8" VAR="2.4646464646464645" WEIGHT="1.8526972153339392"/>
<DICH_DATA CI_END="33.98214755319472" CI_START="0.5357061208667789" EFFECT_SIZE="4.266666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5312508212967313" LOG_CI_START="-0.2710733914403194" LOG_EFFECT_SIZE="0.630088714928206" ORDER="11548" O_E="0.0" SE="1.058694164210483" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="1.1208333333333333" WEIGHT="4.073972022453362"/>
<DICH_DATA CI_END="2.7192628287127705" CI_START="0.40544076444493427" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4344511860881081" LOG_CI_START="-0.39207258794823197" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="11549" O_E="0.0" SE="0.4855041562276122" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.2357142857142857" WEIGHT="19.371942722928484"/>
<DICH_DATA CI_END="2.0308122616365205" CI_START="0.6431527294044694" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.3076697769233316" LOG_CI_START="-0.1916858829679581" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="11550" O_E="0.0" SE="0.2933239864705255" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="0.08603896103896103" WEIGHT="53.0718128937588"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1952935788317984" CI_END="2.8176868491135143" CI_START="0.516167437806283" DF="2.0" EFFECT_SIZE="1.2059843288564664" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-002.20.06" LOG_CI_END="0.4498927250192345" LOG_CI_START="-0.2872093962026463" LOG_EFFECT_SIZE="0.08134166440829414" NO="6" P_CHI2="0.5501048639307922" P_Z="0.6653220623367486" STUDIES="3" TAU2="0.0" TOTAL_1="49" TOTAL_2="52" WEIGHT="100.00000000000001" Z="0.4325770557233541">
<NAME>oculogyric crisis</NAME>
<DICH_DATA CI_END="9.92750288457511" CI_START="0.4625369328100079" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9968400219262878" LOG_CI_START="-0.334853583843439" LOG_EFFECT_SIZE="0.3309932190414244" ORDER="11551" O_E="0.0" SE="0.7822434160188003" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.611904761904762" WEIGHT="30.637032206322015"/>
<DICH_DATA CI_END="8.076548849507702" CI_START="0.015530646828864726" EFFECT_SIZE="0.3541666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9072258241662697" LOG_CI_START="-1.808810456160896" LOG_EFFECT_SIZE="-0.4507923159973133" ORDER="11552" O_E="0.0" SE="1.5954131556605964" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="2.545343137254902" WEIGHT="7.365193958837383"/>
<DICH_DATA CI_END="3.0850202380402436" CI_START="0.3573720478087891" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.48925801739369257" LOG_CI_START="-0.44687941925381647" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="11553" O_E="0.0" SE="0.5498917642417936" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.3023809523809524" WEIGHT="61.99777383484061"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="52.637446088933245" CI_START="0.9952994791430755" DF="0.0" EFFECT_SIZE="7.238095238095238" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-002.20.07" LOG_CI_END="1.7212948096258367" LOG_CI_START="-0.0020462232041299953" LOG_EFFECT_SIZE="0.8596242932108533" NO="7" P_CHI2="1.0" P_Z="0.050546535749747185" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="19" WEIGHT="100.0" Z="1.9553096257010043">
<NAME>Parkinsonism syndrome</NAME>
<DICH_DATA CI_END="52.637446088933245" CI_START="0.9952994791430755" EFFECT_SIZE="7.238095238095238" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7212948096258367" LOG_CI_START="-0.0020462232041299953" LOG_EFFECT_SIZE="0.8596242932108533" ORDER="11554" O_E="0.0" SE="1.0122990533600158" STUDY_ID="STD-Bishop-1966" TOTAL_1="21" TOTAL_2="19" VAR="1.024749373433584" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="25.332797212811897" CI_END="1.4180196033190133" CI_START="0.7870478730815951" DF="14.0" EFFECT_SIZE="1.0564323512559792" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="99" I2="44.735672565524695" ID="CMP-002.20.08" LOG_CI_END="0.15168223476413253" LOG_CI_START="-0.10399885038193028" LOG_EFFECT_SIZE="0.02384169219110115" NO="8" P_CHI2="0.031420625087506204" P_Z="0.7147198780418382" STUDIES="15" TAU2="0.10501916969055039" TOTAL_1="316" TOTAL_2="320" WEIGHT="99.99999999999999" Z="0.36552455961576735">
<NAME>rigidity</NAME>
<DICH_DATA CI_END="2.102230118933325" CI_START="0.3494830898549799" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.32268025399138267" LOG_CI_START="-0.45657383325260914" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="11555" O_E="0.0" SE="0.4577377082170635" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.20952380952380956" WEIGHT="2.7407403446076675"/>
<DICH_DATA CI_END="4.22611053179122" CI_START="0.7666623898326528" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6259408516181508" LOG_CI_START="-0.1153958414115387" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="11556" O_E="0.0" SE="0.4354648431614539" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="0.18962962962962962" WEIGHT="3.028273371832133"/>
<DICH_DATA CI_END="1.860341569367198" CI_START="0.1935128505043594" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.2695926904933656" LOG_CI_START="-0.7132901897260784" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="11557" O_E="0.0" SE="0.5773502691896258" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.33333333333333337" WEIGHT="1.722751073753391"/>
<DICH_DATA CI_END="3.7200230941775247" CI_START="0.5687336948661101" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5705456360224165" LOG_CI_START="-0.24509104102701693" LOG_EFFECT_SIZE="0.16272729749769974" ORDER="11558" O_E="0.0" SE="0.479109021565504" STUDY_ID="STD-Angus-1969" TOTAL_1="22" TOTAL_2="20" VAR="0.22954545454545455" WEIGHT="2.5016847275626803"/>
<DICH_DATA CI_END="8.433620569181464" CI_START="0.2667893322379308" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9260140580948332" LOG_CI_START="-0.5738315399834706" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="11559" O_E="0.0" SE="0.8810167286666446" STUDY_ID="STD-Bankier-1968" TOTAL_1="35" TOTAL_2="35" VAR="0.7761904761904761" WEIGHT="0.7398317494646467"/>
<DICH_DATA CI_END="1.6974126247097794" CI_START="0.14728298609346363" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.22978742796989282" LOG_CI_START="-0.8318474192978551" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11560" O_E="0.0" SE="0.6236095644623235" STUDY_ID="STD-Brauzer-1968" TOTAL_1="18" TOTAL_2="18" VAR="0.38888888888888884" WEIGHT="1.4766437775029069"/>
<DICH_DATA CI_END="70.08142337334066" CI_START="0.12277782085855314" EFFECT_SIZE="2.933333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.845602913892187" LOG_CI_START="-0.910880079031175" LOG_EFFECT_SIZE="0.4673614174305062" ORDER="11561" O_E="0.0" SE="1.6191717548540585" STUDY_ID="STD-Claghorn-1974" TOTAL_1="44" TOTAL_2="43" VAR="2.6217171717171714" WEIGHT="0.21903596776675754"/>
<DICH_DATA CI_END="1.6325898894569715" CI_START="0.8179081902923311" EFFECT_SIZE="1.1555555555555554" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.2128771026089221" LOG_CI_START="-0.08729544289001123" LOG_EFFECT_SIZE="0.06279082985945543" ORDER="11562" O_E="0.0" SE="0.17632283910413754" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="0.031089743589743576" WEIGHT="18.47073316189204"/>
<DICH_DATA CI_END="0.9380892486464605" CI_START="0.21586432238956033" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="-0.027755841417504572" LOG_CI_START="-0.6658191310318081" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="11563" O_E="0.0" SE="0.3748015347836645" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.14047619047619048" WEIGHT="4.087883903821607"/>
<DICH_DATA CI_END="13.534833367737306" CI_START="0.9050720956195932" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1314529133819102" LOG_CI_START="-0.043316824681358924" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="11564" O_E="0.0" SE="0.6900655593423541" STUDY_ID="STD-Gallant-1968" TOTAL_1="12" TOTAL_2="12" VAR="0.4761904761904761" WEIGHT="1.2059257516273743"/>
<DICH_DATA CI_END="2.3229246143525297" CI_START="0.4069077590992667" EFFECT_SIZE="0.9722222222222222" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3660351159121802" LOG_CI_START="-0.39050402874620344" LOG_EFFECT_SIZE="-0.012234456417011635" ORDER="11565" O_E="0.0" SE="0.444394838501498" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.1974867724867725" WEIGHT="2.9077914975609818"/>
<DICH_DATA CI_END="1.027766369928039" CI_START="0.696633352004967" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" LOG_CI_END="0.011894402808552149" LOG_CI_START="-0.15699573710577558" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="11566" O_E="0.0" SE="0.0992069042053518" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.00984200984200985" WEIGHT="58.34685873475297"/>
<DICH_DATA CI_END="29.804512445201865" CI_START="0.5368314623303222" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4742820218511086" LOG_CI_START="-0.27016203919518356" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="11567" O_E="0.0" SE="1.0246950765959597" STUDY_ID="STD-Ramsay-1970" TOTAL_1="10" TOTAL_2="10" VAR="1.0499999999999998" WEIGHT="0.5469051027788545"/>
<DICH_DATA CI_END="18.270642568115434" CI_START="1.1083354033392778" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.2617538215112387" LOG_CI_START="0.04467120603944865" LOG_EFFECT_SIZE="0.6532125137753437" ORDER="11568" O_E="0.0" SE="0.7149203529842405" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="0.5111111111111111" WEIGHT="1.1235333089696031"/>
<DICH_DATA CI_END="3.2431627011004087" CI_START="0.1370404402756741" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5109687366525157" LOG_CI_START="-0.8631512547638782" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="11569" O_E="0.0" SE="0.8071648849616486" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="0.6515151515151514" WEIGHT="0.8814075261063864"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.3899122216307465" CI_END="1.8448585898549896" CI_START="0.6354298311005091" DF="6.0" EFFECT_SIZE="1.082717960576936" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" I2="0.0" ID="CMP-002.20.09" LOG_CI_END="0.2659630826905752" LOG_CI_START="-0.19693240049686436" LOG_EFFECT_SIZE="0.0345153410968554" NO="9" P_CHI2="0.49486104761574956" P_Z="0.7700683229509389" STUDIES="7" TAU2="0.0" TOTAL_1="139" TOTAL_2="144" WEIGHT="100.0" Z="0.2922855284658673">
<NAME>salivation, increased</NAME>
<DICH_DATA CI_END="1.4576054684368849" CI_START="0.07622852240686574" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.16363998895624796" LOG_CI_START="-1.1178824983955729" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11570" O_E="0.0" SE="0.7527726527090809" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.5666666666666665" WEIGHT="13.047082949687006"/>
<DICH_DATA CI_END="22.378714917360774" CI_START="0.2084838212215912" EFFECT_SIZE="2.16" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3498351438400935" LOG_CI_START="-0.6809276415382317" LOG_EFFECT_SIZE="0.3344537511509309" ORDER="11571" O_E="0.0" SE="1.1928801125691395" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="1.422962962962963" WEIGHT="5.195740997662965"/>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" ORDER="11572" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="15.842886438905646"/>
<DICH_DATA CI_END="63.6312363433901" CI_START="0.11791120163472589" EFFECT_SIZE="2.739130434782609" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8036703615812775" LOG_CI_START="-0.9284449347092995" LOG_EFFECT_SIZE="0.43761271343598884" ORDER="11573" O_E="0.0" SE="1.6048580492299167" STUDY_ID="STD-Angus-1969" TOTAL_1="22" TOTAL_2="20" VAR="2.5755693581780537" WEIGHT="2.870568009107181"/>
<DICH_DATA CI_END="13.464902409953368" CI_START="0.7604956715044967" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1292032101075493" LOG_CI_START="-0.11890325346773721" LOG_EFFECT_SIZE="0.505149978319906" ORDER="11574" O_E="0.0" SE="0.733143914930759" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="0.5375" WEIGHT="13.755064195018855"/>
<DICH_DATA CI_END="3.640292411447435" CI_START="0.30286028576523877" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5611362703461713" LOG_CI_START="-0.5187576722062951" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="11575" O_E="0.0" SE="0.6343350474165466" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.4023809523809524" WEIGHT="18.373998473523706"/>
<DICH_DATA CI_END="2.4835704735123474" CI_START="0.3652118947827958" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.39507648799675005" LOG_CI_START="-0.4374550861366262" LOG_EFFECT_SIZE="-0.021189299069938095" ORDER="11576" O_E="0.0" SE="0.48903316774370137" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.23915343915343917" WEIGHT="30.914658936094643"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.471969404965903" CI_END="1.1235138907438602" CI_START="0.754027594648087" DF="12.0" EFFECT_SIZE="0.9204132097005706" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="76" I2="0.0" ID="CMP-002.20.10" LOG_CI_END="0.050578446257697696" LOG_CI_START="-0.12261276025210578" LOG_EFFECT_SIZE="-0.036017156997204036" NO="10" P_CHI2="0.9733384518260578" P_Z="0.41496052370025116" STUDIES="14" TAU2="0.0" TOTAL_1="304" TOTAL_2="308" WEIGHT="100.0" Z="0.8151953203934618">
<NAME>tremor</NAME>
<DICH_DATA CI_END="1.5758663963747823" CI_START="0.6345715615869848" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.19751939476726493" LOG_CI_START="-0.19751939476726496" LOG_EFFECT_SIZE="0.0" ORDER="11577" O_E="0.0" SE="0.23204774044612855" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.05384615384615385" WEIGHT="19.220832393974575"/>
<DICH_DATA CI_END="2.8598840771688376" CI_START="0.261023167323271" EFFECT_SIZE="0.864" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4563484297492444" LOG_CI_START="-0.5833209447914578" LOG_EFFECT_SIZE="-0.06348625752110672" ORDER="11578" O_E="0.0" SE="0.6107069370516132" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="0.372962962962963" WEIGHT="2.7749884061272594"/>
<DICH_DATA CI_END="1.8548992636322397" CI_START="0.3743839129487778" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.2683203288100422" LOG_CI_START="-0.4266828209052918" LOG_EFFECT_SIZE="-0.07918124604762482" ORDER="11579" O_E="0.0" SE="0.4082482904638631" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.1666666666666667" WEIGHT="6.209807388822554"/>
<DICH_DATA CI_END="13.59284306217953" CI_START="0.060800104673556066" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1333103027281066" LOG_CI_START="-1.2160956730445567" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="11580" O_E="0.0" SE="1.3800526999160048" STUDY_ID="STD-Angus-1969" TOTAL_1="22" TOTAL_2="20" VAR="1.9045454545454545" WEIGHT="0.5434198987831991"/>
<DICH_DATA CI_END="3.1082378709914233" CI_START="0.1809707053793092" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.49251424761469187" LOG_CI_START="-0.7423917208312916" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="11581" O_E="0.0" SE="0.7253898787483019" STUDY_ID="STD-Bankier-1968" TOTAL_1="35" TOTAL_2="35" VAR="0.5261904761904761" WEIGHT="1.9669073177266019"/>
<DICH_DATA CI_END="4.309711226077789" CI_START="0.23203410798131058" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6344481710603809" LOG_CI_START="-0.6344481710603809" LOG_EFFECT_SIZE="0.0" ORDER="11582" O_E="0.0" SE="0.7453559924999298" STUDY_ID="STD-Brauzer-1968" TOTAL_1="18" TOTAL_2="18" VAR="0.5555555555555555" WEIGHT="1.862942216646767"/>
<DICH_DATA CI_END="15.131350376360228" CI_START="0.06311809321150688" EFFECT_SIZE="0.9772727272727273" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1798776877609272" LOG_CI_START="-1.1998461295741287" LOG_EFFECT_SIZE="-0.009984220906600895" ORDER="11583" O_E="0.0" SE="1.3978615501254903" STUDY_ID="STD-Claghorn-1974" TOTAL_1="44" TOTAL_2="43" VAR="1.9540169133192389" WEIGHT="0.5296616887409736"/>
<DICH_DATA CI_END="2.58608316478295" CI_START="0.4399617898109134" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.412642487066249" LOG_CI_START="-0.3565850398657619" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="11584" O_E="0.0" SE="0.45184805705753195" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="0.20416666666666666" WEIGHT="5.069230521487801"/>
<DICH_DATA CI_END="1.1062585990027465" CI_START="0.6211510945376004" EFFECT_SIZE="0.8289473684210527" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" LOG_CI_END="0.04385665951146684" LOG_CI_START="-0.20680274516588612" LOG_EFFECT_SIZE="-0.08147304282720963" ORDER="11585" O_E="0.0" SE="0.14723857509154137" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.021679197994987465" WEIGHT="47.74013772909827"/>
<DICH_DATA CI_END="4.32727994825438" CI_START="0.5591857044968582" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.636214992275053" LOG_CI_START="-0.25244393979722657" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="11586" O_E="0.0" SE="0.5220026556319158" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.2724867724867725" WEIGHT="3.798231703842922"/>
<DICH_DATA CI_END="3.6330276653499807" CI_START="0.6193181575409915" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5602687050091748" LOG_CI_START="-0.20808618689781241" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="11587" O_E="0.0" SE="0.45133546692422005" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.20370370370370372" WEIGHT="5.080751499945727"/>
<DICH_DATA CI_END="18.687408406451837" CI_START="0.21404787186108687" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2715490770440216" LOG_CI_START="-0.6694890857160593" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11588" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Ramsay-1970" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="0.7961291524131484"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11589" O_E="0.0" SE="0.0" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.7234986784475137" CI_START="0.25787338859162295" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.23641095473371262" LOG_CI_START="-0.5885934728450752" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="11590" O_E="0.0" SE="0.4846116845975598" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="0.23484848484848478" WEIGHT="4.406960082390203"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.6214121251448579" CI_START="-2.7785878748551425" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.21" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="9.159430495013546E-14" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="7.4524907164148075">
<NAME>Adverse effects: 5c. Extrapyramidal - average daily dose of antiparkinson agent (trihexyphenidyl)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.6214121251448579" CI_START="-2.7785878748551425" EFFECT_SIZE="-2.2" ESTIMABLE="YES" MEAN_1="7.2" MEAN_2="9.4" ORDER="11591" SD_1="0.73" SD_2="1.1" SE="0.2952033197645311" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="19.64734676491504" CI_END="1.4247284553782493" CI_START="0.8757913979245656" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1170339858744782" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="113" I2="44.0127965795204" I2_Q="0.0" ID="CMP-002.22" LOG_CI_END="0.15373209833154192" LOG_CI_START="-0.05759932478929268" LOG_EFFECT_SIZE="0.0480663867711246" METHOD="MH" NO="22" P_CHI2="0.050418096316461436" P_Q="0.0" P_Z="0.3726234228078811" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07520129349260608" TOTALS="YES" TOTAL_1="240" TOTAL_2="245" WEIGHT="100.00000000000001" Z="0.8915700802763296">
<NAME>Adverse events: 5d-i. Extrapyramidal - subgroup analysis - high vs low potency control groups - any effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.9731319146502" CI_END="1.3377034427128578" CI_START="0.7854014829672498" DF="8.0" EFFECT_SIZE="1.025004520808115" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="95" I2="46.57096427386351" ID="CMP-002.22.01" LOG_CI_END="0.12635984477075204" LOG_CI_START="-0.10490828304537471" LOG_EFFECT_SIZE="0.010725780862688614" NO="1" P_CHI2="0.05967003144740457" P_Z="0.8557405575600318" STUDIES="9" TAU2="0.07226149400526996" TOTAL_1="175" TOTAL_2="180" WEIGHT="81.85594751021637" Z="0.1817988876846245">
<NAME>vs high potency control group</NAME>
<DICH_DATA CI_END="46.0587303773455" CI_START="0.9948707841421282" EFFECT_SIZE="6.769230769230769" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.6633119623361476" LOG_CI_START="-0.0022333226494841603" LOG_EFFECT_SIZE="0.8305393198433318" ORDER="11592" O_E="0.0" SE="0.9783495449826878" STUDY_ID="STD-_x002a_Bankier-1973" TOTAL_1="13" TOTAL_2="11" VAR="0.9571678321678322" WEIGHT="1.4926856280400462"/>
<DICH_DATA CI_END="1.2093969629453483" CI_START="0.44466605610459053" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.0825688736648852" LOG_CI_START="-0.3519660214597977" LOG_EFFECT_SIZE="-0.13469857389745624" ORDER="11593" O_E="0.0" SE="0.2552479483786602" STUDY_ID="STD-Bishop-1964" TOTAL_1="7" TOTAL_2="7" VAR="0.06515151515151518" WEIGHT="10.979492121265437"/>
<DICH_DATA CI_END="1.5835717949838224" CI_START="0.5169289494176377" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.1996377579248416" LOG_CI_START="-0.2865691454870222" LOG_EFFECT_SIZE="-0.0434656937810903" ORDER="11594" O_E="0.0" SE="0.2856003418271165" STUDY_ID="STD-Bishop-1966" TOTAL_1="21" TOTAL_2="19" VAR="0.08156755525176579" WEIGHT="9.829775296866357"/>
<DICH_DATA CI_END="2.4472071470738177" CI_START="0.5561895782866699" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.38867073233645727" LOG_CI_START="-0.2547771530752308" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="11595" O_E="0.0" SE="0.3779644730092273" STUDY_ID="STD-Bishop-1970" TOTAL_1="12" TOTAL_2="12" VAR="0.1428571428571429" WEIGHT="7.066924731286045"/>
<DICH_DATA CI_END="2.4807275736590495" CI_START="0.6044094789887149" EFFECT_SIZE="1.2244897959183674" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.3945790739244573" LOG_CI_START="-0.21866873321419733" LOG_EFFECT_SIZE="0.08795517035512998" ORDER="11596" O_E="0.0" SE="0.360224797538849" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.12976190476190474" WEIGHT="7.5184353573175695"/>
<DICH_DATA CI_END="1.034668171367047" CI_START="0.3058045649379075" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.014801089454049815" LOG_CI_START="-0.5145560358872495" LOG_EFFECT_SIZE="-0.24987747321659987" ORDER="11597" O_E="0.0" SE="0.3109469957855103" STUDY_ID="STD-Gallant-1968-II" TOTAL_1="26" TOTAL_2="26" VAR="0.09668803418803418" WEIGHT="8.96508571822849"/>
<DICH_DATA CI_END="1.3051281027257766" CI_START="0.6198992246855172" EFFECT_SIZE="0.8994708994708994" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="21" LOG_CI_END="0.11565314123482448" LOG_CI_START="-0.20767890682476492" LOG_EFFECT_SIZE="-0.046012882794970233" ORDER="11598" O_E="0.0" SE="0.18992684554965356" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.036072206660441954" WEIGHT="13.848782994927594"/>
<DICH_DATA CI_END="2.997540601817565" CI_START="1.021670898516953" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" LOG_CI_END="0.4767650743483349" LOG_CI_START="0.009311023024253864" LOG_EFFECT_SIZE="0.24303804868629442" ORDER="11599" O_E="0.0" SE="0.274584823682638" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.07539682539682538" WEIGHT="10.232548507707476"/>
<DICH_DATA CI_END="1.8500016003275888" CI_START="0.7436589527575561" EFFECT_SIZE="1.1729323308270676" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.2671721040857924" LOG_CI_START="-0.12862618931104086" LOG_EFFECT_SIZE="0.06927295738737577" ORDER="11600" O_E="0.0" SE="0.23249387677445027" STUDY_ID="STD-Simpson-1976" TOTAL_1="19" TOTAL_2="24" VAR="0.05405340273761327" WEIGHT="11.922217154577346"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.37928586373359396" CI_END="2.6657896932482776" CI_START="1.0331932625135904" DF="2.0" EFFECT_SIZE="1.6596011419441394" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="18" I2="0.0" ID="CMP-002.22.02" LOG_CI_END="0.4258258845135338" LOG_CI_START="0.014181565462264888" LOG_EFFECT_SIZE="0.22000372498789936" NO="2" P_CHI2="0.8272545223519556" P_Z="0.03617014888749365" STUDIES="3" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="18.144052489783643" Z="2.0950094899146805">
<NAME>vs low potency control group</NAME>
<DICH_DATA CI_END="3.5481063888087543" CI_START="0.44037574660341444" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5499966335328185" LOG_CI_START="-0.35617660751670577" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="11601" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Gallant-1972" TOTAL_1="12" TOTAL_2="12" VAR="0.2833333333333334" WEIGHT="4.298057820378189"/>
<DICH_DATA CI_END="3.895554234117505" CI_START="0.8853630021706176" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.5905692549984239" LOG_CI_START="-0.052878630413264" LOG_EFFECT_SIZE="0.26884531229257996" ORDER="11602" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.14285714285714285" WEIGHT="7.066924731286047"/>
<DICH_DATA CI_END="3.681880652108193" CI_START="0.7981723982610299" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.566069706772315" LOG_CI_START="-0.09790329470557912" LOG_EFFECT_SIZE="0.23408320603336794" ORDER="11603" O_E="0.0" SE="0.3900210277874798" STUDY_ID="STD-Needham-1969" TOTAL_1="27" TOTAL_2="27" VAR="0.1521164021164021" WEIGHT="6.779069938119406"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="25.332797212811897" CI_END="1.4180196033190133" CI_START="0.7870478730815951" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0564323512559792" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="99" I2="44.735672565524695" I2_Q="0.0" ID="CMP-002.23" LOG_CI_END="0.15168223476413253" LOG_CI_START="-0.10399885038193028" LOG_EFFECT_SIZE="0.02384169219110115" METHOD="MH" NO="23" P_CHI2="0.031420625087506204" P_Q="0.0" P_Z="0.714719878041838" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.10501916969055039" TOTALS="YES" TOTAL_1="316" TOTAL_2="320" WEIGHT="99.99999999999999" Z="0.3655245596157675">
<NAME>Adverse events: 5d-ii. Extrapyramidal - subgroup analysis - high vs low potency control groups - rigidity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="15.36009532743034" CI_END="1.3554902404220073" CI_START="0.7888837309334218" DF="11.0" EFFECT_SIZE="1.0340813305093337" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="78" I2="28.385861119260124" ID="CMP-002.23.01" LOG_CI_END="0.13209639499202874" LOG_CI_START="-0.10298700025690921" LOG_EFFECT_SIZE="0.014554697367559733" NO="1" P_CHI2="0.16659798312448815" P_Z="0.8082423381709467" STUDIES="12" TAU2="0.04876947529915933" TOTAL_1="254" TOTAL_2="259" WEIGHT="80.40877044502149" Z="0.24269415214195914">
<NAME>vs high potency control group</NAME>
<DICH_DATA CI_END="2.102230118933325" CI_START="0.3494830898549799" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.32268025399138267" LOG_CI_START="-0.45657383325260914" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="11604" O_E="0.0" SE="0.4577377082170635" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.20952380952380956" WEIGHT="7.171209493662096"/>
<DICH_DATA CI_END="4.22611053179122" CI_START="0.7666623898326528" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6259408516181508" LOG_CI_START="-0.1153958414115387" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="11605" O_E="0.0" SE="0.4354648431614539" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="0.18962962962962962" WEIGHT="7.655397218353067"/>
<DICH_DATA CI_END="1.860341569367198" CI_START="0.1935128505043594" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.2695926904933656" LOG_CI_START="-0.7132901897260784" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="11606" O_E="0.0" SE="0.5773502691896258" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.33333333333333337" WEIGHT="5.145752751830135"/>
<DICH_DATA CI_END="8.433620569181464" CI_START="0.2667893322379308" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9260140580948332" LOG_CI_START="-0.5738315399834706" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="11607" O_E="0.0" SE="0.8810167286666446" STUDY_ID="STD-Bankier-1968" TOTAL_1="35" TOTAL_2="35" VAR="0.7761904761904761" WEIGHT="2.5597241351705726"/>
<DICH_DATA CI_END="1.6974126247097794" CI_START="0.14728298609346363" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.22978742796989282" LOG_CI_START="-0.8318474192978551" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11608" O_E="0.0" SE="0.6236095644623235" STUDY_ID="STD-Brauzer-1968" TOTAL_1="18" TOTAL_2="18" VAR="0.38888888888888884" WEIGHT="4.56695038585604"/>
<DICH_DATA CI_END="70.08142337334066" CI_START="0.12277782085855314" EFFECT_SIZE="2.933333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.845602913892187" LOG_CI_START="-0.910880079031175" LOG_EFFECT_SIZE="0.4673614174305062" ORDER="11609" O_E="0.0" SE="1.6191717548540585" STUDY_ID="STD-Claghorn-1974" TOTAL_1="44" TOTAL_2="43" VAR="2.6217171717171714" WEIGHT="0.8272356826191195"/>
<DICH_DATA CI_END="1.6325898894569715" CI_START="0.8179081902923311" EFFECT_SIZE="1.1555555555555554" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.2128771026089221" LOG_CI_START="-0.08729544289001123" LOG_EFFECT_SIZE="0.06279082985945543" ORDER="11610" O_E="0.0" SE="0.17632283910413754" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="0.031089743589743576" WEIGHT="16.57241648871025"/>
<DICH_DATA CI_END="13.534833367737306" CI_START="0.9050720956195932" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1314529133819102" LOG_CI_START="-0.043316824681358924" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="11611" O_E="0.0" SE="0.6900655593423541" STUDY_ID="STD-Gallant-1968" TOTAL_1="12" TOTAL_2="12" VAR="0.4761904761904761" WEIGHT="3.88096380487207"/>
<DICH_DATA CI_END="2.3229246143525297" CI_START="0.4069077590992667" EFFECT_SIZE="0.9722222222222222" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3660351159121802" LOG_CI_START="-0.39050402874620344" LOG_EFFECT_SIZE="-0.012234456417011635" ORDER="11612" O_E="0.0" SE="0.444394838501498" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.1974867724867725" WEIGHT="7.456559638040296"/>
<DICH_DATA CI_END="1.027766369928039" CI_START="0.696633352004967" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" LOG_CI_END="0.011894402808552149" LOG_CI_START="-0.15699573710577558" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="11613" O_E="0.0" SE="0.0992069042053518" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.00984200984200985" WEIGHT="19.63808492901082"/>
<DICH_DATA CI_END="29.804512445201865" CI_START="0.5368314623303222" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4742820218511086" LOG_CI_START="-0.27016203919518356" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="11614" O_E="0.0" SE="1.0246950765959597" STUDY_ID="STD-Ramsay-1970" TOTAL_1="10" TOTAL_2="10" VAR="1.0499999999999998" WEIGHT="1.9529144259234295"/>
<DICH_DATA CI_END="3.2431627011004087" CI_START="0.1370404402756741" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5109687366525157" LOG_CI_START="-0.8631512547638782" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="11615" O_E="0.0" SE="0.8071648849616486" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="0.6515151515151514" WEIGHT="2.981561490973606"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.865267601529425" CI_END="4.59998900982776" CI_START="0.3613968976260945" DF="2.0" EFFECT_SIZE="1.2893493542348726" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" I2="79.72685505571144" ID="CMP-002.23.02" LOG_CI_END="0.6627567940779087" LOG_CI_START="-0.44201557991468576" LOG_EFFECT_SIZE="0.11037060708161149" NO="2" P_CHI2="0.007207509552262681" P_Z="0.6953431076869723" STUDIES="3" TAU2="0.9879994405539075" TOTAL_1="62" TOTAL_2="61" WEIGHT="19.591229554978497" Z="0.3916144536634297">
<NAME>vs low potency control group</NAME>
<DICH_DATA CI_END="3.7200230941775247" CI_START="0.5687336948661101" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5705456360224165" LOG_CI_START="-0.24509104102701693" LOG_EFFECT_SIZE="0.16272729749769974" ORDER="11616" O_E="0.0" SE="0.479109021565504" STUDY_ID="STD-Angus-1969" TOTAL_1="22" TOTAL_2="20" VAR="0.22954545454545455" WEIGHT="6.742056497627849"/>
<DICH_DATA CI_END="0.9380892486464605" CI_START="0.21586432238956033" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="-0.027755841417504572" LOG_CI_START="-0.6658191310318081" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="11617" O_E="0.0" SE="0.3748015347836645" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.14047619047619048" WEIGHT="9.188172017486332"/>
<DICH_DATA CI_END="18.270642568115434" CI_START="1.1083354033392778" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.2617538215112387" LOG_CI_START="0.04467120603944865" LOG_EFFECT_SIZE="0.6532125137753437" ORDER="11618" O_E="0.0" SE="0.7149203529842405" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="0.5111111111111111" WEIGHT="3.6610010398643187"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="35.43281638022087" CI_END="1.2500900497494998" CI_START="0.8640186694711104" CI_STUDY="95" CI_TOTAL="95" DF="18.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0392791451307184" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="171" I2="49.19963514374243" I2_Q="0.0" ID="CMP-002.24" LOG_CI_END="0.096941298368618" LOG_CI_START="-0.06347687330735156" LOG_EFFECT_SIZE="0.016732212530633197" METHOD="MH" NO="24" P_CHI2="0.008334108887388725" P_Q="0.0" P_Z="0.6826401450585109" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.06152995432782011" TOTALS="YES" TOTAL_1="354" TOTAL_2="353" WEIGHT="100.0" Z="0.4088630807730806">
<NAME>Adverse events: 5d-iii. Extrapyramidal - subgroup analysis - high vs low potency control groups - anti'p drugs</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="19.100074211882937" CI_END="1.146199781380339" CI_START="0.7560508765757854" DF="12.0" EFFECT_SIZE="0.9309056608720235" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="123" I2="37.1730189795058" ID="CMP-002.24.01" LOG_CI_END="0.05926032128686643" LOG_CI_START="-0.12144897874128444" LOG_EFFECT_SIZE="-0.031094328727209006" NO="1" P_CHI2="0.08614191669255744" P_Z="0.49999663437592723" STUDIES="13" TAU2="0.04661585944573494" TOTAL_1="210" TOTAL_2="220" WEIGHT="69.52707256518214" Z="0.6744950527646889">
<NAME>vs high potency control group</NAME>
<DICH_DATA CI_END="1.4317045869649099" CI_START="0.5378248117737379" EFFECT_SIZE="0.8775" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.15585341637531663" LOG_CI_START="-0.2693591660995934" LOG_EFFECT_SIZE="-0.056752874862138335" ORDER="11619" O_E="0.0" SE="0.24977197578199178" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="0.062386039886039885" WEIGHT="7.165639626260055"/>
<DICH_DATA CI_END="3.9855442667258254" CI_START="0.39204181297015506" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6004876371237167" LOG_CI_START="-0.40666761110760397" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="11620" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Andersen-1974" TOTAL_1="20" TOTAL_2="20" VAR="0.35000000000000003" WEIGHT="2.157649398612005"/>
<DICH_DATA CI_END="3.066407321427068" CI_START="0.5797591746390763" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.48662984317937014" LOG_CI_START="-0.23675236996277021" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="11621" O_E="0.0" SE="0.4249182927993987" STUDY_ID="STD-Brauzer-1968" TOTAL_1="18" TOTAL_2="18" VAR="0.18055555555555552" WEIGHT="3.6678666100007784"/>
<DICH_DATA CI_END="1.359243444419585" CI_START="0.8741888088281169" EFFECT_SIZE="1.0900621118012421" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.133297247092718" LOG_CI_START="-0.058394757552731755" LOG_EFFECT_SIZE="0.03745124476999313" ORDER="11622" O_E="0.0" SE="0.11260083241946371" STUDY_ID="STD-Brauzer-1971" TOTAL_1="13" TOTAL_2="12" VAR="0.01267894746155615" WEIGHT="11.965375272449647"/>
<DICH_DATA CI_END="1.7321877791583402" CI_START="0.3727812010832229" EFFECT_SIZE="0.8035714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2385949702631983" LOG_CI_START="-0.4285459967249118" LOG_EFFECT_SIZE="-0.09497551323085672" ORDER="11623" O_E="0.0" SE="0.39188190640986287" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.15357142857142853" WEIGHT="4.127994653024374"/>
<DICH_DATA CI_END="1.7970991296816015" CI_START="0.6331190967631051" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.25457203386262467" LOG_CI_START="-0.1985145866621376" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="11624" O_E="0.0" SE="0.2661453237111886" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="0.07083333333333336" WEIGHT="6.708335628073422"/>
<DICH_DATA CI_END="0.8564563908028242" CI_START="0.27222754469683214" EFFECT_SIZE="0.4828571428571429" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="-0.0672947456183319" LOG_CI_START="-0.5650679338548721" LOG_EFFECT_SIZE="-0.31618133973660206" ORDER="11625" O_E="0.0" SE="0.2923944347871647" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="0.08549450549450552" WEIGHT="6.039385280104351"/>
<DICH_DATA CI_END="13.534833367737306" CI_START="0.9050720956195932" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1314529133819102" LOG_CI_START="-0.043316824681358924" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="11626" O_E="0.0" SE="0.6900655593423541" STUDY_ID="STD-Gallant-1968" TOTAL_1="12" TOTAL_2="12" VAR="0.4761904761904761" WEIGHT="1.6512992776011592"/>
<DICH_DATA CI_END="1.8374964386018324" CI_START="0.7584838753829498" EFFECT_SIZE="1.1805555555555556" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.26422650601632997" LOG_CI_START="-0.12005364745028142" LOG_EFFECT_SIZE="0.07208642928302428" ORDER="11627" O_E="0.0" SE="0.2257280643637258" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.05095315904139434" WEIGHT="7.893961430029789"/>
<DICH_DATA CI_END="1.4839194109057914" CI_START="0.29950713035902227" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.17141031580198565" LOG_CI_START="-0.5235928339133482" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="11628" O_E="0.0" SE="0.40824829046386296" STUDY_ID="STD-Marjerrison-1966" TOTAL_1="8" TOTAL_2="8" VAR="0.16666666666666663" WEIGHT="3.891106514183221"/>
<DICH_DATA CI_END="1.4741237394803681" CI_START="0.26498793116085095" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.16853394018380938" LOG_CI_START="-0.576773905495659" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="11629" O_E="0.0" SE="0.4377975178854566" STUDY_ID="STD-O_x0027_Brien-1974" TOTAL_1="15" TOTAL_2="15" VAR="0.1916666666666667" WEIGHT="3.506908405723081"/>
<DICH_DATA CI_END="1.6915734129893172" CI_START="0.7084816681675834" EFFECT_SIZE="1.0947368421052632" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.22829085058057919" LOG_CI_START="-0.14967138256071397" LOG_EFFECT_SIZE="0.039309734009932616" ORDER="11630" O_E="0.0" SE="0.22201688669042383" STUDY_ID="STD-Simpson-1976" TOTAL_1="19" TOTAL_2="24" VAR="0.0492914979757085" WEIGHT="8.012323787584712"/>
<DICH_DATA CI_END="0.9101115642724511" CI_START="0.12208515469192392" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="-0.04090536726341229" LOG_CI_START="-0.9133371421759128" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11631" O_E="0.0" SE="0.5124707431905382" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="0.26262626262626254" WEIGHT="2.7392266815355417"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="37.72088993568354" CI_END="3.5045552008164704" CI_START="0.8043830019023478" DF="5.0" EFFECT_SIZE="1.6789891699368515" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="48" I2="86.74474539565394" ID="CMP-002.24.02" LOG_CI_END="0.5446329050161487" LOG_CI_START="-0.09453711542240183" LOG_EFFECT_SIZE="0.22504789479687343" NO="2" P_CHI2="4.2930752264247474E-7" P_Z="0.16753033534957726" STUDIES="6" TAU2="0.6222718411333591" TOTAL_1="144" TOTAL_2="133" WEIGHT="30.472927434817862" Z="1.3801829075017975">
<NAME>vs low potency control group</NAME>
<DICH_DATA CI_END="3.1656512741937846" CI_START="0.7672165632635247" EFFECT_SIZE="1.5584415584415585" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.5004630716018824" LOG_CI_START="-0.11508202985159653" LOG_EFFECT_SIZE="0.19269052087514296" ORDER="11632" O_E="0.0" SE="0.3615742395911671" STUDY_ID="STD-Angus-1969" TOTAL_1="22" TOTAL_2="20" VAR="0.1307359307359307" WEIGHT="4.618278266952184"/>
<DICH_DATA CI_END="2.886458130067041" CI_START="0.9623481972050159" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.46036526215935947" LOG_CI_START="-0.016667762926646703" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="11633" O_E="0.0" SE="0.2802115602870776" STUDY_ID="STD-Bishop-1967" TOTAL_1="27" TOTAL_2="25" VAR="0.07851851851851852" WEIGHT="6.340214501592552"/>
<DICH_DATA CI_END="5.742492463333628" CI_START="0.8428395911538189" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7591004338827771" LOG_CI_START="-0.07425507223836458" LOG_EFFECT_SIZE="0.3424226808222063" ORDER="11634" O_E="0.0" SE="0.48951714947184394" STUDY_ID="STD-Coons-1962" TOTAL_1="39" TOTAL_2="39" VAR="0.2396270396270396" WEIGHT="2.948420180470188"/>
<DICH_DATA CI_END="1.0681050830389196" CI_START="0.7607804209617868" EFFECT_SIZE="0.9014396456256921" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" LOG_CI_END="0.028613981848835762" LOG_CI_START="-0.11874067269744486" LOG_EFFECT_SIZE="-0.04506334542430457" ORDER="11635" O_E="0.0" SE="0.08655685349778912" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.007492088887437728" WEIGHT="12.864547572100294"/>
<DICH_DATA CI_END="153.71117891430487" CI_START="0.6582470547067777" EFFECT_SIZE="10.058823529411764" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.1867054534740453" LOG_CI_START="-0.18161107544628577" LOG_EFFECT_SIZE="1.00254718901388" ORDER="11636" O_E="0.0" SE="1.3911608524436925" STUDY_ID="STD-Marjerrison-1964" TOTAL_1="16" TOTAL_2="8" VAR="1.935328517371861" WEIGHT="0.4446671464455138"/>
<DICH_DATA CI_END="4.429682755520869" CI_START="0.7314293548362745" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6463726240875729" LOG_CI_START="-0.13582761388096082" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="11637" O_E="0.0" SE="0.45946829173634074" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="0.21111111111111114" WEIGHT="3.2567997672571285"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.973131914650198" CI_END="1.3377034427128578" CI_START="0.7854014829672498" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.025004520808115" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="95" I2="46.5709642738635" I2_Q="0.0" ID="CMP-002.25" LOG_CI_END="0.12635984477075204" LOG_CI_START="-0.10490828304537471" LOG_EFFECT_SIZE="0.010725780862688614" METHOD="MH" NO="25" P_CHI2="0.0596700314474049" P_Q="0.0" P_Z="0.8557405575600318" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07226149400526996" TOTALS="YES" TOTAL_1="175" TOTAL_2="180" WEIGHT="100.0" Z="0.18179888768462446">
<NAME>Adverse events: 5d-iv. Extrapyramidal - subgroup analysis - specific drugs - any effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.236394999165508" CI_END="1.4584435649216552" CI_START="0.9090050803524005" DF="4.0" EFFECT_SIZE="1.1514046247610137" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="60" I2="5.580098154493945" ID="CMP-002.25.01" LOG_CI_END="0.16388962857787054" LOG_CI_START="-0.04143368953617553" LOG_EFFECT_SIZE="0.06122796952084754" NO="1" P_CHI2="0.3749576350250994" P_Z="0.24243059201610306" STUDIES="5" TAU2="0.004267954439877645" TOTAL_1="108" TOTAL_2="117" WEIGHT="61.85711875099108" Z="1.168933136378803">
<NAME>vs loxapine</NAME>
<DICH_DATA CI_END="2.4472071470738177" CI_START="0.5561895782866699" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.38867073233645727" LOG_CI_START="-0.2547771530752308" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="11638" O_E="0.0" SE="0.3779644730092273" STUDY_ID="STD-Bishop-1970" TOTAL_1="12" TOTAL_2="12" VAR="0.1428571428571429" WEIGHT="8.578843319409916"/>
<DICH_DATA CI_END="2.4807275736590495" CI_START="0.6044094789887149" EFFECT_SIZE="1.2244897959183674" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.3945790739244573" LOG_CI_START="-0.21866873321419733" LOG_EFFECT_SIZE="0.08795517035512998" ORDER="11639" O_E="0.0" SE="0.360224797538849" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.12976190476190474" WEIGHT="9.134927399447033"/>
<DICH_DATA CI_END="1.3051281027257766" CI_START="0.6198992246855172" EFFECT_SIZE="0.8994708994708994" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="21" LOG_CI_END="0.11565314123482448" LOG_CI_START="-0.20767890682476492" LOG_EFFECT_SIZE="-0.046012882794970233" ORDER="11640" O_E="0.0" SE="0.18992684554965356" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.036072206660441954" WEIGHT="17.035041444972787"/>
<DICH_DATA CI_END="2.997540601817565" CI_START="1.021670898516953" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" LOG_CI_END="0.4767650743483349" LOG_CI_START="0.009311023024253864" LOG_EFFECT_SIZE="0.24303804868629442" ORDER="11641" O_E="0.0" SE="0.274584823682638" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.07539682539682538" WEIGHT="12.498239775452099"/>
<DICH_DATA CI_END="1.8500016003275888" CI_START="0.7436589527575561" EFFECT_SIZE="1.1729323308270676" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.2671721040857924" LOG_CI_START="-0.12862618931104086" LOG_EFFECT_SIZE="0.06927295738737577" ORDER="11642" O_E="0.0" SE="0.23249387677445027" STUDY_ID="STD-Simpson-1976" TOTAL_1="19" TOTAL_2="24" VAR="0.05405340273761327" WEIGHT="14.610066811709242"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.099168623752605" CI_END="1.4274436023195325" CI_START="0.4931699597188389" DF="3.0" EFFECT_SIZE="0.8390305738510595" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="35" I2="57.74153060736559" ID="CMP-002.25.02" LOG_CI_END="0.15455895846935977" LOG_CI_START="-0.3070033852913873" LOG_EFFECT_SIZE="-0.07622221341101376" NO="2" P_CHI2="0.06880331023625585" P_Z="0.5174149808106872" STUDIES="4" TAU2="0.1556889188383341" TOTAL_1="67" TOTAL_2="63" WEIGHT="38.14288124900892" Z="0.6473352738885967">
<NAME>vs other high potency antipsichotics</NAME>
<DICH_DATA CI_END="46.0587303773455" CI_START="0.9948707841421282" EFFECT_SIZE="6.769230769230769" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.6633119623361476" LOG_CI_START="-0.0022333226494841603" LOG_EFFECT_SIZE="0.8305393198433318" ORDER="11643" O_E="0.0" SE="0.9783495449826878" STUDY_ID="STD-_x002a_Bankier-1973" TOTAL_1="13" TOTAL_2="11" VAR="0.9571678321678322" WEIGHT="1.7927108095785453"/>
<DICH_DATA CI_END="1.2093969629453483" CI_START="0.44466605610459053" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.0825688736648852" LOG_CI_START="-0.3519660214597977" LOG_EFFECT_SIZE="-0.13469857389745624" ORDER="11644" O_E="0.0" SE="0.2552479483786602" STUDY_ID="STD-Bishop-1964" TOTAL_1="7" TOTAL_2="7" VAR="0.06515151515151518" WEIGHT="13.4300900042298"/>
<DICH_DATA CI_END="1.5835717949838224" CI_START="0.5169289494176377" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.1996377579248416" LOG_CI_START="-0.2865691454870222" LOG_EFFECT_SIZE="-0.0434656937810903" ORDER="11645" O_E="0.0" SE="0.2856003418271165" STUDY_ID="STD-Bishop-1966" TOTAL_1="21" TOTAL_2="19" VAR="0.08156755525176579" WEIGHT="11.996882836115372"/>
<DICH_DATA CI_END="1.034668171367047" CI_START="0.3058045649379075" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.014801089454049815" LOG_CI_START="-0.5145560358872495" LOG_EFFECT_SIZE="-0.24987747321659987" ORDER="11646" O_E="0.0" SE="0.3109469957855103" STUDY_ID="STD-Gallant-1968-II" TOTAL_1="26" TOTAL_2="26" VAR="0.09668803418803418" WEIGHT="10.923197599085206"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.30456145396778" CI_END="1.3888158282628402" CI_START="0.6306636612936591" CI_STUDY="95" CI_TOTAL="95" DF="15.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9358822976821543" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-002.26" LOG_CI_END="0.14264465749258187" LOG_CI_START="-0.20020219224166305" LOG_EFFECT_SIZE="-0.028778767374540628" METHOD="MH" NO="26" P_CHI2="0.8001574849710129" P_Q="0.0" P_Z="0.7421246441071079" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="363" TOTAL_2="374" WEIGHT="400.0" Z="0.32904107252132053">
<NAME>Adverse events: 6. Gastrointestinal</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.195387695517736E-32" CI_END="4.821991393037175" CI_START="0.5760644412988406" DF="1.0" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-002.26.01" LOG_CI_END="0.6832264308527586" LOG_CI_START="-0.2395289316200458" LOG_EFFECT_SIZE="0.22184874961635637" NO="1" P_CHI2="0.9999999999999999" P_Z="0.3459732206570759" STUDIES="2" TAU2="0.0" TOTAL_1="63" TOTAL_2="66" WEIGHT="100.0" Z="0.9424286803342584">
<NAME>any - unspecified</NAME>
<DICH_DATA CI_END="9.233240658249684" CI_START="0.300845378192964" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9653541553036931" LOG_CI_START="-0.5216566560709803" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="11647" O_E="0.0" SE="0.8734775114237132" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.762962962962963" WEIGHT="38.507462686567166"/>
<DICH_DATA CI_END="6.459691520658577" CI_START="0.4300170942984254" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8102117789742533" LOG_CI_START="-0.3665142797415406" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="11648" O_E="0.0" SE="0.6912147117775906" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.47777777777777775" WEIGHT="61.49253731343284"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0086608078120443" CI_START="0.2212640594748102" DF="0.0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-002.26.02" LOG_CI_END="0.3029066058709399" LOG_CI_START="-0.6550891239823023" LOG_EFFECT_SIZE="-0.17609125905568127" NO="2" P_CHI2="1.0" P_Z="0.47119849141664627" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.7205304052750207">
<NAME>abdominal discomfort</NAME>
<DICH_DATA CI_END="2.0086608078120443" CI_START="0.2212640594748102" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3029066058709399" LOG_CI_START="-0.6550891239823023" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="11649" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.28045376231354424" CI_END="18.599530768074906" CI_START="0.4656867486726142" DF="1.0" EFFECT_SIZE="2.9430519890448856" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-002.26.03" LOG_CI_END="1.2695019879057476" LOG_CI_START="-0.3319061199376595" LOG_EFFECT_SIZE="0.4687979339840441" NO="3" P_CHI2="0.5964040216562798" P_Z="0.251165166191162" STUDIES="2" TAU2="0.0" TOTAL_1="54" TOTAL_2="57" WEIGHT="100.0" Z="1.1475239348861337">
<NAME>diarrhoea</NAME>
<DICH_DATA CI_END="110.41845329723654" CI_START="0.2775272768091579" EFFECT_SIZE="5.535714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0430416594027436" LOG_CI_START="-0.5566943257465988" LOG_EFFECT_SIZE="0.7431736668280723" ORDER="11650" O_E="0.0" SE="1.5270977865773971" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="2.3320276497695853" WEIGHT="37.94421344500031"/>
<DICH_DATA CI_END="20.771505597011338" CI_START="0.1925715004778244" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.317467976976883" LOG_CI_START="-0.7154079856489205" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11651" O_E="0.0" SE="1.1941214033447043" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.425925925925926" WEIGHT="62.055786554999685"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.67757461791499" CI_END="1.3239578712183835" CI_START="0.5111492544560883" DF="10.0" EFFECT_SIZE="0.822642132889233" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="29" I2="0.0" ID="CMP-002.26.04" LOG_CI_END="0.12187416592809246" LOG_CI_START="-0.29145226831528276" LOG_EFFECT_SIZE="-0.08478905119359513" NO="4" P_CHI2="0.7554928918912243" P_Z="0.42132360145172365" STUDIES="11" TAU2="0.0" TOTAL_1="226" TOTAL_2="231" WEIGHT="100.0" Z="0.804127066912527">
<NAME>nausea or vomiting</NAME>
<DICH_DATA CI_END="2.0086608078120443" CI_START="0.2212640594748102" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3029066058709399" LOG_CI_START="-0.6550891239823023" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="11652" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="18.61483608341567"/>
<DICH_DATA CI_END="75.8304681762221" CI_START="0.13764744005310217" EFFECT_SIZE="3.230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8798437373227375" LOG_CI_START="-0.8612318611406102" LOG_EFFECT_SIZE="0.5093059380910637" ORDER="11653" O_E="0.0" SE="1.6101213750804138" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="2.5924908424908426" WEIGHT="2.2737585014641963"/>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" ORDER="11654" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="12.631495913746349"/>
<DICH_DATA CI_END="10.121678114809917" CI_START="0.37743226869609275" EFFECT_SIZE="1.9545454545454546" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.005252521948796" LOG_CI_START="-0.4231609724340354" LOG_EFFECT_SIZE="0.29104577475738025" ORDER="11655" O_E="0.0" SE="0.839057157361308" STUDY_ID="STD-Claghorn-1974" TOTAL_1="44" TOTAL_2="43" VAR="0.7040169133192389" WEIGHT="8.37294954362646"/>
<DICH_DATA CI_END="8.237478993496916" CI_START="0.31355566008779934" EFFECT_SIZE="1.6071428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9157943201034313" LOG_CI_START="-0.5036853552371823" LOG_EFFECT_SIZE="0.20605448243312446" ORDER="11656" O_E="0.0" SE="0.8338093878327919" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.6952380952380952" WEIGHT="8.478675339363987"/>
<DICH_DATA CI_END="72.6889396455693" CI_START="0.1397758214597825" EFFECT_SIZE="3.1875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8614683336055944" LOG_CI_START="-0.8545679467215712" LOG_EFFECT_SIZE="0.5034501934420116" ORDER="11657" O_E="0.0" SE="1.5954131556605964" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="2.545343137254902" WEIGHT="2.3158756109555174"/>
<DICH_DATA CI_END="1.1446122623134711" CI_START="0.18610472602201733" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.05865839422530557" LOG_CI_START="-0.7302425980716918" LOG_EFFECT_SIZE="-0.3357921019231931" ORDER="11658" O_E="0.0" SE="0.46340434799814917" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="0.21474358974358976" WEIGHT="27.449937388678634"/>
<DICH_DATA CI_END="5.7874155850175315" CI_START="0.053329844863336695" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.762484669472499" LOG_CI_START="-1.2730296796791112" LOG_EFFECT_SIZE="-0.255272505103306" ORDER="11659" O_E="0.0" SE="1.1956712046501872" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="1.4296296296296296" WEIGHT="4.123234417440519"/>
<DICH_DATA CI_END="5.1928763992528335" CI_START="0.048142875119456086" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7154079856489205" LOG_CI_START="-1.317467976976883" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11660" O_E="0.0" SE="1.1941214033447043" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.425925925925926" WEIGHT="4.133944117226077"/>
<DICH_DATA CI_END="3.919915520931636" CI_START="0.0102043015433387" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5932767075335775" LOG_CI_START="-1.991216716205615" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="11661" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Menon-1972" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="2.5576169412131033"/>
<DICH_DATA CI_END="7.29711607747592" CI_START="0.3083409906202667" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8631512547638782" LOG_CI_START="-0.5109687366525157" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="11662" O_E="0.0" SE="0.8071648849616486" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="0.6515151515151514" WEIGHT="9.047676142869479"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.363770391679163" CI_END="1.2648106732785256" CI_START="0.5167509875973343" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8084504712969913" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="44" I2="2.532555044808377" I2_Q="0.0" ID="CMP-002.27" LOG_CI_END="0.1020255217932303" LOG_CI_START="-0.2867186846906833" LOG_EFFECT_SIZE="-0.09234658144872651" METHOD="MH" NO="27" P_CHI2="0.422976598468488" P_Q="0.0" P_Z="0.3517589862294108" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.020271969412629612" TOTALS="SUB" TOTAL_1="287" TOTAL_2="302" WEIGHT="800.0" Z="0.9311828740649715">
<NAME>Adverse events: 7. Haematological</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.714866182840065E-32" CI_END="7.3213638398591465" CI_START="0.5217945750880473" DF="0.0" EFFECT_SIZE="1.9545454545454546" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="100.0" ID="CMP-002.27.01" LOG_CI_END="0.8645919899318026" LOG_CI_START="-0.2825004404170421" LOG_EFFECT_SIZE="0.29104577475738025" NO="1" P_CHI2="0.0" P_Z="0.3199391991976146" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="43" WEIGHT="99.99999999999999" Z="0.994582862347971">
<NAME>any haematological abnormality - unpsecified</NAME>
<DICH_DATA CI_END="7.3213638398591465" CI_START="0.5217945750880473" EFFECT_SIZE="1.9545454545454546" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8645919899318026" LOG_CI_START="-0.2825004404170421" LOG_EFFECT_SIZE="0.29104577475738025" ORDER="11663" O_E="0.0" SE="0.6738077717860184" STUDY_ID="STD-Claghorn-1974" TOTAL_1="44" TOTAL_2="43" VAR="0.45401691331923894" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.2829450939935345" CI_START="0.3863027705608614" DF="0.0" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-002.27.02" LOG_CI_END="0.7228760970584055" LOG_CI_START="-0.4130721770869191" LOG_EFFECT_SIZE="0.15490195998574316" NO="2" P_CHI2="1.0" P_Z="0.5929711907653107" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.0" Z="0.5345353650634284">
<NAME>blood cell count - eosinophilia &gt;5%</NAME>
<DICH_DATA CI_END="5.2829450939935345" CI_START="0.3863027705608614" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7228760970584055" LOG_CI_START="-0.4130721770869191" LOG_EFFECT_SIZE="0.15490195998574316" ORDER="11664" O_E="0.0" SE="0.6672616392676078" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.4452380952380952" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.33685015687347714" CI_END="3.145228665636756" CI_START="0.4340442339904526" DF="1.0" EFFECT_SIZE="1.168404196714955" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-002.27.03" LOG_CI_END="0.4976522251753049" LOG_CI_START="-0.3624660087385357" LOG_EFFECT_SIZE="0.06759310821838463" NO="3" P_CHI2="0.5616532059799149" P_Z="0.7580436734571232" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="39" WEIGHT="100.0" Z="0.3080508062439772">
<NAME>blood cell count - leukocytosis</NAME>
<DICH_DATA CI_END="4.001805450607376" CI_START="0.4482192466946533" EFFECT_SIZE="1.3392857142857142" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.602255971411277" LOG_CI_START="-0.3485094986402777" LOG_EFFECT_SIZE="0.1268732363854996" ORDER="11665" O_E="0.0" SE="0.5584843434732633" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.3119047619047619" WEIGHT="81.10646729062346"/>
<DICH_DATA CI_END="6.451069500237951" CI_START="0.06183346292336322" EFFECT_SIZE="0.631578947368421" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.8096317207666651" LOG_CI_START="-1.2087764305770736" LOG_EFFECT_SIZE="-0.19957235490520417" ORDER="11666" O_E="0.0" SE="1.1856229393807987" STUDY_ID="STD-Simpson-1976" TOTAL_1="19" TOTAL_2="24" VAR="1.405701754385965" WEIGHT="18.89353270937655"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.39215599918149757" CI_END="1.3870513032134324" CI_START="0.2481854219972015" DF="1.0" EFFECT_SIZE="0.5867247336015365" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" ID="CMP-002.27.04" LOG_CI_END="0.14209252472897452" LOG_CI_START="-0.6052237318304778" LOG_EFFECT_SIZE="-0.2315656035507516" NO="4" P_CHI2="0.5311686665071291" P_Z="0.22450331139248136" STUDIES="2" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="1.214640358841564">
<NAME>liver enzyme elevation - alkaline phosphatase</NAME>
<DICH_DATA CI_END="2.971656615371363" CI_START="0.21729530844048453" EFFECT_SIZE="0.8035714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4729986238418056" LOG_CI_START="-0.662949650303519" LOG_EFFECT_SIZE="-0.09497551323085672" ORDER="11667" O_E="0.0" SE="0.6672616392676078" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.4452380952380952" WEIGHT="43.6104645057525"/>
<DICH_DATA CI_END="1.4466125692141263" CI_START="0.14725280010183517" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.1603522342414112" LOG_CI_START="-0.8319364380877975" LOG_EFFECT_SIZE="-0.3357921019231931" ORDER="11668" O_E="0.0" SE="0.5828752780343234" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="0.33974358974358976" WEIGHT="56.38953549424749"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07110689190865005" CI_END="0.9199165605621161" CI_START="0.0345459826636416" DF="1.0" EFFECT_SIZE="0.1782678365639065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" ID="CMP-002.27.05" LOG_CI_END="-0.03625156279663666" LOG_CI_START="-1.4616024492580624" LOG_EFFECT_SIZE="-0.7489270060273494" NO="5" P_CHI2="0.7897319181980869" P_Z="0.03943094108326772" STUDIES="2" TAU2="0.0" TOTAL_1="32" TOTAL_2="36" WEIGHT="100.0" Z="2.0596612003478656">
<NAME>liver enzyme elevation - bilirubin</NAME>
<DICH_DATA CI_END="1.0990363038643731" CI_START="0.021535811847190146" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.04101203847222755" LOG_CI_START="-1.6668387517579386" LOG_EFFECT_SIZE="-0.8129133566428556" ORDER="11669" O_E="0.0" SE="1.0032000081789556" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="1.0064102564102566" WEIGHT="69.41625753249646"/>
<DICH_DATA CI_END="4.916480820681672" CI_START="0.012712344923036707" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6916543493074901" LOG_CI_START="-1.8957743319634148" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="11670" O_E="0.0" SE="1.5198684153570663" STUDY_ID="STD-Simpson-1976" TOTAL_1="19" TOTAL_2="24" VAR="2.31" WEIGHT="30.583742467503544"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.322999150030092" CI_END="4.067588476265067" CI_START="0.16532482692061995" DF="3.0" EFFECT_SIZE="0.8200447309890055" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="30.603733753241254" ID="CMP-002.27.06" LOG_CI_END="0.6093370082802662" LOG_CI_START="-0.7816619232887866" LOG_EFFECT_SIZE="-0.08616245750426023" NO="6" P_CHI2="0.22863242623256386" P_Z="0.8081513765246996" STUDIES="4" TAU2="0.8232059096929749" TOTAL_1="82" TOTAL_2="87" WEIGHT="100.0" Z="0.24281156468944348">
<NAME>liver enzyme elevation - SGOT</NAME>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" ORDER="11671" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-_x002a_Itil-1971" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="22.684637435501322"/>
<DICH_DATA CI_END="1.0990363038643731" CI_START="0.021535811847190146" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.04101203847222755" LOG_CI_START="-1.6668387517579386" LOG_EFFECT_SIZE="-0.8129133566428556" ORDER="11672" O_E="0.0" SE="1.0032000081789556" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="1.0064102564102566" WEIGHT="43.165087375838226"/>
<DICH_DATA CI_END="72.92191868001707" CI_START="0.13545380043757582" EFFECT_SIZE="3.142857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8628580870424774" LOG_CI_START="-0.8682088054265785" LOG_EFFECT_SIZE="0.49732464080794936" ORDER="11673" O_E="0.0" SE="1.6042422116354729" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="2.5735930735930737" WEIGHT="17.0852481721685"/>
<DICH_DATA CI_END="87.17257722096096" CI_START="0.16131793332615413" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.940379885911057" LOG_CI_START="-0.7923173504556194" LOG_EFFECT_SIZE="0.5740312677277188" ORDER="11674" O_E="0.0" SE="1.6051998837112675" STUDY_ID="STD-Simpson-1976" TOTAL_1="19" TOTAL_2="24" VAR="2.5766666666666667" WEIGHT="17.065027016491957"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.12218699711378583" CI_END="1.6151535177661678" CI_START="0.048013496645181786" DF="1.0" EFFECT_SIZE="0.27847651248663585" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-002.27.07" LOG_CI_END="0.2082138076269301" LOG_CI_START="-1.31863666482004" LOG_EFFECT_SIZE="-0.555211428596555" NO="7" P_CHI2="0.7266745763203553" P_Z="0.15403855338518455" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="1.4254105735846039">
<NAME>liver enzyme elevation - SGPT</NAME>
<DICH_DATA CI_END="3.563061681864509" CI_START="0.009277934032949613" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5518233406955335" LOG_CI_START="-2.0325487196840215" LOG_EFFECT_SIZE="-0.7403626894942439" ORDER="11675" O_E="0.0" SE="1.5180729411149698" STUDY_ID="STD-Bishop-1966" TOTAL_1="21" TOTAL_2="19" VAR="2.3045454545454547" WEIGHT="35.07554079166542"/>
<DICH_DATA CI_END="3.092335077474975" CI_START="0.03961407704239687" EFFECT_SIZE="0.35" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.490286546829048" LOG_CI_START="-1.402150458128497" LOG_EFFECT_SIZE="-0.4559319556497244" ORDER="11676" O_E="0.0" SE="1.111626864426317" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="1.2357142857142855" WEIGHT="64.92445920833458"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.237478993496916" CI_START="0.31355566008779934" DF="0.0" EFFECT_SIZE="1.6071428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-002.27.08" LOG_CI_END="0.9157943201034313" LOG_CI_START="-0.5036853552371823" LOG_EFFECT_SIZE="0.20605448243312446" NO="8" P_CHI2="1.0" P_Z="0.5693395084123012" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.00000000000001" Z="0.5690245114993372">
<NAME>renal function - urea nitrogen elevated</NAME>
<DICH_DATA CI_END="8.237478993496916" CI_START="0.31355566008779934" EFFECT_SIZE="1.6071428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9157943201034313" LOG_CI_START="-0.5036853552371823" LOG_EFFECT_SIZE="0.20605448243312446" ORDER="11677" O_E="0.0" SE="0.8338093878327919" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.6952380952380952" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.25106411167771" CI_END="1.7446368435964164" CI_START="0.9939755726682742" CI_STUDY="95" CI_TOTAL="95" DF="20.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3168623336218248" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-002.28" LOG_CI_END="0.24170503975603155" LOG_CI_START="-0.002624288425353654" LOG_EFFECT_SIZE="0.11954037566533894" METHOD="MH" NO="28" P_CHI2="0.9394499526194486" P_Q="0.0" P_Z="0.055128652903128704" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="473" TOTAL_2="483" WEIGHT="600.0" Z="1.917860886749681">
<NAME>Adverse events: 8. Neurological</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.360417040788461" CI_END="2.9501687936866032" CI_START="0.45970676749012823" DF="2.0" EFFECT_SIZE="1.1645653951993935" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" ID="CMP-002.28.01" LOG_CI_END="0.4698468648152913" LOG_CI_START="-0.3375191028148735" LOG_EFFECT_SIZE="0.06616388100020892" NO="1" P_CHI2="0.5065114100691261" P_Z="0.7480290812267669" STUDIES="3" TAU2="0.0" TOTAL_1="72" TOTAL_2="78" WEIGHT="100.00000000000001" Z="0.32123926208692083">
<NAME>confusional state</NAME>
<DICH_DATA CI_END="16.360363082235548" CI_START="0.07129426126651824" EFFECT_SIZE="1.08" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2137929376520298" LOG_CI_START="-1.1469454266781303" LOG_EFFECT_SIZE="0.03342375548694973" ORDER="11678" O_E="0.0" SE="1.3867094010509062" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="1.922962962962963" WEIGHT="11.696210135088632"/>
<DICH_DATA CI_END="4.765141425976121" CI_START="0.5205774138155518" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6780757947140219" LOG_CI_START="-0.2835146784627834" LOG_EFFECT_SIZE="0.1972805581256193" ORDER="11679" O_E="0.0" SE="0.5648430038936652" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.319047619047619" WEIGHT="70.49536669148611"/>
<DICH_DATA CI_END="3.3514316123888594" CI_START="0.04093003441908493" EFFECT_SIZE="0.37037037037037035" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5252303618275603" LOG_CI_START="-1.387957890145535" LOG_EFFECT_SIZE="-0.43136376415898736" ORDER="11680" O_E="0.0" SE="1.1238162496435806" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="1.2629629629629628" WEIGHT="17.808423173425272"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="99.34278665287792" CI_START="0.2516539030393281" DF="0.0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.28.02" LOG_CI_END="1.9971363381737377" LOG_CI_START="-0.5991963295017" LOG_EFFECT_SIZE="0.6989700043360189" NO="2" P_CHI2="1.0" P_Z="0.2912877682685008" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="1.0553008494084533">
<NAME>convulsions</NAME>
<DICH_DATA CI_END="99.34278665287792" CI_START="0.2516539030393281" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9971363381737377" LOG_CI_START="-0.5991963295017" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="11681" O_E="0.0" SE="1.5250986610465322" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="2.3259259259259255" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3820020580469547" CI_END="4.613177654383725" CI_START="0.7112950124161106" DF="2.0" EFFECT_SIZE="1.8114442461617737" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="0.0" ID="CMP-002.28.03" LOG_CI_END="0.6640001796966918" LOG_CI_START="-0.14795023655416042" LOG_EFFECT_SIZE="0.2580249715712657" NO="3" P_CHI2="0.826131795308698" P_Z="0.21287789359254472" STUDIES="3" TAU2="0.0" TOTAL_1="62" TOTAL_2="63" WEIGHT="100.00000000000001" Z="1.2456909714432858">
<NAME>dizziness or giddiness</NAME>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.4668351214936106" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="11682" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="47.06385247948401"/>
<DICH_DATA CI_END="21.167401554021893" CI_START="0.21500565855927561" EFFECT_SIZE="2.1333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3256675486187492" LOG_CI_START="-0.6675501100902997" LOG_EFFECT_SIZE="0.32905871926422475" ORDER="11683" O_E="0.0" SE="1.1708259193122321" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="1.3708333333333333" WEIGHT="16.59394190766001"/>
<DICH_DATA CI_END="11.786156401414512" CI_START="0.5302831378726578" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0713721998526826" LOG_CI_START="-0.27549218250860746" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="11684" O_E="0.0" SE="0.79115480528524" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.625925925925926" WEIGHT="36.342205612855984"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.61413494273426" CI_END="1.7657108024534531" CI_START="0.9144432254887249" DF="11.0" EFFECT_SIZE="1.2706857524485826" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="38" I2="0.0" ID="CMP-002.28.04" LOG_CI_END="0.2469195739960519" LOG_CI_START="-0.03884325314259083" LOG_EFFECT_SIZE="0.10403816042673056" NO="4" P_CHI2="0.8294159075693988" P_Z="0.15354102346304965" STUDIES="12" TAU2="0.0" TOTAL_1="267" TOTAL_2="270" WEIGHT="100.0" Z="1.4271348691218066">
<NAME>faintness or weakness</NAME>
<DICH_DATA CI_END="3.4275937504674845" CI_START="0.6564371870771225" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5349893423102396" LOG_CI_START="-0.1828068241988772" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="11685" O_E="0.0" SE="0.42163702135578396" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.1777777777777778" WEIGHT="15.849267613340182"/>
<DICH_DATA CI_END="53.24621860927151" CI_START="0.11314969486641972" EFFECT_SIZE="2.4545454545454546" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.726288770881867" LOG_CI_START="-0.9463466128803427" LOG_EFFECT_SIZE="0.3899710790007623" ORDER="11686" O_E="0.0" SE="1.5699192541804385" STUDY_ID="STD-_x002a_Goldstein-1966" TOTAL_1="10" TOTAL_2="8" VAR="2.4646464646464645" WEIGHT="1.143225860634374"/>
<DICH_DATA CI_END="8.42560757513579" CI_START="0.01529416000590024" EFFECT_SIZE="0.358974358974359" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9256012278834127" LOG_CI_START="-1.8154743705799352" LOG_EFFECT_SIZE="-0.44493657134826115" ORDER="11687" O_E="0.0" SE="1.6101213750804138" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="2.5924908424908426" WEIGHT="1.0868495770645616"/>
<DICH_DATA CI_END="9.996095394793457" CI_START="0.6252441331497659" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.9998303920357164" LOG_CI_START="-0.2039503746916411" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="11688" O_E="0.0" SE="0.7071067811865476" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.5" WEIGHT="5.635295151409843"/>
<DICH_DATA CI_END="32.393026779206984" CI_START="0.49393346626905393" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5104515300445103" LOG_CI_START="-0.30633154738858576" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="11689" O_E="0.0" SE="1.0671873729054748" STUDY_ID="STD-Brauzer-1968" TOTAL_1="18" TOTAL_2="18" VAR="1.1388888888888888" WEIGHT="2.474032017692126"/>
<DICH_DATA CI_END="8.344525565020769" CI_START="0.2575208675515117" EFFECT_SIZE="1.4659090909090908" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9214016495412323" LOG_CI_START="-0.5891875732430718" LOG_EFFECT_SIZE="0.16610703814908032" ORDER="11690" O_E="0.0" SE="0.8873275870007492" STUDY_ID="STD-Claghorn-1974" TOTAL_1="44" TOTAL_2="43" VAR="0.7873502466525721" WEIGHT="3.5786457014323423"/>
<DICH_DATA CI_END="1.6711998348839257" CI_START="0.6597056659454343" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.2230283840635617" LOG_CI_START="-0.18064978592368552" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="11691" O_E="0.0" SE="0.23712255528967766" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.056227106227106236" WEIGHT="50.11190802393769"/>
<DICH_DATA CI_END="20.722972310630787" CI_START="0.19302250372394794" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3164520467067224" LOG_CI_START="-0.7143920553787599" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11692" O_E="0.0" SE="1.1929278784054478" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="1.423076923076923" WEIGHT="1.9799685667115665"/>
<DICH_DATA CI_END="2.184241046140982" CI_START="0.006928221150588447" EFFECT_SIZE="0.12301587301587301" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.33930056408413817" LOG_CI_START="-2.1593782579786813" LOG_EFFECT_SIZE="-0.9100388469472714" ORDER="11693" O_E="0.0" SE="1.4677363087393485" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="2.1542498719918077" WEIGHT="1.3079483547095396"/>
<DICH_DATA CI_END="20.332240770599807" CI_START="0.19673188238966538" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3081852438953019" LOG_CI_START="-0.7061252525673394" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11694" O_E="0.0" SE="1.1832159566199232" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="1.4" WEIGHT="2.0126054112178013"/>
<DICH_DATA CI_END="4.870793607133235" CI_START="0.46193704383304074" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6875997273582211" LOG_CI_START="-0.33541720924685864" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="11695" O_E="0.0" SE="0.6009252125773314" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.36111111111111105" WEIGHT="7.8027163634905525"/>
<DICH_DATA CI_END="4.616411291471565" CI_START="0.38509952115013524" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.664304494614599" LOG_CI_START="-0.41442702139799914" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="11696" O_E="0.0" SE="0.6336522323129237" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="0.4015151515151514" WEIGHT="7.017537358359429"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.925649438310225" CI_START="0.3418044509726267" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-002.28.05" LOG_CI_END="0.4662222862019852" LOG_CI_START="-0.46622228620198514" LOG_EFFECT_SIZE="0.0" NO="5" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.0">
<NAME>parasthesia</NAME>
<DICH_DATA CI_END="2.925649438310225" CI_START="0.3418044509726267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4662222862019852" LOG_CI_START="-0.46622228620198514" LOG_EFFECT_SIZE="0.0" ORDER="11697" O_E="0.0" SE="0.5477225575051662" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.30000000000000004" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="129.11288787863575" CI_START="0.37951284960847026" DF="0.0" EFFECT_SIZE="6.999999999999998" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-002.28.06" LOG_CI_END="2.1109695951340917" LOG_CI_START="-0.42077351510557803" LOG_EFFECT_SIZE="0.8450980400142567" NO="6" P_CHI2="1.0" P_Z="0.1907121311885963" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="1.3084753465974925">
<NAME>urinary incontinence</NAME>
<DICH_DATA CI_END="129.11288787863575" CI_START="0.3795128496084703" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1109695951340917" LOG_CI_START="-0.420773515105578" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="11698" O_E="0.0" SE="1.4871584352852965" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="2.211640211640211" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="33.598587628964715" CI_END="1.1714571499237323" CI_START="0.8237862414105345" CI_STUDY="95" CI_TOTAL="95" DF="29.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9823595484898431" ESTIMABLE="YES" EVENTS_1="184" EVENTS_2="191" I2="13.686848029886704" I2_Q="0.0" ID="CMP-002.29" LOG_CI_END="0.0687264074084214" LOG_CI_START="-0.08418546575345642" LOG_EFFECT_SIZE="-0.007729529172517523" METHOD="MH" NO="29" P_CHI2="0.25425753913381777" P_Q="0.0" P_Z="0.8429291902517274" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.030283816407869115" TOTALS="SUB" TOTAL_1="642" TOTAL_2="643" WEIGHT="200.0" Z="0.19814810298671962">
<NAME>Adverse events: 9. Somnolescence</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="21.07396262247155" CI_END="1.0997061921155757" CI_START="0.7153925230886736" DF="19.0" EFFECT_SIZE="0.8869732732353323" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="135" I2="9.841350958172658" ID="CMP-002.29.01" LOG_CI_END="0.04127667044302238" LOG_CI_START="-0.14545560318383366" LOG_EFFECT_SIZE="-0.05208946637040565" NO="1" P_CHI2="0.33272864445536543" P_Z="0.2741855911959489" STUDIES="20" TAU2="0.022815502698268667" TOTAL_1="409" TOTAL_2="407" WEIGHT="99.99999999999999" Z="1.0934743745895488">
<NAME>drowsiness</NAME>
<DICH_DATA CI_END="3.9855442667258254" CI_START="0.39204181297015506" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6004876371237167" LOG_CI_START="-0.40666761110760397" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="11699" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.35000000000000003" WEIGHT="3.334923957818203"/>
<DICH_DATA CI_END="14.630590273864367" CI_START="0.17497585210715014" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1652618481697905" LOG_CI_START="-0.7570218828579409" LOG_EFFECT_SIZE="0.2041199826559248" ORDER="11700" O_E="0.0" SE="1.1291589790636214" STUDY_ID="STD-_x002a_Goldstein-1966" TOTAL_1="10" TOTAL_2="8" VAR="1.275" WEIGHT="0.9716029526814074"/>
<DICH_DATA CI_END="11.444652444730176" CI_START="0.7863934744601314" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0586026084017597" LOG_CI_START="-0.10436009896243491" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="11701" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="2.5519999543272935"/>
<DICH_DATA CI_END="2.3789416375442554" CI_START="0.007151597267321017" EFFECT_SIZE="0.13043478260869565" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.37638378764323943" LOG_CI_START="-2.1455969502391006" LOG_EFFECT_SIZE="-0.8846065812979305" ORDER="11702" O_E="0.0" SE="1.4814239694380784" STUDY_ID="STD-Angus-1969" TOTAL_1="22" TOTAL_2="20" VAR="2.1946169772256727" WEIGHT="0.5700108578944697"/>
<DICH_DATA CI_END="1.2855505834401182" CI_START="0.19446920503976045" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.10908916979779516" LOG_CI_START="-0.7111491611257575" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11703" O_E="0.0" SE="0.4818120558297158" STUDY_ID="STD-Bishop-1964" TOTAL_1="14" TOTAL_2="14" VAR="0.23214285714285718" WEIGHT="4.832655129715688"/>
<DICH_DATA CI_END="89.07654204661276" CI_START="0.23194835082374035" EFFECT_SIZE="4.545454545454546" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9497633493675712" LOG_CI_START="-0.6346087110119837" LOG_EFFECT_SIZE="0.6575773191777938" ORDER="11704" O_E="0.0" SE="1.5180729411149698" STUDY_ID="STD-Bishop-1966" TOTAL_1="21" TOTAL_2="19" VAR="2.3045454545454547" WEIGHT="0.5431735955543"/>
<DICH_DATA CI_END="2.909786936500758" CI_START="0.7013628045855654" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.46386118977983093" LOG_CI_START="-0.15405726980834458" LOG_EFFECT_SIZE="0.15490195998574316" ORDER="11705" O_E="0.0" SE="0.3629683619078001" STUDY_ID="STD-Brauzer-1968" TOTAL_1="18" TOTAL_2="18" VAR="0.13174603174603175" WEIGHT="7.827061646719253"/>
<DICH_DATA CI_END="8.344525565020769" CI_START="0.2575208675515117" EFFECT_SIZE="1.4659090909090908" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9214016495412323" LOG_CI_START="-0.5891875732430718" LOG_EFFECT_SIZE="0.16610703814908032" ORDER="11706" O_E="0.0" SE="0.8873275870007492" STUDY_ID="STD-Claghorn-1974" TOTAL_1="44" TOTAL_2="43" VAR="0.7873502466525721" WEIGHT="1.5510821618196116"/>
<DICH_DATA CI_END="2.0675087449511245" CI_START="0.40792987501646727" EFFECT_SIZE="0.9183673469387755" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.31544735516581085" LOG_CI_START="-0.38941448767215076" LOG_EFFECT_SIZE="-0.03698356625316997" ORDER="11707" O_E="0.0" SE="0.4140393356054125" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.17142857142857143" WEIGHT="6.287256939011015"/>
<DICH_DATA CI_END="1.2314598688767093" CI_START="0.12992709226159832" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.0904202635081464" LOG_CI_START="-0.8863002808522217" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="11708" O_E="0.0" SE="0.5737304826019501" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="0.32916666666666666" WEIGHT="3.528212284656087"/>
<DICH_DATA CI_END="1.204898190832519" CI_START="0.3142989405523227" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.0809503522821774" LOG_CI_START="-0.5026570829119636" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="11709" O_E="0.0" SE="0.34281389633643433" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="0.11752136752136753" WEIGHT="8.580332410508111"/>
<DICH_DATA CI_END="1.618349356938976" CI_START="0.45604318184956294" EFFECT_SIZE="0.8590909090909091" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.20907227958351238" LOG_CI_START="-0.34099403288143654" LOG_EFFECT_SIZE="-0.06596087664896207" ORDER="11710" O_E="0.0" SE="0.32311167481407166" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.10440115440115438" WEIGHT="9.416177636533853"/>
<DICH_DATA CI_END="1.9625753808153983" CI_START="0.2599666166303771" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.2928263466114058" LOG_CI_START="-0.5850824179678817" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="11711" O_E="0.0" SE="0.515687954032345" STUDY_ID="STD-Gallant-1968-II" TOTAL_1="26" TOTAL_2="26" VAR="0.265934065934066" WEIGHT="4.2813674855901915"/>
<DICH_DATA CI_END="2.1233087251536524" CI_START="0.7358797999979632" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.32701314436989143" LOG_CI_START="-0.13319311835377862" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="11712" O_E="0.0" SE="0.2703274367816243" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.07307692307692307" WEIGHT="12.269819434638807"/>
<DICH_DATA CI_END="1.4164826601408973" CI_START="0.6180683175662813" EFFECT_SIZE="0.935672514619883" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.15121126247719868" LOG_CI_START="-0.20896351794965687" LOG_EFFECT_SIZE="-0.02887612773622908" ORDER="11713" O_E="0.0" SE="0.21156844891665216" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.04476120857699805" WEIGHT="16.899422851346618"/>
<DICH_DATA CI_END="1.3927022324763505" CI_START="0.29077190245175183" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.14385827176067112" LOG_CI_START="-0.5364475620486076" LOG_EFFECT_SIZE="-0.19629464514396822" ORDER="11714" O_E="0.0" SE="0.3996150143477591" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.1596921596921597" WEIGHT="6.675673609600944"/>
<DICH_DATA CI_END="0.8299897544674726" CI_START="0.0033374907191118007" EFFECT_SIZE="0.05263157894736842" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.08092726859465364" LOG_CI_START="-2.4765799333110046" LOG_EFFECT_SIZE="-1.278753600952829" ORDER="11715" O_E="0.0" SE="1.407218233926329" STUDY_ID="STD-Perales-1974" TOTAL_1="15" TOTAL_2="15" VAR="1.9802631578947367" WEIGHT="0.6307823822664207"/>
<DICH_DATA CI_END="3.454197176819389" CI_START="0.2895028710899463" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5383471248818377" LOG_CI_START="-0.5383471248818377" LOG_EFFECT_SIZE="0.0" ORDER="11716" O_E="0.0" SE="0.6324555320336759" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="0.4" WEIGHT="2.9473978842536552"/>
<DICH_DATA CI_END="2.1587847808217293" CI_START="0.3546555482518128" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.334209347679057" LOG_CI_START="-0.4501932416344306" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="11717" O_E="0.0" SE="0.4607619638181816" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.21230158730158727" WEIGHT="5.227922169744727"/>
<DICH_DATA CI_END="2.7308121996385246" CI_START="0.04068793567196556" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4362918343524308" LOG_CI_START="-1.390534343791756" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11718" O_E="0.0" SE="1.0730867399773196" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="1.1515151515151516" WEIGHT="1.0731246553193388"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.08226318331514" CI_END="1.733543132074023" CI_START="0.8698063115597546" DF="9.0" EFFECT_SIZE="1.2279441182883897" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="56" I2="31.20456396658934" ID="CMP-002.29.02" LOG_CI_END="0.2389346517545757" LOG_CI_START="-0.060577445296081084" LOG_EFFECT_SIZE="0.08917860322924734" NO="2" P_CHI2="0.1589191958281272" P_Z="0.24315230367613794" STUDIES="12" TAU2="0.08679275434950375" TOTAL_1="233" TOTAL_2="236" WEIGHT="100.0" Z="1.1671438465562223">
<NAME>insomnia</NAME>
<DICH_DATA CI_END="2.102230118933325" CI_START="0.3494830898549799" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.32268025399138267" LOG_CI_START="-0.45657383325260914" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="11719" O_E="0.0" SE="0.4577377082170635" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.20952380952380956" WEIGHT="9.246551387637355"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11720" O_E="0.0" SE="0.0" STUDY_ID="STD-_x002a_Goldstein-1966" TOTAL_1="10" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.7351153190288175" CI_START="0.6023910395850994" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.5723040148916415" LOG_CI_START="-0.22012149678027912" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="11721" O_E="0.0" SE="0.4654746681256314" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.21666666666666665" WEIGHT="8.979101837412964"/>
<DICH_DATA CI_END="6.998146220293177" CI_START="1.3685266115874877" EFFECT_SIZE="3.0946969696969697" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" LOG_CI_END="0.844983012454268" LOG_CI_START="0.13625324687090082" LOG_EFFECT_SIZE="0.49061812966258445" ORDER="11722" O_E="0.0" SE="0.41631137257259015" STUDY_ID="STD-Claghorn-1974" TOTAL_1="44" TOTAL_2="43" VAR="0.17331515893327398" WEIGHT="10.890985736098125"/>
<DICH_DATA CI_END="4.454629444385608" CI_START="0.2577002639625389" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6488115833556488" LOG_CI_START="-0.5888851366007624" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="11723" O_E="0.0" SE="0.7270291799999699" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.5285714285714286" WEIGHT="3.967742194862508"/>
<DICH_DATA CI_END="27.492357033915862" CI_START="0.3724671546847532" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4392119753087764" LOG_CI_START="-0.42891201866896445" LOG_EFFECT_SIZE="0.505149978319906" ORDER="11724" O_E="0.0" SE="1.0973452814254347" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="1.2041666666666666" WEIGHT="1.7962596043560364"/>
<DICH_DATA CI_END="3.0850202380402436" CI_START="0.3573720478087891" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.48925801739369257" LOG_CI_START="-0.44687941925381647" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="11725" O_E="0.0" SE="0.5498917642417936" STUDY_ID="STD-Freeman-1968" TOTAL_1="20" TOTAL_2="21" VAR="0.3023809523809524" WEIGHT="6.665549659489804"/>
<DICH_DATA CI_END="4.069143309888017" CI_START="0.6826443716120243" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6095029854044213" LOG_CI_START="-0.1658054861717085" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="11726" O_E="0.0" SE="0.45542003404264886" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.20740740740740743" WEIGHT="9.328882660168585"/>
<DICH_DATA CI_END="2.2954067374270584" CI_START="0.5378427627246604" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.3608596520383871" LOG_CI_START="-0.2693446709170368" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="11727" O_E="0.0" SE="0.3701851388657263" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.13703703703703704" WEIGHT="13.252344167935446"/>
<DICH_DATA CI_END="1.217728111067332" CI_START="0.5879607482604614" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.08555033177440872" LOG_CI_START="-0.23065166607163218" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="11728" O_E="0.0" SE="0.1857386187598974" STUDY_ID="STD-Perales-1974" TOTAL_1="15" TOTAL_2="15" VAR="0.03449883449883451" WEIGHT="34.22820007038536"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11729" O_E="0.0" SE="0.0" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.745176453876752" CI_START="0.05268507977100682" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6762523667148672" LOG_CI_START="-1.2783123580428297" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11730" O_E="0.0" SE="1.148120994574099" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="1.3181818181818183" WEIGHT="1.6443826816537999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="32.81882429362823" CI_END="1.2749454912975855" CI_START="0.8237031451683983" CI_STUDY="95" CI_TOTAL="95" DF="37.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0247812503652132" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="112" I2="0.0" I2_Q="0.0" ID="CMP-002.30" LOG_CI_END="0.10549161744862634" LOG_CI_START="-0.08422927573457223" LOG_EFFECT_SIZE="0.01063117085702702" METHOD="MH" NO="30" P_CHI2="0.6654278581673285" P_Q="0.0" P_Z="0.8261386992507945" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="883" TOTAL_2="902" WEIGHT="1600.0" Z="0.21965648214764052">
<NAME>Adverse events: 10. Miscellaneous</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.553222036623472" CI_END="2.195272285887178" CI_START="0.8129719875910943" DF="4.0" EFFECT_SIZE="1.3359247260086715" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="17" I2="0.0" ID="CMP-002.30.01" LOG_CI_END="0.3414883947031588" LOG_CI_START="-0.08992441854394478" LOG_EFFECT_SIZE="0.12578198807960694" NO="1" P_CHI2="0.46983214976934906" P_Z="0.25308530160370046" STUDIES="6" TAU2="0.0" TOTAL_1="114" TOTAL_2="114" WEIGHT="100.0" Z="1.142887549789442">
<NAME>anorexia</NAME>
<DICH_DATA CI_END="3.9855442667258254" CI_START="0.39204181297015506" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6004876371237167" LOG_CI_START="-0.40666761110760397" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="11731" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.35000000000000003" WEIGHT="18.34819044600678"/>
<DICH_DATA CI_END="8.556535477165358" CI_START="0.46747892422987236" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.932297955364332" LOG_CI_START="-0.3302379640363697" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11732" O_E="0.0" SE="0.7416198487095663" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.55" WEIGHT="11.676121192913405"/>
<DICH_DATA CI_END="159.15172261608095" CI_START="0.5089483083723509" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2018113436708746" LOG_CI_START="-0.2933263247922246" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="11733" O_E="0.0" SE="1.4656562175858798" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="2.148148148148148" WEIGHT="2.989489650254553"/>
<DICH_DATA CI_END="2.028563491478506" CI_START="0.5866627540263551" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3071886051225451" LOG_CI_START="-0.23161148334374554" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="11734" O_E="0.0" SE="0.3164938390685515" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.10016835016835018" WEIGHT="64.11073602898838"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11735" O_E="0.0" SE="0.0" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="93.54802690655225" CI_START="0.2672424082762665" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9710346318933951" LOG_CI_START="-0.5730946232213574" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="11736" O_E="0.0" SE="1.4944341180973262" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="2.233333333333333" WEIGHT="2.875462681836884"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.694787682472828" CI_START="0.015664113960972753" DF="0.0" EFFECT_SIZE="0.36904761904761907" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.30.02" LOG_CI_END="0.9392589814558943" LOG_CI_START="-1.8050941659111122" LOG_EFFECT_SIZE="-0.43291759222760895" NO="2" P_CHI2="1.0" P_Z="0.5363362455253172" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="30" WEIGHT="100.0" Z="0.6183627568878907">
<NAME>breathlessness</NAME>
<DICH_DATA CI_END="8.694787682472834" CI_START="0.015664113960972753" EFFECT_SIZE="0.36904761904761907" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9392589814558945" LOG_CI_START="-1.8050941659111122" LOG_EFFECT_SIZE="-0.43291759222760895" ORDER="11737" O_E="0.0" SE="1.6120466235305515" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="2.598694316436252" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.694787682472828" CI_START="0.015664113960972753" DF="0.0" EFFECT_SIZE="0.36904761904761907" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.30.03" LOG_CI_END="0.9392589814558943" LOG_CI_START="-1.8050941659111122" LOG_EFFECT_SIZE="-0.43291759222760895" NO="3" P_CHI2="1.0" P_Z="0.5363362455253172" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="30" WEIGHT="100.0" Z="0.6183627568878907">
<NAME>bulimia</NAME>
<DICH_DATA CI_END="8.694787682472834" CI_START="0.015664113960972753" EFFECT_SIZE="0.36904761904761907" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9392589814558945" LOG_CI_START="-1.8050941659111122" LOG_EFFECT_SIZE="-0.43291759222760895" ORDER="11738" O_E="0.0" SE="1.6120466235305515" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="2.598694316436252" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="129.11288787863575" CI_START="0.37951284960847026" DF="0.0" EFFECT_SIZE="6.999999999999998" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-002.30.04" LOG_CI_END="2.1109695951340917" LOG_CI_START="-0.42077351510557803" LOG_EFFECT_SIZE="0.8450980400142567" NO="4" P_CHI2="1.0" P_Z="0.1907121311885963" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="1.3084753465974925">
<NAME>difficulty swallowing</NAME>
<DICH_DATA CI_END="129.11288787863575" CI_START="0.3795128496084703" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1109695951340917" LOG_CI_START="-0.420773515105578" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="11739" O_E="0.0" SE="1.4871584352852965" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="2.211640211640211" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5583040422540513" CI_START="0.08748700975551946" DF="0.0" EFFECT_SIZE="0.36923076923076925" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-002.30.05" LOG_CI_END="0.19265219723305155" LOG_CI_START="-1.0580564270955506" LOG_EFFECT_SIZE="-0.43270211493124955" NO="5" P_CHI2="1.0" P_Z="0.1750482367114071" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="100.0" Z="1.3561600916517573">
<NAME>eye changes -slight pigmentation</NAME>
<DICH_DATA CI_END="1.5583040422540513" CI_START="0.08748700975551946" EFFECT_SIZE="0.36923076923076925" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.19265219723305155" LOG_CI_START="-1.0580564270955506" LOG_EFFECT_SIZE="-0.43270211493124955" ORDER="11740" O_E="0.0" SE="0.7346724370381603" STUDY_ID="STD-Donlon-1978" TOTAL_1="13" TOTAL_2="12" VAR="0.5397435897435897" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.487949326726408" CI_START="0.3813900959462888" DF="1.0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-002.30.06" LOG_CI_END="1.0206905803623991" LOG_CI_START="-0.41863058903443684" LOG_EFFECT_SIZE="0.3010299956639812" NO="6" P_CHI2="1.0" P_Z="0.4123062106951295" STUDIES="2" TAU2="0.0" TOTAL_1="57" TOTAL_2="57" WEIGHT="100.00000000000001" Z="0.8198419676060228">
<NAME>eye changes - worsening of cataracts</NAME>
<DICH_DATA CI_END="20.897996678081547" CI_START="0.19140590658602802" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3201046558069978" LOG_CI_START="-0.7180446644790353" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11741" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-_x002a_Itil-1971" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="49.87046632124354"/>
<DICH_DATA CI_END="20.771505597011338" CI_START="0.1925715004778244" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.317467976976883" LOG_CI_START="-0.7154079856489205" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11742" O_E="0.0" SE="1.1941214033447043" STUDY_ID="STD-Needham-1969" TOTAL_1="27" TOTAL_2="27" VAR="1.425925925925926" WEIGHT="50.129533678756474"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3795506152754102" CI_END="1.323404052105481" CI_START="0.5871453200375436" DF="4.0" EFFECT_SIZE="0.8814933327668761" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="25" I2="0.0" ID="CMP-002.30.07" LOG_CI_END="0.12169246006755582" LOG_CI_START="-0.23125439640210507" LOG_EFFECT_SIZE="-0.05478096816727465" NO="7" P_CHI2="0.6663259708104414" P_Z="0.5429136070299645" STUDIES="5" TAU2="0.0" TOTAL_1="83" TOTAL_2="86" WEIGHT="100.0" Z="0.6084129816032109">
<NAME>headache</NAME>
<DICH_DATA CI_END="2.550748330704528" CI_START="0.25090676030089926" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.40666761110760385" LOG_CI_START="-0.6004876371237167" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="11743" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.35000000000000003" WEIGHT="12.28077560733639"/>
<DICH_DATA CI_END="2.523907854293063" CI_START="0.22286867527402432" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.40207349514318896" LOG_CI_START="-0.6519509683597887" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="11744" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Amin-1977" TOTAL_1="10" TOTAL_2="10" VAR="0.3833333333333333" WEIGHT="11.21288207626366"/>
<DICH_DATA CI_END="4.103662514777637" CI_START="0.13370905697465066" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6131716371923305" LOG_CI_START="-0.8738391741823428" LOG_EFFECT_SIZE="-0.13033376849500614" ORDER="11745" O_E="0.0" SE="0.8734775114237132" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.762962962962963" WEIGHT="5.633656771326645"/>
<DICH_DATA CI_END="1.3675217895409828" CI_START="0.4895143117448983" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.13593425493382028" LOG_CI_START="-0.3102346063716206" LOG_EFFECT_SIZE="-0.08715017571890014" ORDER="11746" O_E="0.0" SE="0.2620817977022988" STUDY_ID="STD-Perales-1974" TOTAL_1="15" TOTAL_2="15" VAR="0.06868686868686867" WEIGHT="62.5777757050303"/>
<DICH_DATA CI_END="10.248873583471138" CI_START="0.6098231136424284" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.010676136283019" LOG_CI_START="-0.21479611893894357" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="11747" O_E="0.0" SE="0.7198484689028782" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="0.5181818181818181" WEIGHT="8.294909840043003"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="106.9775448127711" CI_START="0.2710296155233445" DF="0.0" EFFECT_SIZE="5.384615384615385" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.30.08" LOG_CI_END="2.0292926264015745" LOG_CI_START="-0.5669832509867339" LOG_EFFECT_SIZE="0.7311546877074201" NO="8" P_CHI2="1.0" P_Z="0.2696290555812896" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="27" WEIGHT="100.0" Z="1.1039172435524995">
<NAME>hiccough</NAME>
<DICH_DATA CI_END="106.9775448127711" CI_START="0.2710296155233445" EFFECT_SIZE="5.384615384615385" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0292926264015745" LOG_CI_START="-0.5669832509867339" LOG_EFFECT_SIZE="0.7311546877074201" ORDER="11748" O_E="0.0" SE="1.5250653021507559" STUDY_ID="STD-_x002a_Simpson-1971" TOTAL_1="25" TOTAL_2="27" VAR="2.325824175824176" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9855442667258254" CI_START="0.39204181297015506" DF="0.0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-002.30.09" LOG_CI_END="0.6004876371237167" LOG_CI_START="-0.40666761110760397" LOG_EFFECT_SIZE="0.09691001300805642" NO="9" P_CHI2="1.0" P_Z="0.706038770313687" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.3771814436168709">
<NAME>joint pain</NAME>
<DICH_DATA CI_END="3.9855442667258254" CI_START="0.39204181297015506" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6004876371237167" LOG_CI_START="-0.40666761110760397" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="11749" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="0.35000000000000003" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.694787682472828" CI_START="0.015664113960972753" DF="0.0" EFFECT_SIZE="0.36904761904761907" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.30.10" LOG_CI_END="0.9392589814558943" LOG_CI_START="-1.8050941659111122" LOG_EFFECT_SIZE="-0.43291759222760895" NO="10" P_CHI2="1.0" P_Z="0.5363362455253172" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="30" WEIGHT="100.0" Z="0.6183627568878907">
<NAME>lacrimation</NAME>
<DICH_DATA CI_END="8.694787682472834" CI_START="0.015664113960972753" EFFECT_SIZE="0.36904761904761907" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9392589814558945" LOG_CI_START="-1.8050941659111122" LOG_EFFECT_SIZE="-0.43291759222760895" ORDER="11750" O_E="0.0" SE="1.6120466235305515" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="2.598694316436252" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.180743077657695" CI_START="0.04825562593098698" DF="0.0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.30.11" LOG_CI_END="0.7143920553787599" LOG_CI_START="-1.3164520467067224" LOG_EFFECT_SIZE="-0.3010299956639812" NO="11" P_CHI2="1.0" P_Z="0.5612087715320974" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="0.5810470130737955">
<NAME>local tissue reactions (IM preparations)</NAME>
<DICH_DATA CI_END="5.180743077657695" CI_START="0.04825562593098698" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7143920553787599" LOG_CI_START="-1.3164520467067224" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11751" O_E="0.0" SE="1.1929278784054478" STUDY_ID="STD-Gallant-1968-II" TOTAL_1="26" TOTAL_2="26" VAR="1.423076923076923" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="129.11288787863575" CI_START="0.37951284960847026" DF="0.0" EFFECT_SIZE="6.999999999999998" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-002.30.12" LOG_CI_END="2.1109695951340917" LOG_CI_START="-0.42077351510557803" LOG_EFFECT_SIZE="0.8450980400142567" NO="12" P_CHI2="1.0" P_Z="0.1907121311885963" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="1.3084753465974925">
<NAME>oedema of face</NAME>
<DICH_DATA CI_END="129.11288787863575" CI_START="0.3795128496084703" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1109695951340917" LOG_CI_START="-0.420773515105578" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="11752" O_E="0.0" SE="1.4871584352852965" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="2.211640211640211" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.16298768059723" CI_END="2.330803797170456" CI_START="0.526603765214583" DF="9.0" EFFECT_SIZE="1.1078853982097647" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="22" I2="11.44336406918567" ID="CMP-002.30.13" LOG_CI_END="0.3675057169386344" LOG_CI_START="-0.2785160400152323" LOG_EFFECT_SIZE="0.044494838461700985" NO="13" P_CHI2="0.33745259857433063" P_Z="0.7871713439966657" STUDIES="10" TAU2="0.1647169560299161" TOTAL_1="245" TOTAL_2="244" WEIGHT="100.00000000000003" Z="0.26998558467772854">
<NAME>rashes</NAME>
<DICH_DATA CI_END="18.55351612686302" CI_START="0.17817566769355403" EFFECT_SIZE="1.8181818181818181" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2684262260690662" LOG_CI_START="-0.749151605057554" LOG_EFFECT_SIZE="0.2596373105057561" ORDER="11753" O_E="0.0" SE="1.1851352051751118" STUDY_ID="STD-Angus-1969" TOTAL_1="22" TOTAL_2="20" VAR="1.4045454545454545" WEIGHT="8.728192605378863"/>
<DICH_DATA CI_END="7.264937143867087" CI_START="0.013187311433658885" EFFECT_SIZE="0.30952380952380953" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8612318611406103" LOG_CI_START="-1.8798437373227375" LOG_EFFECT_SIZE="-0.5093059380910636" ORDER="11754" O_E="0.0" SE="1.6101213750804138" STUDY_ID="STD-Bishop-1967" TOTAL_1="27" TOTAL_2="25" VAR="2.5924908424908426" WEIGHT="4.7287122675055056"/>
<DICH_DATA CI_END="20.77049890470316" CI_START="0.1839266332220485" EFFECT_SIZE="1.9545454545454546" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3174469283577928" LOG_CI_START="-0.735355378843032" LOG_EFFECT_SIZE="0.29104577475738025" ORDER="11755" O_E="0.0" SE="1.205826236785068" STUDY_ID="STD-Claghorn-1974" TOTAL_1="44" TOTAL_2="43" VAR="1.4540169133192389" WEIGHT="8.431224656319081"/>
<DICH_DATA CI_END="9.92750288457511" CI_START="0.4625369328100079" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9968400219262878" LOG_CI_START="-0.334853583843439" LOG_EFFECT_SIZE="0.3309932190414244" ORDER="11756" O_E="0.0" SE="0.7822434160188003" STUDY_ID="STD-Clark-1975" TOTAL_1="14" TOTAL_2="15" VAR="0.611904761904762" WEIGHT="20.03439752964395"/>
<DICH_DATA CI_END="3.6661857415089174" CI_START="0.12122802164996731" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5642144640274329" LOG_CI_START="-0.9163969821387954" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="11757" O_E="0.0" SE="0.869718492622904" STUDY_ID="STD-Gwynne-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.7564102564102564" WEIGHT="16.207002941050952"/>
<DICH_DATA CI_END="78.25308914225548" CI_START="0.14097702564875475" EFFECT_SIZE="3.3214285714285716" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8935014908952192" LOG_CI_START="-0.8508516564717874" LOG_EFFECT_SIZE="0.5213249172117159" ORDER="11758" O_E="0.0" SE="1.6120466235305515" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="2.598694316436252" WEIGHT="4.717424120545983"/>
<DICH_DATA CI_END="11.786156401414512" CI_START="0.5302831378726578" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0713721998526826" LOG_CI_START="-0.27549218250860746" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="11759" O_E="0.0" SE="0.79115480528524" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.625925925925926" WEIGHT="19.5856134767821"/>
<DICH_DATA CI_END="0.7739370437071942" CI_START="0.002929920094383056" EFFECT_SIZE="0.047619047619047616" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" LOG_CI_END="-0.11129436578040626" LOG_CI_START="-2.533144223687432" LOG_EFFECT_SIZE="-1.3222192947339193" ORDER="11760" O_E="0.0" SE="1.4226065948847293" STUDY_ID="STD-Needham-1969" TOTAL_1="27" TOTAL_2="27" VAR="2.023809523809524" WEIGHT="6.057459017786464"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11761" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Schiele-1961" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="4.767444597331939"/>
<DICH_DATA CI_END="14.052704911192018" CI_START="0.07116067734430034" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1477599267279106" LOG_CI_START="-1.1477599267279106" LOG_EFFECT_SIZE="0.0" ORDER="11762" O_E="0.0" SE="1.3483997249264843" STUDY_ID="STD-Sugerman-1965" TOTAL_1="11" TOTAL_2="11" VAR="1.8181818181818183" WEIGHT="6.742528787655171"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0351821932531435" CI_END="2.013619398333439" CI_START="0.46606792525093843" DF="1.0" EFFECT_SIZE="0.9687535368845416" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" I2="50.86434996753058" ID="CMP-002.30.14" LOG_CI_END="0.3039773863645967" LOG_CI_START="-0.33155078414280936" LOG_EFFECT_SIZE="-0.013786698889106327" NO="14" P_CHI2="0.15369618312036304" P_Z="0.9322326540673981" STUDIES="2" TAU2="0.14817570030530058" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.0" Z="0.08503614644421782">
<NAME>sweating, facial</NAME>
<DICH_DATA CI_END="3.6330276653499807" CI_START="0.6193181575409915" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5602687050091748" LOG_CI_START="-0.20808618689781241" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="11763" O_E="0.0" SE="0.45133546692422005" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.20370370370370372" WEIGHT="28.84445751249632"/>
<DICH_DATA CI_END="1.2773166093586028" CI_START="0.4140912409338416" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.10629855948317342" LOG_CI_START="-0.3829039558157363" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="11764" O_E="0.0" SE="0.2873599790780852" STUDY_ID="STD-Perales-1974" TOTAL_1="15" TOTAL_2="15" VAR="0.08257575757575757" WEIGHT="71.15554248750368"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8605500703759148" CI_END="1.7971652798174729" CI_START="0.11923246205152704" DF="2.0" EFFECT_SIZE="0.4629043540799317" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" ID="CMP-002.30.15" LOG_CI_END="0.2545880196865465" LOG_CI_START="-0.9236054881317484" LOG_EFFECT_SIZE="-0.334508734222601" NO="15" P_CHI2="0.39444526673788183" P_Z="0.26573733019685997" STUDIES="3" TAU2="0.0" TOTAL_1="62" TOTAL_2="66" WEIGHT="100.0" Z="1.112932752115439">
<NAME>sweating, general</NAME>
<DICH_DATA CI_END="2.938902847851195" CI_START="0.03780700379134716" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.46818522971347326" LOG_CI_START="-1.4224277391527982" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11765" O_E="0.0" SE="1.1105554165971787" STUDY_ID="STD-_x002a_Doongaji-1989" TOTAL_1="20" TOTAL_2="20" VAR="1.2333333333333332" WEIGHT="38.8354181194474"/>
<DICH_DATA CI_END="2.1238842220746696" CI_START="0.033481632554173676" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.32713083864080644" LOG_CI_START="-1.4751933740962442" LOG_EFFECT_SIZE="-0.5740312677277188" ORDER="11766" O_E="0.0" SE="1.058694164210483" STUDY_ID="STD-Denber-1972" TOTAL_1="15" TOTAL_2="16" VAR="1.1208333333333333" WEIGHT="42.733396889800844"/>
<DICH_DATA CI_END="78.25308914225548" CI_START="0.14097702564875475" EFFECT_SIZE="3.3214285714285716" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8935014908952192" LOG_CI_START="-0.8508516564717874" LOG_EFFECT_SIZE="0.5213249172117159" ORDER="11767" O_E="0.0" SE="1.6120466235305515" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="2.598694316436252" WEIGHT="18.431184990751767"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5512248334884569" CI_END="4.483807674438471" CI_START="0.5176894556121125" DF="1.0" EFFECT_SIZE="1.523555038076887" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" I2="35.53481233592942" ID="CMP-002.30.16" LOG_CI_END="0.6516469759743564" LOG_CI_START="-0.28593068071277594" LOG_EFFECT_SIZE="0.1828581476307902" NO="16" P_CHI2="0.21295519773725435" P_Z="0.4445613065890889" STUDIES="2" TAU2="0.21564119643414165" TOTAL_1="63" TOTAL_2="66" WEIGHT="100.0" Z="0.7645134908662886">
<NAME>unspecified</NAME>
<DICH_DATA CI_END="2.9737713768033207" CI_START="0.26569744498633" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.473307576960196" LOG_CI_START="-0.5756126218549588" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="11768" O_E="0.0" SE="0.6161409170227454" STUDY_ID="STD-Kiloh-1976" TOTAL_1="27" TOTAL_2="30" VAR="0.37962962962962965" WEIGHT="51.479289940828394"/>
<DICH_DATA CI_END="9.250855217272443" CI_START="0.7686976981148537" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9661818839794107" LOG_CI_START="-0.11424441943484842" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="11769" O_E="0.0" SE="0.6346477588219923" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.40277777777777773" WEIGHT="48.5207100591716"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3104790712164607" CI_START="0.5175211927741649" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-002.31" LOG_CI_END="0.1174300895117052" LOG_CI_START="-0.286071860911777" LOG_EFFECT_SIZE="-0.08432088570003592" METHOD="MH" NO="31" P_CHI2="1.0" P_Q="0.0" P_Z="0.4126963559828396" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.8191578699589406">
<NAME>Patient's drug preference: Would prefer a different medication</NAME>
<GROUP_LABEL_1>Trifluoperazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Loxapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lozapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3104790712164607" CI_START="0.5175211927741649" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.1174300895117052" LOG_CI_START="-0.286071860911777" LOG_EFFECT_SIZE="-0.08432088570003592" ORDER="11770" O_E="0.0" SE="0.2370190430456212" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.056178026766262046" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>TRIFLUOPERAZINE versus ATYPICAL ANTIPSYCHOTICS</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8061418641145424" CI_START="0.43746478196909516" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.2567518591460586" LOG_CI_START="-0.3590569040408212" LOG_EFFECT_SIZE="-0.05115252244738131" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.7447185708673227" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.3256111562830066">
<NAME>Global state: 1a. No substantial improvement (defined as slight improvement or worse)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8061418641145424" CI_START="0.43746478196909516" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.2567518591460586" LOG_CI_START="-0.3590569040408212" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="11771" O_E="0.0" SE="0.36172911579851336" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.13084795321637427" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.29925159263083" CI_START="0.43492413061929797" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.3615864959812984" LOG_CI_START="-0.36158649598129833" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.00000000000001" Z="0.0">
<NAME>Global state: 2. Severely ill or worse</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.29925159263083" CI_START="0.43492413061929797" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3615864959812984" LOG_CI_START="-0.36158649598129833" LOG_EFFECT_SIZE="0.0" ORDER="11772" O_E="0.0" SE="0.4247953952428732" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.18045112781954886" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.852099098804148" CI_START="0.5837627188868435" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.8358236353431785" LOG_CI_START="-0.2337636440152162" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.26992117441108376" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="1.10324414127583">
<NAME>Global state: 3. Use of additional sedatives</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.852099098804148" CI_START="0.5837627188868435" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8358236353431785" LOG_CI_START="-0.2337636440152162" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11773" O_E="0.0" SE="0.6282808624375432" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.39473684210526316" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2153332852949501" CI_END="1.3972920907334978" CI_START="0.043223442603667186" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2457555177089163" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.14528720076994167" LOG_CI_START="-1.3642806459619299" LOG_EFFECT_SIZE="-0.6094967225959941" METHOD="MH" NO="4" P_CHI2="0.642618976373089" P_Q="0.0" P_Z="0.11349133583887583" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="38" TOTAL_2="38" WEIGHT="200.0" Z="1.5826935206252193">
<NAME>Mental state</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.590192614031835" CI_START="0.00787901376706469" DF="0.0" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.41333206064527345" LOG_CI_START="-2.1035281406737876" LOG_EFFECT_SIZE="-0.8450980400142569" NO="1" P_CHI2="1.0" P_Z="0.1881026512600156" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="1.316212732805144">
<NAME>emotional lability</NAME>
<DICH_DATA CI_END="2.590192614031835" CI_START="0.00787901376706469" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41333206064527345" LOG_CI_START="-2.1035281406737876" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="11774" O_E="0.0" SE="1.4784161409137435" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="2.185714285714286" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.925270697442083" CI_START="0.03798318945602845" DF="0.0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="0.46616606083383155" LOG_CI_START="-1.4204085702731564" LOG_EFFECT_SIZE="-0.4771212547196625" NO="2" P_CHI2="1.0" P_Z="0.32150820143689296" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.9913633524907374">
<NAME>euphoria</NAME>
<DICH_DATA CI_END="2.925270697442083" CI_START="0.03798318945602845" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.46616606083383155" LOG_CI_START="-1.4204085702731564" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11775" O_E="0.0" SE="1.1081832770072813" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="1.2280701754385965" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1461057552991117" CI_END="3.886383562121602" CI_START="0.11578912829980623" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6708211124411307" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.5895456605695928" LOG_CI_START="-0.9363322155744991" LOG_EFFECT_SIZE="-0.1733932775024531" METHOD="MH" NO="5" P_CHI2="0.7022851058941537" P_Q="0.0" P_Z="0.6560008097702703" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="38" TOTAL_2="38" WEIGHT="200.0" Z="0.4454413873867258">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.060929889863502" CI_START="0.049398036613928026" DF="0.0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.7042303209767762" LOG_CI_START="-1.3062903123047387" LOG_EFFECT_SIZE="-0.3010299956639812" NO="1" P_CHI2="1.0" P_Z="0.5572570625239202" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.5869205617697717">
<NAME>any reason</NAME>
<DICH_DATA CI_END="5.060929889863502" CI_START="0.049398036613928026" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7042303209767762" LOG_CI_START="-1.3062903123047387" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11776" O_E="0.0" SE="1.180989772227204" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="1.3947368421052633" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.848212018999854" CI_START="0.06734817624643254" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="1.1716741602503453" LOG_CI_START="-1.1716741602503453" LOG_EFFECT_SIZE="0.0" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.0">
<NAME>due to deterioration</NAME>
<DICH_DATA CI_END="14.848212018999854" CI_START="0.06734817624643254" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1716741602503453" LOG_CI_START="-1.1716741602503453" LOG_EFFECT_SIZE="0.0" ORDER="11777" O_E="0.0" SE="1.3764944032233706" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="1.8947368421052633" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9309678321354182" CI_START="0.006393518735468961" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.11111111111111109" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.28577503895679124" LOG_CI_START="-2.194260057835441" LOG_EFFECT_SIZE="-0.954242509439325" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.13148550338739748" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="1.5082697445994122">
<NAME>Behaviour: Agitation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9309678321354182" CI_START="0.006393518735468961" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.28577503895679124" LOG_CI_START="-2.194260057835441" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="11778" O_E="0.0" SE="1.4567848922274773" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="2.1222222222222227" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.538554775428725" CI_END="2.450087592741349" CI_START="0.7056143923502163" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3148448836106073" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.38918161104380367" LOG_CI_START="-0.15143256952230455" LOG_EFFECT_SIZE="0.11887452076074959" METHOD="MH" NO="7" P_CHI2="0.8641280749969649" P_Q="0.0" P_Z="0.3887179267693909" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="133" TOTAL_2="133" WEIGHT="700.0" Z="0.8619447574480975">
<NAME>Adverse events: 1. Extrapyramidal</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.3849287248835696" CI_START="0.15661881958098683" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="0.8051560535865078" LOG_CI_START="-0.8051560535865078" LOG_EFFECT_SIZE="0.0" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.0">
<NAME>non-specific - use of antiparkinson drugs</NAME>
<DICH_DATA CI_END="6.3849287248835696" CI_START="0.15661881958098683" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8051560535865078" LOG_CI_START="-0.8051560535865078" LOG_EFFECT_SIZE="0.0" ORDER="11779" O_E="0.0" SE="0.9459053029269173" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.8947368421052633" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.549880408511372" CI_START="0.12519983585329295" DF="0.0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-003.07.02" LOG_CI_END="0.5502137224076437" LOG_CI_START="-0.9023962405190062" LOG_EFFECT_SIZE="-0.17609125905568127" NO="2" P_CHI2="1.0" P_Z="0.6346518877605023" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="99.99999999999999" Z="0.47518953407987274">
<NAME>specific - akathisia</NAME>
<DICH_DATA CI_END="3.549880408511372" CI_START="0.12519983585329295" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5502137224076437" LOG_CI_START="-0.9023962405190062" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="11780" O_E="0.0" SE="0.853270282758398" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.7280701754385965" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="26.327436276978744" CI_START="0.34184870510425597" DF="0.0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-003.07.03" LOG_CI_END="1.4204085702731564" LOG_CI_START="-0.4661660608338316" LOG_EFFECT_SIZE="0.4771212547196624" NO="3" P_CHI2="1.0" P_Z="0.32150820143689307" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.9913633524907371">
<NAME>specific - dyskinesia, oral</NAME>
<DICH_DATA CI_END="26.327436276978744" CI_START="0.34184870510425597" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4204085702731564" LOG_CI_START="-0.4661660608338316" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="11781" O_E="0.0" SE="1.1081832770072813" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="1.2280701754385965" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="97.69696229084639" CI_START="0.2558933196466676" DF="0.0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-003.07.04" LOG_CI_END="1.9898810603325618" LOG_CI_START="-0.5919410516605246" LOG_EFFECT_SIZE="0.6989700043360189" NO="4" P_CHI2="1.0" P_Z="0.28858452647172994" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="1.0612319326019242">
<NAME>specific - dystonic reaction</NAME>
<DICH_DATA CI_END="97.69696229084639" CI_START="0.2558933196466676" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9898810603325618" LOG_CI_START="-0.5919410516605246" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="11782" O_E="0.0" SE="1.5165750888103102" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="2.3000000000000003" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.169895635269663" CI_START="0.343871115240617" DF="0.0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-003.07.05" LOG_CI_END="0.7134817760757654" LOG_CI_START="-0.46360430285916565" LOG_EFFECT_SIZE="0.12493873660829992" NO="5" P_CHI2="1.0" P_Z="0.6773583828712484" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.41607054642558644">
<NAME>specific - rigidity</NAME>
<DICH_DATA CI_END="5.169895635269663" CI_START="0.343871115240617" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7134817760757654" LOG_CI_START="-0.46360430285916565" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="11783" O_E="0.0" SE="0.6914261894364405" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.4780701754385965" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.64953952036916" CI_START="0.4145275524864603" DF="0.0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-003.07.06" LOG_CI_END="0.9845065891433494" LOG_CI_START="-0.38244659781538703" LOG_EFFECT_SIZE="0.3010299956639812" NO="6" P_CHI2="1.0" P_Z="0.3880026266668175" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.8632452894459833">
<NAME>specific - salivation, excessive</NAME>
<DICH_DATA CI_END="9.64953952036916" CI_START="0.4145275524864603" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9845065891433494" LOG_CI_START="-0.38244659781538703" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11784" O_E="0.0" SE="0.8029550685469663" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.6447368421052633" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4260495494020744" CI_START="0.29188135944342175" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-003.07.07" LOG_CI_END="0.5347936396791975" LOG_CI_START="-0.5347936396791975" LOG_EFFECT_SIZE="0.0" NO="7" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.0">
<NAME>specific - tremor</NAME>
<DICH_DATA CI_END="3.4260495494020744" CI_START="0.29188135944342175" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5347936396791975" LOG_CI_START="-0.5347936396791975" LOG_EFFECT_SIZE="0.0" ORDER="11785" O_E="0.0" SE="0.6282808624375432" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.39473684210526316" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.894105002038959" CI_END="4.019946884668145" CI_START="0.5083479706757108" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4295215427006327" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.6042203148138421" LOG_CI_START="-0.29383890580636" LOG_EFFECT_SIZE="0.15519070450374098" METHOD="MH" NO="8" P_CHI2="0.929175438094713" P_Q="0.0" P_Z="0.49815851222460217" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="133" TOTAL_2="133" WEIGHT="700.0" Z="0.6773900530806221">
<NAME>Adverse events: 2. Miscellaneous</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.31319328145675" CI_START="0.1298454099994229" DF="0.0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="1.8408159073966481" LOG_CI_START="-0.8865733979573234" LOG_EFFECT_SIZE="0.4771212547196624" NO="1" P_CHI2="1.0" P_Z="0.4928768494435124" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.6857403698646046">
<NAME>dry mouth</NAME>
<DICH_DATA CI_END="69.31319328145675" CI_START="0.1298454099994229" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8408159073966481" LOG_CI_START="-0.8865733979573234" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="11786" O_E="0.0" SE="1.6020819787597222" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="2.566666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.3849287248835696" CI_START="0.15661881958098683" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.08.02" LOG_CI_END="0.8051560535865078" LOG_CI_START="-0.8051560535865078" LOG_EFFECT_SIZE="0.0" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.0">
<NAME>headache</NAME>
<DICH_DATA CI_END="6.3849287248835696" CI_START="0.15661881958098683" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8051560535865078" LOG_CI_START="-0.8051560535865078" LOG_EFFECT_SIZE="0.0" ORDER="11787" O_E="0.0" SE="0.9459053029269173" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="0.8947368421052633" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.31319328145675" CI_START="0.1298454099994229" DF="0.0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.08.03" LOG_CI_END="1.8408159073966481" LOG_CI_START="-0.8865733979573234" LOG_EFFECT_SIZE="0.4771212547196624" NO="3" P_CHI2="1.0" P_Z="0.4928768494435124" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.6857403698646046">
<NAME>nausea</NAME>
<DICH_DATA CI_END="69.31319328145675" CI_START="0.1298454099994229" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8408159073966481" LOG_CI_START="-0.8865733979573234" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="11788" O_E="0.0" SE="1.6020819787597222" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="2.566666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.848212018999854" CI_START="0.06734817624643254" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-003.08.04" LOG_CI_END="1.1716741602503453" LOG_CI_START="-1.1716741602503453" LOG_EFFECT_SIZE="0.0" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.0">
<NAME>perspiration, excessive</NAME>
<DICH_DATA CI_END="14.848212018999854" CI_START="0.06734817624643254" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1716741602503453" LOG_CI_START="-1.1716741602503453" LOG_EFFECT_SIZE="0.0" ORDER="11789" O_E="0.0" SE="1.3764944032233706" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="1.8947368421052633" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.701465920161863" CI_START="0.014427267777713661" DF="0.0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.08.05" LOG_CI_END="0.8865733979573234" LOG_CI_START="-1.8408159073966481" LOG_EFFECT_SIZE="-0.4771212547196625" NO="5" P_CHI2="1.0" P_Z="0.4928768494435123" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.6857403698646047">
<NAME>rash</NAME>
<DICH_DATA CI_END="7.701465920161863" CI_START="0.014427267777713661" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8865733979573234" LOG_CI_START="-1.8408159073966481" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="11790" O_E="0.0" SE="1.6020819787597222" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="2.566666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.31319328145675" CI_START="0.1298454099994229" DF="0.0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.08.06" LOG_CI_END="1.8408159073966481" LOG_CI_START="-0.8865733979573234" LOG_EFFECT_SIZE="0.4771212547196624" NO="6" P_CHI2="1.0" P_Z="0.4928768494435124" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.6857403698646046">
<NAME>urinary frequency</NAME>
<DICH_DATA CI_END="69.31319328145675" CI_START="0.1298454099994229" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8408159073966481" LOG_CI_START="-0.8865733979573234" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="11791" O_E="0.0" SE="1.6020819787597222" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="2.566666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.31319328145675" CI_START="0.1298454099994229" DF="0.0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.08.07" LOG_CI_END="1.8408159073966481" LOG_CI_START="-0.8865733979573234" LOG_EFFECT_SIZE="0.4771212547196624" NO="7" P_CHI2="1.0" P_Z="0.4928768494435124" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.6857403698646046">
<NAME>weakness/lethargy</NAME>
<DICH_DATA CI_END="69.31319328145675" CI_START="0.1298454099994229" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8408159073966481" LOG_CI_START="-0.8865733979573234" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="11792" O_E="0.0" SE="1.6020819787597222" STUDY_ID="STD-Edwards-1980" TOTAL_1="19" TOTAL_2="19" VAR="2.566666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>